IEPA.d0 IEPA.d0.s0.e0 IEPA.d0.s0.e1	Oxytocin	IP3	[INST]Context: [PMID: 1645753 Vasopressin-stimulated phosphoinositide hydrolysis in cultured rat inner medullary collecting duct cells is mediated by the oxytocin receptor. Studies were performed to identify the receptor that mediates AVP-stimulated phosphoinositide (PI) hydrolysis in cultured rat inner medullary collecting tubule (RIMCT) cells. While the selective V1 receptor agonist [Ho1, Phe2, Orn8] VT has no effect on inositol trisphosphate (IP3) production over the range of 10(-13)-10(-7) M, the selective V2 receptor agonist VDAVP stimulates IP3 production in dose-dependent fashion. Oxytocin stimulates IP3 production in dose-dependent fashion as well. AVP-stimulated phospholipase C activity is not inhibited by the V1 receptor antagonist d(CH2)5Tyr(Me)AVP(10(-7) M) but is eliminated by the V2 receptor antagonist d(CH2)5DTyr(Et)VAVP (10(-7) M). Similarly, the response to oxytocin is eliminated by the V2 receptor antagonist. The selective oxytocin receptor agonist [Thr4, Gly7] oxytocin does not stimulate cAMP production in RIMCT cells but does promote PI hydrolysis. The selective oxytocin receptor antagonist desGlyNH2d(CH2)5[Tyr(Me)-Thr4]OVT (10(-7) M) does not inhibit AVP-stimulated cAMP production but eliminates IP3 production in response to AVP or the V2 receptor agonist VDAVP. These studies demonstrate that AVP or a V2 receptor agonist stimulate PI hydrolysis in cultured RIMCT cells via occupancy of the oxytocin receptor.] Question: Based on the provided context, do the terms [Oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin stimulates the production of inositol trisphosphate (IP3) in a dose-dependent manner. This suggests that oxytocin interacts with the oxytocin receptor, which in turn triggers a signaling cascade that leads to the production of IP3. Therefore, oxytocin and IP3 are interacting in the sense that oxytocin's binding to the receptor initiates a process that results in the production of IP3.</s>
IEPA.d1 IEPA.d1.s1.e0 IEPA.d1.s1.e1	inositol trisphosphate	oxytocin	[INST]Context: [PMID: 1936930 Inositol phosphate formation in uterine tissue from two species of reptiles is stimulated by arginine vasotocin and influenced by stage of reproduction. Phosphoinositide hydrolysis, resulting in inositol trisphosphate (IP3) and diacylglycerol (DG) formation, has been implicated in oxytocin-stimulated pulsatile secretion of prostaglandin F2 alpha (PGF2 alpha) from uterine endometrium of sheep and other mammals. In reptiles, arginine vasotocin (AVT) stimulates uterine secretion of PGF2 alpha. These studies investigated the ability of AVT to stimulate incorporation of [3H]inositol into inositol mono-, bis-, and trisphosphates in two reptilian species. In Experiment 1, AVT stimulated (P less than 0.01) IP formation in uterine from late-gravid (150 to 291%) and postpartum (104 to 363%) Yarrow's spiny lizards (Sceloporus jarrovi). Inositol phosphate formation, in response to AVT, was greater (P less than 0.01 for IP3 and P less than 0.05 for total IP) for gravid (stage 40 embryos) and postpartum (1-2 days) lizards near the time of parturition than for lizards at other stages (stage 38-39 embryos or 7 days postpartum). Inositol phosphate formation was greater (P less than 0.05) in uterine tissue from gravid than from postpartum lizards. In Experiment 2, basal IP formation and the response to AVT were the greatest (P less than 0.01) in endometrium from late-gravid American alligators (Alligator mississippiensis). AVT stimulated (P less than 0.02) IP synthesis in uterine endometrium from vitellogenic (136 to 394%), early-gravid (7 to 270%), late-gravid (315 to 1002%), postpartum (86 to 313%), and nonreproductive (292 to 322%) alligators. Results indicate that (1) AVT stimulates IP formation in the uterus of reptiles; (2) uterine IP formation increases in late-gravid reptiles; and (3) increased responsiveness to AVT may occur at parturition or oviposition.] Question: Based on the provided context, do the terms [inositol trisphosphate protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the role of arginine vasotocin (AVT) in stimulating inositol trisphosphate (IP3) formation in the uterine tissue of reptiles. It also mentions the involvement of oxytocin in stimulating prostaglandin F2 alpha (PGF2 alpha) secretion in mammals. However, there is no direct interaction mentioned between inositol trisphosphate protein and oxytocin protein. Instead, they are presented as separate entities involved in different physiological processes. Therefore, based on the provided context, there is no evidence of a direct interaction between inositol trisphosphate protein and oxytocin protein.</s>
IEPA.d2 IEPA.d2.s2.e0 IEPA.d2.s2.e2	inositol trisphosphate	oxytocin	[INST]Context: [PMID: 1963324 Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [inositol trisphosphate protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin induces the synthesis of inositol trisphosphate (IP3) in the endometrium. Specifically, it mentions that SP ewes had greater incorporation of [3H]inositol into IP3 in response to oxytocin compared to oCSP ewes. This suggests that oxytocin protein interacts with the inositol trisphosphate protein pathway, leading to the production of IP3. Therefore, the terms "inositol trisphosphate protein" and "oxytocin protein" are interacting in the context provided.</s>
IEPA.d2 IEPA.d2.s2.e1 IEPA.d2.s2.e2	inositol phosphate	oxytocin	[INST]Context: [PMID: 1963324 Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [inositol phosphate protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin induces the synthesis of inositol phosphate (IP3) and total inositol phosphate (IP) in the endometrium. This suggests that oxytocin protein interacts with the inositol phosphate protein pathway, leading to the production of IP3 and IP. The study specifically mentions the incorporation of [3H]inositol into IP3 and total IP in response to oxytocin, demonstrating a direct interaction between oxytocin and the inositol phosphate pathway.</s>
IEPA.d2 IEPA.d2.s2.e2 IEPA.d2.s2.e3	oxytocin	IP3	[INST]Context: [PMID: 1963324 Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin protein and IP3 protein interact with each other. Specifically, it mentions that oxytocin induces the synthesis of IP3 in the endometrium. This suggests that oxytocin protein triggers a signaling pathway that results in the production of IP3 protein, demonstrating a direct interaction between the two.</s>
IEPA.d2 IEPA.d2.s2.e2 IEPA.d2.s2.e4	oxytocin	IP	[INST]Context: [PMID: 1963324 Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [oxytocin protein] and [IP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin protein and IP protein (inositol trisphosphate) interact with each other. Oxytocin induces the synthesis of IP3 (inositol trisphosphate) in the endometrium, which is a key step in the process of luteolysis. This interaction is described as oxytocin-induced synthesis of IP3, suggesting a direct interaction between oxytocin and the production of IP3.</s>
IEPA.d2 IEPA.d2.s3.e1 IEPA.d2.s3.e2	oxytocin	IP3	[INST]Context: [PMID: 1963324 Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin protein and IP3 protein interact with each other. Specifically, it mentions that oxytocin induces the synthesis of IP3 in the endometrium. This suggests that oxytocin protein triggers a signaling pathway that results in the production of IP3 protein, demonstrating a direct interaction between the two.</s>
IEPA.d4 IEPA.d4.s6.e0 IEPA.d4.s6.e1	oxytocin	IP	[INST]Context: [PMID: 2229283 Regulation of intracellular free calcium in human myometrial cells by prostaglandin F2 alpha: comparison with oxytocin. The effects of prostaglandin F2 alpha (PGF2 alpha) on intracellular Ca2+ concentration ([Ca2+]i) and inositol phosphate (IP) generation in human myometrial cells were evaluated and compared to the effects of oxytocin. Basal [Ca2+]i levels were 146 and 153 nM in the absence and presence of 1 mM extracellular Ca, respectively. In Ca-containing medium, both PGF2 alpha and oxytocin significantly (P less than 0.01) increased [Ca2+]i over control values, eliciting half-maximal stimulation (ED50) at 4 and 1 nM, respectively. In Ca-free medium the potency of PGF2 alpha to raise [Ca2+]i was drastically reduced (ED50, 2 microM), whereas that of oxytocin remained the same, although maximal responses were markedly decreased. PGF2 alpha had no effect on total IP production in the concentration range that significantly raised [Ca2+]i. However, at a 100 times higher concentration (10 microM), PGF2 alpha produced a maximum 48% increase in total IP, with a rapid (15-30 s) rise in IP3 and IP2, followed by IP1. A similar increase in IP production was obtained when [Ca2+]i levels were raised by A23187 to the same level as that obtained with 10-50 microM PGF2 alpha. The effect of PGF2 alpha was dependent on extracellular Ca and could be suppressed by verapamil, but not by pertussis toxin, or phorbol ester. In contrast, the potencies of oxytocin to raise IP and [Ca2+]i were similar and independent of extracellular Ca2+, and could be suppressed by pertussis toxin and phorbol ester, but not by verapamil. These data provide evidence that in isolated human myometrial cells, PGF2 alpha and oxytocin trigger an increase in [Ca2+]i by different mechanisms. The action of PGF2 alpha depends on extracellular Ca2+, whereas oxytocin activates the G-protein-dependent phospholipase-C-IP3-Ca2+ signal-transducing pathway, complemented by the influx of extracellular Ca2+.] Question: Based on the provided context, do the terms [oxytocin protein] and [IP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of oxytocin and prostaglandin F2 alpha (PGF2 alpha) on intracellular calcium concentration ([Ca2+]i) and inositol phosphate (IP) generation in human myometrial cells. While both substances influence these cellular processes, there is no direct interaction mentioned between oxytocin protein and IP protein. Instead, the context describes how oxytocin and PGF2 alpha trigger increases in [Ca2+]i through different mechanisms, with oxytocin activating the G-protein-dependent phospholipase-C-IP3-Ca2+ signal-transducing pathway and PGF2 alpha relying on extracellular calcium influx. Therefore, the terms [oxytocin protein] and [IP protein] are presented as separate entities with distinct roles in the cellular processes described.</s>
IEPA.d4 IEPA.d4.s7.e0 IEPA.d4.s7.e1	oxytocin	IP3	[INST]Context: [PMID: 2229283 Regulation of intracellular free calcium in human myometrial cells by prostaglandin F2 alpha: comparison with oxytocin. The effects of prostaglandin F2 alpha (PGF2 alpha) on intracellular Ca2+ concentration ([Ca2+]i) and inositol phosphate (IP) generation in human myometrial cells were evaluated and compared to the effects of oxytocin. Basal [Ca2+]i levels were 146 and 153 nM in the absence and presence of 1 mM extracellular Ca, respectively. In Ca-containing medium, both PGF2 alpha and oxytocin significantly (P less than 0.01) increased [Ca2+]i over control values, eliciting half-maximal stimulation (ED50) at 4 and 1 nM, respectively. In Ca-free medium the potency of PGF2 alpha to raise [Ca2+]i was drastically reduced (ED50, 2 microM), whereas that of oxytocin remained the same, although maximal responses were markedly decreased. PGF2 alpha had no effect on total IP production in the concentration range that significantly raised [Ca2+]i. However, at a 100 times higher concentration (10 microM), PGF2 alpha produced a maximum 48% increase in total IP, with a rapid (15-30 s) rise in IP3 and IP2, followed by IP1. A similar increase in IP production was obtained when [Ca2+]i levels were raised by A23187 to the same level as that obtained with 10-50 microM PGF2 alpha. The effect of PGF2 alpha was dependent on extracellular Ca and could be suppressed by verapamil, but not by pertussis toxin, or phorbol ester. In contrast, the potencies of oxytocin to raise IP and [Ca2+]i were similar and independent of extracellular Ca2+, and could be suppressed by pertussis toxin and phorbol ester, but not by verapamil. These data provide evidence that in isolated human myometrial cells, PGF2 alpha and oxytocin trigger an increase in [Ca2+]i by different mechanisms. The action of PGF2 alpha depends on extracellular Ca2+, whereas oxytocin activates the G-protein-dependent phospholipase-C-IP3-Ca2+ signal-transducing pathway, complemented by the influx of extracellular Ca2+.] Question: Based on the provided context, do the terms [oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of oxytocin and prostaglandin F2 alpha (PGF2 alpha) on intracellular calcium concentration ([Ca2+]i) and inositol phosphate (IP) generation in human myometrial cells. While it mentions that oxytocin activates the G-protein-dependent phospholipase-C-IP3-Ca2+ signal-transducing pathway, it does not indicate a direct interaction between oxytocin protein and IP3 protein. Instead, it describes the mechanisms by which each substance affects the cellular processes, highlighting their distinct pathways and effects. Therefore, there is no direct interaction mentioned between oxytocin protein and IP3 protein.</s>
IEPA.d8 IEPA.d8.s16.e0 IEPA.d8.s16.e1	oxytocin	inositol phosphate	[INST]Context: [PMID: 7581972 Signal transduction in rat myometrial cells: comparison of the actions of endothelin-1, oxytocin and prostaglandin F2 alpha. The objectives of this study were to evaluate and compare the actions of endothelin-1 (ET-1), oxytocin, prostaglandin F2 alpha (PGF2 alpha) and inositol 1,4,5-trisphosphate (IP3) on 45Ca2+ mobilization in permeabilized rat myometrial cells and to examine the activation of the inositol lipid cycle in intact myocytes. Cells were isolated from late pregnant rat myometrium and used as confluent monolayers after a single passage. All four agonists caused a biphasic release of 45Ca2+ from non-mitochondrial pool(s), with the rank order of potency: oxytocin > PGF2 alpha > ET-1 > IP3. Inhibitors of phospholipase C blocked ET-1- and oxytocin-promoted but not PGF2 alpha-promoted 45Ca2+ efflux. Similarly, heparin, an IP3 receptor blocker, failed to inhibit PGF2 alpha-induced 45Ca2+ release while inhibiting the action of the other agonists. Endothelin-1 and oxytocin stimulated inositol phosphate accumulation at concentrations similar to those that promoted 45Ca2+ efflux, whereas about 100 times higher concentrations of PGF2 alpha were needed to activate this signaling pathway in intact cells. It is concluded that the primary action of PGF2 alpha in myometrial cells is to enhance Ca2+ influx, whereas oxytocin and ET-1 receptors are coupled to phospholipase C, generating IP3 and raising the intracellular concentration of free Ca2+ from intracellular as well as extracellular sources.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin and inositol phosphate protein interact with each other. Oxytocin stimulates the inositol lipid cycle, which leads to the accumulation of inositol phosphates. This suggests that oxytocin activates a signaling pathway that involves the production of inositol phosphates, thereby demonstrating an interaction between oxytocin and inositol phosphate protein.</s>
IEPA.d8 IEPA.d8.s17.e0 IEPA.d8.s17.e1	oxytocin	IP3	[INST]Context: [PMID: 7581972 Signal transduction in rat myometrial cells: comparison of the actions of endothelin-1, oxytocin and prostaglandin F2 alpha. The objectives of this study were to evaluate and compare the actions of endothelin-1 (ET-1), oxytocin, prostaglandin F2 alpha (PGF2 alpha) and inositol 1,4,5-trisphosphate (IP3) on 45Ca2+ mobilization in permeabilized rat myometrial cells and to examine the activation of the inositol lipid cycle in intact myocytes. Cells were isolated from late pregnant rat myometrium and used as confluent monolayers after a single passage. All four agonists caused a biphasic release of 45Ca2+ from non-mitochondrial pool(s), with the rank order of potency: oxytocin > PGF2 alpha > ET-1 > IP3. Inhibitors of phospholipase C blocked ET-1- and oxytocin-promoted but not PGF2 alpha-promoted 45Ca2+ efflux. Similarly, heparin, an IP3 receptor blocker, failed to inhibit PGF2 alpha-induced 45Ca2+ release while inhibiting the action of the other agonists. Endothelin-1 and oxytocin stimulated inositol phosphate accumulation at concentrations similar to those that promoted 45Ca2+ efflux, whereas about 100 times higher concentrations of PGF2 alpha were needed to activate this signaling pathway in intact cells. It is concluded that the primary action of PGF2 alpha in myometrial cells is to enhance Ca2+ influx, whereas oxytocin and ET-1 receptors are coupled to phospholipase C, generating IP3 and raising the intracellular concentration of free Ca2+ from intracellular as well as extracellular sources.] Question: Based on the provided context, do the terms [oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the actions of oxytocin and IP3 on 45Ca2+ mobilization and the activation of the inositol lipid cycle in rat myometrial cells. While both oxytocin and IP3 are involved in the signaling pathways that lead to calcium release, there is no direct interaction mentioned between oxytocin protein and IP3 protein. Instead, they are presented as separate agents that activate different signaling pathways to achieve similar outcomes. Oxytocin stimulates the inositol lipid cycle, leading to the production of IP3, which then promotes calcium release. However, this does not imply a direct interaction between the oxytocin protein and the IP3 protein.</s>
IEPA.d9 IEPA.d9.s19.e0 IEPA.d9.s19.e1	OT	inositol 1,4,5-trisphosphate	[INST]Context: [PMID: 7619502 Oxytocin induced a biphasic increase in the intracellular Ca2+ concentration of porcine myometrial cells: participation of a pertussis toxin-insensitive G-protein, inositol 1,4,5-trisphosphate-sensitive Ca2+ pool, and Ca2+ channels. This study investigated the underlying mechanisms of oxytocin (OT)-induced increases in intracellular Ca2+ concentrations ([Ca2+]i) in acutely dispersed myometrial cells from prepartum sows. A dose-dependent increase in [Ca2+]i was induced by OT (0.1 nM to 1 microM) in the presence and absence of extracellular Ca2+ ([Ca2+]e). [Ca2+]i was elevated by OT in a biphasic pattern, with a spike followed by a sustained plateau in the presence of [Ca2+]e. However, in the absence of [Ca2+]e, the [Ca2+]i response to OT became monophasic with a lower amplitude and no plateau, and this monophasic increase was abolished by pretreatment with ionomycin, a Ca2+ ionophore. Administration of OT (1 microM) for 15 sec increased inositol 1,4,5-trisphosphate (IP3) formation by 61%. Pretreatment with pertussis toxin (PTX, 1 microgram/ml) for 2 hr failed to alter the OT-induced increase in [Ca2+]i and IP3 formation. U-73122 (30 nM to 3 microM), a phospholipase C (PLC) inhibitor, depressed the rise in [Ca2+]i by OT dose dependently. U-73122 (3 microM) also abolished the OT-induced IP3 formation. Thapsigargin (2 microM), an inhibitor of Ca(2+)-ATPase in the endoplasmic reticulum, did not increase [Ca2+]i. However, it did time-dependently inhibit the OT-induced increase in [Ca2+]i. Nimodipine (1 microM), a voltage-dependent Ca2+ channel (VDCC) blocker, inhibited the OT-induced plateau by 26%. La3+ (1 mM), a nonspecific Ca2+ channel blocker, abrogated the OT-induced plateau. In whole-cell patch-clamp studies used to evaluate VDCC activities, OT (0.1 microM) increased Ca2+ current (ICa) by 40% with no apparent changes in the current-voltage relationship.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [OT protein] and [inositol 1,4,5-trisphosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) induces an increase in inositol 1,4,5-trisphosphate (IP3) formation, which is a key step in the signaling pathway that leads to the increase in intracellular calcium concentration ([Ca2+]i). This suggests that OT protein interacts with the signaling pathway involving inositol 1,4,5-trisphosphate protein to produce the observed effects on [Ca2+]i.</s>
IEPA.d9 IEPA.d9.s20.e0 IEPA.d9.s20.e1	OT	IP3	[INST]Context: [PMID: 7619502 Oxytocin induced a biphasic increase in the intracellular Ca2+ concentration of porcine myometrial cells: participation of a pertussis toxin-insensitive G-protein, inositol 1,4,5-trisphosphate-sensitive Ca2+ pool, and Ca2+ channels. This study investigated the underlying mechanisms of oxytocin (OT)-induced increases in intracellular Ca2+ concentrations ([Ca2+]i) in acutely dispersed myometrial cells from prepartum sows. A dose-dependent increase in [Ca2+]i was induced by OT (0.1 nM to 1 microM) in the presence and absence of extracellular Ca2+ ([Ca2+]e). [Ca2+]i was elevated by OT in a biphasic pattern, with a spike followed by a sustained plateau in the presence of [Ca2+]e. However, in the absence of [Ca2+]e, the [Ca2+]i response to OT became monophasic with a lower amplitude and no plateau, and this monophasic increase was abolished by pretreatment with ionomycin, a Ca2+ ionophore. Administration of OT (1 microM) for 15 sec increased inositol 1,4,5-trisphosphate (IP3) formation by 61%. Pretreatment with pertussis toxin (PTX, 1 microgram/ml) for 2 hr failed to alter the OT-induced increase in [Ca2+]i and IP3 formation. U-73122 (30 nM to 3 microM), a phospholipase C (PLC) inhibitor, depressed the rise in [Ca2+]i by OT dose dependently. U-73122 (3 microM) also abolished the OT-induced IP3 formation. Thapsigargin (2 microM), an inhibitor of Ca(2+)-ATPase in the endoplasmic reticulum, did not increase [Ca2+]i. However, it did time-dependently inhibit the OT-induced increase in [Ca2+]i. Nimodipine (1 microM), a voltage-dependent Ca2+ channel (VDCC) blocker, inhibited the OT-induced plateau by 26%. La3+ (1 mM), a nonspecific Ca2+ channel blocker, abrogated the OT-induced plateau. In whole-cell patch-clamp studies used to evaluate VDCC activities, OT (0.1 microM) increased Ca2+ current (ICa) by 40% with no apparent changes in the current-voltage relationship.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) induces an increase in inositol 1,4,5-trisphosphate (IP3) formation. This suggests that OT protein interacts with the signaling pathway that leads to the production of IP3 protein. Specifically, the study shows that OT increases IP3 formation, which is a key step in the signaling cascade that ultimately leads to the increase in intracellular calcium concentration ([Ca2+]i). Therefore, OT protein and IP3 protein are interacting in this context.</s>
IEPA.d9 IEPA.d9.s21.e0 IEPA.d9.s21.e1	OT	IP3	[INST]Context: [PMID: 7619502 Oxytocin induced a biphasic increase in the intracellular Ca2+ concentration of porcine myometrial cells: participation of a pertussis toxin-insensitive G-protein, inositol 1,4,5-trisphosphate-sensitive Ca2+ pool, and Ca2+ channels. This study investigated the underlying mechanisms of oxytocin (OT)-induced increases in intracellular Ca2+ concentrations ([Ca2+]i) in acutely dispersed myometrial cells from prepartum sows. A dose-dependent increase in [Ca2+]i was induced by OT (0.1 nM to 1 microM) in the presence and absence of extracellular Ca2+ ([Ca2+]e). [Ca2+]i was elevated by OT in a biphasic pattern, with a spike followed by a sustained plateau in the presence of [Ca2+]e. However, in the absence of [Ca2+]e, the [Ca2+]i response to OT became monophasic with a lower amplitude and no plateau, and this monophasic increase was abolished by pretreatment with ionomycin, a Ca2+ ionophore. Administration of OT (1 microM) for 15 sec increased inositol 1,4,5-trisphosphate (IP3) formation by 61%. Pretreatment with pertussis toxin (PTX, 1 microgram/ml) for 2 hr failed to alter the OT-induced increase in [Ca2+]i and IP3 formation. U-73122 (30 nM to 3 microM), a phospholipase C (PLC) inhibitor, depressed the rise in [Ca2+]i by OT dose dependently. U-73122 (3 microM) also abolished the OT-induced IP3 formation. Thapsigargin (2 microM), an inhibitor of Ca(2+)-ATPase in the endoplasmic reticulum, did not increase [Ca2+]i. However, it did time-dependently inhibit the OT-induced increase in [Ca2+]i. Nimodipine (1 microM), a voltage-dependent Ca2+ channel (VDCC) blocker, inhibited the OT-induced plateau by 26%. La3+ (1 mM), a nonspecific Ca2+ channel blocker, abrogated the OT-induced plateau. In whole-cell patch-clamp studies used to evaluate VDCC activities, OT (0.1 microM) increased Ca2+ current (ICa) by 40% with no apparent changes in the current-voltage relationship.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) induces an increase in inositol 1,4,5-trisphosphate (IP3) formation. This suggests that OT protein interacts with the signaling pathway that leads to the production of IP3 protein. Specifically, the study shows that OT increases IP3 formation, which is a key step in the signaling cascade that ultimately leads to the increase in intracellular calcium concentration ([Ca2+]i). Therefore, OT protein and IP3 protein are interacting in this context.</s>
IEPA.d10 IEPA.d10.s22.e0 IEPA.d10.s22.e1	Amyloid	phospholipase C	[INST]Context: [PMID: 7700473 Amyloid beta protein disruption of cholinergic and growth factor phospholipase C signals could underlie cognitive and neurodegerative aspects of Alzheimer's disease. ] Question: Based on the provided context, do the terms [Amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein disrupts cholinergic and growth factor phospholipase C signals, which suggests an interaction between amyloid beta protein and phospholipase C. The disruption of these signals implies that amyloid beta protein influences the activity or function of phospholipase C, thereby indicating an interaction between the two.</s>
IEPA.d11 IEPA.d11.s23.e0 IEPA.d11.s23.e1	Amyloid	phospholipases	[INST]Context: [PMID: 7781763 Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. [3H]Myristic acid prelabeled LA-N-2 cells were exposed to varying concentrations of amyloid beta protein (25-35), from 20 to 250 micrograms/ml, and the activation of phospholipases A and D estimated. A progressive increase in phosphatidylethanol formation, a measure of phospholipase D activity, and of free fatty acid release, a measure of phospholipase A activity, was observed over a time-course of 60 min. [3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of A beta P, from 20 to 125 micrograms/ml, and phospholipase C activation was measured. There was an increased release of inositol phosphates in the presence of amyloid beta protein as a function of incubation time. The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the A beta P mediated stimulation of phospholipase C activity was investigated. Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the A beta P stimulation of phospholipase C activity in [3H]inositol prelabeled LA-N-2 cells. This suggests that amyloid beta protein activation of phospholipase C may be receptor mediated. The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P. However, this activation was not effected by tocopherol, propylgallate, or vitamin C.] Question: Based on the provided context, do the terms [Amyloid protein] and [phospholipases protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates the activities of phospholipases A, C, and D in LA-N-2 cells. This suggests a direct interaction between amyloid beta protein and phospholipases, as the protein activates these enzymes. The stimulation of phospholipase C activity is further supported by the effects of various antagonists, which indicates a receptor-mediated interaction. Therefore, the terms "Amyloid protein" and "phospholipases protein" are interacting in this context.</s>
IEPA.d11 IEPA.d11.s25.e0 IEPA.d11.s25.e1	A beta P	phospholipase C	[INST]Context: [PMID: 7781763 Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. [3H]Myristic acid prelabeled LA-N-2 cells were exposed to varying concentrations of amyloid beta protein (25-35), from 20 to 250 micrograms/ml, and the activation of phospholipases A and D estimated. A progressive increase in phosphatidylethanol formation, a measure of phospholipase D activity, and of free fatty acid release, a measure of phospholipase A activity, was observed over a time-course of 60 min. [3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of A beta P, from 20 to 125 micrograms/ml, and phospholipase C activation was measured. There was an increased release of inositol phosphates in the presence of amyloid beta protein as a function of incubation time. The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the A beta P mediated stimulation of phospholipase C activity was investigated. Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the A beta P stimulation of phospholipase C activity in [3H]inositol prelabeled LA-N-2 cells. This suggests that amyloid beta protein activation of phospholipase C may be receptor mediated. The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P. However, this activation was not effected by tocopherol, propylgallate, or vitamin C.] Question: Based on the provided context, do the terms [A beta P protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that amyloid beta protein (A beta P) stimulates phospholipase C (PLC) activity in LA-N-2 cells. This stimulation is receptor-mediated and can be blocked by antagonists of beta adrenergic, metabotropic amino acid, and bombesin receptors. The phospholipase C inhibitor U 71322 also prevents the activation of PLC by A beta P. These findings suggest that A beta P interacts with PLC through a receptor-mediated pathway, leading to the activation of PLC.</s>
IEPA.d11 IEPA.d11.s26.e0 IEPA.d11.s26.e1	A beta P	phospholipase C	[INST]Context: [PMID: 7781763 Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. [3H]Myristic acid prelabeled LA-N-2 cells were exposed to varying concentrations of amyloid beta protein (25-35), from 20 to 250 micrograms/ml, and the activation of phospholipases A and D estimated. A progressive increase in phosphatidylethanol formation, a measure of phospholipase D activity, and of free fatty acid release, a measure of phospholipase A activity, was observed over a time-course of 60 min. [3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of A beta P, from 20 to 125 micrograms/ml, and phospholipase C activation was measured. There was an increased release of inositol phosphates in the presence of amyloid beta protein as a function of incubation time. The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the A beta P mediated stimulation of phospholipase C activity was investigated. Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the A beta P stimulation of phospholipase C activity in [3H]inositol prelabeled LA-N-2 cells. This suggests that amyloid beta protein activation of phospholipase C may be receptor mediated. The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P. However, this activation was not effected by tocopherol, propylgallate, or vitamin C.] Question: Based on the provided context, do the terms [A beta P protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that amyloid beta protein (A beta P) stimulates phospholipase C (PLC) activity in LA-N-2 cells. This stimulation is receptor-mediated and can be blocked by antagonists of beta adrenergic, metabotropic amino acid, and bombesin receptors. The phospholipase C inhibitor U 71322 also prevents the activation of PLC by A beta P. These findings suggest that A beta P interacts with PLC through a receptor-mediated pathway, leading to the activation of PLC.</s>
IEPA.d11 IEPA.d11.s27.e0 IEPA.d11.s27.e1	amyloid	phospholipase C	[INST]Context: [PMID: 7781763 Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. [3H]Myristic acid prelabeled LA-N-2 cells were exposed to varying concentrations of amyloid beta protein (25-35), from 20 to 250 micrograms/ml, and the activation of phospholipases A and D estimated. A progressive increase in phosphatidylethanol formation, a measure of phospholipase D activity, and of free fatty acid release, a measure of phospholipase A activity, was observed over a time-course of 60 min. [3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of A beta P, from 20 to 125 micrograms/ml, and phospholipase C activation was measured. There was an increased release of inositol phosphates in the presence of amyloid beta protein as a function of incubation time. The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the A beta P mediated stimulation of phospholipase C activity was investigated. Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the A beta P stimulation of phospholipase C activity in [3H]inositol prelabeled LA-N-2 cells. This suggests that amyloid beta protein activation of phospholipase C may be receptor mediated. The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P. However, this activation was not effected by tocopherol, propylgallate, or vitamin C.] Question: Based on the provided context, do the terms [amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates the activity of phospholipase C in LA-N-2 cells. This stimulation is receptor-mediated and can be blocked by antagonists of beta adrenergic, metabotropic amino acid, and bombesin receptors. The phospholipase C inhibitor U 71322 also prevents the activation of phospholipase C by amyloid beta protein. Therefore, there is a clear interaction between amyloid beta protein and phospholipase C protein.</s>
IEPA.d11 IEPA.d11.s28.e1 IEPA.d11.s28.e2	phospholipase C	A beta P	[INST]Context: [PMID: 7781763 Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. [3H]Myristic acid prelabeled LA-N-2 cells were exposed to varying concentrations of amyloid beta protein (25-35), from 20 to 250 micrograms/ml, and the activation of phospholipases A and D estimated. A progressive increase in phosphatidylethanol formation, a measure of phospholipase D activity, and of free fatty acid release, a measure of phospholipase A activity, was observed over a time-course of 60 min. [3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of A beta P, from 20 to 125 micrograms/ml, and phospholipase C activation was measured. There was an increased release of inositol phosphates in the presence of amyloid beta protein as a function of incubation time. The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the A beta P mediated stimulation of phospholipase C activity was investigated. Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the A beta P stimulation of phospholipase C activity in [3H]inositol prelabeled LA-N-2 cells. This suggests that amyloid beta protein activation of phospholipase C may be receptor mediated. The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P. However, this activation was not effected by tocopherol, propylgallate, or vitamin C.] Question: Based on the provided context, do the terms [phospholipase C protein] and [A beta P protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that amyloid beta protein (A beta P) stimulates the activity of phospholipase C (PLC) in LA-N-2 cells. This stimulation is receptor-mediated and can be blocked by antagonists of beta adrenergic, metabotropic amino acid, and bombesin receptors. The fact that A beta P activates PLC suggests a direct interaction between the two proteins, where A beta P triggers a signaling cascade that leads to the activation of PLC.</s>
IEPA.d12 IEPA.d12.s29.e0 IEPA.d12.s29.e2	APP-S	phospholipase C	[INST]Context: [PMID: 7876266 Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. The Alzheimer amyloid precursor protein (APP) undergoes complex processing resulting in the production of a 4-kDa amyloid peptide (A beta) which has been implicated in the pathogenesis of Alzheimer's disease. Recent studies have shown that cells can secrete carboxyl terminus truncated APP derivatives (APP-S) in response to physiological stimulus. We have used human central nervous system neurons (NT2N) derived from a teratocarcinoma cell line (NT2) to study the signal transduction pathways involved in APP-S secretion and A beta production. Muscarinic receptors (m2 and m3) as well as the heterotrimeric GTP-binding protein Gq and the beta 1 isoform of phospholipase C were present in NT2N neurons. Stimulation of the muscarinic receptor with carbachol resulted in phospholipase C activation as shown by a transient increase in the second messengers 1,2-diacyl-sn-glycerol and inositol 1,4,5-trisphosphate. Carbachol also caused an increase in intracellular Ca2+ levels measured in single NT2N neurons. Under these conditions, carbachol caused a time-dependent 2-fold increase in APP-S secretion into the medium. In contrast, prolonged treatment with carbachol caused a decrease in A beta production into the medium. These results suggest that APP-S secretion and A beta production in NT2N neurons are regulated by the muscarinic/phospholipase C signal transduction pathway. Furthermore, activation of this pathway results in dissociation of APP-S secretion and A beta production.] Question: Based on the provided context, do the terms [APP-S protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the muscarinic receptor stimulation leads to the activation of phospholipase C, which in turn results in the secretion of APP-S. This suggests that the activation of phospholipase C is a necessary step in the pathway that leads to the secretion of APP-S. Therefore, there is an interaction between the APP-S protein and the phospholipase C protein in the sense that the activity of phospholipase C is required for the secretion of APP-S.</s>
IEPA.d15 IEPA.d15.s32.e0 IEPA.d15.s32.e1	amyloid	phospholipase C	[INST]Context: [PMID: 7986826 Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. Phosphatidylinositol 4-kinase (PI 4-kinase) and phosphatidylinositol 4-phosphate kinase (PIP kinase) were assayed in membranes prepared from samples of human frontal cortex initially frozen at autopsy. PI 4-kinase activity was significantly lower in Alzheimer's disease patients relative to age-matched controls or patients with Parkinson's disease. PIP kinase was not different in Alzheimer's versus age-matched controls. The beta amyloid protein fragment 1-40 inhibited PI 4-kinase activity in assays of control human or rat cortical membranes. Fragments 1-28 and 25-35 could not mimic the effects of fragment 1-40 while a reverse peptide 40-1 was equipotent. The inhibition of PI 4-kinase by fragment 1-40 was competitive with substrate. The beta amyloid protein fragments had diverse effects on phosphoinositide-specific phospholipase C (PI-PLC) as assayed in rat cortical membranes. Low concentrations of fragment 1-40 stimulated, while high concentrations of 1-40 or 40-1 inhibited PI-PLC activity. Fragment 25-35 stimulated PI-PLC nearly 3-fold, while fragment 1-28 had only minor effects on the enzyme. The results suggest alterations in phosphoinositide metabolism in Alzheimer's disease which could affect signal transduction and/or cytoskeletal organization.] Question: Based on the provided context, do the terms [amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the beta amyloid protein fragments, specifically fragment 1-40, have diverse effects on phosphoinositide-specific phospholipase C (PI-PLC) in rat cortical membranes. Low concentrations of fragment 1-40 stimulate PI-PLC activity, while high concentrations of 1-40 or 40-1 inhibit it. This suggests that the amyloid protein fragments interact with the phospholipase C protein, influencing its activity.</s>
IEPA.d17 IEPA.d17.s34.e0 IEPA.d17.s34.e2	oxytocin	inositol phosphate	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates in porcine myometrial cells. Specifically, the study shows that the addition of oxytocin along with hCG significantly increases the formation of inositol phosphates (IPs), particularly IP1 and IP3. This suggests that oxytocin and inositol phosphate proteins interact in the sense that oxytocin influences the production of inositol phosphates in the presence of hCG.</s>
IEPA.d17 IEPA.d17.s34.e1 IEPA.d17.s34.e2	oxytocin	inositol phosphate	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates in porcine myometrial cells. Specifically, the study shows that the addition of oxytocin along with hCG significantly increases the formation of inositol phosphates (IPs), particularly IP1 and IP3. This suggests that oxytocin and inositol phosphate proteins interact in the sense that oxytocin influences the production of inositol phosphates in the presence of hCG.</s>
IEPA.d17 IEPA.d17.s35.e0 IEPA.d17.s35.e1	inositol phosphates	oxytocin	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [inositol phosphates protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates in porcine myometrial cells. Specifically, the study shows that the addition of oxytocin and hCG together leads to a significant increase in the formation of inositol phosphates (IPs), particularly IP1 and IP3. This suggests that oxytocin and hCG interact to produce a combined effect on the accumulation of inositol phosphates in the cells.</s>
IEPA.d17 IEPA.d17.s36.e0 IEPA.d17.s36.e3	IP1	oxytocin	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [IP1 protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates (IPs) in porcine myometrial cells. Specifically, the study mentions that the highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05). This suggests that oxytocin and hCG interact to produce a combined effect on the formation of IPs, which is different from the effect of either agent alone. Therefore, the terms [IP1 protein] and [oxytocin protein] are interacting in this context.</s>
IEPA.d17 IEPA.d17.s36.e1 IEPA.d17.s36.e3	IP1	oxytocin	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [IP1 protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates (IPs) in porcine myometrial cells. Specifically, the study mentions that the highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05). This suggests that oxytocin and hCG interact to produce a combined effect on the formation of IPs, which is different from the effect of either agent alone. Therefore, the terms [IP1 protein] and [oxytocin protein] are interacting in this context.</s>
IEPA.d17 IEPA.d17.s36.e2 IEPA.d17.s36.e3	IP3	oxytocin	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [IP3 protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates (IPs) in porcine myometrial cells. Specifically, the addition of 1000 mU hCG plus oxytocin resulted in a significant increase in IP1 and IP3 formations. This suggests that oxytocin and hCG interact to produce a combined effect on the accumulation of inositol phosphates, which is different from the effect of either agent alone. Therefore, the terms [IP3 protein] and [oxytocin protein] are interacting in this context.</s>
IEPA.d17 IEPA.d17.s37.e0 IEPA.d17.s37.e1	oxytocin	IPs	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [IPs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of oxytocin and hCG on inositol phosphate (IP) formations in porcine myometrial cells. While it mentions that oxytocin and hCG can increase the accumulation of inositol phosphates, it does not indicate a direct interaction between oxytocin protein and IPs protein. Instead, it describes how these hormones influence the production of inositol phosphates, which are different entities. Therefore, there is no direct interaction between oxytocin protein and IPs protein mentioned in the context.</s>
IEPA.d17 IEPA.d17.s38.e0 IEPA.d17.s38.e1	oxytocin	inositol phosphate	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin and hCG can increase the accumulation of inositol phosphates in porcine myometrial cells. Specifically, the study shows that the addition of oxytocin along with hCG significantly increases the formation of inositol phosphates (IPs), particularly IP1 and IP3. This suggests that oxytocin and inositol phosphate proteins interact in the sense that oxytocin influences the production of inositol phosphates in the presence of hCG.</s>
IEPA.d17 IEPA.d17.s39.e0 IEPA.d17.s39.e1	oxytocin	inositol phosphates	[INST]Context: [PMID: 8527814 The effect of oxytocin on hCG action in phosphoinositide turnover in porcine myometrial smooth muscle cells. The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts. Myometrial cells were treated with radioactive myo-[3H]inositol for 48 hours, washed and pre-incubated with 10 mM LiCl, and then different doses of hCG (10, 100, 1000 mU) were added over 24 h. At the end of the last day of culture some wells were treated with 1 microM oxytocin for 30 min. The highest production of total inositol phosphates (d.p.m.) was found in cells from ovariectomized gilts given in vivo estradiol benzoate and progesterone for five consecutive days and treated with 1000 mU hCG and 100 mU hCG plus 1 microM oxytocin (984 +/- 84 and 1063 +/- 131 vs 314 +/- 36, respectively). There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively). Myometrial cells harvested from ovariectomized, untreated in vivo, gilts did not respond to both oxytocin and hCG in vitro. Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01). Myometrial cells obtained from cyclic pigs during the luteal and follicular phases of the estrous cycle responded to lower doses of hCG (10 mU), causing significant production of IPs (p < 0.05). The highest dose of hCG plus oxytocin provoked accumulation of total [3H]inositol phosphate (p < 0.05) 53% over the basal level on days 21/1 of the estrous cycle. The present study demonstrates that hCG and oxytocin can increase the accumulation of inositol phosphates in porcine myometrial cells. However, this formation is dependent on the steroid hormone status of animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphates protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of oxytocin and hCG on inositol phosphate (IP) formations in porcine myometrial cells. While it mentions that oxytocin and hCG can increase the accumulation of inositol phosphates, it does not indicate a direct interaction between oxytocin protein and inositol phosphates protein. Instead, it describes how these hormones influence the production of inositol phosphates, which are different entities. Therefore, there is no direct interaction mentioned between oxytocin protein and inositol phosphates protein.</s>
IEPA.d20 IEPA.d20.s42.e0 IEPA.d20.s42.e1	OT	IP3	[INST]Context: [PMID: 8713996 A proposed role for oxytocin in regulation of endometrial prostaglandin F2 alpha secretion during luteolysis in swine. Pulsatile secretion of endometrial prostaglandin (PG)F2 alpha is stimulated by oxytocin (OT) during late diestrus in domestic ruminants (i.e., cattle, sheep and goats) and results in corpus luteum (CL) regression leading to the onset of a new estrous cycle. Pulsatile PGF2 alpha release is also responsible for CL regression in swine, but the stimulus for its secretion from the uterine endometrium is not known. We propose that OT binds to specific OT receptors (OTR) on the endometrium to stimulate phosphoinositide (PI) hydrolysis, thereby activating the inositol trisphosphate (IP3)-diacylglycerol (DAG) second-messenger system to promote pulsatile PGF2 alpha secretion. Exogenous OT administered to cyclic gilts during late diestrus (days 10-16) decreased interestrous interval in three of four experiments. However, OT did not promote CL regression in hysterectomized gilts indicating that the effect of OT was uterine-dependent. Circulating concentrations of 13,14-dihydro-15-keto PGF2 alpha (the major stable metabolite of PGF2 alpha) were increased (p < 0.01) 10 min after i.v. injection of OT on days 14 and 16 in cyclic gilts and on days 10-16 in pregnant gilts, but the magnitude of the response to OT on all days in pregnant gilts was markedly reduced compared to the response in cyclic gilts on days 14 and 16. Mean density and Kd of OTR detected on endometrium of cyclic pigs 15 days post-estrus were 29.2 +/- 5.5 fmol/mg protein and 1.59 +/- 0.23 nM, respectively. Density of OTR was correlated with OT-stimulated PI hydrolysis (r = 0.83, p < 0.05) and PGF2 alpha secretion (r = 0.87, p < 0.10). Endometrial IP3 was increased within 30 seconds after OT treatment and preceded the increase in PGF2 alpha release stimulated by OT. Endometrial PI hydrolysis and PGF2 alpha secretion were similarly increased by AIF4-(phospholipase C activator), but not by cholera toxin (adenylyl cyclase activator). Although OT binding to OTR could be displaced by lysine-vasopressin and lysine-vasopressin stimulated PI hydrolysis, lysine-vasopressin did not stimulate PGF2 alpha release. Distinct receptors for OT and lysine-vasopressin on pig endometrium were confirmed by treatment with 100 nM OT + 100 nM lysine-vasopressin which stimulated PI hydrolysis more than 100-200 nM OT or lysine-vasopressin alone. These results support the hypothesis that OT stimulates phospholipase C to hydrolyze PI, yielding IP3 and DAG second-messengers which promote endometrial PGF2 alpha release during CL regression in pigs.] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) binds to specific oxytocin receptors (OTR) on the endometrium, which stimulates phosphoinositide (PI) hydrolysis. This hydrolysis process generates inositol trisphosphate (IP3) as a second messenger. The increase in IP3 levels precedes the increase in prostaglandin F2 alpha (PGF2 alpha) release stimulated by OT, suggesting that OT and IP3 interact in a signaling pathway that promotes PGF2 alpha secretion. Therefore, OT and IP3 are part of the same signaling pathway, indicating an interaction between them.</s>
IEPA.d20 IEPA.d20.s43.e0 IEPA.d20.s43.e1	IP3	OT	[INST]Context: [PMID: 8713996 A proposed role for oxytocin in regulation of endometrial prostaglandin F2 alpha secretion during luteolysis in swine. Pulsatile secretion of endometrial prostaglandin (PG)F2 alpha is stimulated by oxytocin (OT) during late diestrus in domestic ruminants (i.e., cattle, sheep and goats) and results in corpus luteum (CL) regression leading to the onset of a new estrous cycle. Pulsatile PGF2 alpha release is also responsible for CL regression in swine, but the stimulus for its secretion from the uterine endometrium is not known. We propose that OT binds to specific OT receptors (OTR) on the endometrium to stimulate phosphoinositide (PI) hydrolysis, thereby activating the inositol trisphosphate (IP3)-diacylglycerol (DAG) second-messenger system to promote pulsatile PGF2 alpha secretion. Exogenous OT administered to cyclic gilts during late diestrus (days 10-16) decreased interestrous interval in three of four experiments. However, OT did not promote CL regression in hysterectomized gilts indicating that the effect of OT was uterine-dependent. Circulating concentrations of 13,14-dihydro-15-keto PGF2 alpha (the major stable metabolite of PGF2 alpha) were increased (p < 0.01) 10 min after i.v. injection of OT on days 14 and 16 in cyclic gilts and on days 10-16 in pregnant gilts, but the magnitude of the response to OT on all days in pregnant gilts was markedly reduced compared to the response in cyclic gilts on days 14 and 16. Mean density and Kd of OTR detected on endometrium of cyclic pigs 15 days post-estrus were 29.2 +/- 5.5 fmol/mg protein and 1.59 +/- 0.23 nM, respectively. Density of OTR was correlated with OT-stimulated PI hydrolysis (r = 0.83, p < 0.05) and PGF2 alpha secretion (r = 0.87, p < 0.10). Endometrial IP3 was increased within 30 seconds after OT treatment and preceded the increase in PGF2 alpha release stimulated by OT. Endometrial PI hydrolysis and PGF2 alpha secretion were similarly increased by AIF4-(phospholipase C activator), but not by cholera toxin (adenylyl cyclase activator). Although OT binding to OTR could be displaced by lysine-vasopressin and lysine-vasopressin stimulated PI hydrolysis, lysine-vasopressin did not stimulate PGF2 alpha release. Distinct receptors for OT and lysine-vasopressin on pig endometrium were confirmed by treatment with 100 nM OT + 100 nM lysine-vasopressin which stimulated PI hydrolysis more than 100-200 nM OT or lysine-vasopressin alone. These results support the hypothesis that OT stimulates phospholipase C to hydrolyze PI, yielding IP3 and DAG second-messengers which promote endometrial PGF2 alpha release during CL regression in pigs.] Question: Based on the provided context, do the terms [IP3 protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) binds to specific oxytocin receptors (OTR) on the endometrium, which stimulates phosphoinositide (PI) hydrolysis. This hydrolysis results in the production of inositol trisphosphate (IP3) as a second messenger. The increase in IP3 precedes the increase in prostaglandin F2 alpha (PGF2 alpha) release stimulated by OT, suggesting that IP3 is involved in the signaling pathway triggered by OT. Therefore, OT and IP3 are interacting in this pathway.</s>
IEPA.d20 IEPA.d20.s44.e0 IEPA.d20.s44.e1	OT	IP3	[INST]Context: [PMID: 8713996 A proposed role for oxytocin in regulation of endometrial prostaglandin F2 alpha secretion during luteolysis in swine. Pulsatile secretion of endometrial prostaglandin (PG)F2 alpha is stimulated by oxytocin (OT) during late diestrus in domestic ruminants (i.e., cattle, sheep and goats) and results in corpus luteum (CL) regression leading to the onset of a new estrous cycle. Pulsatile PGF2 alpha release is also responsible for CL regression in swine, but the stimulus for its secretion from the uterine endometrium is not known. We propose that OT binds to specific OT receptors (OTR) on the endometrium to stimulate phosphoinositide (PI) hydrolysis, thereby activating the inositol trisphosphate (IP3)-diacylglycerol (DAG) second-messenger system to promote pulsatile PGF2 alpha secretion. Exogenous OT administered to cyclic gilts during late diestrus (days 10-16) decreased interestrous interval in three of four experiments. However, OT did not promote CL regression in hysterectomized gilts indicating that the effect of OT was uterine-dependent. Circulating concentrations of 13,14-dihydro-15-keto PGF2 alpha (the major stable metabolite of PGF2 alpha) were increased (p < 0.01) 10 min after i.v. injection of OT on days 14 and 16 in cyclic gilts and on days 10-16 in pregnant gilts, but the magnitude of the response to OT on all days in pregnant gilts was markedly reduced compared to the response in cyclic gilts on days 14 and 16. Mean density and Kd of OTR detected on endometrium of cyclic pigs 15 days post-estrus were 29.2 +/- 5.5 fmol/mg protein and 1.59 +/- 0.23 nM, respectively. Density of OTR was correlated with OT-stimulated PI hydrolysis (r = 0.83, p < 0.05) and PGF2 alpha secretion (r = 0.87, p < 0.10). Endometrial IP3 was increased within 30 seconds after OT treatment and preceded the increase in PGF2 alpha release stimulated by OT. Endometrial PI hydrolysis and PGF2 alpha secretion were similarly increased by AIF4-(phospholipase C activator), but not by cholera toxin (adenylyl cyclase activator). Although OT binding to OTR could be displaced by lysine-vasopressin and lysine-vasopressin stimulated PI hydrolysis, lysine-vasopressin did not stimulate PGF2 alpha release. Distinct receptors for OT and lysine-vasopressin on pig endometrium were confirmed by treatment with 100 nM OT + 100 nM lysine-vasopressin which stimulated PI hydrolysis more than 100-200 nM OT or lysine-vasopressin alone. These results support the hypothesis that OT stimulates phospholipase C to hydrolyze PI, yielding IP3 and DAG second-messengers which promote endometrial PGF2 alpha release during CL regression in pigs.] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) binds to specific oxytocin receptors (OTR) on the endometrium, which stimulates phosphoinositide (PI) hydrolysis. This hydrolysis process generates inositol trisphosphate (IP3) as a second messenger. The increase in IP3 levels precedes the increase in prostaglandin F2 alpha (PGF2 alpha) release stimulated by OT, suggesting that OT and IP3 interact in a signaling pathway that promotes PGF2 alpha secretion. Therefore, OT and IP3 are part of the same signaling pathway, indicating an interaction between them.</s>
IEPA.d21 IEPA.d21.s45.e0 IEPA.d21.s45.e1	IP3	oxytocin	[INST]Context: [PMID: 8713999 Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium. Oxytocin increases myometrial intracellular free calcium by promotion of calcium entry and release of calcium from intracellular stores. Calcium release from intracellular stores is secondary to an increase in phosphoinositide (PI) turnover and generation of IP3. We have explored the biochemical basis for the coupling of oxytocin (OT) to phospholipase C (PLC). Rat myometrial membranes contain PLC beta, gamma, and delta isoforms as well as the GTP-binding proteins G alpha(q) and G alpha(11). Oxytocin stimulates both GTPase and PLC activity in rat and human myometrial membranes. These data and available structural information suggest that the oxytocin receptor couples to PLC through a GTP-binding protein. In support of this hypothesis, an antibody generated against the specific C-terminal region of G alpha(q) and G alpha(11) inhibits both the oxytocin-stimulated GTPase and PLC activities. This inhibition is reversed by neutralization of the antibody with the antigenic peptide. The data indicate that the oxytocin receptor couples to PLC, presumably of the beta subclass, via interaction with proteins of the G alpha(q/11) subclass. In the nonpregnant, estrogen-primed rat, the stimulation of PI turnover by oxytocin is inhibited by the hormone relaxin and by pertussis toxin. The effects of both of these agents are mediated by the action of cAMP-dependent protein kinase. In plasma membranes, GTP-stimulated PLC activity can also be inhibited by treatment with protein kinase A. These data suggest that cAMP-dependent phosphorylation at a step involving GTP-binding protein/PLC coupling can exert a negative effect on the stimulation of IP3 formation by oxytocin and thereby affect contraction/relaxation in the myometrium.] Question: Based on the provided context, do the terms [IP3 protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin stimulates phosphoinositide (PI) turnover, which leads to the generation of IP3 (inositol 1,4,5-trisphosphate). IP3 is a key second messenger that mediates the release of calcium from intracellular stores, thereby contributing to the contraction/relaxation of the myometrium. This suggests that oxytocin and IP3 are part of the same signaling pathway, where oxytocin triggers the production of IP3, indicating an interaction between the oxytocin protein and the IP3 protein.</s>
IEPA.d22 IEPA.d22.s46.e3 IEPA.d22.s46.e4	prion protein	kinase	[INST]Context: [PMID: 8735881 The UK epidemic of BSE: slow virus or chronic pesticide-initiated modification of the prion protein? Part 1: Mechanisms for a chemically induced pathogenesis/transmissibility. It is proposed that exposure of the bovine embryo to specific high-dose lipophilic formulations of organophosphate insecticide (containing phthalimide) applied exclusively in the UK during the 1980s/early 1990s was the primary trigger that initiated the UK's bovine spongioform encephalopathy epidemic. Multi-site binding organophosphate toxic metabolites penetrate the fetus, covalently binding with, phosphorylating and ageing serine, tyrosine or histidine active sites on fetal central nervous system prion protein. An abnormal negative charge corrupts prion protein molecular surface, which blocks both proteases and chaperones from accessing their cleavage/bonding sites. This impairs normal degradation and folding of prion protein respectively. Once the abnormally phosphorylated abnormal prion protein isoform agent is initiated, any stress event ensuing in adult life induces a nerve growth factor-mediated synthesis of normal cellular prion protein isoform that aggregates to abnormally phosphorylated abnormal prion protein isoform, thereby becoming 'infected'/transformed into the same; due to the vicious circle of positive feedback invoked by the blocking of a prion protein-specific kinase. Prion protein could therefore serve as a hitherto unrecognized critical link in a chain of delayed neuroexcitotoxic proteins that are triggered off by chronic exposure to specific classes of chemical/metal that 'hit and run' during the vulnerable in utero period, producing spongioform encephalopathy disease years later.] Question: Based on the provided context, do the terms [prion protein protein] and [kinase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that prion protein and kinase protein interact in the mechanism of the UK epidemic of bovine spongiform encephalopathy. Specifically, it mentions that the abnormally phosphorylated abnormal prion protein isoform agent is initiated by the phosphorylation of prion protein by a prion protein-specific kinase. This phosphorylation event is crucial in the process of prion protein misfolding and aggregation, which leads to the development of the disease. Therefore, the terms [prion protein protein] and [kinase protein] are interacting in the context of the proposed mechanism.</s>
IEPA.d23 IEPA.d23.s47.e2 IEPA.d23.s47.e3	prion protein	protein kinase	[INST]Context: [PMID: 8735882 The UK epidemic of BSE: slow virus or chronic pesticide-initiated modification of the prion protein? Part 2: An epidemiological perspective. This paper elucidates the flaws in the official hypothesis that bovine spongioform encephalopathy originated from alterations in the way that scrapie-contaminated cattlefeeds were manufactured in the UK. An alternative hypothesis is proposed that cites exposure of the bovine embryo to various specific high-dose lipophilic formulations of organophosphates, such as the high-dose phthalimide containing organophosphate phosmet, (which were applied compulsorily and exclusively in the UK during the 1980s/early 1990s) as the primary trigger that initiated the deformation of prion protein and the onset of the bovine spongioform encephalopathy epidemic. The multi-site binding metabolites of these organophosphates penetrate the fetus, covalently phosphorylating various active sites on fetal prion protein. The extra charged phosphate groups left on aged prion protein blocks both proteases and chaperones from accessing their catalytic/bonding sites, creating the undergradable, misfolded isoform of prion protein, PrPsc. The resulting abnormally phosphorylated PrPsc aggregates to freshly synthesized PrPc, transforming it into same; due to a system of positive feedback invoked by the organophosphate-induced blockage of a prion protein-specific protein kinase. Both the timing, distribution and dynamics of usage of these specific organophosphates correlates with the epidemiology of bovine spongioform encephalopathy as well as accounting for the 23,000 cattle that have developed the disease, yet were born after the 1988 ban on scrapie-contaminated cattlefeed.] Question: Based on the provided context, do the terms [prion protein protein] and [protein kinase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the organophosphate-induced blockage of a prion protein-specific protein kinase is part of a system of positive feedback. This implies that the prion protein and the protein kinase interact in a regulatory mechanism where the phosphorylation of prion protein by the protein kinase is involved in the transformation of prion protein into its misfolded isoform (PrPsc). Therefore, the terms "prion protein" and "protein kinase protein" are interacting in this context.</s>
IEPA.d24 IEPA.d24.s48.e0 IEPA.d24.s48.e1	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d24 IEPA.d24.s49.e0 IEPA.d24.s49.e1	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d24 IEPA.d24.s50.e0 IEPA.d24.s50.e1	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d24 IEPA.d24.s51.e2 IEPA.d24.s51.e3	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d24 IEPA.d24.s52.e0 IEPA.d24.s52.e1	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d24 IEPA.d24.s53.e0 IEPA.d24.s53.e1	oxytocin	insulin	[INST]Context: [PMID: 8739893 Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. The aim of the present study was to investigate how oxytocin given subcutaneously (SC) and intracerebroventricularly (ICV) influences the secretion of insulin, glucagon and glucose and to investigate whether the effect on these variables of suckling in lactating rats is mediated by oxytocinergic mechanisms. Male rats were given oxytocin in doses of 2 or 20 ng (SC) or 2 or 200 ng (ICV). Trunk blood was collected and hormone analysis performed by radioimmunoassay. Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly. Two nanograms oxytocin given ICV had no effect on glucagon and glucose levels but caused a significant rise in insulin levels at this time point. This effect was abolished by atropine. The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate. Intracerebroventricular injections of 200 ng oxytocin caused a significant rise not only of insulin but also of glucagon and glucose levels. Since this dose of oxytocin also caused a substantial rise of circulating oxytocin levels, these effects on glucose and glucagon may have been exerted at a peripheral site. Suckling in lactating rats was followed by a significant increase of glucose and glucagon levels. These effects were completely abolished by pretreatment with an oxytocin antagonist. In conclusion, oxytocin seems to influence pancreatic hormone secretion by two different mechanisms. Elevated circulating levels of oxytocin-e.g. as seen in response to suckling in lactating rats-are accompanied by a rise of glucagon and glucose levels which is blocked by the oxytocin antagonist. In contrast, nanogram amounts of oxytocin administered ICV cause a rise of insulin levels. Since this effect was blocked by atropine, it is likely to involve activation of vagal cholinergic neurons, innervating pancreatic beta-cells.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin influences the secretion of insulin. Specifically, it mentions that subcutaneous injections of oxytocin increased insulin levels significantly, and that nanogram amounts of oxytocin administered intracerebroventricularly (ICV) caused a significant rise in insulin levels. This suggests that oxytocin and insulin interact in a way that affects the secretion of insulin, indicating an interaction between the oxytocin protein and the insulin protein.</s>
IEPA.d25 IEPA.d25.s55.e0 IEPA.d25.s55.e1	OT	insulin	[INST]Context: [PMID: 8771561 Different effects of the serotonergic agonists buspirone and sumatriptan on the posterior pituitary hormonal responses to hypoglycemia in humans. The responses of serum oxytocin (OT) and vasopressin (AVP) to the serotonergic HT1A agonist buspirone (15 mg p.o.) or the HTD1 agonist sumatriptan (6 mg injected subcutaneously) were evaluated in 7 normal men either in basal conditions or during an insulin (0.15 iu/kg as an i.v. bolus) tolerance test (ITT). Neither buspirone nor sumatriptan administration modified the basal secretion of AVP and OT. Stimulation of 5HT-1D receptors with sumatriptan was unable to change neither AVP nor OT response to insulin-induced hypoglycemia. On the other hand, the pretreatment with the 5HT1A agonist buspirone significantly enhanced the OT response during hypoglycemia, without modifying the AVP rise. The results of this study suggest that serotonergic 5HT1A receptors may interact with hypoglycemia in the stimulation of OT, but not AVP secretion.] Question: Based on the provided context, do the terms [OT protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of serotonergic agonists buspirone and sumatriptan on the hormonal responses to hypoglycemia in humans, specifically focusing on oxytocin (OT) and vasopressin (AVP). While it mentions that buspirone enhances the OT response during hypoglycemia, it does not indicate any direct interaction between OT protein and insulin protein. Instead, it describes how different serotonergic agonists influence the hormonal responses to insulin-induced hypoglycemia. Therefore, there is no direct interaction mentioned between OT protein and insulin protein.</s>
IEPA.d27 IEPA.d27.s57.e0 IEPA.d27.s57.e1	insulin	oxytocin	[INST]Context: [PMID: 8795088 The oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5-HT1A receptor agonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin. The aim of the present study was to investigate whether the 5-HT1A receptor agonist 8-OH-DPAT, which previously has been shown to release oxytocin, also influences plasma levels of gastrointestinal and pancreatic hormones, and if so, whether such an effect is mediated by an oxytocinergic mechanism. For this purpose 8-OH-DPAT (0.5 mg/kg s.c.) was injected to male rats pretreated with the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin (1 mg/kg s.c.), or vehicle. Thirty min after injection of 8-OH-DPAT, plasma levels of oxytocin were significantly increased. 8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist. Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin. In previous experiments, we have shown that following i.c.v. application of oxytocin, plasma levels of insulin are increased through a cholinergic mechanism. In this study, 2 ng of oxytocin decreased plasma levels of CCK, gastrin and somatostatin, effects that were blocked by pretreatment with atropine. Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the 5-HT1A receptor agonist 8-OH-DPAT increases plasma levels of insulin through an oxytocinergic mechanism. This suggests that oxytocin and insulin interact in a way that influences plasma levels of insulin. Specifically, the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin blocks the effect of 8-OH-DPAT on insulin levels, further supporting the interaction between oxytocin and insulin.</s>
IEPA.d27 IEPA.d27.s58.e0 IEPA.d27.s58.e1	insulin	oxytocin	[INST]Context: [PMID: 8795088 The oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5-HT1A receptor agonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin. The aim of the present study was to investigate whether the 5-HT1A receptor agonist 8-OH-DPAT, which previously has been shown to release oxytocin, also influences plasma levels of gastrointestinal and pancreatic hormones, and if so, whether such an effect is mediated by an oxytocinergic mechanism. For this purpose 8-OH-DPAT (0.5 mg/kg s.c.) was injected to male rats pretreated with the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin (1 mg/kg s.c.), or vehicle. Thirty min after injection of 8-OH-DPAT, plasma levels of oxytocin were significantly increased. 8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist. Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin. In previous experiments, we have shown that following i.c.v. application of oxytocin, plasma levels of insulin are increased through a cholinergic mechanism. In this study, 2 ng of oxytocin decreased plasma levels of CCK, gastrin and somatostatin, effects that were blocked by pretreatment with atropine. Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the 5-HT1A receptor agonist 8-OH-DPAT increases plasma levels of insulin through an oxytocinergic mechanism. This suggests that oxytocin and insulin interact in a way that influences plasma levels of insulin. Specifically, the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin blocks the effect of 8-OH-DPAT on insulin levels, further supporting the interaction between oxytocin and insulin.</s>
IEPA.d27 IEPA.d27.s59.e0 IEPA.d27.s59.e1	oxytocin	insulin	[INST]Context: [PMID: 8795088 The oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5-HT1A receptor agonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin. The aim of the present study was to investigate whether the 5-HT1A receptor agonist 8-OH-DPAT, which previously has been shown to release oxytocin, also influences plasma levels of gastrointestinal and pancreatic hormones, and if so, whether such an effect is mediated by an oxytocinergic mechanism. For this purpose 8-OH-DPAT (0.5 mg/kg s.c.) was injected to male rats pretreated with the oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin (1 mg/kg s.c.), or vehicle. Thirty min after injection of 8-OH-DPAT, plasma levels of oxytocin were significantly increased. 8-OH-DPAT also increased insulin and decreased CCK and somatostatin levels, effects that were blocked by pretreatment with the oxytocin antagonist. Taken together, these data suggest that the effect of 8-OH-DPAT on plasma levels of insulin, somatostatin and CCK may be mediated by oxytocin. In previous experiments, we have shown that following i.c.v. application of oxytocin, plasma levels of insulin are increased through a cholinergic mechanism. In this study, 2 ng of oxytocin decreased plasma levels of CCK, gastrin and somatostatin, effects that were blocked by pretreatment with atropine. Since oxytocinergic fibers which originate in the PVN project to the DMX, we suggest that the effect on the release of insulin, CCK and somatostatin induced by the 5 HT1A receptor agonist 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the 5-HT1A receptor agonist 8-OH-DPAT increases plasma levels of insulin through an oxytocinergic mechanism. Specifically, it mentions that oxytocinergic fibers originating in the PVN project to the DMX, and that the effect on the release of insulin induced by 8-OH-DPAT may be mediated by an oxytocinergic activation of a vagal mechanism. This suggests that oxytocin and insulin interact in a pathway where oxytocin influences the release of insulin.</s>
IEPA.d28 IEPA.d28.s60.e0 IEPA.d28.s60.e1	oxytocin	inositol 1,4,5-trisphosphate	[INST]Context: [PMID: 8851493 Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line. 1. In a human vascular smooth muscle cell line (HVSMC), binding experiments with [3H]-arginine8-vasopressin (AVP) have shown the existence of a homogeneous population of binding sites with affinity (Kd value) of 0.65 nM and a maximum number of binding sites (Bmax) of 122 fmol mg-1 protein. 2. Nonlabelled compounds compete for [3H]-AVP binding in the HVSMC membrane with an order of potency of oxytocin > lyspressin > or = AVP > Thr4, Gly7-oxytocin > (beta-mercapto-beta-beta-cyclopentamethylenepropionyl-O-Me Tyr2, Arg8) vasopressin > desmopressin > OPC21268 > OPC31260. This order was markedly different from that observed in rat vascular smooth muscle cells (A10), a well-established V1A receptor system. 3. In HVSMC both oxytocin and AVP increased inositol 1,4,5-trisphosphate (IP3) production and [Ca2+]i response, but the efficacy of the responses was greater for oxytocin than AVP. 4. Reverse transcription-polymerase chain reaction (RT-PCR) assay detected only oxytocin receptor but not V1A or V2 receptors in HVSMC, whereas only V1A receptors were found in A10 cells. 5. In conclusion, in HVSMC only oxytocin receptors are expressed among the vasopressin receptor family, and they coupled to phosphatidyl inositol (PI) turnover/Ca2+ signalling. This unexpected observation should provide new insight into the functional role of the oxytocin receptor in a human vascular smooth muscle cell line.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol 1,4,5-trisphosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin increases inositol 1,4,5-trisphosphate (IP3) production and [Ca2+]i response in HVSMC. This suggests that oxytocin interacts with the cellular signaling pathway involving IP3, leading to a downstream effect on calcium signaling. Therefore, oxytocin protein and inositol 1,4,5-trisphosphate protein are part of the same signaling pathway, indicating an interaction.</s>
IEPA.d31 IEPA.d31.s63.e0 IEPA.d31.s63.e1	OT	inositol (1,4,5)-trisphosphate	[INST]Context: [PMID: 8886594 The role of phosphoinositide-derived second messengers in oxytocin-stimulated prostaglandin F2 alpha release from endometrium of pigs. The mechanism for prostaglandin (PG) F2 alpha release from pig endometrium after oxytocin (OT) treatment is unknown. OT may rapidly stimulate inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) formation, consistent with the concept of rapid activation of a second-messenger system. In support of this hypothesis, endometrial IP3 levels were increased (P < 0.05) within 0.5 min after treatment with 0.1 microM OT. In contrast, increased DAG formation was not detected after treatment with OT. However, similar to the stimulation of endometrial PGF2 alpha secretion observed after OT treatment (P < 0.001), PGF2 alpha release was increased (P < 0.01) after treatment with phorbol-12-myristate-13-acetate (PMA), which mimics DAG activation of protein kinase C. Further, stimulation of endometrial PGF2 alpha secretion did not result from cell death induced by PMA or OT because lactate dehydrogenase, a cytosolic marker of cellular integrity, did not leak into the medium after PMA or OT treatment. In contrast, 0.5% saponin (positive control for cell death and concomitant release of lactate dehydrogenase) increased PGF2 alpha secretion (P < 0.05) and lactate dehydrogenase release (P < 0.001). These results indicate that OT induces endometrial IP3 production in a rapid manner indicative of a second-messenger system. The finding that increased DAG was not also detected after OT treatment may reflect rapid metabolism or compartmentalized production of DAG involved in the second-messenger stimulation of phospholipase C. The high background of DAG used in the biosynthesis of cellular lipids would obscure the rather small spatially localized changes in DAG levels resulting from the activation of phospholipase C. The finding that DAG was present at approximately 10 to 20-fold higher levels than IP3 in resting cells was consistent with this conclusion.] Question: Based on the provided context, do the terms [OT protein] and [inositol (1,4,5)-trisphosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) rapidly stimulates the formation of inositol (1,4,5)-trisphosphate (IP3) in the endometrium of pigs. This suggests that OT protein interacts with the signaling pathway that leads to the production of IP3 protein, thereby activating a second-messenger system. The increased IP3 levels observed after OT treatment are indicative of this interaction.</s>
IEPA.d31 IEPA.d31.s64.e0 IEPA.d31.s64.e1	IP3	OT	[INST]Context: [PMID: 8886594 The role of phosphoinositide-derived second messengers in oxytocin-stimulated prostaglandin F2 alpha release from endometrium of pigs. The mechanism for prostaglandin (PG) F2 alpha release from pig endometrium after oxytocin (OT) treatment is unknown. OT may rapidly stimulate inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) formation, consistent with the concept of rapid activation of a second-messenger system. In support of this hypothesis, endometrial IP3 levels were increased (P < 0.05) within 0.5 min after treatment with 0.1 microM OT. In contrast, increased DAG formation was not detected after treatment with OT. However, similar to the stimulation of endometrial PGF2 alpha secretion observed after OT treatment (P < 0.001), PGF2 alpha release was increased (P < 0.01) after treatment with phorbol-12-myristate-13-acetate (PMA), which mimics DAG activation of protein kinase C. Further, stimulation of endometrial PGF2 alpha secretion did not result from cell death induced by PMA or OT because lactate dehydrogenase, a cytosolic marker of cellular integrity, did not leak into the medium after PMA or OT treatment. In contrast, 0.5% saponin (positive control for cell death and concomitant release of lactate dehydrogenase) increased PGF2 alpha secretion (P < 0.05) and lactate dehydrogenase release (P < 0.001). These results indicate that OT induces endometrial IP3 production in a rapid manner indicative of a second-messenger system. The finding that increased DAG was not also detected after OT treatment may reflect rapid metabolism or compartmentalized production of DAG involved in the second-messenger stimulation of phospholipase C. The high background of DAG used in the biosynthesis of cellular lipids would obscure the rather small spatially localized changes in DAG levels resulting from the activation of phospholipase C. The finding that DAG was present at approximately 10 to 20-fold higher levels than IP3 in resting cells was consistent with this conclusion.] Question: Based on the provided context, do the terms [IP3 protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the rapid formation of inositol (1,4,5)-trisphosphate (IP3) in the endometrium of pigs. This suggests that OT protein interacts with the cellular machinery to induce the production of IP3 protein, which is a key second messenger in the signaling pathway. The increased levels of IP3 after OT treatment are indicative of an interaction between OT and the IP3 production pathway.</s>
IEPA.d31 IEPA.d31.s65.e0 IEPA.d31.s65.e1	OT	IP3	[INST]Context: [PMID: 8886594 The role of phosphoinositide-derived second messengers in oxytocin-stimulated prostaglandin F2 alpha release from endometrium of pigs. The mechanism for prostaglandin (PG) F2 alpha release from pig endometrium after oxytocin (OT) treatment is unknown. OT may rapidly stimulate inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) formation, consistent with the concept of rapid activation of a second-messenger system. In support of this hypothesis, endometrial IP3 levels were increased (P < 0.05) within 0.5 min after treatment with 0.1 microM OT. In contrast, increased DAG formation was not detected after treatment with OT. However, similar to the stimulation of endometrial PGF2 alpha secretion observed after OT treatment (P < 0.001), PGF2 alpha release was increased (P < 0.01) after treatment with phorbol-12-myristate-13-acetate (PMA), which mimics DAG activation of protein kinase C. Further, stimulation of endometrial PGF2 alpha secretion did not result from cell death induced by PMA or OT because lactate dehydrogenase, a cytosolic marker of cellular integrity, did not leak into the medium after PMA or OT treatment. In contrast, 0.5% saponin (positive control for cell death and concomitant release of lactate dehydrogenase) increased PGF2 alpha secretion (P < 0.05) and lactate dehydrogenase release (P < 0.001). These results indicate that OT induces endometrial IP3 production in a rapid manner indicative of a second-messenger system. The finding that increased DAG was not also detected after OT treatment may reflect rapid metabolism or compartmentalized production of DAG involved in the second-messenger stimulation of phospholipase C. The high background of DAG used in the biosynthesis of cellular lipids would obscure the rather small spatially localized changes in DAG levels resulting from the activation of phospholipase C. The finding that DAG was present at approximately 10 to 20-fold higher levels than IP3 in resting cells was consistent with this conclusion.] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the rapid formation of inositol (1,4,5)-trisphosphate (IP3) in the endometrium of pigs. This suggests that OT protein interacts with the cellular machinery to induce the production of IP3 protein, which is a key second messenger in the signaling pathway. The increased IP3 levels observed after OT treatment are indicative of this interaction.</s>
IEPA.d33 IEPA.d33.s71.e0 IEPA.d33.s71.e1	oxytocin	inositol phosphates	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphates protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the formation of inositol phosphates (IPs) in the myometrium of pregnant rabbits. Specifically, it mentions that OT receptors become detectable on Day 28 of pregnancy, and OT can induce the formation of IPs. This suggests a direct interaction between oxytocin protein and inositol phosphates protein, where the binding of oxytocin to its receptor triggers a signaling cascade that results in the production of inositol phosphates.</s>
IEPA.d33 IEPA.d33.s72.e1 IEPA.d33.s72.e2	IP3	OT	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [IP3 protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates the formation of inositol trisphosphate (IP3) in the myometrium of pregnant rabbits. This suggests that OT and IP3 are part of a signaling pathway where OT triggers the production of IP3, indicating an interaction between the two proteins.</s>
IEPA.d33 IEPA.d33.s74.e0 IEPA.d33.s74.e1	OT	inositol phosphates	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [OT protein] and [inositol phosphates protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the formation of inositol phosphates (IPs) in the myometrium of pregnant rabbits. This suggests that OT protein interacts with the signaling pathways that lead to the production of inositol phosphates protein. Specifically, the stimulatory effect of OT on IP3 formation and the OT receptor levels in the myometrium demonstrate a direct interaction between OT and the signaling mechanisms involving inositol phosphates.</s>
IEPA.d33 IEPA.d33.s75.e0 IEPA.d33.s75.e1	OT	IPs	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [OT protein] and [IPs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the formation of inositol phosphates (IPs) in the myometrium of pregnant rabbits. Specifically, it mentions that OT receptors become detectable on Day 28 of pregnancy, and OT can induce the formation of IPs. This suggests a direct interaction between OT and IPs, where OT triggers the production of IPs through its receptors.</s>
IEPA.d33 IEPA.d33.s76.e0 IEPA.d33.s76.e1	OT	IPs	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [OT protein] and [IPs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) stimulates the formation of inositol phosphates (IPs) in the myometrium of pregnant rabbits. Specifically, it mentions that OT receptors become detectable on Day 28 of pregnancy, and OT can induce the formation of IPs. This suggests a direct interaction between OT and IPs, where OT triggers the production of IPs through its receptors.</s>
IEPA.d33 IEPA.d33.s77.e0 IEPA.d33.s77.e1	OT	IP3	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates the formation of inositol trisphosphate (IP3) in the myometrium of pregnant rabbits. This suggests that OT protein interacts with IP3 protein in the process of signal transduction, where OT binding to its receptor triggers a cascade that leads to the production of IP3. This interaction is crucial for the physiological processes involved in parturition.</s>
IEPA.d33 IEPA.d33.s78.e0 IEPA.d33.s78.e1	OT	IP3	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [OT protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates the formation of inositol trisphosphate (IP3) in the myometrium of pregnant rabbits. This suggests that OT protein interacts with IP3 protein in the process of signal transduction, where OT binding to its receptor triggers a cascade that leads to the production of IP3. This interaction is crucial for the physiological processes involved in parturition.</s>
IEPA.d33 IEPA.d33.s79.e0 IEPA.d33.s79.e1	IPs	OT	[INST]Context: [PMID: 8987334 Correlation between the stimulatory effect of oxytocin on the formation of inositol phosphates and the oxytocin receptor level in the pregnant rabbit myometrium. OBJECTIVE: In order to elucidate the roles of inositol trisphosphate (IP3) and oxytocin (OT) receptors in rabbit parturition, the concentration of IP3 induced by OT and the OT receptor levels were determined in rabbit myometria before and after parturition. METHODS: The effects of OT on IP3 formation and OT receptor levels were determined in the myometria of non-pregnant rabbits, Days 26, 28 and 30 of pregnancy rabbits, postpartum rabbits within 12 hours and steroid-treated ovariectomized rabbits. Prostaglandins (PGs) levels were also measured in the myometrial and decidual tissues. RESULTS: OT receptors were not detectable in the myometria of non-pregnant rabbits, and OT had no effect on the formation of inositol phosphates (IPs). On Day 28 of pregnancy, OT receptors became detectable, and then OT could induce the formation of IPs. Thereafter, the stimulatory effects of OT on IPs formation and the OT receptor levels dramatically increased toward the end of pregnancy and reduced rapidly after parturition. When the ovariectomized pregnant rabbits were treated with estrogen, OT receptors in the myometrium were induced, and OT acquired the ability to stimulate IP3 formation. However, OT had no effect on the production of cAMP, cGMP, prostaglandin (PG) E2 and F2 alpha in the myometria, even if receptors existed, although PGE2 production in the decidual tissues was markedly stimulated. In addition, an OT receptor antagonist inhibited the stimulatory effects of OT on IP3 formation. CONCLUSIONS: These results suggest that the formation of IPs by OT, the OT receptor levels in the myometrium, and the production of PGF2 in the decidua might play crucial roles in parturition.] Question: Based on the provided context, do the terms [IPs protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates the formation of inositol phosphates (IPs) in the myometrium of pregnant rabbits. Specifically, it mentions that OT receptors become detectable on Day 28 of pregnancy, and OT can induce the formation of IPs. This suggests a direct interaction between OT and IPs, where OT triggers the formation of IPs through its receptors. Therefore, the terms [IPs protein] and [OT protein] interact with each other.</s>
IEPA.d38 IEPA.d38.s92.e1 IEPA.d38.s92.e2	phospholipase C	insulin	[INST]Context: [PMID: 9057099 Different mechanisms are involved in intracellular calcium increase by insulin-like growth factors 1 and 2 in articular chondrocytes: voltage-gated calcium channels, and/or phospholipase C coupled to a pertussis-sensitive G-protein. This study describes the mechanisms involved in the IGF-1 and IGF-2-induced increases in intracellular calcium concentration [Ca2+]i in cultured chondrocytes and the involvement of type 1 IGF receptors. It shows that IGF-1, IGF-2, and insulin increased the cytosolic free calcium concentration [Ca2+]i in a dose-dependent manner, with a plateau from 25 to 100 ng/ml for both IGF-1 and IGF-2 and from 1 to 2 micrograms/ml for insulin. The effect of IGF-1 was twice as great as the one of IGF-2, and the effect of insulin was 40% lower than IGF-1 effect. Two different mechanisms are involved in the intracellular [Ca2+]i increase. 1) IGF-1 and insulin but not IGF-2 involved a Ca2+ influx through voltage-gated calcium channels: pretreatment of the cells by EGTA and verapamil diminished the IGF-1 or insulin-induced [Ca2+]i but did not block the effect of IGF-2. 2) IGF-1, IGF-2, and insulin also induced a Ca2+ mobilization from the endoplasmic reticulum: phospholipase C (PLC) inhibitors, neomycin, or U-73122 partially blocked the intracellular [Ca2+]i increase induced by IGF-1 and insulin and totally inhibited the effect of IGF-2. This Ca2+ mobilization was pertussis toxin (PTX) dependent, suggesting an activation of a PLC coupled to a PTX-sensitive G-protein. Lastly, preincubation of the cells with IGF1 receptor antibodies diminished the IGF-1-induced Ca2+ spike and totally abolished the Ca2+ influx, but did not modify the effect of IGF-2. These results suggest that IGF-1 action on Ca2+ influx involves the IGF1 receptor, while part of IGF-1 and all of IGF-2 Ca2+ mobilization do not implicate this receptor.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that both insulin and phospholipase C (PLC) are involved in the mechanisms that increase intracellular calcium concentration ([Ca2+]i) in articular chondrocytes. Specifically, it mentions that IGF-1 and insulin induce a Ca2+ influx through voltage-gated calcium channels and a Ca2+ mobilization from the endoplasmic reticulum via phospholipase C (PLC). This suggests that insulin interacts with PLC to produce a combined effect on the intracellular calcium levels.</s>
IEPA.d41 IEPA.d41.s100.e0 IEPA.d41.s100.e1	insulin	phospholipase C	[INST]Context: [PMID: 9142890 Regulation of insulin secretion via ATP-sensitive K+ channel independent mechanisms: role of phospholipase C. Groups of rat or mouse islets were isolated and perifused with 20 mM glucose plus 200 microM diazoxide. The further addition of 30 mM K+ resulted in a rapid and sustained biphasic insulin secretory response. The onset of secretion in response to the addition of K+ was comparable in both species, but the magnitude of the response was significantly greater from rat islets. After the labeling of islet phosphoinositide pools with 2-[3H]inositol, the accumulation of labeled inositol phosphates (IP) in response to 30 mM K+ addition in the simultaneous presence of 20 mM glucose plus diazoxide was assessed. The addition of 30 mM K+ significantly increased IP accumulation approximately 300% in rat islets, whereas only an insignificant 25-30% increase was observed in mouse islets. The protein kinase C inhibitor staurosporine (50 nM) dramatically reduced the sustained secretory response from rat islets in the presence of 30 mM K+, 20 mM glucose, and diazoxide. Its effect was minimal on mouse islets and a significant inhibitory effect on insulin secretion was observed only during the final 5 min of the perifusion. The further addition of carbachol, an agonist that activates an isozyme of phospholipase C distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of insulin secretion from mouse but not rat islets. K+ (30 mM)-induced insulin secretion in the presence of 3 mM glucose was similar from perifused rat or mouse islets, a finding that would seem to preclude the activation of voltage-regulated Ca2+ channels as the pertinent difference. These results confirm previous observations with these species and document another anomaly that exists between the responses of rat islets compared with mouse islets. The inability to activate a nutrient- and calcium-regulated phospholipase C isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different insulin secretory responses under these unique conditions.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) plays a role in the regulation of insulin secretion. Specifically, the study shows that the addition of 30 mM K+ in the presence of glucose and diazoxide results in an increase in inositol phosphates (IP) accumulation, which is a marker of PLC activity. Furthermore, the inhibition of protein kinase C (PKC), which is downstream of PLC, reduces the sustained secretory response from rat islets. This suggests that PLC is involved in the signaling pathway that leads to insulin secretion. Therefore, the terms "insulin protein" and "phospholipase C protein" interact in the sense that PLC activity influences insulin secretion.</s>
IEPA.d41 IEPA.d41.s101.e0 IEPA.d41.s101.e1	phospholipase C	insulin	[INST]Context: [PMID: 9142890 Regulation of insulin secretion via ATP-sensitive K+ channel independent mechanisms: role of phospholipase C. Groups of rat or mouse islets were isolated and perifused with 20 mM glucose plus 200 microM diazoxide. The further addition of 30 mM K+ resulted in a rapid and sustained biphasic insulin secretory response. The onset of secretion in response to the addition of K+ was comparable in both species, but the magnitude of the response was significantly greater from rat islets. After the labeling of islet phosphoinositide pools with 2-[3H]inositol, the accumulation of labeled inositol phosphates (IP) in response to 30 mM K+ addition in the simultaneous presence of 20 mM glucose plus diazoxide was assessed. The addition of 30 mM K+ significantly increased IP accumulation approximately 300% in rat islets, whereas only an insignificant 25-30% increase was observed in mouse islets. The protein kinase C inhibitor staurosporine (50 nM) dramatically reduced the sustained secretory response from rat islets in the presence of 30 mM K+, 20 mM glucose, and diazoxide. Its effect was minimal on mouse islets and a significant inhibitory effect on insulin secretion was observed only during the final 5 min of the perifusion. The further addition of carbachol, an agonist that activates an isozyme of phospholipase C distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of insulin secretion from mouse but not rat islets. K+ (30 mM)-induced insulin secretion in the presence of 3 mM glucose was similar from perifused rat or mouse islets, a finding that would seem to preclude the activation of voltage-regulated Ca2+ channels as the pertinent difference. These results confirm previous observations with these species and document another anomaly that exists between the responses of rat islets compared with mouse islets. The inability to activate a nutrient- and calcium-regulated phospholipase C isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different insulin secretory responses under these unique conditions.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) is involved in the regulation of insulin secretion. Specifically, the addition of 30 mM K+ in the presence of 20 mM glucose and diazoxide resulted in a significant increase in inositol phosphates (IP) accumulation, which is a product of PLC activity. This increase in IP accumulation was associated with an amplified insulin secretory response. The protein kinase C inhibitor staurosporine also reduced the sustained secretory response, further supporting the role of PLC in insulin secretion. Therefore, the terms "phospholipase C protein" and "insulin protein" interact in the sense that the activation of PLC leads to changes in insulin secretion.</s>
IEPA.d41 IEPA.d41.s102.e0 IEPA.d41.s102.e1	phospholipase C	insulin	[INST]Context: [PMID: 9142890 Regulation of insulin secretion via ATP-sensitive K+ channel independent mechanisms: role of phospholipase C. Groups of rat or mouse islets were isolated and perifused with 20 mM glucose plus 200 microM diazoxide. The further addition of 30 mM K+ resulted in a rapid and sustained biphasic insulin secretory response. The onset of secretion in response to the addition of K+ was comparable in both species, but the magnitude of the response was significantly greater from rat islets. After the labeling of islet phosphoinositide pools with 2-[3H]inositol, the accumulation of labeled inositol phosphates (IP) in response to 30 mM K+ addition in the simultaneous presence of 20 mM glucose plus diazoxide was assessed. The addition of 30 mM K+ significantly increased IP accumulation approximately 300% in rat islets, whereas only an insignificant 25-30% increase was observed in mouse islets. The protein kinase C inhibitor staurosporine (50 nM) dramatically reduced the sustained secretory response from rat islets in the presence of 30 mM K+, 20 mM glucose, and diazoxide. Its effect was minimal on mouse islets and a significant inhibitory effect on insulin secretion was observed only during the final 5 min of the perifusion. The further addition of carbachol, an agonist that activates an isozyme of phospholipase C distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of insulin secretion from mouse but not rat islets. K+ (30 mM)-induced insulin secretion in the presence of 3 mM glucose was similar from perifused rat or mouse islets, a finding that would seem to preclude the activation of voltage-regulated Ca2+ channels as the pertinent difference. These results confirm previous observations with these species and document another anomaly that exists between the responses of rat islets compared with mouse islets. The inability to activate a nutrient- and calcium-regulated phospholipase C isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different insulin secretory responses under these unique conditions.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) is involved in the regulation of insulin secretion. Specifically, the addition of 30 mM K+ in the presence of 20 mM glucose and diazoxide resulted in a significant increase in inositol phosphates (IP) accumulation, which is a product of PLC activity. This increase in IP accumulation was associated with an amplified insulin secretory response. The protein kinase C inhibitor staurosporine also reduced the sustained secretory response, further supporting the role of PLC in insulin secretion. Therefore, the terms "phospholipase C protein" and "insulin protein" interact in the sense that the activation of PLC leads to changes in insulin secretion.</s>
IEPA.d43 IEPA.d43.s108.e0 IEPA.d43.s108.e1	leptin	uncoupling protein-2	[INST]Context: [PMID: 9177227 Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. We have studied mechanisms by which leptin overexpression, which reduces body weight via anorexic and thermogenic actions, induces triglyceride depletion in adipocytes and nonadipocytes. Here we show that leptin alters in pancreatic islets the mRNA of the genes encoding enzymes of free fatty acid metabolism and uncoupling protein-2 (UCP-2). In animals infused with a recombinant adenovirus containing the leptin cDNA, the levels of mRNAs encoding enzymes of mitochondrial and peroxisomal oxidation rose 2- to 3-fold, whereas mRNA encoding an enzyme of esterification declined in islets from hyperleptinemic rats. Islet UCP-2 mRNA rose 6-fold. All in vivo changes occurred in vitro in normal islets cultured with recombinant leptin, indicating direct extraneural effects. Leptin overexpression increased UCP-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-receptor-defective obese rats. By directly regulating the expression of enzymes of free fatty acid metabolism and of UCP-2, leptin controls intracellular triglyceride content of certain nonadipocytes, as well as adipocytes.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin directly regulates the expression of uncoupling protein-2 (UCP-2) in various tissues, including pancreatic islets and fat tissue. Specifically, it mentions that leptin overexpression increases UCP-2 mRNA levels by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal rats. This suggests that leptin and UCP-2 interact in a regulatory manner, where leptin influences the expression of UCP-2.</s>
IEPA.d43 IEPA.d43.s109.e0 IEPA.d43.s109.e1	leptin	uncoupling protein-2	[INST]Context: [PMID: 9177227 Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. We have studied mechanisms by which leptin overexpression, which reduces body weight via anorexic and thermogenic actions, induces triglyceride depletion in adipocytes and nonadipocytes. Here we show that leptin alters in pancreatic islets the mRNA of the genes encoding enzymes of free fatty acid metabolism and uncoupling protein-2 (UCP-2). In animals infused with a recombinant adenovirus containing the leptin cDNA, the levels of mRNAs encoding enzymes of mitochondrial and peroxisomal oxidation rose 2- to 3-fold, whereas mRNA encoding an enzyme of esterification declined in islets from hyperleptinemic rats. Islet UCP-2 mRNA rose 6-fold. All in vivo changes occurred in vitro in normal islets cultured with recombinant leptin, indicating direct extraneural effects. Leptin overexpression increased UCP-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-receptor-defective obese rats. By directly regulating the expression of enzymes of free fatty acid metabolism and of UCP-2, leptin controls intracellular triglyceride content of certain nonadipocytes, as well as adipocytes.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin directly regulates the expression of uncoupling protein-2 (UCP-2) in various tissues, including pancreatic islets and fat tissue. Specifically, it mentions that leptin overexpression increases UCP-2 mRNA levels by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal rats. This suggests that leptin and UCP-2 interact in a regulatory manner, where leptin influences the expression of UCP-2.</s>
IEPA.d43 IEPA.d43.s110.e0 IEPA.d43.s110.e1	Leptin	UCP-2	[INST]Context: [PMID: 9177227 Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. We have studied mechanisms by which leptin overexpression, which reduces body weight via anorexic and thermogenic actions, induces triglyceride depletion in adipocytes and nonadipocytes. Here we show that leptin alters in pancreatic islets the mRNA of the genes encoding enzymes of free fatty acid metabolism and uncoupling protein-2 (UCP-2). In animals infused with a recombinant adenovirus containing the leptin cDNA, the levels of mRNAs encoding enzymes of mitochondrial and peroxisomal oxidation rose 2- to 3-fold, whereas mRNA encoding an enzyme of esterification declined in islets from hyperleptinemic rats. Islet UCP-2 mRNA rose 6-fold. All in vivo changes occurred in vitro in normal islets cultured with recombinant leptin, indicating direct extraneural effects. Leptin overexpression increased UCP-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-receptor-defective obese rats. By directly regulating the expression of enzymes of free fatty acid metabolism and of UCP-2, leptin controls intracellular triglyceride content of certain nonadipocytes, as well as adipocytes.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin directly regulates the expression of UCP-2. Specifically, it mentions that leptin overexpression increases UCP-2 mRNA levels in both adipocytes and nonadipocytes, including pancreatic islets. This suggests that leptin and UCP-2 interact in a regulatory manner, where leptin influences the expression of UCP-2, thereby controlling intracellular triglyceride content.</s>
IEPA.d43 IEPA.d43.s111.e0 IEPA.d43.s111.e1	UCP-2	leptin	[INST]Context: [PMID: 9177227 Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. We have studied mechanisms by which leptin overexpression, which reduces body weight via anorexic and thermogenic actions, induces triglyceride depletion in adipocytes and nonadipocytes. Here we show that leptin alters in pancreatic islets the mRNA of the genes encoding enzymes of free fatty acid metabolism and uncoupling protein-2 (UCP-2). In animals infused with a recombinant adenovirus containing the leptin cDNA, the levels of mRNAs encoding enzymes of mitochondrial and peroxisomal oxidation rose 2- to 3-fold, whereas mRNA encoding an enzyme of esterification declined in islets from hyperleptinemic rats. Islet UCP-2 mRNA rose 6-fold. All in vivo changes occurred in vitro in normal islets cultured with recombinant leptin, indicating direct extraneural effects. Leptin overexpression increased UCP-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-receptor-defective obese rats. By directly regulating the expression of enzymes of free fatty acid metabolism and of UCP-2, leptin controls intracellular triglyceride content of certain nonadipocytes, as well as adipocytes.] Question: Based on the provided context, do the terms [UCP-2 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin directly regulates the expression of uncoupling protein-2 (UCP-2) in various tissues, including pancreatic islets and fat tissue. Specifically, it mentions that leptin overexpression increases UCP-2 mRNA levels by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal rats. This suggests that leptin and UCP-2 interact in a regulatory manner, where leptin influences the expression of UCP-2. Therefore, the terms [UCP-2 protein] and [leptin protein] interact with each other.</s>
IEPA.d48 IEPA.d48.s123.e0 IEPA.d48.s123.e1	Leptin	uncoupling protein	[INST]Context: [PMID: 9252501 Leptin increases uncoupling protein expression and energy expenditure. In ob/ob mice, leptin increases energy expenditure and sympathetic outflow to brown adipose tissue (BAT). To test whether the mechanism of increased energy expenditure may involve increased thermogenesis in BAT, we acclimated normal rats to thermoneutrality for 2 wk followed by leptin administration for 1 wk. Some rats were food restricted for 1 wk to the level of food consumption in the leptin-treated ad libitum-fed rats, and the same rats were both food restricted and administered leptin for a second week. We examined oxygen consumption and uncoupling protein (UCP) expression in BAT. Leptin increased oxygen consumption after the 5th and 6th days in ad libitum-fed rats and after the 4th, 5th, and 6th days in food-restricted rats. Leptin increased BAT UCP mRNA levels greater than twofold in both ad libitum-fed and food-restricted rats. These data demonstrate a leptin-induced increase in energy expenditure in nonmutant rodents and suggest that one mechanism by which leptin increases energy expenditure is through increased thermogenesis in BAT, including increased expression of UCP.] Question: Based on the provided context, do the terms [Leptin protein] and [uncoupling protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin increases the expression of uncoupling protein (UCP) in brown adipose tissue (BAT). This suggests that leptin and uncoupling protein interact in the sense that leptin administration leads to an increase in the expression of UCP, thereby influencing energy expenditure and thermogenesis in BAT. This interaction is a direct effect of leptin on the expression of UCP, which is a key mechanism by which leptin increases energy expenditure.</s>
IEPA.d48 IEPA.d48.s124.e0 IEPA.d48.s124.e1	Leptin	UCP	[INST]Context: [PMID: 9252501 Leptin increases uncoupling protein expression and energy expenditure. In ob/ob mice, leptin increases energy expenditure and sympathetic outflow to brown adipose tissue (BAT). To test whether the mechanism of increased energy expenditure may involve increased thermogenesis in BAT, we acclimated normal rats to thermoneutrality for 2 wk followed by leptin administration for 1 wk. Some rats were food restricted for 1 wk to the level of food consumption in the leptin-treated ad libitum-fed rats, and the same rats were both food restricted and administered leptin for a second week. We examined oxygen consumption and uncoupling protein (UCP) expression in BAT. Leptin increased oxygen consumption after the 5th and 6th days in ad libitum-fed rats and after the 4th, 5th, and 6th days in food-restricted rats. Leptin increased BAT UCP mRNA levels greater than twofold in both ad libitum-fed and food-restricted rats. These data demonstrate a leptin-induced increase in energy expenditure in nonmutant rodents and suggest that one mechanism by which leptin increases energy expenditure is through increased thermogenesis in BAT, including increased expression of UCP.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin increases the expression of uncoupling protein (UCP) in brown adipose tissue (BAT). This suggests that leptin and UCP are interacting in a way that increases energy expenditure and thermogenesis in BAT. The increase in UCP expression is a direct result of leptin administration, demonstrating an interaction between the two proteins.</s>
IEPA.d48 IEPA.d48.s125.e1 IEPA.d48.s125.e2	leptin	UCP	[INST]Context: [PMID: 9252501 Leptin increases uncoupling protein expression and energy expenditure. In ob/ob mice, leptin increases energy expenditure and sympathetic outflow to brown adipose tissue (BAT). To test whether the mechanism of increased energy expenditure may involve increased thermogenesis in BAT, we acclimated normal rats to thermoneutrality for 2 wk followed by leptin administration for 1 wk. Some rats were food restricted for 1 wk to the level of food consumption in the leptin-treated ad libitum-fed rats, and the same rats were both food restricted and administered leptin for a second week. We examined oxygen consumption and uncoupling protein (UCP) expression in BAT. Leptin increased oxygen consumption after the 5th and 6th days in ad libitum-fed rats and after the 4th, 5th, and 6th days in food-restricted rats. Leptin increased BAT UCP mRNA levels greater than twofold in both ad libitum-fed and food-restricted rats. These data demonstrate a leptin-induced increase in energy expenditure in nonmutant rodents and suggest that one mechanism by which leptin increases energy expenditure is through increased thermogenesis in BAT, including increased expression of UCP.] Question: Based on the provided context, do the terms [leptin protein] and [UCP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin increases the expression of uncoupling protein (UCP) in brown adipose tissue (BAT). This suggests that leptin and UCP are interacting in a way that increases energy expenditure and thermogenesis in BAT. The increase in UCP expression is a direct result of leptin administration, demonstrating an interaction between the leptin protein and the UCP protein.</s>
IEPA.d52 IEPA.d52.s135.e0 IEPA.d52.s135.e1	Uncoupling protein-3	leptin	[INST]Context: [PMID: 9305858 Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. Mitochondrial uncoupling proteins (UCPs) are transporters that are important for thermogenesis. The net result of their activity is the exothermic movement of protons through the inner mitochondrial membrane, uncoupled from ATP synthesis. We have cloned a third member of the UCP family, UCP3. UCP3 is expressed at high levels in muscle and rodent brown adipose tissue. Overexpression in yeast reduced the mitochondrial membrane potential, showing that UCP3 is a functional uncoupling protein. UCP3 RNA levels are regulated by hormonal and dietary manipulations. In contrast, levels of UCP2, a widely expressed UCP family member, showed little hormonal regulation. In particular, muscle UCP3 levels were decreased 3-fold in hypothyroid rats and increased 6-fold in hyperthyroid rats. Thus UCP3 is a strong candidate to explain the effects of thyroid hormone on thermogenesis. White adipose UCP3 levels were greatly increased by treatment with the beta3-adrenergic agonist, CL214613, suggesting another pathway for increasing thermogenesis. UCP3 mRNA levels were also regulated by dexamethasone, leptin, and starvation, albeit differently in muscle and brown adipose tissue. Starvation caused increased muscle and decreased BAT UCP3, suggesting that muscle assumes a larger role in thermoregulation during starvation. The UCP3 gene is located close to that encoding UCP2, in a chromosomal region implicated in previous linkage studies as contributing to obesity.] Question: Based on the provided context, do the terms [Uncoupling protein-3 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that UCP3 mRNA levels are regulated by leptin, suggesting an interaction between the UCP3 protein and leptin. Specifically, it mentions that UCP3 mRNA levels were also regulated by leptin, implying that leptin influences the expression of UCP3. This regulatory effect suggests an interaction between the UCP3 protein and leptin in the context of thermogenesis.</s>
IEPA.d52 IEPA.d52.s136.e0 IEPA.d52.s136.e1	UCP3	leptin	[INST]Context: [PMID: 9305858 Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. Mitochondrial uncoupling proteins (UCPs) are transporters that are important for thermogenesis. The net result of their activity is the exothermic movement of protons through the inner mitochondrial membrane, uncoupled from ATP synthesis. We have cloned a third member of the UCP family, UCP3. UCP3 is expressed at high levels in muscle and rodent brown adipose tissue. Overexpression in yeast reduced the mitochondrial membrane potential, showing that UCP3 is a functional uncoupling protein. UCP3 RNA levels are regulated by hormonal and dietary manipulations. In contrast, levels of UCP2, a widely expressed UCP family member, showed little hormonal regulation. In particular, muscle UCP3 levels were decreased 3-fold in hypothyroid rats and increased 6-fold in hyperthyroid rats. Thus UCP3 is a strong candidate to explain the effects of thyroid hormone on thermogenesis. White adipose UCP3 levels were greatly increased by treatment with the beta3-adrenergic agonist, CL214613, suggesting another pathway for increasing thermogenesis. UCP3 mRNA levels were also regulated by dexamethasone, leptin, and starvation, albeit differently in muscle and brown adipose tissue. Starvation caused increased muscle and decreased BAT UCP3, suggesting that muscle assumes a larger role in thermoregulation during starvation. The UCP3 gene is located close to that encoding UCP2, in a chromosomal region implicated in previous linkage studies as contributing to obesity.] Question: Based on the provided context, do the terms [UCP3 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, medium confidence; Explanation: The context indicates that UCP3 mRNA levels are regulated by leptin, suggesting an interaction between the UCP3 protein and leptin protein. However, the specific mechanism of this interaction is not detailed, and it is not clear if the interaction is direct or indirect. Therefore, the confidence level is medium.</s>
IEPA.d55 IEPA.d55.s140.e0 IEPA.d55.s140.e1	AVP	protein kinase C	[INST]Context: [PMID: 9369264 Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. We investigated the effects of arginine vasopressin (AVP) on nitric oxide (NO) synthase activity in cardiac myocytes by measuring the production of nitrite, a stable metabolite of NO, and the expression of inducible NO synthase (iNOS) mRNA and protein. Incubation of cultured neonatal rat cardiac myocytes for 24 hours with interleukin-1beta (IL-1beta) caused a significant increase in NO production. Both AVP and V1a receptor agonist [Phe2,Ile3,Orn8]vasopressin augmented NO synthesis in IL-1beta-stimulated, but not in unstimulated myocytes, in a dose-dependent manner. The V1a receptor antagonist [d(CH2)[5]1,O-Me-Tyr2,Arg8]vasopressin completely inhibited the effect of AVP. The AVP-induced NO production by IL-1beta-stimulated cells was accompanied by increased iNOS mRNA and protein accumulation. AVP caused a significant increase in cytosolic free Ca2+ levels of cardiac myocytes, whereas it showed no effect on cytosolic cAMP levels. After protein kinase C activity was functionally depleted by treating cells with phorbol 12-myristate 13-acetate for 24 hours, AVP did not augment IL-1beta-induced NO production. The effect of AVP was also inhibited in the presence of the protein kinase C inhibitor calphostin C. The addition of AVP increased protein kinase C activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C. These results support the hypothesis that the heart may be a target organ for AVP and that AVP modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of protein kinase C.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) increases protein kinase C (PKC) activity in cardiac myocytes. Specifically, it mentions that AVP caused a significant increase in PKC activity and that this effect was inhibited in the presence of the PKC inhibitor calphostin C. This suggests that AVP and protein kinase C interact with each other, as AVP modulates PKC activity in cardiac myocytes.</s>
IEPA.d55 IEPA.d55.s141.e0 IEPA.d55.s141.e1	AVP	protein kinase C	[INST]Context: [PMID: 9369264 Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. We investigated the effects of arginine vasopressin (AVP) on nitric oxide (NO) synthase activity in cardiac myocytes by measuring the production of nitrite, a stable metabolite of NO, and the expression of inducible NO synthase (iNOS) mRNA and protein. Incubation of cultured neonatal rat cardiac myocytes for 24 hours with interleukin-1beta (IL-1beta) caused a significant increase in NO production. Both AVP and V1a receptor agonist [Phe2,Ile3,Orn8]vasopressin augmented NO synthesis in IL-1beta-stimulated, but not in unstimulated myocytes, in a dose-dependent manner. The V1a receptor antagonist [d(CH2)[5]1,O-Me-Tyr2,Arg8]vasopressin completely inhibited the effect of AVP. The AVP-induced NO production by IL-1beta-stimulated cells was accompanied by increased iNOS mRNA and protein accumulation. AVP caused a significant increase in cytosolic free Ca2+ levels of cardiac myocytes, whereas it showed no effect on cytosolic cAMP levels. After protein kinase C activity was functionally depleted by treating cells with phorbol 12-myristate 13-acetate for 24 hours, AVP did not augment IL-1beta-induced NO production. The effect of AVP was also inhibited in the presence of the protein kinase C inhibitor calphostin C. The addition of AVP increased protein kinase C activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C. These results support the hypothesis that the heart may be a target organ for AVP and that AVP modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of protein kinase C.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) increases protein kinase C (PKC) activity in cardiac myocytes. Specifically, it mentions that AVP caused a significant increase in PKC activity and that this effect was inhibited in the presence of the PKC inhibitor calphostin C. This suggests that AVP and protein kinase C interact with each other, as AVP modulates PKC activity in cardiac myocytes.</s>
IEPA.d55 IEPA.d55.s142.e1 IEPA.d55.s142.e2	AVP	protein kinase C	[INST]Context: [PMID: 9369264 Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. We investigated the effects of arginine vasopressin (AVP) on nitric oxide (NO) synthase activity in cardiac myocytes by measuring the production of nitrite, a stable metabolite of NO, and the expression of inducible NO synthase (iNOS) mRNA and protein. Incubation of cultured neonatal rat cardiac myocytes for 24 hours with interleukin-1beta (IL-1beta) caused a significant increase in NO production. Both AVP and V1a receptor agonist [Phe2,Ile3,Orn8]vasopressin augmented NO synthesis in IL-1beta-stimulated, but not in unstimulated myocytes, in a dose-dependent manner. The V1a receptor antagonist [d(CH2)[5]1,O-Me-Tyr2,Arg8]vasopressin completely inhibited the effect of AVP. The AVP-induced NO production by IL-1beta-stimulated cells was accompanied by increased iNOS mRNA and protein accumulation. AVP caused a significant increase in cytosolic free Ca2+ levels of cardiac myocytes, whereas it showed no effect on cytosolic cAMP levels. After protein kinase C activity was functionally depleted by treating cells with phorbol 12-myristate 13-acetate for 24 hours, AVP did not augment IL-1beta-induced NO production. The effect of AVP was also inhibited in the presence of the protein kinase C inhibitor calphostin C. The addition of AVP increased protein kinase C activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C. These results support the hypothesis that the heart may be a target organ for AVP and that AVP modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of protein kinase C.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) increases protein kinase C (PKC) activity in cardiac myocytes. Specifically, it mentions that AVP caused a significant increase in PKC activity and that this effect was inhibited in the presence of the PKC inhibitor calphostin C. This suggests that AVP and protein kinase C interact with each other, as AVP modulates PKC activity in cardiac myocytes.</s>
IEPA.d57 IEPA.d57.s146.e0 IEPA.d57.s146.e1	PLC	insulin	[INST]Context: [PMID: 9389497 A role for phospholipase C activity in GLUT4-mediated glucose transport. Overexpression of surrogate receptors [epidermal growth factor (EGF) receptor (EGFR) and platelet-derived growth factor receptor] in adipocytes has demonstrated that multiple signaling pathways may lead to GLUT4-mediated glucose uptake. These implicated pathways function independently of IRS-1 phosphorylation and PI3-kinase activation. In addition, we previously demonstrated that EGFR tyrosyl autophosphorylation is required to stimulate GLUT4-mediated glucose transport in 3T3-L1 adipocytes. This observation suggests that signaling molecules that are dependent on EGFR autophosphorylation, such as phospholipase C (PLC), may lie in the signaling pathway to glucose transport. As PLC has been implicated in glucose transport by several clinical and basic mechanistic studies, we investigated whether EGFR signaling may promote glucose transport via modulation of PLC activity. Activation of EGFR overexpressing 3T3-L1 adipocytes leads to a 3.4 +/- 1.2-fold stimulation of PLC activity over basal levels vs. only 1.06 +/- 0.01-fold stimulation by insulin. Pharmacological inhibition of PLC by 50 microM U73122 reduced phosphoinositide accumulation by 79.2 +/- 16.9% and resulted in a concomitant 56.0 +/- 12.7% decrease in EGF-induced glucose transport. This inhibition of glucose transport by U73122 was specific, because the inactive congener, U73343, failed to block EGF-induced glucose transport. Despite the low levels of insulin-induced PLC activity, insulin-stimulated glucose transport activity was similarly inhibited by U73122 (55.9 +/- 13.1% inhibition). Inhibition of PLC activation did not impair either EGF- or insulin-induced activation of glycogen synthase or incorporation of glucose into lipid, supporting the hypothesis that both EGF- and insulin-induced glucose disposal can be independent of GLUT4-mediated glucose transport. The diminution of glucose transport secondary to inhibition of PLC activity was reflected by a decrease in GLUT4 translocation to the plasma membrane upon either EGF or insulin stimulation. These results are consistent with either a permissive or an active role for PLC activity in the translocation of GLUT4 to the plasma membrane.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that both EGF and insulin stimulate PLC activity, which in turn influences GLUT4-mediated glucose transport. Specifically, it mentions that activation of EGFR overexpressing 3T3-L1 adipocytes leads to a stimulation of PLC activity, and that inhibition of PLC by U73122 reduces EGF-induced glucose transport. Additionally, it states that insulin-stimulated glucose transport activity is similarly inhibited by U73122. This suggests that PLC activity is involved in the signaling pathways of both EGF and insulin, indicating an interaction between PLC and insulin in the context of glucose transport.</s>
IEPA.d57 IEPA.d57.s147.e0 IEPA.d57.s147.e1	insulin	PLC	[INST]Context: [PMID: 9389497 A role for phospholipase C activity in GLUT4-mediated glucose transport. Overexpression of surrogate receptors [epidermal growth factor (EGF) receptor (EGFR) and platelet-derived growth factor receptor] in adipocytes has demonstrated that multiple signaling pathways may lead to GLUT4-mediated glucose uptake. These implicated pathways function independently of IRS-1 phosphorylation and PI3-kinase activation. In addition, we previously demonstrated that EGFR tyrosyl autophosphorylation is required to stimulate GLUT4-mediated glucose transport in 3T3-L1 adipocytes. This observation suggests that signaling molecules that are dependent on EGFR autophosphorylation, such as phospholipase C (PLC), may lie in the signaling pathway to glucose transport. As PLC has been implicated in glucose transport by several clinical and basic mechanistic studies, we investigated whether EGFR signaling may promote glucose transport via modulation of PLC activity. Activation of EGFR overexpressing 3T3-L1 adipocytes leads to a 3.4 +/- 1.2-fold stimulation of PLC activity over basal levels vs. only 1.06 +/- 0.01-fold stimulation by insulin. Pharmacological inhibition of PLC by 50 microM U73122 reduced phosphoinositide accumulation by 79.2 +/- 16.9% and resulted in a concomitant 56.0 +/- 12.7% decrease in EGF-induced glucose transport. This inhibition of glucose transport by U73122 was specific, because the inactive congener, U73343, failed to block EGF-induced glucose transport. Despite the low levels of insulin-induced PLC activity, insulin-stimulated glucose transport activity was similarly inhibited by U73122 (55.9 +/- 13.1% inhibition). Inhibition of PLC activation did not impair either EGF- or insulin-induced activation of glycogen synthase or incorporation of glucose into lipid, supporting the hypothesis that both EGF- and insulin-induced glucose disposal can be independent of GLUT4-mediated glucose transport. The diminution of glucose transport secondary to inhibition of PLC activity was reflected by a decrease in GLUT4 translocation to the plasma membrane upon either EGF or insulin stimulation. These results are consistent with either a permissive or an active role for PLC activity in the translocation of GLUT4 to the plasma membrane.] Question: Based on the provided context, do the terms [insulin protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that both insulin and epidermal growth factor (EGF) stimulate PLC activity, which in turn influences GLUT4-mediated glucose transport. Specifically, the inhibition of PLC activity by U73122 reduces both EGF- and insulin-induced glucose transport, suggesting that PLC activity is involved in the signaling pathways for both insulin and EGF. This implies that insulin protein and PLC protein interact in the context of glucose transport signaling.</s>
IEPA.d58 IEPA.d58.s150.e0 IEPA.d58.s150.e1	AVP	protein kinase C	[INST]Context: [PMID: 9397959 Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion. We have recently shown that AVP causes a protein kinase C (PKC)-dependent increase in ACTH release and biosynthesis in ovine anterior pituitary cells. In these cells, AVP also causes the translocation of PKC from the cytosol to the cell membrane which is maximal at 5 min, but the intracellular events distal to protein kinase C activation that underlie ACTH secretion have not been well characterized to date. Since the MARCKS protein has been implicated in neurosecretion and is phosphorylated by PKC in synaptosomes, studies were carried out to determine whether AVP might cause MARCKS phosphorylation in the ovine anterior pituitary, and to determine whether this phenomenon might be temporally correlated with PKC translocation and the release of ACTH. When cytosolic fractions of rat brain, ovine anterior pituitary, and cultured ovine anterior pituitary cells were incubated with purified PKC, several proteins were phosphorylated including those in the region of 83-85 kDa. After precipitation of the proteins with 40% acetic acid, the 83-85 kDa phosphoproteins were selectively recovered in the acid soluble phase. Phosphopeptide maps of either the 83 or 85 kDa proteins were generated with Staphylococcus aureus V8 protease and revealed 13 and 9 kDa phosphopeptides, which are characteristic of the authentic MARCKS protein. An identical phosphopeptide map was also obtained when the MARCKS protein was selectively extracted from intact 32P-labeled anterior pituitary cells. MARCKS phosphorylation was markedly increased when ovine anterior pituitary cells were exposed to 1 microM phorbol 12-myristate 13-acetate (PMA). When the cells were exposed to 1 microM AVP, MARCKS phosphorylation increased at 15 s and reached the maximal plateau value at 30 s. MARCKS phosphorylation then started to diminish at 2 min, and baseline levels were attained by 10 min. In the same cells, AVP stimulated ACTH release in a biphasic manner - during the first 30 s, there resulted a rapid burst of ACTH secretion that was followed by a slower, but sustained rate of secretion. We conclude that: (1) AVP causes a rapid, and reversible, phosphorylation of the MARCKS protein in the ovine anterior pituitary; (2) since the AVP-induced increase in MARCKS phosphorylation occurs much earlier in these cells than does PKC trans-location, MARCKS phosphorylation may provide a more sensitive index of the onset of PKC activation than the translocation assay; (3) the close temporal association between MARCKS phosphorylation and the rapid early release of ACTH suggests that MARCKS phosphorylation may be involved in the initial intracellular events that underly exocytosis of the hormone.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) causes the translocation of protein kinase C (PKC) from the cytosol to the cell membrane in ovine anterior pituitary cells. This translocation is a key event in the signaling pathway that leads to the phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein and the subsequent release of adrenocorticotropin (ACTH). Therefore, AVP and protein kinase C interact in the sense that AVP triggers the activation of PKC, which in turn phosphorylates MARCKS and leads to ACTH secretion.</s>
IEPA.d58 IEPA.d58.s151.e0 IEPA.d58.s151.e1	AVP	PKC	[INST]Context: [PMID: 9397959 Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion. We have recently shown that AVP causes a protein kinase C (PKC)-dependent increase in ACTH release and biosynthesis in ovine anterior pituitary cells. In these cells, AVP also causes the translocation of PKC from the cytosol to the cell membrane which is maximal at 5 min, but the intracellular events distal to protein kinase C activation that underlie ACTH secretion have not been well characterized to date. Since the MARCKS protein has been implicated in neurosecretion and is phosphorylated by PKC in synaptosomes, studies were carried out to determine whether AVP might cause MARCKS phosphorylation in the ovine anterior pituitary, and to determine whether this phenomenon might be temporally correlated with PKC translocation and the release of ACTH. When cytosolic fractions of rat brain, ovine anterior pituitary, and cultured ovine anterior pituitary cells were incubated with purified PKC, several proteins were phosphorylated including those in the region of 83-85 kDa. After precipitation of the proteins with 40% acetic acid, the 83-85 kDa phosphoproteins were selectively recovered in the acid soluble phase. Phosphopeptide maps of either the 83 or 85 kDa proteins were generated with Staphylococcus aureus V8 protease and revealed 13 and 9 kDa phosphopeptides, which are characteristic of the authentic MARCKS protein. An identical phosphopeptide map was also obtained when the MARCKS protein was selectively extracted from intact 32P-labeled anterior pituitary cells. MARCKS phosphorylation was markedly increased when ovine anterior pituitary cells were exposed to 1 microM phorbol 12-myristate 13-acetate (PMA). When the cells were exposed to 1 microM AVP, MARCKS phosphorylation increased at 15 s and reached the maximal plateau value at 30 s. MARCKS phosphorylation then started to diminish at 2 min, and baseline levels were attained by 10 min. In the same cells, AVP stimulated ACTH release in a biphasic manner - during the first 30 s, there resulted a rapid burst of ACTH secretion that was followed by a slower, but sustained rate of secretion. We conclude that: (1) AVP causes a rapid, and reversible, phosphorylation of the MARCKS protein in the ovine anterior pituitary; (2) since the AVP-induced increase in MARCKS phosphorylation occurs much earlier in these cells than does PKC trans-location, MARCKS phosphorylation may provide a more sensitive index of the onset of PKC activation than the translocation assay; (3) the close temporal association between MARCKS phosphorylation and the rapid early release of ACTH suggests that MARCKS phosphorylation may be involved in the initial intracellular events that underly exocytosis of the hormone.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) causes the translocation of protein kinase C (PKC) from the cytosol to the cell membrane in ovine anterior pituitary cells. This translocation is a key event in the signaling pathway that leads to the phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein and the subsequent release of adrenocorticotropin (ACTH). Therefore, AVP and PKC interact in the sense that AVP triggers the activation of PKC, which in turn phosphorylates MARCKS and leads to ACTH secretion.</s>
IEPA.d60 IEPA.d60.s155.e0 IEPA.d60.s155.e1	AVP	protein kinase C	[INST]Context: [PMID: 9459490 Stimulation of 42/44 kDa mitogen-activated protein kinases by arginine vasopressin in rat cardiomyocytes. Vasoconstrictors, such as angiotensin II (Ang II), are involved in the regulatory mechanisms of post myocardial infarction (MI) hypertrophy. Arginine vasopressin (AVP), may be another vasoconstrictor that influences the mechanisms that lead to post MI hypertrophy. In these studies we investigated the possible activation of the 42/44 kDa mitogen-activated protein kinases (MAPKs), also referred as extracellular signal regulated kinases (ERKs), in cultured cardiomyocytes. Treatment of rat cardiomyocytes with AVP, Ang II and phorbol 12-myristate 13-acetate (PMA) increases the activation of ERKs. The activity of the 42/44 kDa MAPKs was tested using the phosphorylation of: (1) EGF receptor peptide (EGFR-P); (2) myelin basic protein (MBP) immobilized in poly acrylamide gels; and (3) T183 and Y185 residues of these proteins. The activity of the MAPKs, induced by AVP or PMA was inhibited by downregulation of protein kinase C (PKC), by the tyrosine kinase inhibitor genistein and by MAPK kinase (MEK) inhibitor, PD98059. In addition, the AVP-induced stimulation of MAPKs was shown to be mediated through a V1 receptor. We suggest that AVP activates the 42/44kDa MAPKs through a signal transduction pathway that involves stimulation of AVP-V1 receptor, tyrosine kinase, PKC and MEK. These results suggest that AVP may be involved in ERKs dependent regulatory functions of cardiomyocytes growth.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) activates the 42/44 kDa mitogen-activated protein kinases (MAPKs) through a signal transduction pathway that involves stimulation of AVP-V1 receptor, tyrosine kinase, protein kinase C (PKC), and MEK. This suggests that AVP and protein kinase C interact within this pathway, as the activation of MAPKs by AVP is mediated through PKC. Therefore, AVP protein and protein kinase C protein interact with each other in this context.</s>
IEPA.d60 IEPA.d60.s156.e0 IEPA.d60.s156.e1	AVP	PKC	[INST]Context: [PMID: 9459490 Stimulation of 42/44 kDa mitogen-activated protein kinases by arginine vasopressin in rat cardiomyocytes. Vasoconstrictors, such as angiotensin II (Ang II), are involved in the regulatory mechanisms of post myocardial infarction (MI) hypertrophy. Arginine vasopressin (AVP), may be another vasoconstrictor that influences the mechanisms that lead to post MI hypertrophy. In these studies we investigated the possible activation of the 42/44 kDa mitogen-activated protein kinases (MAPKs), also referred as extracellular signal regulated kinases (ERKs), in cultured cardiomyocytes. Treatment of rat cardiomyocytes with AVP, Ang II and phorbol 12-myristate 13-acetate (PMA) increases the activation of ERKs. The activity of the 42/44 kDa MAPKs was tested using the phosphorylation of: (1) EGF receptor peptide (EGFR-P); (2) myelin basic protein (MBP) immobilized in poly acrylamide gels; and (3) T183 and Y185 residues of these proteins. The activity of the MAPKs, induced by AVP or PMA was inhibited by downregulation of protein kinase C (PKC), by the tyrosine kinase inhibitor genistein and by MAPK kinase (MEK) inhibitor, PD98059. In addition, the AVP-induced stimulation of MAPKs was shown to be mediated through a V1 receptor. We suggest that AVP activates the 42/44kDa MAPKs through a signal transduction pathway that involves stimulation of AVP-V1 receptor, tyrosine kinase, PKC and MEK. These results suggest that AVP may be involved in ERKs dependent regulatory functions of cardiomyocytes growth.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the activity of the 42/44 kDa MAPKs induced by arginine vasopressin (AVP) is inhibited by downregulation of protein kinase C (PKC). This suggests that AVP and PKC interact in a signaling pathway that involves the activation of the 42/44 kDa MAPKs. Specifically, the AVP-induced stimulation of MAPKs is mediated through a V1 receptor, which then activates tyrosine kinase, PKC, and MEK, leading to the activation of the 42/44 kDa MAPKs. Therefore, AVP and PKC interact in this signaling pathway.</s>
IEPA.d61 IEPA.d61.s157.e0 IEPA.d61.s157.e1	beta-amyloid	phospholipase Cgamma1	[INST]Context: [PMID: 9473570 Secreted form of beta-amyloid precursor protein activates protein kinase C and phospholipase Cgamma1 in cultured embryonic rat neocortical cells. The secreted form of beta-amyloid precursor protein (sAPP) has been reported to exert various biological activities in cultured neurons. The signal transduction mechanisms underlying these physiological functions of sAPP remain unclear. We now report that treatment of neural cells with the secreted form of APP695 (sAPP695) leads to dose- and time-dependent increase in phosphorylation of the endogenous substrates with a molecular mass of 80, 57 and 43 kDa. Pretreatment of cells with protein kinase C (PKC) inhibitor H-7 reduced phosphorylation of the 80- and 43-kDa proteins in a dose-dependent manner. The effect of sAPP695 on the phosphorylation is mimicked by phorbol 12-myristate-13-acetate (PMA). Downregulation of PKC by prolonged treatment of cells with PMA abolished sAPP695-enhanced phosphorylation of the 80- and 43-kDa proteins, indicating PKC is involved in the sAPP695-enhanced phosphorylation of these proteins in the cells. We also suggest that the 80- and 43-kDa proteins phosphorylated by sAPP695-stimulation are the major PKC substrates myristoylated alanine-rich C-kinase substrate and growth-associated protein-43. Furthermore, we demonstrate that tyrosine phosphorylation of phospholipase Cgamma1 and formation of inositol 1,4,5-trisphosphate were increased by sAPP695-stimulation. These observations suggest that sAPP695 induces the activation of the signaling pathways through a stimulation of phosphoinositide-PKC cascade.] Question: Based on the provided context, do the terms [beta-amyloid protein] and [phospholipase Cgamma1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the secreted form of beta-amyloid precursor protein (sAPP) activates protein kinase C (PKC) and phospholipase Cgamma1 (PLCgamma1) in cultured embryonic rat neocortical cells. Specifically, it mentions that tyrosine phosphorylation of PLCgamma1 and formation of inositol 1,4,5-trisphosphate were increased by sAPP695-stimulation. This suggests that sAPP695, which is derived from beta-amyloid precursor protein, interacts with PLCgamma1 to induce signaling pathways through the phosphoinositide-PKC cascade. Therefore, beta-amyloid protein and phospholipase Cgamma1 protein interact with each other in this context.</s>
IEPA.d61 IEPA.d61.s158.e0 IEPA.d61.s158.e1	phospholipase Cgamma1	sAPP695	[INST]Context: [PMID: 9473570 Secreted form of beta-amyloid precursor protein activates protein kinase C and phospholipase Cgamma1 in cultured embryonic rat neocortical cells. The secreted form of beta-amyloid precursor protein (sAPP) has been reported to exert various biological activities in cultured neurons. The signal transduction mechanisms underlying these physiological functions of sAPP remain unclear. We now report that treatment of neural cells with the secreted form of APP695 (sAPP695) leads to dose- and time-dependent increase in phosphorylation of the endogenous substrates with a molecular mass of 80, 57 and 43 kDa. Pretreatment of cells with protein kinase C (PKC) inhibitor H-7 reduced phosphorylation of the 80- and 43-kDa proteins in a dose-dependent manner. The effect of sAPP695 on the phosphorylation is mimicked by phorbol 12-myristate-13-acetate (PMA). Downregulation of PKC by prolonged treatment of cells with PMA abolished sAPP695-enhanced phosphorylation of the 80- and 43-kDa proteins, indicating PKC is involved in the sAPP695-enhanced phosphorylation of these proteins in the cells. We also suggest that the 80- and 43-kDa proteins phosphorylated by sAPP695-stimulation are the major PKC substrates myristoylated alanine-rich C-kinase substrate and growth-associated protein-43. Furthermore, we demonstrate that tyrosine phosphorylation of phospholipase Cgamma1 and formation of inositol 1,4,5-trisphosphate were increased by sAPP695-stimulation. These observations suggest that sAPP695 induces the activation of the signaling pathways through a stimulation of phosphoinositide-PKC cascade.] Question: Based on the provided context, do the terms [phospholipase Cgamma1 protein] and [sAPP695 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that sAPP695 stimulates the activation of the signaling pathways through a stimulation of phosphoinositide-PKC cascade, which includes the tyrosine phosphorylation of phospholipase Cgamma1 and the formation of inositol 1,4,5-trisphosphate. This suggests that sAPP695 directly influences the activity of phospholipase Cgamma1, indicating an interaction between the two proteins.</s>
IEPA.d62 IEPA.d62.s159.e0 IEPA.d62.s159.e1	Oxytocin	insulin	[INST]Context: [PMID: 9505272 Postnatal oxytocin injections cause sustained weight gain and increased nociceptive thresholds in male and female rats. The aim of the present study was to investigate possible long-term effects of postnatally administered oxytocin on weight gain, gastrointestinal hormone levels, and nociceptive thresholds in rats. For this purpose, s.c. daily injections of oxytocin (1 mg/kg) or saline (NaCl, 0.9%) were given to male and female rat pups on d 10-14 after birth. The animals were killed at the age of 60 or 94 d. Treatment with oxytocin resulted in higher body weight in males, 60 d after birth, and in females from d 60 and throughout the rest of the experiment, compared with controls. The higher body weight was due to an increased weight gain in oxytocin-treated rats, compared with controls, which was most pronounced between 40 and 60 d after birth. Oxytocin-treated male rats had increased circulating levels of cholecystokinin, a tendency to increased plasma levels of insulin (p = 0.066), and relatively more adipose tissue in the thigh and interscapular region, compared with controls. At the age of 60 d, oxytocin-treated female and male rats had a prolonged withdrawal latency when measured in the tail-flick test, compared with controls. This study shows that oxytocin can induce long-lasting changes in weight gain, hormone levels, and nociceptive thresholds, when administered postnatally, in female and male rats.] Question: Based on the provided context, do the terms [Oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between oxytocin protein and insulin protein. While oxytocin treatment resulted in a tendency to increased plasma levels of insulin in male rats, this is presented as an effect of oxytocin rather than a direct interaction between the two proteins. The context describes the effects of oxytocin on weight gain, hormone levels, and nociceptive thresholds, but it does not suggest that oxytocin and insulin interact with each other.</s>
IEPA.d63 IEPA.d63.s160.e0 IEPA.d63.s160.e1	UCP1	leptin	[INST]Context: [PMID: 9520493 Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Uncoupling protein 2 (UCP2) maps to a region on distal mouse chromosome 7 that has been linked to the phenotypes of obesity and type II diabetes. We recently reported that UCP2 expression is increased by high fat feeding in adipose tissue of the A/J strain of mice, which is resistant to the development of dietary obesity. More recently, a third UCP (UCP3) was identified, which is expressed largely in skeletal muscle and brown adipose tissue. The UCP2 and UCP3 genes are located adjacent to one another on mouse chromosome 7. Thus, the roles of these UCPs in both metabolic efficiency and the linkage to obesity and diabetes syndromes is unclear. For this reason, we examined the expression of UCP2 and UCP3 in white adipose tissue and interscapular brown adipose tissue and in gastrocnemius/soleus muscle preparations from the obesity-resistant A/J and C57BL/KsJ (KsJ) strains and the obesity-prone C57BL/6J (B6) mouse strain. In both KsJ and A/J mice, UCP2 expression in white fat was increased approximately 2-fold in response to 2 weeks of a high fat diet, but there was no effect of diet on UCP2 levels in B6 mice. In skeletal muscle and in brown fat, neither UCP2 nor UCP3 expression was affected by diet in A/J, B6, or KsJ mice. However, in brown fat, we observed a 2-3-fold increase in the expression of UCP1 in response to dietary fat challenge, which may be related to diet-induced elevations in plasma leptin levels. Together, these results indicate that the consumption of a high fat diet selectively regulates UCP2 expression in white fat and UCP1 expression in brown fat and that resistance to obesity is correlated with this early, selective induction of UCP1 and UCP2 and is not associated with changes in expression of UCP3.] Question: Based on the provided context, do the terms [UCP1 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that diet-induced elevations in plasma leptin levels are related to diet-induced elevations in the expression of UCP1 in brown fat. This suggests an interaction between leptin and UCP1, where leptin influences the expression of UCP1 in response to dietary fat challenge.</s>
IEPA.d65 IEPA.d65.s163.e0 IEPA.d65.s163.e1	Vasopressin	protein kinase C	[INST]Context: [PMID: 9561804 Vasopressin-induced activation of protein kinase C in renal epithelial cells. Recent studies indicate that the actions of arginine vasopressin (AVP) and other agonists that stimulate electrogenic sodium transport in renal epithelial A6 cells are linked to a Ca(2+)-mobilizing signal transduction mechanism that involves generation of inositol trisphosphate. Since diacylglycerol is the other product in this pathway, studies were performed to determine the possible role of PKC in the stimulation of sodium transport. AVP induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and PKC activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). To determine the PKC isoform(s) involved in this process, immunoblot analysis was performed using antisera that recognize both classical PKC isoforms, XPKC-I and XPCK-II, cloned from Xenopus oocytes. The transcripts of both isoforms were expressed in the A6 cell. Since protein recognized by antisera was translocated from cytosol to the particulate fraction after exposure to AVP, one or both isoforms were activated in the A6 cell. Further studies showed that cyclohexyladenosine and insulin, additional agonists of sodium transport in A6 cells, also stimulated phosphorylation of MARCKS. These results argue that Ca(2+)-dependent PKC is involved in the action of AVP, and that of other agonists, which stimulate sodium transport.] Question: Based on the provided context, do the terms [Vasopressin protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that arginine vasopressin (AVP) induces a biphasic increase in diacylglycerol generation and activates protein kinase C (PKC) in renal epithelial A6 cells. This activation is reflected by the phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). The study also shows that AVP stimulates the translocation of PKC isoforms from the cytosol to the particulate fraction, indicating that PKC is involved in the action of AVP. Therefore, the terms "Vasopressin protein" and "protein kinase C protein" interact with each other in the context of AVP-induced activation of PKC in renal epithelial cells.</s>
IEPA.d65 IEPA.d65.s164.e0 IEPA.d65.s164.e1	AVP	PKC	[INST]Context: [PMID: 9561804 Vasopressin-induced activation of protein kinase C in renal epithelial cells. Recent studies indicate that the actions of arginine vasopressin (AVP) and other agonists that stimulate electrogenic sodium transport in renal epithelial A6 cells are linked to a Ca(2+)-mobilizing signal transduction mechanism that involves generation of inositol trisphosphate. Since diacylglycerol is the other product in this pathway, studies were performed to determine the possible role of PKC in the stimulation of sodium transport. AVP induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and PKC activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). To determine the PKC isoform(s) involved in this process, immunoblot analysis was performed using antisera that recognize both classical PKC isoforms, XPKC-I and XPCK-II, cloned from Xenopus oocytes. The transcripts of both isoforms were expressed in the A6 cell. Since protein recognized by antisera was translocated from cytosol to the particulate fraction after exposure to AVP, one or both isoforms were activated in the A6 cell. Further studies showed that cyclohexyladenosine and insulin, additional agonists of sodium transport in A6 cells, also stimulated phosphorylation of MARCKS. These results argue that Ca(2+)-dependent PKC is involved in the action of AVP, and that of other agonists, which stimulate sodium transport.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) induces a biphasic increase in diacylglycerol generation and activates protein kinase C (PKC) in renal epithelial A6 cells. This activation is reflected by the phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). The study also shows that AVP stimulates the translocation of PKC isoforms from the cytosol to the particulate fraction, indicating that AVP interacts with PKC to activate it. Therefore, the terms [AVP protein] and [PKC protein] interact with each other.</s>
IEPA.d65 IEPA.d65.s165.e0 IEPA.d65.s165.e1	PKC	AVP	[INST]Context: [PMID: 9561804 Vasopressin-induced activation of protein kinase C in renal epithelial cells. Recent studies indicate that the actions of arginine vasopressin (AVP) and other agonists that stimulate electrogenic sodium transport in renal epithelial A6 cells are linked to a Ca(2+)-mobilizing signal transduction mechanism that involves generation of inositol trisphosphate. Since diacylglycerol is the other product in this pathway, studies were performed to determine the possible role of PKC in the stimulation of sodium transport. AVP induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and PKC activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). To determine the PKC isoform(s) involved in this process, immunoblot analysis was performed using antisera that recognize both classical PKC isoforms, XPKC-I and XPCK-II, cloned from Xenopus oocytes. The transcripts of both isoforms were expressed in the A6 cell. Since protein recognized by antisera was translocated from cytosol to the particulate fraction after exposure to AVP, one or both isoforms were activated in the A6 cell. Further studies showed that cyclohexyladenosine and insulin, additional agonists of sodium transport in A6 cells, also stimulated phosphorylation of MARCKS. These results argue that Ca(2+)-dependent PKC is involved in the action of AVP, and that of other agonists, which stimulate sodium transport.] Question: Based on the provided context, do the terms [PKC protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) induces a biphasic increase in diacylglycerol generation and activates protein kinase C (PKC) in renal epithelial A6 cells. This activation is reflected by the phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS). The translocation of PKC isoforms from cytosol to the particulate fraction after exposure to AVP further supports the interaction between AVP and PKC. Therefore, AVP and PKC interact in the process of stimulating sodium transport in renal epithelial cells.</s>
IEPA.d66 IEPA.d66.s166.e0 IEPA.d66.s166.e1	AVP	protein kinase C	[INST]Context: [PMID: 9575789 Nerve growth factor regulates HCO3- absorption in thick ascending limb: modifying effects of vasopressin. Growth factors stimulate Na+/H+ exchange activity in many cell types but their effects on acid secretion via this mechanism in renal tubules are poorly understood. We examined the regulation of HCO3- absorption by nerve growth factor (NGF) in the rat medullary thick ascending limb (MTAL), which absorbs HCO3- via apical membrane Na+/H+ exchange. MTAL were perfused in vitro with 25 mM HCO3- solutions (pH 7.4; 290 mosmol/kgH2O). Addition of 0.7 nM NGF to the bath decreased HCO3- absorption from 13.1 +/- 1.1 to 9.6 +/- 0.8 pmol.min-1.mm-1 (P < 0.001). In contrast, with 10(-10) M arginine vasopressin (AVP) in the bath, addition of NGF to the bath increased HCO3- absorption from 8.0 +/- 1.6 to 12.5 +/- 1.3 pmol.min-1.mm-1 (P < 0.01). Both effects of NGF were blocked by genistein, consistent with the involvement of tyrosine kinase pathways. However, the AVP-dependent stimulation required activation of protein kinase C (PKC), whereas the inhibition was PKC independent, indicating that the NGF-induced signaling pathways leading to inhibition and stimulation of HCO3- absorption are distinct. Hypertonicity blocked the inhibition but not the AVP-dependent stimulation, suggesting that hypertonicity and NGF may inhibit HCO3- absorption via a common mechanism. These data demonstrate that NGF inhibits HCO3- absorption in the MTAL under basal conditions but stimulates HCO3- absorption in the presence of AVP, effects that are mediated through distinct signal transduction pathways. They also show that AVP is a critical determinant of the response of the MTAL to growth factor stimulation and suggest that NGF can either inhibit or stimulate apical Na+/H+ exchange activity depending on its interactions with other regulatory factors. Locally produced growth factors such as NGF may play a role in regulating renal tubule HCO3- absorption.] Question: Based on the provided context, do the terms [AVP protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) and protein kinase C (PKC) interact in the regulation of HCO3- absorption in the rat medullary thick ascending limb (MTAL). Specifically, the AVP-dependent stimulation of HCO3- absorption requires the activation of protein kinase C (PKC), suggesting a direct interaction between AVP and PKC in this signaling pathway.</s>
IEPA.d67 IEPA.d67.s167.e1 IEPA.d67.s167.e2	PLCgamma	insulin	[INST]Context: [PMID: 9593725 Association of the insulin receptor with phospholipase C-gamma (PLCgamma) in 3T3-L1 adipocytes suggests a role for PLCgamma in metabolic signaling by insulin. Phospholipase C-gamma (PLCgamma) is the isozyme of PLC phosphorylated by multiple tyrosine kinases including epidermal growth factor, platelet-derived growth factor, nerve growth factor receptors, and nonreceptor tyrosine kinases. In this paper, we present evidence for the association of the insulin receptor (IR) with PLCgamma. Precipitation of the IR with glutathione S-transferase fusion proteins derived from PLCgamma and coimmunoprecipitation of the IR and PLCgamma were observed in 3T3-L1 adipocytes. To determine the functional significance of the interaction of PLCgamma and the IR, we used a specific inhibitor of PLC, U73122, or microinjection of SH2 domain glutathione S-transferase fusion proteins derived from PLCgamma to block insulin-stimulated GLUT4 translocation. We demonstrate inhibition of 2-deoxyglucose uptake in isolated primary rat adipocytes and 3T3-L1 adipocytes pretreated with U73122. Antilipolytic effect of insulin in 3T3-L1 adipocytes is unaffected by U73122. U73122 selectively inhibits mitogen-activated protein kinase, leaving the Akt and p70 S6 kinase pathways unperturbed. We conclude that PLCgamma is an active participant in metabolic and perhaps mitogenic signaling by the insulin receptor in 3T3-L1 adipocytes.] Question: Based on the provided context, do the terms [PLCgamma protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that the insulin receptor (IR) and phospholipase C-gamma (PLCgamma) interact with each other. The evidence includes the precipitation of the IR with glutathione S-transferase fusion proteins derived from PLCgamma and the coimmunoprecipitation of the IR and PLCgamma in 3T3-L1 adipocytes. This interaction is further supported by the functional significance of the interaction, as demonstrated by the inhibition of insulin-stimulated GLUT4 translocation and mitogen-activated protein kinase activity when PLCgamma is blocked. Therefore, the terms [PLCgamma protein] and [insulin protein] interact with each other.</s>
IEPA.d70 IEPA.d70.s171.e1 IEPA.d70.s171.e2	OT	insulin	[INST]Context: [PMID: 9633016 5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. The present study was undertaken in order to establish the possible involvement of 5-HT3 serotonergic receptors in the control of basal and/or hypoglycemia-stimulated arginine vasopressin (AVP) and/or oxytocin (OT) secretion. For this purpose, 12 normal men were injected intravenously with a bolus of 4 mg ondansetron, a specific 5-HT3 receptor antagonist, under basal conditions (n = 6) or 30 min before insulin (0.15 IU/kg body weight) administration (n = 6) (insulin tolerance test (ITT)). Control experiments with normal saline instead of ondansetron treatment were performed. Furthermore, on a different occasion, the same subjects were tested in identical experimental conditions with 8 mg ondansetron. Our results showed that the hypoglycemic response to insulin was similar during the ITT and ondansetron plus ITT. Inhibition of 5-HT3 serotonergic receptors with ondansetron (4 or 8 mg) did not modify the basal secretion of AVP and OT and the OT response to insulin-induced hypoglycemia. In contrast, the administration of 4 or 8 mg ondansetron significantly reduced in a similar manner hypoglycemia-induced AVP rise. Mean peak level at 45 min after insulin injection was 2.25 times higher than baseline in the control ITT and 1.5 times higher than basal value in the ondansetron (4 or 8 mg) plus ITT. These data demonstrate that 5-HT3 serotonergic receptors at least partially mediate the AVP response to hypoglycemia, without modifying the simultaneous OT response. On the other hand, 5-HT3 receptors do not appear to be involved in the control of basal posterior pituitary hormone secretions.] Question: Based on the provided context, do the terms [OT protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of ondansetron, a 5-HT3 receptor antagonist, on the secretion of arginine vasopressin (AVP) and oxytocin (OT) in response to insulin-induced hypoglycemia. While it mentions that ondansetron affects AVP secretion, it does not indicate any direct interaction between OT protein and insulin protein. Instead, it describes the separate responses of AVP and OT to hypoglycemia and the influence of ondansetron on AVP secretion. Therefore, there is no evidence of a direct interaction between OT protein and insulin protein in the context provided.</s>
IEPA.d71 IEPA.d71.s172.e0 IEPA.d71.s172.e1	GA3	alpha-amylase	[INST]Context: [PMID: 9634587 Identification of a negative regulator of gibberellin action, HvSPY, in barley. To broaden our understanding of the molecular mechanisms of gibberellin (GA) action, we isolated a spindly clone (HvSPY) from barley cultivar Himalaya and tested whether the HvSPY protein would modulate GA action in barley aleurone. The HvSPY cDNA showed high sequence identity to Arabidopsis SPY along its entire length, and the barley protein functionally complemented the spy-3 mutation. HvSPY and SPY proteins showed sequence relatedness with animal O-linked N-acetylglucosamine transferases (OGTs), suggesting that they may also have OGT activity. HvSPY has a locus distinct from that of Sln, a mutation that causes the constitutive GA responses of slender barley, which phenotypically resembles Arabidopsis spy mutants. The possibility that the HvSPY gene encodes a negative regulator of GA action was tested by expressing HvSPY in a barley aleurone transient assay system. HvSPY coexpression largely abolished GA3-induced activity of an alpha-amylase promoter. Surprisingly, HvSPY coexpression increased reporter gene activity from an abscisic acid (ABA)-inducible gene promoter (dehydrin), even in the absence of exogenous ABA. These results show that HvSPY modulates the transcriptional activities of two hormonally regulated promoters: negatively for a GA-induced promoter and positively for an ABA-induced promoter.] Question: Based on the provided context, do the terms [GA3 protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that GA3 (gibberellin) induces the activity of an alpha-amylase promoter. The expression of HvSPY, which acts as a negative regulator of GA action, largely abolishes this GA3-induced activity. This suggests that GA3 and alpha-amylase are part of the same regulatory pathway, where GA3 influences the activity of the alpha-amylase promoter. Therefore, GA3 and alpha-amylase interact in the sense that GA3 regulates the expression of alpha-amylase.</s>
IEPA.d74 IEPA.d74.s176.e0 IEPA.d74.s176.e1	leptin	uncoupling proteins	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling proteins protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin infusion affects the expression of uncoupling proteins (UCPs) in various tissues. Specifically, it mentions that intracerebroventricular leptin administration maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3) while pair-feeding leads to a marked depression in UCP expression. This suggests that leptin interacts with uncoupling proteins to influence their expression levels, thereby affecting energy metabolism and homeostasis.</s>
IEPA.d74 IEPA.d74.s177.e0 IEPA.d74.s177.e1	leptin	UCP1	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP1. This suggests that leptin influences the expression of UCP1, implying an interaction between the leptin protein and UCP1 protein. The maintenance of high UCP1 expression in the presence of leptin is a direct effect of leptin on UCP1, indicating an interaction.</s>
IEPA.d74 IEPA.d74.s177.e0 IEPA.d74.s177.e2	leptin	UCP2	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP2. This suggests that leptin influences the expression of UCP2, implying an interaction between the leptin protein and the UCP2 protein. The maintenance of high UCP2 mRNA levels in the presence of leptin compared to the decreased levels in pair-fed rats supports this interaction.</s>
IEPA.d74 IEPA.d74.s177.e0 IEPA.d74.s177.e3	leptin	UCP3	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP3. This suggests that leptin influences the expression of UCP3, thereby indicating an interaction between leptin protein and UCP3 protein. The maintenance of high UCP3 expression in the presence of leptin is a direct effect of leptin on UCP3, demonstrating their interaction.</s>
IEPA.d74 IEPA.d74.s178.e0 IEPA.d74.s178.e1	leptin	UCP1	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP1. This suggests that leptin influences the expression of UCP1, implying an interaction between the leptin protein and UCP1 protein. The maintenance of high UCP1 expression in the presence of leptin is a direct effect of leptin on UCP1, indicating an interaction.</s>
IEPA.d74 IEPA.d74.s178.e0 IEPA.d74.s178.e2	leptin	UCP2	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP2. This suggests that leptin influences the expression of UCP2, implying an interaction between the leptin protein and the UCP2 protein. The maintenance of high UCP2 mRNA levels in the presence of leptin compared to the decreased levels in pair-fed rats supports this interaction.</s>
IEPA.d74 IEPA.d74.s178.e0 IEPA.d74.s178.e3	leptin	UCP3	[INST]Context: [PMID: 9648822 Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Continuous (4 days) intracerebroventricular leptin infusion (12 microg/day) was performed in lean rats, and its hormonometabolic effects were determined. Intracerebroventricular leptin administration did not result in leakage of the hormone into the peripheral circulation. Thus, its effects were elicited by its presence within the central nervous system. Intracerebroventricular leptin infusion produced marked decreases in food intake and body weight gain relative to vehicle-infused fed ad libitum rats. Because decreases in food intake alter hormonometabolic homeostasis, additional control rats pair-fed to the amount of food consumed by leptin-infused ones were included in the study. Intracerebroventricular leptin-infused and vehicle-infused pair-fed rats were characterized, relative to vehicle-infused ad libitum-fed animals, by decreases in body weight and insulinemia and by increases in insulin-stimulated overall glucose utilization and muscle and brown adipose tissue glucose utilization index. Brown adipose tissue uncoupling protein (UCP)1, UCP2, and UCP3 mRNA levels were markedly decreased in pair-fed animals relative to those of fed ad libitum control animals, as were liver and white adipose tissue UCP2 and muscle UCP3 mRNA levels. In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues. Thus, despite analogies between leptin's effects and those of pair-feeding with regard to glucose handling, their respective underlying mechanisms differ. While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats. This effect of leptin may prevent subsequent excessive storage processes, thereby maintaining normal body homeostasis.] Question: Based on the provided context, do the terms [leptin protein] and [UCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that intracerebroventricular leptin infusion leads to the maintenance or enhancement of uncoupling protein (UCP) expression, including UCP3. This suggests that leptin influences the expression of UCP3, thereby indicating an interaction between leptin protein and UCP3 protein. The maintenance of high UCP3 expression in the presence of leptin is a direct effect of leptin on UCP3, demonstrating their interaction.</s>
IEPA.d76 IEPA.d76.s182.e0 IEPA.d76.s182.e1	oxytocin	insulin	[INST]Context: [PMID: 9660095 Melatonin inhibits oxytocin response to insulin-induced hypoglycemia, but not to angiotensin II in normal men. In order to establish whether melatonin alters basal and/or stimulated oxytocin secretion, 18 normal men were treated (p.o.) with 6 or 12 mg melatonin or placebo in basal conditions (N-6 subjects) or concomitantly to the administration of insulin (O.15 IU/kg body weight in an i.v. bolus) (N-6 subjects) or angiotensin II (increasing doses of 4, 8 and 16 ng/kg/min, at intervals of 20 min). The administration of 6 or 12 mg melatonin did not change basal and angiotensin II-stimulated oxytocin secretion. In contrast, the oxytocin response to insulin-induced hypoglycemia was significantly reduced by melatonin treatment. In fact, the mean peak oxytocin response to hypoglycemia was 2.2 times higher than baseline in the absence of melatonin, whereas it was 1.6 times higher than basal value after administration of 6 or 12 mg melatonin. These data indicate an involvement of melatonin in the regulation of the oxytocin response to hypoglycemia in normal men. The lack of effects of melatonin on basal and angiotensin II-stimulated oxytocin secretion argues against the possibility that melatonin exerts an overall modulatory role on oxytocin secretion in humans.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that melatonin inhibits the oxytocin response to insulin-induced hypoglycemia. This suggests that insulin and oxytocin interact in a physiological pathway where insulin administration leads to a response in oxytocin secretion. The fact that melatonin alters this response implies that insulin and oxytocin are part of the same regulatory mechanism, thus interacting with each other.</s>
IEPA.d76 IEPA.d76.s184.e0 IEPA.d76.s184.e1	oxytocin	insulin	[INST]Context: [PMID: 9660095 Melatonin inhibits oxytocin response to insulin-induced hypoglycemia, but not to angiotensin II in normal men. In order to establish whether melatonin alters basal and/or stimulated oxytocin secretion, 18 normal men were treated (p.o.) with 6 or 12 mg melatonin or placebo in basal conditions (N-6 subjects) or concomitantly to the administration of insulin (O.15 IU/kg body weight in an i.v. bolus) (N-6 subjects) or angiotensin II (increasing doses of 4, 8 and 16 ng/kg/min, at intervals of 20 min). The administration of 6 or 12 mg melatonin did not change basal and angiotensin II-stimulated oxytocin secretion. In contrast, the oxytocin response to insulin-induced hypoglycemia was significantly reduced by melatonin treatment. In fact, the mean peak oxytocin response to hypoglycemia was 2.2 times higher than baseline in the absence of melatonin, whereas it was 1.6 times higher than basal value after administration of 6 or 12 mg melatonin. These data indicate an involvement of melatonin in the regulation of the oxytocin response to hypoglycemia in normal men. The lack of effects of melatonin on basal and angiotensin II-stimulated oxytocin secretion argues against the possibility that melatonin exerts an overall modulatory role on oxytocin secretion in humans.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that melatonin inhibits the oxytocin response to insulin-induced hypoglycemia. This suggests that insulin and oxytocin interact in a physiological pathway where insulin administration leads to a response in oxytocin secretion. The fact that melatonin alters this response implies that insulin and oxytocin are part of the same regulatory mechanism, thus interacting with each other.</s>
IEPA.d77 IEPA.d77.s186.e0 IEPA.d77.s186.e1	insulin	oxytocin	[INST]Context: [PMID: 9662044 Upregulation of hypothalamic nitric oxide synthase gene expression in streptozotocin-induced diabetic rats. Plasma arginine vasopressin (AVP) is known to be elevated in patients with uncontrolled insulin-dependent diabetes mellitus who have plasma hyperosmolality with hyperglycaemia. Although osmotic stimuli cause an increase in nitric oxide synthase (NOS) activity as well as synthesis of AVP and oxytocin in the paraventricular (PVN) and supraoptic nuclei (SON), it is not known whether NOS activity in the hypothalamus changes in the diabetic patients who have plasma hyperosmolality with hyperglycaemia caused by insulin deficiency. Expression of the neuronal (n) NOS gene in the PVN and SON in streptozotocin (STZ)-induced diabetic rats was investigated by using in situ hybridization histochemistry and NADPH-diaphorase histochemical staining. Four weeks after intraperitoneal (i. p.) administration of STZ, male Wistar rats developed hyperglycaemia and plasma hyperosmolality. The expression of nNOS gene and NADPH-diaphorase staining in the PVN and SON remarkably increased in STZ-induced diabetic rats compared to control rats. Three weeks after administration of STZ, the diabetic rats were subcutaneously treated with insulin for 1 week, which resulted in significant suppression of the induction of nNOS, AVP and oxytocin gene expression in the PVN and SON. Furthermore, the induction of nNOS gene expression in the PVN and SON was suppressed in STZ-induced diabetic rats treated with phlorizin and diet to normalize hyperglycaemia without insulin treatment. These results suggest that upregulation of nNOS gene expression as well as AVP and oxytocin gene expression in the PVN and SON in STZ-induced diabetic rats may be associated with hyperglycaemia and plamsa hyperosmolality.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of streptozotocin (STZ)-induced diabetes on the expression of nitric oxide synthase (NOS) and the hormones AVP and oxytocin in the hypothalamus. While it mentions that plasma arginine vasopressin (AVP) is elevated in diabetic patients and that the expression of AVP and oxytocin genes is upregulated in the PVN and SON of STZ-induced diabetic rats, there is no direct interaction mentioned between insulin protein and oxytocin protein. Instead, the context focuses on the effects of hyperglycaemia and plasma hyperosmolality on the expression of these genes and proteins. Therefore, based on the provided information, there is no evidence of a direct interaction between insulin protein and oxytocin protein.</s>
IEPA.d80 IEPA.d80.s191.e0 IEPA.d80.s191.e1	leptin	UCP-1	[INST]Context: [PMID: 9682828 Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Leptin is an adipocyte-derived blood-borne satiety factor that decreases food intake and increases energy expenditure, thereby leading to a substantial decrease in body weight. To explore the possible roles of the hypothalamic melanocortin system in leptin action, we examined the effects of intracerebroventricular (i.c.v.) injection of leptin with or without SHU9119, a potent antagonist of alpha-melanocyte stimulating hormone, on food intake, body weight, and mitochondrial uncoupling protein-1 (UCP-1) mRNA expression in the brown adipose tissue (BAT) in rats. A single i.c.v. injection of leptin decreased cumulative food intake and body weight gain, and increased UCP-1 mRNA expression during 3 h at the onset of the dark phase. Inhibition of food intake and body weight change with leptin was reversed by co-injection of SHU9119 in a dose-dependent manner. Co-injection of SHU9119 also inhibited completely the leptin-induced increase in UCP-1 mRNA expression in the BAT. Treatment with SHU9119 alone did not affect food intake, body weight, and UCP-1 mRNA expression in rats. The present study provides evidence that the hypothalamic melanocortin system plays a central role in both satiety effect and sympathetic activation of leptin.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin, an adipocyte-derived blood-borne satiety factor, increases the expression of UCP-1 (uncoupling protein-1) mRNA in the brown adipose tissue (BAT). This suggests that leptin influences the expression of UCP-1, indicating an interaction between the leptin protein and the UCP-1 protein. The study demonstrates that leptin's effects on food intake, body weight, and UCP-1 mRNA expression are mediated through the hypothalamic melanocortin system, further supporting the interaction between leptin and UCP-1.</s>
IEPA.d80 IEPA.d80.s192.e0 IEPA.d80.s192.e1	leptin	UCP-1	[INST]Context: [PMID: 9682828 Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Leptin is an adipocyte-derived blood-borne satiety factor that decreases food intake and increases energy expenditure, thereby leading to a substantial decrease in body weight. To explore the possible roles of the hypothalamic melanocortin system in leptin action, we examined the effects of intracerebroventricular (i.c.v.) injection of leptin with or without SHU9119, a potent antagonist of alpha-melanocyte stimulating hormone, on food intake, body weight, and mitochondrial uncoupling protein-1 (UCP-1) mRNA expression in the brown adipose tissue (BAT) in rats. A single i.c.v. injection of leptin decreased cumulative food intake and body weight gain, and increased UCP-1 mRNA expression during 3 h at the onset of the dark phase. Inhibition of food intake and body weight change with leptin was reversed by co-injection of SHU9119 in a dose-dependent manner. Co-injection of SHU9119 also inhibited completely the leptin-induced increase in UCP-1 mRNA expression in the BAT. Treatment with SHU9119 alone did not affect food intake, body weight, and UCP-1 mRNA expression in rats. The present study provides evidence that the hypothalamic melanocortin system plays a central role in both satiety effect and sympathetic activation of leptin.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin, an adipocyte-derived blood-borne satiety factor, increases the expression of UCP-1 (uncoupling protein-1) mRNA in the brown adipose tissue (BAT). This suggests that leptin influences the expression of UCP-1, indicating an interaction between the leptin protein and the UCP-1 protein. The study demonstrates that leptin's effects on food intake, body weight, and UCP-1 mRNA expression are mediated through the hypothalamic melanocortin system, further supporting the interaction between leptin and UCP-1.</s>
IEPA.d81 IEPA.d81.s193.e0 IEPA.d81.s193.e1	amyloid	phospholipase C	[INST]Context: [PMID: 9685679 (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid beta peptide. It has been established that amyloid beta peptide (AbetaP) activates phospholipase A2, phospholipase C and phospholipase D of LA-N-2 cells and other cell types. Nicotine in addition to being a cholinergic agonist, may be neuroprotective. We have investigated the ability of (-)nicotine to blunt the phospholipase activations by AbetaP in LA-N-2 cells. (-)Nicotine inhibits the AbetaP activation of phospholipase A2, with an IC50 of 76 microM and of phospholipase D with an IC50 of 252 microM. (-)Nicotine did not blunt the AbetaP activation of phospholipase C. These inhibitions of AbetaP activations were not observed with (+)nicotine or cotinine. The (-)nicotine inhibition of AbetaP activation of these two phospholipases was unaffected by hexamethonium and D-tubocurarine. There was no inhibition of the phospholipase A2 activity present in homogenates of LA-N-2 cells. Exposure of LA-N-2 cells to (-)nicotine for 2 h resulted in the blockade of phospholipase A2 activation by kainate and AbetaP but did not affect the ability of quisqualate and AbetaP to activate phospholipase D. These data suggest that if the nicotine inhibition of AbetaP activations is receptor occupancy mediated then it is by an atypical receptor type.] Question: Based on the provided context, do the terms [amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta peptide (AbetaP) activates phospholipase C in LA-N-2 cells. This suggests that there is an interaction between amyloid protein and phospholipase C protein, as the activation of one enzyme by the other is described.</s>
IEPA.d81 IEPA.d81.s194.e0 IEPA.d81.s194.e1	AbetaP	phospholipase C	[INST]Context: [PMID: 9685679 (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid beta peptide. It has been established that amyloid beta peptide (AbetaP) activates phospholipase A2, phospholipase C and phospholipase D of LA-N-2 cells and other cell types. Nicotine in addition to being a cholinergic agonist, may be neuroprotective. We have investigated the ability of (-)nicotine to blunt the phospholipase activations by AbetaP in LA-N-2 cells. (-)Nicotine inhibits the AbetaP activation of phospholipase A2, with an IC50 of 76 microM and of phospholipase D with an IC50 of 252 microM. (-)Nicotine did not blunt the AbetaP activation of phospholipase C. These inhibitions of AbetaP activations were not observed with (+)nicotine or cotinine. The (-)nicotine inhibition of AbetaP activation of these two phospholipases was unaffected by hexamethonium and D-tubocurarine. There was no inhibition of the phospholipase A2 activity present in homogenates of LA-N-2 cells. Exposure of LA-N-2 cells to (-)nicotine for 2 h resulted in the blockade of phospholipase A2 activation by kainate and AbetaP but did not affect the ability of quisqualate and AbetaP to activate phospholipase D. These data suggest that if the nicotine inhibition of AbetaP activations is receptor occupancy mediated then it is by an atypical receptor type.] Question: Based on the provided context, do the terms [AbetaP protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between AbetaP protein and phospholipase C protein. While it mentions that AbetaP activates phospholipase C, it also states that (-)nicotine does not blunt the AbetaP activation of phospholipase C. This suggests that the activation of phospholipase C by AbetaP is not affected by (-)nicotine, implying that there is no direct interaction between AbetaP and phospholipase C in this context.</s>
IEPA.d82 IEPA.d82.s195.e0 IEPA.d82.s195.e1	leptin	uncoupling protein	[INST]Context: [PMID: 9688683 Neural site of leptin influence on neuropeptide Y signaling pathways altering feeding and uncoupling protein. Inhibition of a signal that produces positive energy balance involving neuropeptide Y (NPY) projection from arcuate nucleus (Arc; site of NPY synthesis) to paraventricular nucleus (PVN; site of NPY release) is one potential mechanism of leptin action. NPY in the PVN increases feeding and decreases uncoupling protein (UCP) activity in brown fat, whereas leptin decreases NPY biosynthesis in the Arc, which presumably decreases PVN NPY. It is hypothesized that decreased NPY activity is necessary for the satiety and thermogenic effects of leptin. To test this, we first determined the effect of leptin on feeding in two paradigms: satiated rats and food-deprived rats. Leptin was effective in decreasing feeding in the satiated rats but ineffective in the food-deprived rats. Next, we determined that leptin decreases NPY and increases UCP gene expression. Finally, we injected leptin intracerebroventricularly before specific PVN NPY microinjection. We found that repletion of NPY in PVN by specific NPY microinjection reverses the feeding-inhibitory and thermogenic effects of centrally administered leptin, the first functional evidence indicating that leptin acts on the Arc-PVN feeding-regulatory pathway.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin influences the expression of uncoupling protein (UCP) gene. Specifically, it mentions that leptin increases UCP gene expression. This suggests that leptin and uncoupling protein are part of the same regulatory pathway, where leptin's action on the Arc-PVN feeding-regulatory pathway affects the expression of UCP, thereby influencing thermogenic effects. Therefore, leptin and uncoupling protein interact in a regulatory manner.</s>
IEPA.d82 IEPA.d82.s197.e0 IEPA.d82.s197.e1	leptin	UCP	[INST]Context: [PMID: 9688683 Neural site of leptin influence on neuropeptide Y signaling pathways altering feeding and uncoupling protein. Inhibition of a signal that produces positive energy balance involving neuropeptide Y (NPY) projection from arcuate nucleus (Arc; site of NPY synthesis) to paraventricular nucleus (PVN; site of NPY release) is one potential mechanism of leptin action. NPY in the PVN increases feeding and decreases uncoupling protein (UCP) activity in brown fat, whereas leptin decreases NPY biosynthesis in the Arc, which presumably decreases PVN NPY. It is hypothesized that decreased NPY activity is necessary for the satiety and thermogenic effects of leptin. To test this, we first determined the effect of leptin on feeding in two paradigms: satiated rats and food-deprived rats. Leptin was effective in decreasing feeding in the satiated rats but ineffective in the food-deprived rats. Next, we determined that leptin decreases NPY and increases UCP gene expression. Finally, we injected leptin intracerebroventricularly before specific PVN NPY microinjection. We found that repletion of NPY in PVN by specific NPY microinjection reverses the feeding-inhibitory and thermogenic effects of centrally administered leptin, the first functional evidence indicating that leptin acts on the Arc-PVN feeding-regulatory pathway.] Question: Based on the provided context, do the terms [leptin protein] and [UCP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin influences the expression of UCP (uncoupling protein) genes. Specifically, it mentions that leptin increases UCP gene expression. This suggests that leptin and UCP proteins are part of the same regulatory pathway, where leptin's action on NPY signaling pathways leads to changes in UCP expression, thereby affecting thermogenic activity. Therefore, leptin and UCP proteins interact in a regulatory manner.</s>
IEPA.d84 IEPA.d84.s199.e0 IEPA.d84.s199.e1	insulin	oxytocin	[INST]Context: [PMID: 9698023 Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics. OBJECTIVES: Arginine-vasopressin (AVP) and oxytocin (OT) secretions are abnormally stimulated by hypoglycaemia in patients with IDDM. Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous insulin secretion, we wondered whether this factor also regulates OT secretion. DESIGN: Case-control study: the OT response to insulin-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion. SUBJECTS: Ten normal male subjects, 10 C-peptide positive (CpP) and 11 C-peptide negative (CpN) male diabetic patients. PRELIMINARY STUDIES: plasma C-peptide levels were measured after intravenous administration of 1 mg glucagon. Insulin tolerance test (ITT): diabetics were studied after optimization of their metabolic status by 3 days of treatment with constant subcutaneous insulin infusion. CpP and CpN diabetics and normal controls were tested with an intravenous administration of 0.15 IU per kg body weight insulin. Blood samples for OT assay were taken just before the rapid injection of insulin (time 0) and at time 15, 30, 45 and 60 min. RESULTS: The basal concentrations of OT were similar in all groups. Insulin induced a similar hypoglycaemic nadir in all groups at 30 min, even though diabetic groups showed a delayed recovery in blood glucose levels. The glycaemic pattern was similar in all diabetic patients. Hypoglycaemia-induced OT rise was significantly higher in the two diabetic groups than in the normal group. However, CpN patients showed significantly higher OT increments than CpP subjects. CONCLUSIONS: These data indicate that a residual endogenous insulin secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that residual endogenous insulin secretion influences the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics. Specifically, it mentions that the oxytocin (OT) response to insulin-induced hypoglycaemia is significantly higher in diabetic patients with residual endogenous insulin secretion compared to those without it. This suggests that insulin secretion and oxytocin secretion are interacting in a way that affects the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM. Therefore, the terms "insulin protein" and "oxytocin protein" are interacting in this context.</s>
IEPA.d84 IEPA.d84.s200.e0 IEPA.d84.s200.e1	insulin	OT	[INST]Context: [PMID: 9698023 Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics. OBJECTIVES: Arginine-vasopressin (AVP) and oxytocin (OT) secretions are abnormally stimulated by hypoglycaemia in patients with IDDM. Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous insulin secretion, we wondered whether this factor also regulates OT secretion. DESIGN: Case-control study: the OT response to insulin-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion. SUBJECTS: Ten normal male subjects, 10 C-peptide positive (CpP) and 11 C-peptide negative (CpN) male diabetic patients. PRELIMINARY STUDIES: plasma C-peptide levels were measured after intravenous administration of 1 mg glucagon. Insulin tolerance test (ITT): diabetics were studied after optimization of their metabolic status by 3 days of treatment with constant subcutaneous insulin infusion. CpP and CpN diabetics and normal controls were tested with an intravenous administration of 0.15 IU per kg body weight insulin. Blood samples for OT assay were taken just before the rapid injection of insulin (time 0) and at time 15, 30, 45 and 60 min. RESULTS: The basal concentrations of OT were similar in all groups. Insulin induced a similar hypoglycaemic nadir in all groups at 30 min, even though diabetic groups showed a delayed recovery in blood glucose levels. The glycaemic pattern was similar in all diabetic patients. Hypoglycaemia-induced OT rise was significantly higher in the two diabetic groups than in the normal group. However, CpN patients showed significantly higher OT increments than CpP subjects. CONCLUSIONS: These data indicate that a residual endogenous insulin secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM.] Question: Based on the provided context, do the terms [insulin protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that residual endogenous insulin secretion influences the abnormal oxytocin (OT) response to hypoglycaemia in insulin-dependent diabetics. Specifically, it mentions that the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM is partially protected by residual endogenous insulin secretion. This suggests that insulin and OT interact in a regulatory manner, where insulin secretion influences the secretion of OT.</s>
IEPA.d84 IEPA.d84.s201.e0 IEPA.d84.s201.e1	OT	insulin	[INST]Context: [PMID: 9698023 Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics. OBJECTIVES: Arginine-vasopressin (AVP) and oxytocin (OT) secretions are abnormally stimulated by hypoglycaemia in patients with IDDM. Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous insulin secretion, we wondered whether this factor also regulates OT secretion. DESIGN: Case-control study: the OT response to insulin-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion. SUBJECTS: Ten normal male subjects, 10 C-peptide positive (CpP) and 11 C-peptide negative (CpN) male diabetic patients. PRELIMINARY STUDIES: plasma C-peptide levels were measured after intravenous administration of 1 mg glucagon. Insulin tolerance test (ITT): diabetics were studied after optimization of their metabolic status by 3 days of treatment with constant subcutaneous insulin infusion. CpP and CpN diabetics and normal controls were tested with an intravenous administration of 0.15 IU per kg body weight insulin. Blood samples for OT assay were taken just before the rapid injection of insulin (time 0) and at time 15, 30, 45 and 60 min. RESULTS: The basal concentrations of OT were similar in all groups. Insulin induced a similar hypoglycaemic nadir in all groups at 30 min, even though diabetic groups showed a delayed recovery in blood glucose levels. The glycaemic pattern was similar in all diabetic patients. Hypoglycaemia-induced OT rise was significantly higher in the two diabetic groups than in the normal group. However, CpN patients showed significantly higher OT increments than CpP subjects. CONCLUSIONS: These data indicate that a residual endogenous insulin secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM.] Question: Based on the provided context, do the terms [OT protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that residual endogenous insulin secretion influences the abnormal oxytocin (OT) response to hypoglycaemia in insulin-dependent diabetics. Specifically, it mentions that the OT response is higher in diabetic patients with residual endogenous insulin secretion compared to those without it. This suggests that insulin and OT interact in a regulatory manner, where the presence of residual insulin affects the secretion of OT. Therefore, the terms [OT protein] and [insulin protein] are interacting in the sense that insulin secretion influences the secretion of OT.</s>
IEPA.d84 IEPA.d84.s203.e0 IEPA.d84.s203.e1	insulin	OT	[INST]Context: [PMID: 9698023 Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics. OBJECTIVES: Arginine-vasopressin (AVP) and oxytocin (OT) secretions are abnormally stimulated by hypoglycaemia in patients with IDDM. Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous insulin secretion, we wondered whether this factor also regulates OT secretion. DESIGN: Case-control study: the OT response to insulin-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion. SUBJECTS: Ten normal male subjects, 10 C-peptide positive (CpP) and 11 C-peptide negative (CpN) male diabetic patients. PRELIMINARY STUDIES: plasma C-peptide levels were measured after intravenous administration of 1 mg glucagon. Insulin tolerance test (ITT): diabetics were studied after optimization of their metabolic status by 3 days of treatment with constant subcutaneous insulin infusion. CpP and CpN diabetics and normal controls were tested with an intravenous administration of 0.15 IU per kg body weight insulin. Blood samples for OT assay were taken just before the rapid injection of insulin (time 0) and at time 15, 30, 45 and 60 min. RESULTS: The basal concentrations of OT were similar in all groups. Insulin induced a similar hypoglycaemic nadir in all groups at 30 min, even though diabetic groups showed a delayed recovery in blood glucose levels. The glycaemic pattern was similar in all diabetic patients. Hypoglycaemia-induced OT rise was significantly higher in the two diabetic groups than in the normal group. However, CpN patients showed significantly higher OT increments than CpP subjects. CONCLUSIONS: These data indicate that a residual endogenous insulin secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM.] Question: Based on the provided context, do the terms [insulin protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that residual endogenous insulin secretion influences the abnormal oxytocin (OT) response to hypoglycaemia in insulin-dependent diabetics. Specifically, it mentions that the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM is partially protected by residual endogenous insulin secretion. This suggests that insulin and OT interact in a regulatory manner, where insulin secretion influences the secretion of OT.</s>
IEPA.d89 IEPA.d89.s209.e0 IEPA.d89.s209.e3	UCP2	leptin	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [UCP2 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin administration increases the gene expression of UCP2 in EWAT. This suggests that leptin and UCP2 protein are part of a regulatory pathway where leptin influences the expression of UCP2, thereby implying an interaction between the two proteins.</s>
IEPA.d89 IEPA.d89.s209.e1 IEPA.d89.s209.e3	UCP3	leptin	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [UCP3 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of leptin administration and food restriction on the expression of various genes, including UCP1, UCP2, UCP3, and leptin itself. While it mentions that leptin increases the expression of UCP3 in brown adipose tissue (BAT), it does not indicate a direct interaction between the UCP3 protein and the leptin protein. Instead, it describes how leptin influences the expression of these genes, but not a direct interaction between the proteins themselves.</s>
IEPA.d89 IEPA.d89.s211.e0 IEPA.d89.s211.e1	Leptin	UCP1	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin administration increases the gene expression of UCP1 in brown adipose tissue (BAT). This suggests that leptin and UCP1 are part of a regulatory pathway where leptin influences the expression of UCP1, indicating an interaction between the two proteins.</s>
IEPA.d89 IEPA.d89.s211.e0 IEPA.d89.s211.e2	Leptin	UCP3	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of leptin administration and food restriction on the gene expression of various proteins, including UCP3, in different tissues. While it mentions that leptin increases UCP3 mRNA levels in brown adipose tissue (BAT), it does not indicate a direct interaction between the leptin protein and the UCP3 protein. Instead, it describes the modulation of gene expression by leptin, which is a separate process from a direct protein-protein interaction. Therefore, based on the given information, there is no evidence of a direct interaction between leptin protein and UCP3 protein.</s>
IEPA.d89 IEPA.d89.s211.e0 IEPA.d89.s211.e3	Leptin	UCP2	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin administration increases the gene expression of UCP2 in EWAT. This suggests that leptin and UCP2 are interacting in a regulatory manner, where leptin influences the expression of UCP2. Therefore, the terms [Leptin protein] and [UCP2 protein] interact with each other.</s>
IEPA.d89 IEPA.d89.s212.e0 IEPA.d89.s212.e1	leptin	UCP2	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [leptin protein] and [UCP2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin administration increases the gene expression of UCP2 in EWAT. This suggests that leptin and UCP2 are part of a regulatory pathway where leptin influences the expression of UCP2. Therefore, there is an interaction between leptin protein and UCP2 protein in the sense that leptin affects the expression of UCP2.</s>
IEPA.d89 IEPA.d89.s212.e0 IEPA.d89.s212.e2	leptin	UCP1	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [leptin protein] and [UCP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of leptin administration and food restriction on the gene expression of various proteins, including leptin, UCP1, UCP2, LPL, beta3AR, and HSL in different adipose tissues. While it mentions that leptin increases the gene expression of UCP1 in brown adipose tissue (BAT), it does not indicate a direct interaction between the leptin protein and the UCP1 protein. Instead, it describes the effects of leptin on the expression of UCP1 as part of a broader set of changes in gene expression. Therefore, there is no direct interaction mentioned between leptin protein and UCP1 protein.</s>
IEPA.d89 IEPA.d89.s212.e0 IEPA.d89.s212.e3	leptin	UCP3	[INST]Context: [PMID: 9795377 UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats. The groups were administered leptin for 1 week, or had food restricted to the amount of food consumed by the leptin-treated animals, or had free access to food. Leptin administration increased serum leptin concentrations 50-fold and decreased food consumption by 43%, whereas serum insulin and corticosterone concentrations were unchanged. Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT. In contrast, UCP2 mRNA levels were unchanged in PWAT and BAT. In WAT from food-restricted rats, leptin gene expression was diminished by 40% compared with those fed ad libitum. With leptin administration, there was a further 50% decrease in leptin expression. LPL mRNA levels were decreased by food restriction but not by leptin in WAT, whereas beta3AR and HSL mRNA levels were unchanged with either food restriction or leptin treatment. The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT. In addition, with leptin administration there is a decrease in leptin gene expression in WAT, independent of food intake and serum insulin and corticosterone concentrations.] Question: Based on the provided context, do the terms [leptin protein] and [UCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of leptin administration and food restriction on the gene expression of various proteins, including UCP3, in different tissues. While it mentions that leptin increases UCP3 mRNA levels in brown adipose tissue (BAT), it does not indicate a direct interaction between the leptin protein and the UCP3 protein. Instead, it describes the modulation of gene expression by leptin, which is a separate process from a direct protein-protein interaction. Therefore, based on the given information, there is no evidence of a direct interaction between leptin protein and UCP3 protein.</s>
IEPA.d91 IEPA.d91.s215.e0 IEPA.d91.s215.e1	insulin	phospholipase C	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (Oxy) stimulates insulin release through both phospholipase C (PLC)-dependent and -independent pathways. Specifically, Oxy increases intracellular calcium concentration ([Ca2+]i) and inositol 1,4,5-triphosphate (IP3) levels, which are mediated by PLC. The inhibition of PLC by U-73122 reduces Oxy-induced increases in [Ca2+]i and IP3, and consequently, it also reduces Oxy-induced insulin release. This suggests that PLC plays a role in the signaling pathway leading to insulin release, indicating an interaction between the phospholipase C protein and the insulin protein.</s>
IEPA.d91 IEPA.d91.s216.e0 IEPA.d91.s216.e1	insulin	PLC	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [insulin protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (Oxy) stimulates insulin release through both phospholipase C (PLC)-dependent and -independent pathways. Specifically, it mentions that U-73122, a PLC inhibitor, reduces the Oxy-induced increase in insulin release. This suggests that PLC is involved in the signaling pathway that leads to insulin release, indicating an interaction between the PLC protein and the insulin protein.</s>
IEPA.d91 IEPA.d91.s217.e0 IEPA.d91.s217.e1	Oxy	inositol 1, 4, 5-triphosphate	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [inositol 1, 4, 5-triphosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (Oxy) increases insulin release through both phospholipase C (PLC) and non-PLC mediated signal transduction mechanisms. Specifically, it mentions that Oxy-induced increases in intracellular calcium concentration ([Ca2+]i) and inositol 1,4,5-triphosphate (IP3) are inhibited by U-73122, a PLC inhibitor. This suggests that Oxy interacts with the PLC pathway, which in turn influences the production of IP3. Therefore, Oxy and inositol 1,4,5-triphosphate are part of the same signaling pathway, indicating an interaction.</s>
IEPA.d91 IEPA.d91.s218.e0 IEPA.d91.s218.e1	Oxy	IP3	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (Oxy) increases the intracellular concentration of inositol 1,4,5-triphosphate (IP3) through a phospholipase C (PLC)-dependent pathway. This suggests that Oxy protein interacts with the IP3 protein in the signaling pathway leading to insulin release. The inhibition of PLC by U-73122 reduces the Oxy-induced increase in IP3, further supporting the interaction between Oxy and IP3 in this signaling cascade.</s>
IEPA.d91 IEPA.d91.s219.e0 IEPA.d91.s219.e1	Oxytocin	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d91 IEPA.d91.s220.e0 IEPA.d91.s220.e1	oxytocin	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d91 IEPA.d91.s221.e0 IEPA.d91.s221.e1	Oxy	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d91 IEPA.d91.s222.e0 IEPA.d91.s222.e1	Oxy	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d91 IEPA.d91.s223.e1 IEPA.d91.s223.e2	Oxy	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d91 IEPA.d91.s224.e0 IEPA.d91.s224.e1	Oxy	insulin	[INST]Context: [PMID: 9863156 Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways. AIM: To study the mechanisms underlying oxytocin (Oxy)-induced insulin release. METHODS: In a clonal pancreatic beta-cell line, RINm5F cells. RESULTS: Oxy increased insulin release and [Ca2+]i in a concentration-dependent manner. Oxy-induced insulin release was not altered by pretreatment with pertussis toxin (PT). U-73122 (2-8 mumol.L-1), a phospholipase C (PLC) inhibitor, concentration-dependently inhibited Oxy-induced increases in [Ca2+]i with IC50 value of 2.8 +/- 0.2 mumol.L-1. In addition, U-73122 diminished the Oxy-induced increase in intracellular concentration of inositol 1, 4, 5-triphosphate (IP3). U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively. CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms.] Question: Based on the provided context, do the terms [Oxy protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (Oxy) stimulates insulin release in a clonal beta-cell line RINm5F. This suggests that oxytocin interacts with the insulin-producing cells to induce the release of insulin. The study details the mechanisms involved, including phospholipase C-dependent and -independent pathways, which further support the interaction between oxytocin and insulin release.</s>
IEPA.d93 IEPA.d93.s226.e0 IEPA.d93.s226.e1	protein kinase C	AVP	[INST]Context: [PMID: 9870709 Interaction between arginine vasopressin- and raised extracellular potassium-stimulated pathways in adrenocorticotropin secretion. The intracellular regulation of adrenocorticotropin (ACTH) secretion from pituitary corticotroph cells was investigated by simultaneously exposing cultured ovine corticotrophs to arginine vasopressin (AVP) and raised extracellular K+ concentration ([K+]e). Both of these secretagogues activate L-type voltage-sensitive calcium channels (L-VSCC) as part of their respective ACTH secretory responses. When given together at high concentrations, AVP and raised [K+]e caused ACTH responses that were smaller in magnitude than the sum of the individual responses. However, at low agonist concentrations the simultaneous responses were greater in magnitude (i.e., synergistic). Further investigation suggested that activation of protein kinase C (PKC), which is part of the AVP-induced intracellular signalling pathway, is necessary and sufficient for the generation of the synergistic response, although it is not obligatory for AVP-induced ACTH release.] Question: Based on the provided context, do the terms [protein kinase C protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the activation of protein kinase C (PKC) is necessary and sufficient for the generation of the synergistic response in ACTH secretion when arginine vasopressin (AVP) and raised extracellular potassium concentration ([K+]e) are given together. This suggests that AVP interacts with PKC as part of its intracellular signaling pathway to stimulate ACTH release. Therefore, AVP protein and protein kinase C protein interact with each other.</s>
IEPA.d96 IEPA.d96.s231.e0 IEPA.d96.s231.e2	uncoupling protein 2	leptin	[INST]Context: [PMID: 9892233 Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. The mechanisms underlying the increase in energy expenditure during leptin treatment are not clear. We recently showed that a 5-h intravenous or intracerebroventricular infusion of leptin elevated basal glucose uptake in skeletal muscle (SM) and brown adipose tissue and increased whole-body glucose turnover in C57Bl/6J mice (Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ: Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-377, 1997). We extended the previous study by measuring steady-state levels of uncoupling protein (UCP)-2 mRNA and UCP-3 mRNA in white adipose tissue (WAT) and SM. Leptin by intravenous or intracerebroventricular infusion for 5 h was associated with a decrease in UCP-2 mRNA in WAT (47-52%) and UCP-3 mRNA in SM (33-37%). Because overexpression of UCP-2 or UCP-3 can depolarize the inner mitochondrial membrane, suppression of UCP-2 mRNA and UCP-3 mRNA may in fact lower respiratory demands in WAT and SM. This is consistent with the parallel suppression of cytochrome oxidase subunit IV (COX-IV) mRNA in WAT (35-39%) after leptin infusion. COX-IV mRNA in SM did not respond to acute leptin treatment. Mitochondrial inorganic phosphate carrier (P1C) mRNA was also suppressed in WAT (33-35%) by either method of leptin infusion, but only intravenous infusion of leptin reduced P1C mRNA in SM (40%). Denervation suppressed mRNA levels for UCP-2 (49%), UCP-3 (36%), and COX-IV (59%) and eliminated the acute response to leptin in SM. The comparable response to leptin under intravenous or intracerebroventricular infusion and the loss of responsiveness after denervation strongly suggest that the acute effects of leptin involve central signaling pathways.] Question: Based on the provided context, do the terms [uncoupling protein 2 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin treatment leads to a decrease in uncoupling protein 2 (UCP-2) mRNA in white adipose tissue (WAT). This suggests that leptin influences the expression of UCP-2, which implies an interaction between leptin protein and UCP-2 protein. The decrease in UCP-2 mRNA levels is a direct effect of leptin treatment, indicating that leptin protein interacts with the regulatory mechanisms of UCP-2 protein expression.</s>
IEPA.d96 IEPA.d96.s231.e1 IEPA.d96.s231.e2	uncoupling protein 3	leptin	[INST]Context: [PMID: 9892233 Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. The mechanisms underlying the increase in energy expenditure during leptin treatment are not clear. We recently showed that a 5-h intravenous or intracerebroventricular infusion of leptin elevated basal glucose uptake in skeletal muscle (SM) and brown adipose tissue and increased whole-body glucose turnover in C57Bl/6J mice (Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ: Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-377, 1997). We extended the previous study by measuring steady-state levels of uncoupling protein (UCP)-2 mRNA and UCP-3 mRNA in white adipose tissue (WAT) and SM. Leptin by intravenous or intracerebroventricular infusion for 5 h was associated with a decrease in UCP-2 mRNA in WAT (47-52%) and UCP-3 mRNA in SM (33-37%). Because overexpression of UCP-2 or UCP-3 can depolarize the inner mitochondrial membrane, suppression of UCP-2 mRNA and UCP-3 mRNA may in fact lower respiratory demands in WAT and SM. This is consistent with the parallel suppression of cytochrome oxidase subunit IV (COX-IV) mRNA in WAT (35-39%) after leptin infusion. COX-IV mRNA in SM did not respond to acute leptin treatment. Mitochondrial inorganic phosphate carrier (P1C) mRNA was also suppressed in WAT (33-35%) by either method of leptin infusion, but only intravenous infusion of leptin reduced P1C mRNA in SM (40%). Denervation suppressed mRNA levels for UCP-2 (49%), UCP-3 (36%), and COX-IV (59%) and eliminated the acute response to leptin in SM. The comparable response to leptin under intravenous or intracerebroventricular infusion and the loss of responsiveness after denervation strongly suggest that the acute effects of leptin involve central signaling pathways.] Question: Based on the provided context, do the terms [uncoupling protein 3 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin treatment leads to a decrease in UCP-3 mRNA in skeletal muscle. This suggests that leptin influences the expression of UCP-3, which is a protein involved in energy expenditure. Therefore, leptin and UCP-3 protein interact in the sense that leptin modulates the expression of UCP-3, thereby affecting energy metabolism.</s>
IEPA.d96 IEPA.d96.s232.e0 IEPA.d96.s232.e1	Leptin	UCP-2	[INST]Context: [PMID: 9892233 Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. The mechanisms underlying the increase in energy expenditure during leptin treatment are not clear. We recently showed that a 5-h intravenous or intracerebroventricular infusion of leptin elevated basal glucose uptake in skeletal muscle (SM) and brown adipose tissue and increased whole-body glucose turnover in C57Bl/6J mice (Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ: Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-377, 1997). We extended the previous study by measuring steady-state levels of uncoupling protein (UCP)-2 mRNA and UCP-3 mRNA in white adipose tissue (WAT) and SM. Leptin by intravenous or intracerebroventricular infusion for 5 h was associated with a decrease in UCP-2 mRNA in WAT (47-52%) and UCP-3 mRNA in SM (33-37%). Because overexpression of UCP-2 or UCP-3 can depolarize the inner mitochondrial membrane, suppression of UCP-2 mRNA and UCP-3 mRNA may in fact lower respiratory demands in WAT and SM. This is consistent with the parallel suppression of cytochrome oxidase subunit IV (COX-IV) mRNA in WAT (35-39%) after leptin infusion. COX-IV mRNA in SM did not respond to acute leptin treatment. Mitochondrial inorganic phosphate carrier (P1C) mRNA was also suppressed in WAT (33-35%) by either method of leptin infusion, but only intravenous infusion of leptin reduced P1C mRNA in SM (40%). Denervation suppressed mRNA levels for UCP-2 (49%), UCP-3 (36%), and COX-IV (59%) and eliminated the acute response to leptin in SM. The comparable response to leptin under intravenous or intracerebroventricular infusion and the loss of responsiveness after denervation strongly suggest that the acute effects of leptin involve central signaling pathways.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin treatment leads to a decrease in UCP-2 mRNA levels in white adipose tissue (WAT). This suggests that leptin influences the expression of UCP-2, which is a protein involved in regulating energy expenditure. Therefore, leptin and UCP-2 protein interact in the sense that leptin modulates the expression of UCP-2, thereby affecting its function.</s>
IEPA.d96 IEPA.d96.s232.e0 IEPA.d96.s232.e2	Leptin	UCP-3	[INST]Context: [PMID: 9892233 Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. The mechanisms underlying the increase in energy expenditure during leptin treatment are not clear. We recently showed that a 5-h intravenous or intracerebroventricular infusion of leptin elevated basal glucose uptake in skeletal muscle (SM) and brown adipose tissue and increased whole-body glucose turnover in C57Bl/6J mice (Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ: Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-377, 1997). We extended the previous study by measuring steady-state levels of uncoupling protein (UCP)-2 mRNA and UCP-3 mRNA in white adipose tissue (WAT) and SM. Leptin by intravenous or intracerebroventricular infusion for 5 h was associated with a decrease in UCP-2 mRNA in WAT (47-52%) and UCP-3 mRNA in SM (33-37%). Because overexpression of UCP-2 or UCP-3 can depolarize the inner mitochondrial membrane, suppression of UCP-2 mRNA and UCP-3 mRNA may in fact lower respiratory demands in WAT and SM. This is consistent with the parallel suppression of cytochrome oxidase subunit IV (COX-IV) mRNA in WAT (35-39%) after leptin infusion. COX-IV mRNA in SM did not respond to acute leptin treatment. Mitochondrial inorganic phosphate carrier (P1C) mRNA was also suppressed in WAT (33-35%) by either method of leptin infusion, but only intravenous infusion of leptin reduced P1C mRNA in SM (40%). Denervation suppressed mRNA levels for UCP-2 (49%), UCP-3 (36%), and COX-IV (59%) and eliminated the acute response to leptin in SM. The comparable response to leptin under intravenous or intracerebroventricular infusion and the loss of responsiveness after denervation strongly suggest that the acute effects of leptin involve central signaling pathways.] Question: Based on the provided context, do the terms [Leptin protein] and [UCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin treatment leads to a decrease in UCP-3 mRNA in skeletal muscle. This suggests that leptin influences the expression of UCP-3, which is a protein involved in energy expenditure. Therefore, leptin and UCP-3 protein interact in the sense that leptin modulates the expression of UCP-3, thereby affecting energy metabolism.</s>
IEPA.d97 IEPA.d97.s234.e0 IEPA.d97.s234.e1	protein kinase C	AVP	[INST]Context: [PMID: 9893131 Hormone-stimulated Ca2+ reabsorption in rabbit kidney cortical collecting system is cAMP-independent and involves a phorbol ester-insensitive PKC isotype. BACKGROUND: Hormones such as parathyroid hormone (PTH), arginine vasopressin (AVP), and prostaglandin E2 (PGE2) are generally believed to act through cAMP to stimulate active Ca2+ reabsorption in the distal part of the nephron. METHODS: This study investigates the relationship between intracellular cAMP levels and the rate of Ca2+ reabsorption in immunodissected rabbit connecting and cortical collecting tubules cultured to confluence on permeable supports. RESULTS: Basolateral PTH, AVP, and PGE2 and apical adenosine dose dependently increased Ca2+ reabsorption from 48 to 110 nmol. hr-1. cm-2. Measurement of intracellular cAMP levels revealed that in the case of PTH and AVP, the dose-response curve for the increase in cAMP virtually matched that for transcellular Ca2+ transport. By contrast, with PGE2, this curve was shifted two decades to the right, whereas in the case of adenosine, no increase in cAMP was observed. The results with the latter two hormones disagree with the classic concept that Ca2+ reabsorption is stimulated via a cAMP-dependent mechanism. Furthermore, the potent adenylyl cyclase inhibitor 2', 5'-dideoxyadenosine (DDA; 100 micrometers) suppressed the PTH- and AVP-induced increase in cAMP completely without affecting Ca2+ reabsorption. Similarly, concentrations of PGE2, which maximally stimulated Ca2+ reabsorption without increasing cAMP, were not inhibited by DDA. The specific protein kinase C (PKC) inhibitor chelerythrine (5 micrometers) inhibited PTH-, AVP-, PGE2-, and adenosine-stimulated Ca2+ reabsorption by 77%, 67%, 79%, and 100%, respectively. Down-regulation of phorbol ester-sensitive PKC isotypes by prolonged (120 hr) treatment with 0.1 micrometers 12-O-tetradecanoylphorbol 13-acetate did not interfere with the inhibitory action of chelerythrine on hormone-stimulated Ca2+ transport. CONCLUSION: PTH, AVP, PGE2, and adenosine stimulate Ca2+ reabsorption via a pathway that is independent of cAMP and that involves a phorbol ester-insensitive PKC isotype.] Question: Based on the provided context, do the terms [protein kinase C protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that both arginine vasopressin (AVP) and protein kinase C (PKC) are involved in the stimulation of Ca2+ reabsorption in the rabbit kidney cortical collecting system. Specifically, it mentions that PTH, AVP, and PGE2 stimulate Ca2+ reabsorption via a pathway that involves a phorbol ester-insensitive PKC isotype. This suggests that AVP interacts with PKC to mediate the process of Ca2+ reabsorption.</s>
IEPA.d97 IEPA.d97.s235.e0 IEPA.d97.s235.e1	AVP	PKC	[INST]Context: [PMID: 9893131 Hormone-stimulated Ca2+ reabsorption in rabbit kidney cortical collecting system is cAMP-independent and involves a phorbol ester-insensitive PKC isotype. BACKGROUND: Hormones such as parathyroid hormone (PTH), arginine vasopressin (AVP), and prostaglandin E2 (PGE2) are generally believed to act through cAMP to stimulate active Ca2+ reabsorption in the distal part of the nephron. METHODS: This study investigates the relationship between intracellular cAMP levels and the rate of Ca2+ reabsorption in immunodissected rabbit connecting and cortical collecting tubules cultured to confluence on permeable supports. RESULTS: Basolateral PTH, AVP, and PGE2 and apical adenosine dose dependently increased Ca2+ reabsorption from 48 to 110 nmol. hr-1. cm-2. Measurement of intracellular cAMP levels revealed that in the case of PTH and AVP, the dose-response curve for the increase in cAMP virtually matched that for transcellular Ca2+ transport. By contrast, with PGE2, this curve was shifted two decades to the right, whereas in the case of adenosine, no increase in cAMP was observed. The results with the latter two hormones disagree with the classic concept that Ca2+ reabsorption is stimulated via a cAMP-dependent mechanism. Furthermore, the potent adenylyl cyclase inhibitor 2', 5'-dideoxyadenosine (DDA; 100 micrometers) suppressed the PTH- and AVP-induced increase in cAMP completely without affecting Ca2+ reabsorption. Similarly, concentrations of PGE2, which maximally stimulated Ca2+ reabsorption without increasing cAMP, were not inhibited by DDA. The specific protein kinase C (PKC) inhibitor chelerythrine (5 micrometers) inhibited PTH-, AVP-, PGE2-, and adenosine-stimulated Ca2+ reabsorption by 77%, 67%, 79%, and 100%, respectively. Down-regulation of phorbol ester-sensitive PKC isotypes by prolonged (120 hr) treatment with 0.1 micrometers 12-O-tetradecanoylphorbol 13-acetate did not interfere with the inhibitory action of chelerythrine on hormone-stimulated Ca2+ transport. CONCLUSION: PTH, AVP, PGE2, and adenosine stimulate Ca2+ reabsorption via a pathway that is independent of cAMP and that involves a phorbol ester-insensitive PKC isotype.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that both AVP (arginine vasopressin) and PKC (protein kinase C) are involved in the stimulation of Ca2+ reabsorption in the rabbit kidney cortical collecting system. Specifically, it mentions that AVP stimulates Ca2+ reabsorption via a pathway that is independent of cAMP and involves a phorbol ester-insensitive PKC isotype. This suggests that AVP and PKC interact in the process of stimulating Ca2+ reabsorption, even though the interaction is not direct but rather part of a signaling pathway.</s>
IEPA.d98 IEPA.d98.s236.e0 IEPA.d98.s236.e1	prion	tyrosine kinase	[INST]Context: [PMID: 9920656 Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. Microglial interaction with amyloid fibrils in the brains of Alzheimer's and prion disease patients results in the inflammatory activation of these cells. We observed that primary microglial cultures and the THP-1 monocytic cell line are stimulated by fibrillar beta-amyloid and prion peptides to activate identical tyrosine kinase-dependent inflammatory signal transduction cascades. The tyrosine kinases Lyn and Syk are activated by the fibrillar peptides and initiate a signaling cascade resulting in a transient release of intracellular calcium that results in the activation of classical PKC and the recently described calcium-sensitive tyrosine kinase PYK2. Activation of the MAP kinases ERK1 and ERK2 follows as a subsequent downstream signaling event. We demonstrate that PYK2 is positioned downstream of Lyn, Syk, and PKC. PKC is a necessary intermediate required for ERK activation. Importantly, the signaling response elicited by beta-amyloid and prion fibrils leads to the production of neurotoxic products. We have demonstrated in a tissue culture model that conditioned media from beta-amyloid- and prion-stimulated microglia or from THP-1 monocytes are neurotoxic to mouse cortical neurons. This toxicity can be ameliorated by treating THP-1 cells with specific enzyme inhibitors that target various components of the signal transduction pathway linked to the inflammatory responses.] Question: Based on the provided context, do the terms [prion protein] and [tyrosine kinase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that both prion peptides and beta-amyloid fibrils activate similar tyrosine kinase-dependent inflammatory signal transduction cascades in microglial cells. Specifically, the tyrosine kinases Lyn and Syk are activated by these peptides, initiating a signaling cascade that involves the activation of various downstream signaling molecules, including PKC and the calcium-sensitive tyrosine kinase PYK2. This suggests that the prion protein and tyrosine kinase proteins interact within the same signaling pathway, leading to the activation of inflammatory responses and neurotoxic effects.</s>
IEPA.d99 IEPA.d99.s237.e0 IEPA.d99.s237.e1	phospholipase C	insulin	[INST]Context: [PMID: 9920735 Enhanced phosphoinositide hydrolysis via overexpression of phospholipase C beta1 or delta1 inhibits stimulus-induced insulin release in insulinoma MIN6 cells. To study the effects of enhanced phosphoinositide hydrolysis on insulin secretion, phosphoinositide-specific phospholipase Cbeta1 (PLCbeta1) or PLCdelta1 was overexpressed in insulinoma MIN6 cells via adenoviral vectors. Inositol phosphate production stimulated by NaF (with AlCl3) in PLCbeta1-overexpressing cells and that stimulated by KCl or glucose in both PLCbeta1- and PLCdelta1-overexpressing cells were greater than that in control cells. In addition, reduced phosphatidylinositol-4,5-bisphosphate levels were observed in these cells stimulated by NaF or KCl. The greater phosphoinositide hydrolysis was accompanied by 25-45% inhibition of insulin secretion. These data suggest that excessive phosphoinositide hydrolysis inhibits secretagogue-induced insulin release in MIN6 cells.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the overexpression of phospholipase C beta1 (PLCbeta1) or delta1 (PLCdelta1) in MIN6 cells leads to enhanced phosphoinositide hydrolysis, which in turn inhibits stimulus-induced insulin release. This suggests that the phospholipase C protein (PLC) interacts with the insulin protein by influencing the signaling pathways involved in insulin secretion. The inhibition of insulin release due to excessive phosphoinositide hydrolysis demonstrates a direct interaction between the two proteins.</s>
IEPA.d100 IEPA.d100.s239.e0 IEPA.d100.s239.e1	oxytocin	insulin	[INST]Context: [PMID: 9924739 Oxytocin may mediate the benefits of positive social interaction and emotions. During breastfeeding or suckling, maternal oxytocin levels are raised by somatosensory stimulation. Oxytocin may, however, also be released by nonnoxious stimuli such as touch, warm temperature etc. in plasma and in cerebrospinal fluid. Consequently, oxytocin may be involved in physiological and behavioral effects induced by social interaction in a more general context. In both male and female rats oxytocin exerts potent physiological antistress effects. If daily oxytocin injections are repeated over a 5-day period, blood pressure is decreased by 10-20 mmHg, the withdrawal latency to heat stimuli is prolonged, cortisol levels are decreased and insulin and cholecystokinin levels are increased. These effects last from 1 to several weeks after the last injection. After repeated oxytocin treatment weight gain may be promoted and the healing rate of wounds increased. Most behavioral and physiological effects induced by oxytocin can be blocked by oxytocin antagonists. In contrast, the antistress effects can not, suggesting that unidentified oxytocin receptors may exist. The prolonged latency in the tail-flick test can be temporarily reversed by administration of naloxone, suggesting that endogenous opioid activity has been increased by the oxytocin injections. In contrast, the long-term lowering of blood pressure and of cortisol levels as well as the sedative effects of oxytocin have been found to be related to an increased activity of central alpha 2-adrenoceptors. Positive social interactions have been related to health-promoting effects. Oxytocin released in response to social stimuli may be part of a neuroendocrine substrate which underlies the benefits of positive social experiences. Such processes may in addition explain the health-promoting effects of certain alternative therapies. Because of the special properties of oxytocin, including the fact that it can become conditioned to psychological state or imagery, oxytocin may also mediate the benefits attributed to therapies such as hypnosis or meditation.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of oxytocin on various physiological and behavioral parameters, including the increase in insulin levels. However, it does not mention any direct interaction between oxytocin protein and insulin protein. Instead, it describes the effects of oxytocin on insulin levels as part of a broader set of physiological changes induced by oxytocin treatment. Therefore, there is no evidence of a direct interaction between oxytocin protein and insulin protein based on the given information.</s>
IEPA.d106 IEPA.d106.s245.e0 IEPA.d106.s245.e1	Protein kinase C	AVP	[INST]Context: [PMID: 10070167 AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. The present study examined how arginine vasopressin (AVP) affects nitric oxide (NO) metabolism in cultured rat glomerular mesangial cells (GMC). GMC were incubated with test agents and nitrite, and intracellular cGMP content, inducible nitric oxide synthase (iNOS) mRNA, and iNOS protein were analyzed by the Griess method, enzyme immunoassay, and Northern and Western blotting, respectively. AVP inhibited lipopolysaccharide (LPS)- and interleukin-1beta (IL-1beta)-induced nitrite production in a dose- and time-dependent manner, with concomitant changes in cGMP content, iNOS mRNA, and iNOS protein. This inhibition by AVP was reversed by V1- but not by oxytocin-receptor antagonist. Inhibition by AVP was also reproduced on LPS and interferon-gamma (IFN-gamma). Protein kinase C (PKC) inhibitors reversed AVP inhibition, whereas PKC activator inhibited nitrite production. Although dexamethasone and pyrrolidinedithiocarbamate (PDTC), inhibitors of nuclear factor-kappaB, inhibited nitrite production, further inhibition by AVP was not observed. AVP did not show further inhibition of nitrite production with actinomycin D, an inhibitor of transcription, or cycloheximide, an inhibitor of protein synthesis. In conclusion, AVP inhibits LPS- and IL-1beta-induced NO production through a V1 receptor. The inhibitory action of AVP involves both the activation of PKC and the transcription of iNOS mRNA in cultured rat GMC.] Question: Based on the provided context, do the terms [Protein kinase C protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that AVP (arginine vasopressin) inhibits LPS- and IL-1beta-induced NO production through a V1 receptor in cultured rat glomerular mesangial cells (GMC). It also mentions that protein kinase C (PKC) inhibitors reverse AVP inhibition, while PKC activators inhibit nitrite production. This suggests that AVP and PKC interact in the pathway leading to the inhibition of NO production. The activation of PKC is part of the mechanism by which AVP exerts its inhibitory effect, indicating a direct interaction between AVP and PKC.</s>
IEPA.d106 IEPA.d106.s246.e0 IEPA.d106.s246.e1	AVP	PKC	[INST]Context: [PMID: 10070167 AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. The present study examined how arginine vasopressin (AVP) affects nitric oxide (NO) metabolism in cultured rat glomerular mesangial cells (GMC). GMC were incubated with test agents and nitrite, and intracellular cGMP content, inducible nitric oxide synthase (iNOS) mRNA, and iNOS protein were analyzed by the Griess method, enzyme immunoassay, and Northern and Western blotting, respectively. AVP inhibited lipopolysaccharide (LPS)- and interleukin-1beta (IL-1beta)-induced nitrite production in a dose- and time-dependent manner, with concomitant changes in cGMP content, iNOS mRNA, and iNOS protein. This inhibition by AVP was reversed by V1- but not by oxytocin-receptor antagonist. Inhibition by AVP was also reproduced on LPS and interferon-gamma (IFN-gamma). Protein kinase C (PKC) inhibitors reversed AVP inhibition, whereas PKC activator inhibited nitrite production. Although dexamethasone and pyrrolidinedithiocarbamate (PDTC), inhibitors of nuclear factor-kappaB, inhibited nitrite production, further inhibition by AVP was not observed. AVP did not show further inhibition of nitrite production with actinomycin D, an inhibitor of transcription, or cycloheximide, an inhibitor of protein synthesis. In conclusion, AVP inhibits LPS- and IL-1beta-induced NO production through a V1 receptor. The inhibitory action of AVP involves both the activation of PKC and the transcription of iNOS mRNA in cultured rat GMC.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that AVP (arginine vasopressin) inhibits LPS- and IL-1beta-induced NO production through a V1 receptor in cultured rat glomerular mesangial cells (GMC). It also mentions that the inhibitory action of AVP involves the activation of protein kinase C (PKC). This suggests that AVP and PKC interact in the process of inhibiting NO production, as the activation of PKC is a mechanism through which AVP exerts its inhibitory effect.</s>
IEPA.d107 IEPA.d107.s247.e0 IEPA.d107.s247.e1	gibberellin	Osamy-c	[INST]Context: [PMID: 10080713 Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice. To understand the molecular mechanism of gibberellin-dependent gene regulation, the effect of three phosphatase inhibitors on the germination of rice seeds and the expression of a target gene, the alpha-amylase gene, Osamy-c, were measured. We found that okadaic acid, microcystin-LR, and calyculin A, which are known to specifically inhibit Ser/Thr phosphatases 1 and 2A, strongly inhibit the expression of the Osamy-c and may be involved in the germination of rice seeds. The protein phosphatase enzyme activity assays showed that there is no obvious effect of GA3 on total PP1/PP2A activities. To further understand the possible role of protein phosphatases 1 and 2A in the GA-dependent expression of Osamy-c, we isolated cDNA clones encoding protein phosphatase 1 and protein phosphatase 2A from a rice aleurone cDNA library. These were designated OsPP1c and OsPP2Ac, respectively. Comparison of the deduced amino acid sequences of OsPP1c and OsPP2Ac with the catalytic subunits of PP1 or PP2A of rabbit skeletal muscle, Arabidopsis thaliana, maize and Brassica napus showed that the catalytic subunit sequences of PP1 or PP2A among these organisms are highly conserved (73% to 90% similarity). Genomic Southern blot analysis indicated that there are only one or two copies of OsPP1c genes and more than two copies of OsPP2Ac genes in the rice genome. Northern blot analysis showed that OsPP1c and OsPP2Ac genes are expressed in several organs of rice, including seed, shoot and root. We also showed by using 3' gene-specific probes of OsPP1c and OsPP2Ac cDNA, that the expression of neither gene is regulated by GA. Taken together, our results suggest that protein phosphatases PP1 or PP2A are involved in the GA-dependent expression of the rice Osamy-c gene, though the PP1 or/and PP2A enzymatic activities as well as mRNA levels do not increase upon GA3 treatment.] Question: Based on the provided context, do the terms [gibberellin protein] and [Osamy-c protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin (GA) plays a role in the expression of the Osamy-c gene in rice. Specifically, it mentions that gibberellin-dependent gene regulation involves the inhibition of protein phosphatases 1 and 2A, which in turn affects the expression of the Osamy-c gene. This suggests that gibberellin and the Osamy-c protein are part of the same regulatory pathway, implying an interaction between them.</s>
IEPA.d107 IEPA.d107.s248.e0 IEPA.d107.s248.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10080713 Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice. To understand the molecular mechanism of gibberellin-dependent gene regulation, the effect of three phosphatase inhibitors on the germination of rice seeds and the expression of a target gene, the alpha-amylase gene, Osamy-c, were measured. We found that okadaic acid, microcystin-LR, and calyculin A, which are known to specifically inhibit Ser/Thr phosphatases 1 and 2A, strongly inhibit the expression of the Osamy-c and may be involved in the germination of rice seeds. The protein phosphatase enzyme activity assays showed that there is no obvious effect of GA3 on total PP1/PP2A activities. To further understand the possible role of protein phosphatases 1 and 2A in the GA-dependent expression of Osamy-c, we isolated cDNA clones encoding protein phosphatase 1 and protein phosphatase 2A from a rice aleurone cDNA library. These were designated OsPP1c and OsPP2Ac, respectively. Comparison of the deduced amino acid sequences of OsPP1c and OsPP2Ac with the catalytic subunits of PP1 or PP2A of rabbit skeletal muscle, Arabidopsis thaliana, maize and Brassica napus showed that the catalytic subunit sequences of PP1 or PP2A among these organisms are highly conserved (73% to 90% similarity). Genomic Southern blot analysis indicated that there are only one or two copies of OsPP1c genes and more than two copies of OsPP2Ac genes in the rice genome. Northern blot analysis showed that OsPP1c and OsPP2Ac genes are expressed in several organs of rice, including seed, shoot and root. We also showed by using 3' gene-specific probes of OsPP1c and OsPP2Ac cDNA, that the expression of neither gene is regulated by GA. Taken together, our results suggest that protein phosphatases PP1 or PP2A are involved in the GA-dependent expression of the rice Osamy-c gene, though the PP1 or/and PP2A enzymatic activities as well as mRNA levels do not increase upon GA3 treatment.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin (GA) plays a role in the expression of the alpha-amylase gene (Osamy-c) in rice. Specifically, it mentions that gibberellin-dependent gene regulation involves the inhibition of protein phosphatases 1 and 2A, which in turn affects the expression of Osamy-c. This suggests that gibberellin interacts with the alpha-amylase protein through a regulatory pathway involving protein phosphatases.</s>
IEPA.d107 IEPA.d107.s249.e0 IEPA.d107.s249.e1	GA	Osamy-c	[INST]Context: [PMID: 10080713 Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice. To understand the molecular mechanism of gibberellin-dependent gene regulation, the effect of three phosphatase inhibitors on the germination of rice seeds and the expression of a target gene, the alpha-amylase gene, Osamy-c, were measured. We found that okadaic acid, microcystin-LR, and calyculin A, which are known to specifically inhibit Ser/Thr phosphatases 1 and 2A, strongly inhibit the expression of the Osamy-c and may be involved in the germination of rice seeds. The protein phosphatase enzyme activity assays showed that there is no obvious effect of GA3 on total PP1/PP2A activities. To further understand the possible role of protein phosphatases 1 and 2A in the GA-dependent expression of Osamy-c, we isolated cDNA clones encoding protein phosphatase 1 and protein phosphatase 2A from a rice aleurone cDNA library. These were designated OsPP1c and OsPP2Ac, respectively. Comparison of the deduced amino acid sequences of OsPP1c and OsPP2Ac with the catalytic subunits of PP1 or PP2A of rabbit skeletal muscle, Arabidopsis thaliana, maize and Brassica napus showed that the catalytic subunit sequences of PP1 or PP2A among these organisms are highly conserved (73% to 90% similarity). Genomic Southern blot analysis indicated that there are only one or two copies of OsPP1c genes and more than two copies of OsPP2Ac genes in the rice genome. Northern blot analysis showed that OsPP1c and OsPP2Ac genes are expressed in several organs of rice, including seed, shoot and root. We also showed by using 3' gene-specific probes of OsPP1c and OsPP2Ac cDNA, that the expression of neither gene is regulated by GA. Taken together, our results suggest that protein phosphatases PP1 or PP2A are involved in the GA-dependent expression of the rice Osamy-c gene, though the PP1 or/and PP2A enzymatic activities as well as mRNA levels do not increase upon GA3 treatment.] Question: Based on the provided context, do the terms [GA protein] and [Osamy-c protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin (GA) plays a role in the expression of the Osamy-c gene in rice. Specifically, it mentions that gibberellin-dependent gene regulation involves the inhibition of protein phosphatases 1 and 2A, which in turn affects the expression of the Osamy-c gene. This suggests that GA and Osamy-c are part of the same regulatory pathway, implying an interaction between them.</s>
IEPA.d107 IEPA.d107.s250.e0 IEPA.d107.s250.e1	GA	Osamy-c	[INST]Context: [PMID: 10080713 Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice. To understand the molecular mechanism of gibberellin-dependent gene regulation, the effect of three phosphatase inhibitors on the germination of rice seeds and the expression of a target gene, the alpha-amylase gene, Osamy-c, were measured. We found that okadaic acid, microcystin-LR, and calyculin A, which are known to specifically inhibit Ser/Thr phosphatases 1 and 2A, strongly inhibit the expression of the Osamy-c and may be involved in the germination of rice seeds. The protein phosphatase enzyme activity assays showed that there is no obvious effect of GA3 on total PP1/PP2A activities. To further understand the possible role of protein phosphatases 1 and 2A in the GA-dependent expression of Osamy-c, we isolated cDNA clones encoding protein phosphatase 1 and protein phosphatase 2A from a rice aleurone cDNA library. These were designated OsPP1c and OsPP2Ac, respectively. Comparison of the deduced amino acid sequences of OsPP1c and OsPP2Ac with the catalytic subunits of PP1 or PP2A of rabbit skeletal muscle, Arabidopsis thaliana, maize and Brassica napus showed that the catalytic subunit sequences of PP1 or PP2A among these organisms are highly conserved (73% to 90% similarity). Genomic Southern blot analysis indicated that there are only one or two copies of OsPP1c genes and more than two copies of OsPP2Ac genes in the rice genome. Northern blot analysis showed that OsPP1c and OsPP2Ac genes are expressed in several organs of rice, including seed, shoot and root. We also showed by using 3' gene-specific probes of OsPP1c and OsPP2Ac cDNA, that the expression of neither gene is regulated by GA. Taken together, our results suggest that protein phosphatases PP1 or PP2A are involved in the GA-dependent expression of the rice Osamy-c gene, though the PP1 or/and PP2A enzymatic activities as well as mRNA levels do not increase upon GA3 treatment.] Question: Based on the provided context, do the terms [GA protein] and [Osamy-c protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin (GA) plays a role in the expression of the Osamy-c gene in rice. Specifically, it mentions that gibberellin-dependent gene regulation involves the inhibition of protein phosphatases 1 and 2A, which in turn affects the expression of the Osamy-c gene. This suggests that GA and Osamy-c are part of the same regulatory pathway, implying an interaction between them.</s>
IEPA.d109 IEPA.d109.s256.e0 IEPA.d109.s256.e1	leptin	uncoupling protein	[INST]Context: [PMID: 10098482 Fasting and leptin modulate adipose and muscle uncoupling protein: divergent effects between messenger ribonucleic acid and protein expression. Leptin is believed to act through hypothalamic centers to decrease appetite and increase energy utilization, in part through enhanced thermogenesis. In this study, we examined the effects of fasting for 2 days and exogenous s.c. leptin, 200 microg every 8 h for 2 days, on the regulation of uncoupling protein (UCP) subtypes in brown adipose tissue (BAT) and gastrocnemius muscle. Northern blot analysis (UCP-1) and ribonuclease protection (UCP-2 and 3) were used for quantitative messenger RNA (mRNA) analysis, and specific antibodies were used to measure UCP-1 and UCP-3 total protein expression. Leptin, compared with vehicle, did not alter BAT UCP-1 or UCP-3 mRNA or protein expression when administered to normal ad libitum fed rats. Fasting significantly decreased BAT UCP-1 and UCP-3 mRNA expression, to 31% and 30% of ad libitum fed controls, respectively, effects which were prevented by administration of leptin to fasted rats. Fasting also significantly decreased BAT UCP-1 protein expression, to 67% of control; however, that effect was not prevented by leptin treatment. Fasting also decreased BAT UCP-3 protein, to 85% of control, an effect that was not statistically significant. Fasting, with or without leptin administration, did not affect BAT UCP-2 mRNA; however, leptin administration to ad libitum fed rats significantly increased BAT UCP-2 mRNA, to 138% of control. Fasting significantly enhanced gastrocnemius muscle UCP-3 mRNA (411% of control) and protein expression (168% of control), whereas leptin administration to fasted rats did not alter either of these effects. In summary, UCP subtype mRNA and protein are regulated in tissue- and subtype-specific fashion by leptin and food restriction. Under certain conditions, the effects of these perturbations on UCP mRNA and protein are discordant.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and uncoupling proteins (UCPs) interact in a regulatory manner. Specifically, leptin administration affects the expression of UCP subtypes in brown adipose tissue (BAT) and gastrocnemius muscle. The study demonstrates that leptin modulates the mRNA and protein expression of UCPs in response to fasting, suggesting a direct interaction between leptin and UCPs in the regulation of thermogenesis and energy utilization.</s>
IEPA.d109 IEPA.d109.s263.e0 IEPA.d109.s263.e1	UCP	leptin	[INST]Context: [PMID: 10098482 Fasting and leptin modulate adipose and muscle uncoupling protein: divergent effects between messenger ribonucleic acid and protein expression. Leptin is believed to act through hypothalamic centers to decrease appetite and increase energy utilization, in part through enhanced thermogenesis. In this study, we examined the effects of fasting for 2 days and exogenous s.c. leptin, 200 microg every 8 h for 2 days, on the regulation of uncoupling protein (UCP) subtypes in brown adipose tissue (BAT) and gastrocnemius muscle. Northern blot analysis (UCP-1) and ribonuclease protection (UCP-2 and 3) were used for quantitative messenger RNA (mRNA) analysis, and specific antibodies were used to measure UCP-1 and UCP-3 total protein expression. Leptin, compared with vehicle, did not alter BAT UCP-1 or UCP-3 mRNA or protein expression when administered to normal ad libitum fed rats. Fasting significantly decreased BAT UCP-1 and UCP-3 mRNA expression, to 31% and 30% of ad libitum fed controls, respectively, effects which were prevented by administration of leptin to fasted rats. Fasting also significantly decreased BAT UCP-1 protein expression, to 67% of control; however, that effect was not prevented by leptin treatment. Fasting also decreased BAT UCP-3 protein, to 85% of control, an effect that was not statistically significant. Fasting, with or without leptin administration, did not affect BAT UCP-2 mRNA; however, leptin administration to ad libitum fed rats significantly increased BAT UCP-2 mRNA, to 138% of control. Fasting significantly enhanced gastrocnemius muscle UCP-3 mRNA (411% of control) and protein expression (168% of control), whereas leptin administration to fasted rats did not alter either of these effects. In summary, UCP subtype mRNA and protein are regulated in tissue- and subtype-specific fashion by leptin and food restriction. Under certain conditions, the effects of these perturbations on UCP mRNA and protein are discordant.] Question: Based on the provided context, do the terms [UCP protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and UCP protein expression are regulated in a tissue- and subtype-specific manner by fasting and leptin administration. Specifically, leptin administration to fasted rats prevented the decrease in BAT UCP-1 and UCP-3 mRNA expression caused by fasting. This suggests that leptin influences the expression of UCP proteins, indicating an interaction between leptin and UCP proteins.</s>
IEPA.d114 IEPA.d114.s274.e0 IEPA.d114.s274.e1	UCP-2	leptin	[INST]Context: [PMID: 10331406 Adenovirus-mediated overexpression of uncoupling protein-2 in pancreatic islets of Zucker diabetic rats increases oxidative activity and improves beta-cell function. The discovery of uncoupling protein (UCP)-2, a ubiquitously expressed protein homologous to UCP-1, has raised the possibility that energy balance of cells might be regulated in tissues other than brown adipocytes. In normal pancreatic islets, UCP-2 is upregulated by leptin and is low in leptin-resistant islets of ZDF rats. To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats. Although ATP was reduced by 23% in both groups of islets, the ATP:ADP ratio increased by 42 and 141%, respectively. [3H]palmitate oxidation was increased by 50%, and [3H]glucose oxidation was 42-63% higher. Preproinsulin mRNA was 2.9-fold above control levels, and glucose-stimulated insulin secretion, which was negligible in control ZDF rat islets, was improved in UCP-2-overexpressing islets. The high fat content of the islets was not reduced, however. We conclude that UCP-2 has uncoupling function when overexpressed in leptin-insensitive islets and that its overexpression corrects the underexpression of the insulin gene and ameliorates glucose-stimulated insulin secretion, possibly by increasing the ATP:ADP ratio.] Question: Based on the provided context, do the terms [UCP-2 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that UCP-2 is upregulated by leptin in normal pancreatic islets. This suggests that leptin and UCP-2 interact in a regulatory pathway where leptin influences the expression of UCP-2. The fact that UCP-2 is low in leptin-resistant islets of ZDF rats further supports this interaction, as it implies that the absence or resistance to leptin affects the expression of UCP-2. Therefore, the terms [UCP-2 protein] and [leptin protein] interact with each other.</s>
IEPA.d122 IEPA.d122.s290.e0 IEPA.d122.s290.e1	leptin	uncoupling proteins	[INST]Context: [PMID: 10433228 Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Centrally administered leptin has been shown to increase insulin-stimulated glucose utilization and to favor the expression of uncoupling proteins (UCPs). To study if leptin also has direct peripherally mediated effects on these processes, this hormone (1 mg/day) or its vehicle was infused i.v. for 4 days to lean rats and insulin-stimulated glucose utilization in skeletal muscle and adipose tissue as well as the expression of UCP messenger RNAs (mRNAs) in brown adipose tissue were measured. I.v. leptin administration resulted in decreases in food intake (31%), body weight gain, and plasma insulin levels (45%), in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. Most of these changes were mimicked, in control rats, by giving them the same amount of food as that consumed by the leptin-infused group (pair-feeding). I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen. Relative UCP expression levels were 100, 104, and 33 for UCP1, 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively. These results suggest that the overall effect of leptin on glucose utilization and on the expression of UCPs may be mediated through central mechanism.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling proteins protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin has direct effects on the expression of uncoupling proteins (UCPs) in brown adipose tissue. Specifically, it mentions that "I.v. leptin infusion resulted in decreases in food intake, body weight gain, and plasma insulin levels, in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen." This suggests that leptin interacts with the expression of UCPs, influencing their levels in brown adipose tissue.</s>
IEPA.d122 IEPA.d122.s291.e0 IEPA.d122.s291.e1	leptin	uncoupling proteins	[INST]Context: [PMID: 10433228 Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Centrally administered leptin has been shown to increase insulin-stimulated glucose utilization and to favor the expression of uncoupling proteins (UCPs). To study if leptin also has direct peripherally mediated effects on these processes, this hormone (1 mg/day) or its vehicle was infused i.v. for 4 days to lean rats and insulin-stimulated glucose utilization in skeletal muscle and adipose tissue as well as the expression of UCP messenger RNAs (mRNAs) in brown adipose tissue were measured. I.v. leptin administration resulted in decreases in food intake (31%), body weight gain, and plasma insulin levels (45%), in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. Most of these changes were mimicked, in control rats, by giving them the same amount of food as that consumed by the leptin-infused group (pair-feeding). I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen. Relative UCP expression levels were 100, 104, and 33 for UCP1, 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively. These results suggest that the overall effect of leptin on glucose utilization and on the expression of UCPs may be mediated through central mechanism.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling proteins protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin has direct effects on the expression of uncoupling proteins (UCPs) in brown adipose tissue. Specifically, it mentions that "I.v. leptin infusion resulted in decreases in food intake, body weight gain, and plasma insulin levels, in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen." This suggests that leptin interacts with the expression of UCPs, influencing their levels in brown adipose tissue.</s>
IEPA.d122 IEPA.d122.s293.e0 IEPA.d122.s293.e1	leptin	UCPs	[INST]Context: [PMID: 10433228 Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Centrally administered leptin has been shown to increase insulin-stimulated glucose utilization and to favor the expression of uncoupling proteins (UCPs). To study if leptin also has direct peripherally mediated effects on these processes, this hormone (1 mg/day) or its vehicle was infused i.v. for 4 days to lean rats and insulin-stimulated glucose utilization in skeletal muscle and adipose tissue as well as the expression of UCP messenger RNAs (mRNAs) in brown adipose tissue were measured. I.v. leptin administration resulted in decreases in food intake (31%), body weight gain, and plasma insulin levels (45%), in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. Most of these changes were mimicked, in control rats, by giving them the same amount of food as that consumed by the leptin-infused group (pair-feeding). I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen. Relative UCP expression levels were 100, 104, and 33 for UCP1, 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively. These results suggest that the overall effect of leptin on glucose utilization and on the expression of UCPs may be mediated through central mechanism.] Question: Based on the provided context, do the terms [leptin protein] and [UCPs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin has direct effects on the expression of uncoupling proteins (UCPs) in brown adipose tissue. Specifically, it mentions that "I.v. leptin infusion resulted in decreases in food intake, body weight gain, and plasma insulin levels, in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen." This suggests that leptin influences the expression of UCPs, indicating an interaction between the leptin protein and UCPs protein.</s>
IEPA.d122 IEPA.d122.s295.e0 IEPA.d122.s295.e1	leptin	UCPs	[INST]Context: [PMID: 10433228 Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Centrally administered leptin has been shown to increase insulin-stimulated glucose utilization and to favor the expression of uncoupling proteins (UCPs). To study if leptin also has direct peripherally mediated effects on these processes, this hormone (1 mg/day) or its vehicle was infused i.v. for 4 days to lean rats and insulin-stimulated glucose utilization in skeletal muscle and adipose tissue as well as the expression of UCP messenger RNAs (mRNAs) in brown adipose tissue were measured. I.v. leptin administration resulted in decreases in food intake (31%), body weight gain, and plasma insulin levels (45%), in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. Most of these changes were mimicked, in control rats, by giving them the same amount of food as that consumed by the leptin-infused group (pair-feeding). I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen. Relative UCP expression levels were 100, 104, and 33 for UCP1, 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively. These results suggest that the overall effect of leptin on glucose utilization and on the expression of UCPs may be mediated through central mechanism.] Question: Based on the provided context, do the terms [leptin protein] and [UCPs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin has direct effects on the expression of uncoupling proteins (UCPs) in brown adipose tissue. Specifically, it mentions that "I.v. leptin infusion resulted in decreases in food intake, body weight gain, and plasma insulin levels, in increases in overall (23%) as well as brown adipose tissue and muscle glucose utilization, and in decreases in white adipose tissue glucose uptake. I.v. leptin infusion also favored the expression of UCPs in brown adipose tissue, either by increasing their expression or preventing the fall occurring during the pair-feeding regimen." This suggests that leptin influences the expression of UCPs, indicating an interaction between the leptin protein and UCPs protein.</s>
IEPA.d126 IEPA.d126.s299.e3 IEPA.d126.s299.e4	leptin	UCP2	[INST]Context: [PMID: 10477827 Up-regulation of uterine UCP2 and UCP3 in pregnant rats. Pregnancy produces profound changes in hormone dynamics, thermoregulation and energy metabolism. Uncoupling proteins (UCPs) have been identified in a variety of tissues and UCP1 is known to play important roles in energy homeostasis, while the regulation of UCP2 and UCP3 is still unclear. The present study aimed to investigate the effects of the changes during pregnancy on UCP gene expression in the uterus, as well as in brown adipose tissue (BAT), white adipose tissue (WAT), soleus muscle (Muscle), and liver, throughout the estrus and metestrus periods, at early, middle and late stages in pregnancy, and during post-gestational stages. The expression of uterine UCP2 and UCP3 were up-regulated by 3.2- and 1. 5-fold, respectively, during the late stage of pregnancy with an increase of WAT leptin mRNA expression and exogenous administration of leptin resulted in induction of the uterine UCP2 and UCP3 levels. Contrary to uterine UCPs, UCP1 mRNA expression in BAT was down-regulated by 0.5-fold and there were no remarkable changes in WAT or liver UCP2, or Muscle UCP3 expression throughout the periods. These results indicate that UCP gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine UCP2 and UCP3 mRNA may be due to increased leptin levels.] Question: Based on the provided context, do the terms [leptin protein] and [UCP2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that exogenous administration of leptin resulted in the induction of uterine UCP2 and UCP3 levels. This suggests that leptin protein interacts with UCP2 protein, as the increase in leptin levels leads to an increase in UCP2 expression. This interaction is tissue-dependent, specifically in the uterus, and is part of the regulatory mechanism of UCP gene expression during pregnancy.</s>
IEPA.d126 IEPA.d126.s299.e3 IEPA.d126.s299.e5	leptin	UCP3	[INST]Context: [PMID: 10477827 Up-regulation of uterine UCP2 and UCP3 in pregnant rats. Pregnancy produces profound changes in hormone dynamics, thermoregulation and energy metabolism. Uncoupling proteins (UCPs) have been identified in a variety of tissues and UCP1 is known to play important roles in energy homeostasis, while the regulation of UCP2 and UCP3 is still unclear. The present study aimed to investigate the effects of the changes during pregnancy on UCP gene expression in the uterus, as well as in brown adipose tissue (BAT), white adipose tissue (WAT), soleus muscle (Muscle), and liver, throughout the estrus and metestrus periods, at early, middle and late stages in pregnancy, and during post-gestational stages. The expression of uterine UCP2 and UCP3 were up-regulated by 3.2- and 1. 5-fold, respectively, during the late stage of pregnancy with an increase of WAT leptin mRNA expression and exogenous administration of leptin resulted in induction of the uterine UCP2 and UCP3 levels. Contrary to uterine UCPs, UCP1 mRNA expression in BAT was down-regulated by 0.5-fold and there were no remarkable changes in WAT or liver UCP2, or Muscle UCP3 expression throughout the periods. These results indicate that UCP gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine UCP2 and UCP3 mRNA may be due to increased leptin levels.] Question: Based on the provided context, do the terms [leptin protein] and [UCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that exogenous administration of leptin resulted in the induction of uterine UCP2 and UCP3 levels. This suggests that leptin protein interacts with UCP3 protein, as the increase in leptin levels leads to an increase in UCP3 expression. Therefore, there is a direct interaction between leptin protein and UCP3 protein in the context provided.</s>
IEPA.d126 IEPA.d126.s300.e1 IEPA.d126.s300.e3	UCP2	leptin	[INST]Context: [PMID: 10477827 Up-regulation of uterine UCP2 and UCP3 in pregnant rats. Pregnancy produces profound changes in hormone dynamics, thermoregulation and energy metabolism. Uncoupling proteins (UCPs) have been identified in a variety of tissues and UCP1 is known to play important roles in energy homeostasis, while the regulation of UCP2 and UCP3 is still unclear. The present study aimed to investigate the effects of the changes during pregnancy on UCP gene expression in the uterus, as well as in brown adipose tissue (BAT), white adipose tissue (WAT), soleus muscle (Muscle), and liver, throughout the estrus and metestrus periods, at early, middle and late stages in pregnancy, and during post-gestational stages. The expression of uterine UCP2 and UCP3 were up-regulated by 3.2- and 1. 5-fold, respectively, during the late stage of pregnancy with an increase of WAT leptin mRNA expression and exogenous administration of leptin resulted in induction of the uterine UCP2 and UCP3 levels. Contrary to uterine UCPs, UCP1 mRNA expression in BAT was down-regulated by 0.5-fold and there were no remarkable changes in WAT or liver UCP2, or Muscle UCP3 expression throughout the periods. These results indicate that UCP gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine UCP2 and UCP3 mRNA may be due to increased leptin levels.] Question: Based on the provided context, do the terms [UCP2 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the exogenous administration of leptin resulted in the induction of uterine UCP2 and UCP3 levels. This suggests that leptin protein interacts with UCP2 protein in the uterus, leading to an up-regulation of UCP2 expression. Therefore, there is a direct interaction between leptin protein and UCP2 protein in the uterus during pregnancy.</s>
IEPA.d126 IEPA.d126.s300.e2 IEPA.d126.s300.e3	UCP3	leptin	[INST]Context: [PMID: 10477827 Up-regulation of uterine UCP2 and UCP3 in pregnant rats. Pregnancy produces profound changes in hormone dynamics, thermoregulation and energy metabolism. Uncoupling proteins (UCPs) have been identified in a variety of tissues and UCP1 is known to play important roles in energy homeostasis, while the regulation of UCP2 and UCP3 is still unclear. The present study aimed to investigate the effects of the changes during pregnancy on UCP gene expression in the uterus, as well as in brown adipose tissue (BAT), white adipose tissue (WAT), soleus muscle (Muscle), and liver, throughout the estrus and metestrus periods, at early, middle and late stages in pregnancy, and during post-gestational stages. The expression of uterine UCP2 and UCP3 were up-regulated by 3.2- and 1. 5-fold, respectively, during the late stage of pregnancy with an increase of WAT leptin mRNA expression and exogenous administration of leptin resulted in induction of the uterine UCP2 and UCP3 levels. Contrary to uterine UCPs, UCP1 mRNA expression in BAT was down-regulated by 0.5-fold and there were no remarkable changes in WAT or liver UCP2, or Muscle UCP3 expression throughout the periods. These results indicate that UCP gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine UCP2 and UCP3 mRNA may be due to increased leptin levels.] Question: Based on the provided context, do the terms [UCP3 protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the exogenous administration of leptin resulted in the induction of uterine UCP2 and UCP3 levels. This suggests that leptin protein interacts with UCP3 protein, as the increase in leptin levels leads to an increase in UCP3 expression. Therefore, there is a direct interaction between leptin protein and UCP3 protein in the context provided.</s>
IEPA.d127 IEPA.d127.s301.e0 IEPA.d127.s301.e1	PI-PLC	Abeta40	[INST]Context: [PMID: 10480887 Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. The Alzheimer's amyloid protein (Abeta) is released from the larger amyloid beta-protein precursor (APP) by unidentified enzymes referred to as beta- and gamma-secretase. beta-Secretase cleaves APP on the amino side of Abeta producing a large secreted derivative (sAPPbeta) and an Abeta-bearing C-terminal derivative that is subsequently cleaved by gamma-secretase to release Abeta. Alternative cleavage of the APP by alpha-secretase at Abeta16/17 releases the secreted derivative sAPPalpha. In yeast, alpha-secretase activity has been attributed to glycosylphosphatidylinositol (GPI)-anchored aspartyl proteases. To examine the role of GPI-anchored proteins, we specifically removed these proteins from the surface of mammalian cells using phosphatidylinositol-specific phospholipase C (PI-PLC). PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of Abeta40 and Abeta42 in the medium but had no effect on sAPPalpha. A mutant CHO cell line (gpi85), which lacks GPI-anchored proteins, secreted lower levels of Abeta40, Abeta42, and sAPPbeta than its parental line (GPI+). When this parental line was treated with PI-PLC, Abeta40, Abeta42, and sAPPbeta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of PI-PLC. These findings provide strong evidence that one or more GPI-anchored proteins play an important role in beta-secretase activity and Abeta secretion in mammalian cells. The cell-surface GPI-anchored protein(s) involved in Abeta biogenesis may be excellent therapeutic target(s) in Alzheimer's disease.] Question: Based on the provided context, do the terms [PI-PLC protein] and [Abeta40 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided discusses the role of phosphatidylinositol-specific phospholipase C (PI-PLC) in reducing the levels of Abeta40 and Abeta42 in mammalian cells. However, it does not indicate a direct interaction between PI-PLC protein and Abeta40 protein. Instead, PI-PLC is used to remove GPI-anchored proteins from the cell surface, which subsequently affects the secretion of Abeta40 and Abeta42. This suggests that PI-PLC influences the process indirectly rather than directly interacting with Abeta40 protein.</s>
IEPA.d127 IEPA.d127.s301.e0 IEPA.d127.s301.e2	PI-PLC	Abeta42	[INST]Context: [PMID: 10480887 Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. The Alzheimer's amyloid protein (Abeta) is released from the larger amyloid beta-protein precursor (APP) by unidentified enzymes referred to as beta- and gamma-secretase. beta-Secretase cleaves APP on the amino side of Abeta producing a large secreted derivative (sAPPbeta) and an Abeta-bearing C-terminal derivative that is subsequently cleaved by gamma-secretase to release Abeta. Alternative cleavage of the APP by alpha-secretase at Abeta16/17 releases the secreted derivative sAPPalpha. In yeast, alpha-secretase activity has been attributed to glycosylphosphatidylinositol (GPI)-anchored aspartyl proteases. To examine the role of GPI-anchored proteins, we specifically removed these proteins from the surface of mammalian cells using phosphatidylinositol-specific phospholipase C (PI-PLC). PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of Abeta40 and Abeta42 in the medium but had no effect on sAPPalpha. A mutant CHO cell line (gpi85), which lacks GPI-anchored proteins, secreted lower levels of Abeta40, Abeta42, and sAPPbeta than its parental line (GPI+). When this parental line was treated with PI-PLC, Abeta40, Abeta42, and sAPPbeta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of PI-PLC. These findings provide strong evidence that one or more GPI-anchored proteins play an important role in beta-secretase activity and Abeta secretion in mammalian cells. The cell-surface GPI-anchored protein(s) involved in Abeta biogenesis may be excellent therapeutic target(s) in Alzheimer's disease.] Question: Based on the provided context, do the terms [PI-PLC protein] and [Abeta42 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that PI-PLC treatment of fetal guinea pig brain cultures and CHO cells significantly reduced the levels of Abeta42 in the medium. This suggests that PI-PLC affects the biogenesis of Abeta42, implying an interaction between PI-PLC and Abeta42. The reduction in Abeta42 levels after PI-PLC treatment demonstrates that PI-PLC influences the process of Abeta42 secretion, thus indicating an interaction.</s>
IEPA.d127 IEPA.d127.s302.e0 IEPA.d127.s302.e2	PI-PLC	Abeta42	[INST]Context: [PMID: 10480887 Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. The Alzheimer's amyloid protein (Abeta) is released from the larger amyloid beta-protein precursor (APP) by unidentified enzymes referred to as beta- and gamma-secretase. beta-Secretase cleaves APP on the amino side of Abeta producing a large secreted derivative (sAPPbeta) and an Abeta-bearing C-terminal derivative that is subsequently cleaved by gamma-secretase to release Abeta. Alternative cleavage of the APP by alpha-secretase at Abeta16/17 releases the secreted derivative sAPPalpha. In yeast, alpha-secretase activity has been attributed to glycosylphosphatidylinositol (GPI)-anchored aspartyl proteases. To examine the role of GPI-anchored proteins, we specifically removed these proteins from the surface of mammalian cells using phosphatidylinositol-specific phospholipase C (PI-PLC). PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of Abeta40 and Abeta42 in the medium but had no effect on sAPPalpha. A mutant CHO cell line (gpi85), which lacks GPI-anchored proteins, secreted lower levels of Abeta40, Abeta42, and sAPPbeta than its parental line (GPI+). When this parental line was treated with PI-PLC, Abeta40, Abeta42, and sAPPbeta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of PI-PLC. These findings provide strong evidence that one or more GPI-anchored proteins play an important role in beta-secretase activity and Abeta secretion in mammalian cells. The cell-surface GPI-anchored protein(s) involved in Abeta biogenesis may be excellent therapeutic target(s) in Alzheimer's disease.] Question: Based on the provided context, do the terms [PI-PLC protein] and [Abeta42 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that PI-PLC treatment of fetal guinea pig brain cultures and CHO cells significantly reduced the levels of Abeta42 in the medium. This suggests that PI-PLC affects the biogenesis of Abeta42, implying an interaction between PI-PLC and Abeta42. The reduction in Abeta42 levels after PI-PLC treatment demonstrates that PI-PLC influences the process of Abeta42 secretion, thus indicating an interaction.</s>
IEPA.d128 IEPA.d128.s303.e0 IEPA.d128.s303.e1	amyloid	PI-PLC	[INST]Context: [PMID: 10492523 Alteration of phosphoinositide degradation by cytosolic and membrane-bound phospholipases after forebrain ischemia-reperfusion in gerbil: effects of amyloid beta peptide. The reperfusion of previously ischemic brain is associated with exacerbation of cellular injury. Reperfusion occasionally potentates release of intracellular enzymes, influx of Ca2+, breakdown of membrane phospholipids, accumulation of amyloid precursor protein or amyloid beta-(like) proteins, and apolipoprotein E. In this study, the effect of reperfusion injury on the activity of cerebral cortex enzymes acting on phosphatidyl [3H] inositol (PI) and [14C-arachidonoyl] PI was investigated. Moreover the effect of amyloid beta25-35 on PI degradation by phospholipase(s) of normoxic brain and subjected to ischemia-reperfusion injury was determined. Brain ischemia in gerbils (Meriones unguiculatus) was induced by ligation of both common carotid arteries for 5 min and then brains were perfused for 15 min, 2 h and 7 days. Statistically significant activation of enzyme(s) involved in phosphatidylinositol degradation in gerbils subjected to ischemia-reperfusion injury was observed. Nearly all gerbils showed a higher activity of cytosolic PI phospholipase C (PLC) at 15 min after ischemia. Concomitantly, the significant enhancement of the level of DAG and AA radioactivity at this short reperfusion time confirmed the active PI degradation by phospholipase(s) in cerebral cortex and hippocampus. After a prolonged reperfusion time of 7 days after ischemia, both cytosolic and membrane-bound forms of PI-PLC were activated. The question arises if alteration of membranes by the degradation of phospholipids occurring after an ischemic episode potentiates the effect of Abeta on membrane-bound enzymes. A neurotoxic fragment of amyloid, Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the PI-PLC activity of normoxic brain. In its non-aggregated form, Abeta 25-35 activates PI-PLC but in the aggregated form the enzymatic activity decreased. Thus, Abeta 25-35 exerts a similar effect on the membrane-bound PI-PLC from normoxic brain or subjected to ischemia reperfusion injury. We conclude that the degradation of phosphatidylinositol by cytosolic phosphoinositide-phospholipase C may contribute to the pathophysiology of delayed neuronal death following cerebral ischemia. Thus, a specific inhibitor of this enzyme(s) may offer therapeutic strategies to protect the brain from damage triggered by ischemia. Ischemia-reperfusion injury had no effect on Abeta-evoked alterations of synaptic plasma membrane-bound PI-PLC.] Question: Based on the provided context, do the terms [amyloid protein] and [PI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that amyloid beta 25-35 (Abeta 25-35) interacts with PI-PLC (phosphatidylinositol-phospholipase C). Specifically, it mentions that Abeta 25-35, in both its aggregated and non-aggregated forms, affects the activity of membrane-bound PI-PLC. This suggests a direct interaction between the amyloid protein and the PI-PLC protein, influencing the enzymatic activity of PI-PLC.</s>
IEPA.d128 IEPA.d128.s304.e0 IEPA.d128.s304.e1	Abeta 25-35	PI-PLC	[INST]Context: [PMID: 10492523 Alteration of phosphoinositide degradation by cytosolic and membrane-bound phospholipases after forebrain ischemia-reperfusion in gerbil: effects of amyloid beta peptide. The reperfusion of previously ischemic brain is associated with exacerbation of cellular injury. Reperfusion occasionally potentates release of intracellular enzymes, influx of Ca2+, breakdown of membrane phospholipids, accumulation of amyloid precursor protein or amyloid beta-(like) proteins, and apolipoprotein E. In this study, the effect of reperfusion injury on the activity of cerebral cortex enzymes acting on phosphatidyl [3H] inositol (PI) and [14C-arachidonoyl] PI was investigated. Moreover the effect of amyloid beta25-35 on PI degradation by phospholipase(s) of normoxic brain and subjected to ischemia-reperfusion injury was determined. Brain ischemia in gerbils (Meriones unguiculatus) was induced by ligation of both common carotid arteries for 5 min and then brains were perfused for 15 min, 2 h and 7 days. Statistically significant activation of enzyme(s) involved in phosphatidylinositol degradation in gerbils subjected to ischemia-reperfusion injury was observed. Nearly all gerbils showed a higher activity of cytosolic PI phospholipase C (PLC) at 15 min after ischemia. Concomitantly, the significant enhancement of the level of DAG and AA radioactivity at this short reperfusion time confirmed the active PI degradation by phospholipase(s) in cerebral cortex and hippocampus. After a prolonged reperfusion time of 7 days after ischemia, both cytosolic and membrane-bound forms of PI-PLC were activated. The question arises if alteration of membranes by the degradation of phospholipids occurring after an ischemic episode potentiates the effect of Abeta on membrane-bound enzymes. A neurotoxic fragment of amyloid, Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the PI-PLC activity of normoxic brain. In its non-aggregated form, Abeta 25-35 activates PI-PLC but in the aggregated form the enzymatic activity decreased. Thus, Abeta 25-35 exerts a similar effect on the membrane-bound PI-PLC from normoxic brain or subjected to ischemia reperfusion injury. We conclude that the degradation of phosphatidylinositol by cytosolic phosphoinositide-phospholipase C may contribute to the pathophysiology of delayed neuronal death following cerebral ischemia. Thus, a specific inhibitor of this enzyme(s) may offer therapeutic strategies to protect the brain from damage triggered by ischemia. Ischemia-reperfusion injury had no effect on Abeta-evoked alterations of synaptic plasma membrane-bound PI-PLC.] Question: Based on the provided context, do the terms [Abeta 25-35 protein] and [PI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that Abeta 25-35 protein interacts with PI-PLC protein. Specifically, it mentions that Abeta 25-35, in both its aggregated and non-aggregated forms, affects the activity of PI-PLC. This suggests a direct interaction between the two proteins, where Abeta 25-35 influences the activity of PI-PLC.</s>
IEPA.d128 IEPA.d128.s305.e0 IEPA.d128.s305.e1	Abeta 25-35	PI-PLC	[INST]Context: [PMID: 10492523 Alteration of phosphoinositide degradation by cytosolic and membrane-bound phospholipases after forebrain ischemia-reperfusion in gerbil: effects of amyloid beta peptide. The reperfusion of previously ischemic brain is associated with exacerbation of cellular injury. Reperfusion occasionally potentates release of intracellular enzymes, influx of Ca2+, breakdown of membrane phospholipids, accumulation of amyloid precursor protein or amyloid beta-(like) proteins, and apolipoprotein E. In this study, the effect of reperfusion injury on the activity of cerebral cortex enzymes acting on phosphatidyl [3H] inositol (PI) and [14C-arachidonoyl] PI was investigated. Moreover the effect of amyloid beta25-35 on PI degradation by phospholipase(s) of normoxic brain and subjected to ischemia-reperfusion injury was determined. Brain ischemia in gerbils (Meriones unguiculatus) was induced by ligation of both common carotid arteries for 5 min and then brains were perfused for 15 min, 2 h and 7 days. Statistically significant activation of enzyme(s) involved in phosphatidylinositol degradation in gerbils subjected to ischemia-reperfusion injury was observed. Nearly all gerbils showed a higher activity of cytosolic PI phospholipase C (PLC) at 15 min after ischemia. Concomitantly, the significant enhancement of the level of DAG and AA radioactivity at this short reperfusion time confirmed the active PI degradation by phospholipase(s) in cerebral cortex and hippocampus. After a prolonged reperfusion time of 7 days after ischemia, both cytosolic and membrane-bound forms of PI-PLC were activated. The question arises if alteration of membranes by the degradation of phospholipids occurring after an ischemic episode potentiates the effect of Abeta on membrane-bound enzymes. A neurotoxic fragment of amyloid, Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the PI-PLC activity of normoxic brain. In its non-aggregated form, Abeta 25-35 activates PI-PLC but in the aggregated form the enzymatic activity decreased. Thus, Abeta 25-35 exerts a similar effect on the membrane-bound PI-PLC from normoxic brain or subjected to ischemia reperfusion injury. We conclude that the degradation of phosphatidylinositol by cytosolic phosphoinositide-phospholipase C may contribute to the pathophysiology of delayed neuronal death following cerebral ischemia. Thus, a specific inhibitor of this enzyme(s) may offer therapeutic strategies to protect the brain from damage triggered by ischemia. Ischemia-reperfusion injury had no effect on Abeta-evoked alterations of synaptic plasma membrane-bound PI-PLC.] Question: Based on the provided context, do the terms [Abeta 25-35 protein] and [PI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that Abeta 25-35 protein interacts with PI-PLC protein. Specifically, it mentions that Abeta 25-35, in both its aggregated and non-aggregated forms, affects the activity of PI-PLC. This suggests a direct interaction between the two proteins, where Abeta 25-35 influences the activity of PI-PLC.</s>
IEPA.d128 IEPA.d128.s306.e0 IEPA.d128.s306.e1	Abeta	PI-PLC	[INST]Context: [PMID: 10492523 Alteration of phosphoinositide degradation by cytosolic and membrane-bound phospholipases after forebrain ischemia-reperfusion in gerbil: effects of amyloid beta peptide. The reperfusion of previously ischemic brain is associated with exacerbation of cellular injury. Reperfusion occasionally potentates release of intracellular enzymes, influx of Ca2+, breakdown of membrane phospholipids, accumulation of amyloid precursor protein or amyloid beta-(like) proteins, and apolipoprotein E. In this study, the effect of reperfusion injury on the activity of cerebral cortex enzymes acting on phosphatidyl [3H] inositol (PI) and [14C-arachidonoyl] PI was investigated. Moreover the effect of amyloid beta25-35 on PI degradation by phospholipase(s) of normoxic brain and subjected to ischemia-reperfusion injury was determined. Brain ischemia in gerbils (Meriones unguiculatus) was induced by ligation of both common carotid arteries for 5 min and then brains were perfused for 15 min, 2 h and 7 days. Statistically significant activation of enzyme(s) involved in phosphatidylinositol degradation in gerbils subjected to ischemia-reperfusion injury was observed. Nearly all gerbils showed a higher activity of cytosolic PI phospholipase C (PLC) at 15 min after ischemia. Concomitantly, the significant enhancement of the level of DAG and AA radioactivity at this short reperfusion time confirmed the active PI degradation by phospholipase(s) in cerebral cortex and hippocampus. After a prolonged reperfusion time of 7 days after ischemia, both cytosolic and membrane-bound forms of PI-PLC were activated. The question arises if alteration of membranes by the degradation of phospholipids occurring after an ischemic episode potentiates the effect of Abeta on membrane-bound enzymes. A neurotoxic fragment of amyloid, Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the PI-PLC activity of normoxic brain. In its non-aggregated form, Abeta 25-35 activates PI-PLC but in the aggregated form the enzymatic activity decreased. Thus, Abeta 25-35 exerts a similar effect on the membrane-bound PI-PLC from normoxic brain or subjected to ischemia reperfusion injury. We conclude that the degradation of phosphatidylinositol by cytosolic phosphoinositide-phospholipase C may contribute to the pathophysiology of delayed neuronal death following cerebral ischemia. Thus, a specific inhibitor of this enzyme(s) may offer therapeutic strategies to protect the brain from damage triggered by ischemia. Ischemia-reperfusion injury had no effect on Abeta-evoked alterations of synaptic plasma membrane-bound PI-PLC.] Question: Based on the provided context, do the terms [Abeta protein] and [PI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that amyloid beta (Abeta) protein interacts with PI-PLC (phosphatidylinositol-phospholipase C) enzymes. Specifically, it mentions that Abeta 25-35, a neurotoxic fragment of amyloid, activates PI-PLC in both normoxic and ischemia-reperfusion injured brains. This suggests a direct interaction between Abeta protein and PI-PLC protein, where Abeta influences the activity of PI-PLC enzymes.</s>
IEPA.d130 IEPA.d130.s312.e0 IEPA.d130.s312.e1	Amyloid	phospholipase(s) C	[INST]Context: [PMID: 10527454 Amyloid beta peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. Phosphoinositide-specific phospholipase C (PLC) is a key enzyme in signal transduction. A subset of muscarinic cholinergic receptors are linked to G-proteins that activate phospholipase C. Cholinergic pathways are important in learning and memory, and deficits in cholinergic transmission have been implicated in Alzheimer's disease (AD). AD is also associated with increased beta-amyloid plaques. In the present study, we have investigated the effect of the amyloid beta (A beta) synthetic peptide homologous to residue 25-35 of A beta in nonaggregated and aggregated forms on the degradation of inositol phospholipids. Synaptic plasma membranes (SPM) and the cytosolic fraction from rat brain cortex served as a source of enzymes. The studies were carried out with radioactive inositol phospholipids in the presence of endogenous and 2 mM CaCl2. The enzyme(s) activity was evaluated by determination of the product formation of [3H]inositol-1-phosphate (IP1) or [3H]inositol-1,4,5-trisphosphate (IP3). Results show that the PI-PLC activity was significantly higher in cytosol compared to SPM, and this enzyme was stimulated by 2 mM CaCl2, but not by GTPgammaS or carbachol, a cholinergic receptor agonist. Activity of the SPM-bound PIP2-PLC was similar to that in cytosol and was not activated by 2 mM CaCl2. The SPM PIP2-PLC was significantly stimulated by GTPgammaS together with the cholinergic agonist, carbachol. Fresh-water-soluble A beta 25-35 activated PI-PLC in SPM markedly by two- to threefold, but this effect was absent in the presence of 2 mM CaCl2. Moreover, A beta 25-35 had no effect on basal PIP2-PLC activity and cytosolic PI-PLC and PIP2-PLC. The aggregated form of A beta 25-35 significantly inhibited PIP2-PLC only in the presence of endogenous CaCl2. It also inhibited the carbachol and GTP(gamma)S-stimulated PIP2-PLC. Our findings show that depending on the aggregation state and Ca2+ concentration, A beta modulates phosphoinositide degradation differently and exclusively in brain synaptic plasma membranes. Our data suggested that aggregated A beta peptide may be responsible for the significant impairment of phosphoinositide signaling found in brain membranes during AD.] Question: Based on the provided context, do the terms [Amyloid protein] and [phospholipase(s) C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the amyloid beta (A beta) peptide 25-35 modulates the hydrolysis of phosphoinositides by membrane phospholipase(s) C (PLC) in adult brain cortex. Specifically, it mentions that A beta 25-35 activates PI-PLC in synaptic plasma membranes (SPM) and that aggregated A beta 25-35 inhibits PIP2-PLC in the presence of endogenous CaCl2. This suggests a direct interaction between the amyloid protein and the phospholipase C protein, as the amyloid peptide influences the activity of the phospholipase C enzyme.</s>
IEPA.d130 IEPA.d130.s313.e0 IEPA.d130.s313.e1	A beta	PI-PLC	[INST]Context: [PMID: 10527454 Amyloid beta peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. Phosphoinositide-specific phospholipase C (PLC) is a key enzyme in signal transduction. A subset of muscarinic cholinergic receptors are linked to G-proteins that activate phospholipase C. Cholinergic pathways are important in learning and memory, and deficits in cholinergic transmission have been implicated in Alzheimer's disease (AD). AD is also associated with increased beta-amyloid plaques. In the present study, we have investigated the effect of the amyloid beta (A beta) synthetic peptide homologous to residue 25-35 of A beta in nonaggregated and aggregated forms on the degradation of inositol phospholipids. Synaptic plasma membranes (SPM) and the cytosolic fraction from rat brain cortex served as a source of enzymes. The studies were carried out with radioactive inositol phospholipids in the presence of endogenous and 2 mM CaCl2. The enzyme(s) activity was evaluated by determination of the product formation of [3H]inositol-1-phosphate (IP1) or [3H]inositol-1,4,5-trisphosphate (IP3). Results show that the PI-PLC activity was significantly higher in cytosol compared to SPM, and this enzyme was stimulated by 2 mM CaCl2, but not by GTPgammaS or carbachol, a cholinergic receptor agonist. Activity of the SPM-bound PIP2-PLC was similar to that in cytosol and was not activated by 2 mM CaCl2. The SPM PIP2-PLC was significantly stimulated by GTPgammaS together with the cholinergic agonist, carbachol. Fresh-water-soluble A beta 25-35 activated PI-PLC in SPM markedly by two- to threefold, but this effect was absent in the presence of 2 mM CaCl2. Moreover, A beta 25-35 had no effect on basal PIP2-PLC activity and cytosolic PI-PLC and PIP2-PLC. The aggregated form of A beta 25-35 significantly inhibited PIP2-PLC only in the presence of endogenous CaCl2. It also inhibited the carbachol and GTP(gamma)S-stimulated PIP2-PLC. Our findings show that depending on the aggregation state and Ca2+ concentration, A beta modulates phosphoinositide degradation differently and exclusively in brain synaptic plasma membranes. Our data suggested that aggregated A beta peptide may be responsible for the significant impairment of phosphoinositide signaling found in brain membranes during AD.] Question: Based on the provided context, do the terms [A beta protein] and [PI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the amyloid beta (A beta) peptide 25-35 modulates the hydrolysis of phosphoinositides by membrane phospholipase(s) C (PI-PLC) in adult brain cortex. Specifically, it mentions that A beta 25-35 activates PI-PLC in synaptic plasma membranes (SPM) and that aggregated A beta 25-35 inhibits PIP2-PLC in the presence of endogenous CaCl2. This suggests a direct interaction between A beta protein and PI-PLC protein, where A beta influences the activity of PI-PLC.</s>
IEPA.d130 IEPA.d130.s315.e0 IEPA.d130.s315.e1	A beta	PIP2-PLC	[INST]Context: [PMID: 10527454 Amyloid beta peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. Phosphoinositide-specific phospholipase C (PLC) is a key enzyme in signal transduction. A subset of muscarinic cholinergic receptors are linked to G-proteins that activate phospholipase C. Cholinergic pathways are important in learning and memory, and deficits in cholinergic transmission have been implicated in Alzheimer's disease (AD). AD is also associated with increased beta-amyloid plaques. In the present study, we have investigated the effect of the amyloid beta (A beta) synthetic peptide homologous to residue 25-35 of A beta in nonaggregated and aggregated forms on the degradation of inositol phospholipids. Synaptic plasma membranes (SPM) and the cytosolic fraction from rat brain cortex served as a source of enzymes. The studies were carried out with radioactive inositol phospholipids in the presence of endogenous and 2 mM CaCl2. The enzyme(s) activity was evaluated by determination of the product formation of [3H]inositol-1-phosphate (IP1) or [3H]inositol-1,4,5-trisphosphate (IP3). Results show that the PI-PLC activity was significantly higher in cytosol compared to SPM, and this enzyme was stimulated by 2 mM CaCl2, but not by GTPgammaS or carbachol, a cholinergic receptor agonist. Activity of the SPM-bound PIP2-PLC was similar to that in cytosol and was not activated by 2 mM CaCl2. The SPM PIP2-PLC was significantly stimulated by GTPgammaS together with the cholinergic agonist, carbachol. Fresh-water-soluble A beta 25-35 activated PI-PLC in SPM markedly by two- to threefold, but this effect was absent in the presence of 2 mM CaCl2. Moreover, A beta 25-35 had no effect on basal PIP2-PLC activity and cytosolic PI-PLC and PIP2-PLC. The aggregated form of A beta 25-35 significantly inhibited PIP2-PLC only in the presence of endogenous CaCl2. It also inhibited the carbachol and GTP(gamma)S-stimulated PIP2-PLC. Our findings show that depending on the aggregation state and Ca2+ concentration, A beta modulates phosphoinositide degradation differently and exclusively in brain synaptic plasma membranes. Our data suggested that aggregated A beta peptide may be responsible for the significant impairment of phosphoinositide signaling found in brain membranes during AD.] Question: Based on the provided context, do the terms [A beta protein] and [PIP2-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the amyloid beta (A beta) peptide 25-35 modulates the hydrolysis of phosphoinositides by membrane phospholipase(s) C (PLC), specifically PIP2-PLC. The study shows that A beta 25-35 activates PI-PLC in synaptic plasma membranes (SPM) and inhibits PIP2-PLC in the presence of aggregated A beta 25-35. This suggests that A beta protein and PIP2-PLC interact with each other, as the presence of A beta peptide directly affects the activity of PIP2-PLC.</s>
IEPA.d131 IEPA.d131.s316.e0 IEPA.d131.s316.e1	Vasopressin	PKC	[INST]Context: [PMID: 10562440 Vasopressin stimulates tyrosine phosphorylation by activation of PKC in the rat smooth muscle cell line, A-10. Arginine vasopressin (AVP)-induced tyrosine phosphorylation was studied in a rat smooth muscle cell line, A-10, by western blotting, using a monoclonal antibody against phosphotyrosine. AVP stimulated the phosphorylation of several cellular proteins of molecular mass 60-130 kDa in a time- and dose-dependent manner. Phosphorylation was mediated largely by V(1)receptor subtype since it was inhibited by selective V(1)antagonist and was only partially elicited by the V(2)agonist, desmopressin. Heterotrimeric G-proteins seemed to be involved in the phosphorylation mechanism because fluoraluminates, an activator of heterotrimeric G-proteins (and thus an uncoupler of the receptor-G-protein interaction) inhibited the AVP-induced phosphorylation. The protein kinase C (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the AVP-stimulated phosphorylation. The last of these has been shown to be one of the most selective inhibitors of PKC. These results indicate that PKC is upstream of the phosphorylation, a motion which is supported by the fact that the AVP-stimulated phosphorylation was downregulated by phorbol esters.] Question: Based on the provided context, do the terms [Vasopressin protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that vasopressin (AVP) stimulates tyrosine phosphorylation in rat smooth muscle cells, and this phosphorylation is mediated by the activation of protein kinase C (PKC). Specifically, the PKC inhibitors staurosporine, H7, and GF109203X are able to block the AVP-stimulated phosphorylation, suggesting that PKC is upstream of the phosphorylation process. This implies that vasopressin and PKC interact in a signaling pathway where vasopressin activates PKC, which in turn leads to the phosphorylation of cellular proteins.</s>
IEPA.d131 IEPA.d131.s317.e0 IEPA.d131.s317.e1	protein kinase C	AVP	[INST]Context: [PMID: 10562440 Vasopressin stimulates tyrosine phosphorylation by activation of PKC in the rat smooth muscle cell line, A-10. Arginine vasopressin (AVP)-induced tyrosine phosphorylation was studied in a rat smooth muscle cell line, A-10, by western blotting, using a monoclonal antibody against phosphotyrosine. AVP stimulated the phosphorylation of several cellular proteins of molecular mass 60-130 kDa in a time- and dose-dependent manner. Phosphorylation was mediated largely by V(1)receptor subtype since it was inhibited by selective V(1)antagonist and was only partially elicited by the V(2)agonist, desmopressin. Heterotrimeric G-proteins seemed to be involved in the phosphorylation mechanism because fluoraluminates, an activator of heterotrimeric G-proteins (and thus an uncoupler of the receptor-G-protein interaction) inhibited the AVP-induced phosphorylation. The protein kinase C (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the AVP-stimulated phosphorylation. The last of these has been shown to be one of the most selective inhibitors of PKC. These results indicate that PKC is upstream of the phosphorylation, a motion which is supported by the fact that the AVP-stimulated phosphorylation was downregulated by phorbol esters.] Question: Based on the provided context, do the terms [protein kinase C protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) stimulates tyrosine phosphorylation in rat smooth muscle cells, and this phosphorylation is mediated by the activation of protein kinase C (PKC). Specifically, the PKC inhibitors staurosporine, H7, and GF109203X are able to block the AVP-stimulated phosphorylation, suggesting that PKC is upstream of the phosphorylation process. This implies that AVP and protein kinase C interact in a signaling pathway where AVP activates PKC, which in turn leads to the phosphorylation of cellular proteins.</s>
IEPA.d131 IEPA.d131.s318.e0 IEPA.d131.s318.e1	PKC	AVP	[INST]Context: [PMID: 10562440 Vasopressin stimulates tyrosine phosphorylation by activation of PKC in the rat smooth muscle cell line, A-10. Arginine vasopressin (AVP)-induced tyrosine phosphorylation was studied in a rat smooth muscle cell line, A-10, by western blotting, using a monoclonal antibody against phosphotyrosine. AVP stimulated the phosphorylation of several cellular proteins of molecular mass 60-130 kDa in a time- and dose-dependent manner. Phosphorylation was mediated largely by V(1)receptor subtype since it was inhibited by selective V(1)antagonist and was only partially elicited by the V(2)agonist, desmopressin. Heterotrimeric G-proteins seemed to be involved in the phosphorylation mechanism because fluoraluminates, an activator of heterotrimeric G-proteins (and thus an uncoupler of the receptor-G-protein interaction) inhibited the AVP-induced phosphorylation. The protein kinase C (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the AVP-stimulated phosphorylation. The last of these has been shown to be one of the most selective inhibitors of PKC. These results indicate that PKC is upstream of the phosphorylation, a motion which is supported by the fact that the AVP-stimulated phosphorylation was downregulated by phorbol esters.] Question: Based on the provided context, do the terms [PKC protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) stimulates tyrosine phosphorylation in rat smooth muscle cells, and this phosphorylation is mediated by the activation of protein kinase C (PKC). Specifically, the PKC inhibitors staurosporine, H7, and GF109203X are able to block the AVP-stimulated phosphorylation, suggesting that PKC is upstream of the phosphorylation process. This implies that AVP and PKC interact in a signaling pathway where AVP activates PKC, which in turn leads to the phosphorylation of cellular proteins.</s>
IEPA.d132 IEPA.d132.s319.e0 IEPA.d132.s319.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10563891 2-fluoroabscisic acid analogues: their synthesis and biological activities. Fluorine was introduced into the 2-position of the side chain of abscisic acid (ABA) analogues by Wittig reaction of alpha-ionone derivatives with ethyl triethylphosphono-2-fluoroacetate. The effects of the fluorinated analogues were evaluated on inhibition of cress seed germination and inhibition of gibberellin-inducible alpha-amylase induction in embryoless barley half-seeds. (2E, 4E)-2-Fluoro-5-(1'-hydroxy-2',6', 6'-trimethyl-2'-cyclohexen-1'-yl)-3-methyl-2,4-pentadienoic acid (5b) showed potent inhibitory activity at the same level as ABA in the cress seed germination test, and 5b also inhibited gibberellin-inducible alpha-amylase induction at 4 x 10(-)(6), 3 times the concentration of ABA (1 x 10(-)(6)) for 50% inhibition of alpha-amylase production. 5b also showed dehydrin induction activity. These results indicate that fluorinated ABA analogues mimic ABA action and can be a lead for a plant growth regulator which regulates plant growth or protects plants from environmental stresses.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin induces alpha-amylase production in embryoless barley half-seeds. The fluorinated ABA analogues, such as 5b, inhibit this gibberellin-inducible alpha-amylase induction. This suggests that gibberellin and alpha-amylase are part of the same regulatory pathway, where gibberellin stimulates the production of alpha-amylase. Therefore, gibberellin protein and alpha-amylase protein interact in the sense that gibberellin regulates the expression of alpha-amylase.</s>
IEPA.d132 IEPA.d132.s320.e0 IEPA.d132.s320.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10563891 2-fluoroabscisic acid analogues: their synthesis and biological activities. Fluorine was introduced into the 2-position of the side chain of abscisic acid (ABA) analogues by Wittig reaction of alpha-ionone derivatives with ethyl triethylphosphono-2-fluoroacetate. The effects of the fluorinated analogues were evaluated on inhibition of cress seed germination and inhibition of gibberellin-inducible alpha-amylase induction in embryoless barley half-seeds. (2E, 4E)-2-Fluoro-5-(1'-hydroxy-2',6', 6'-trimethyl-2'-cyclohexen-1'-yl)-3-methyl-2,4-pentadienoic acid (5b) showed potent inhibitory activity at the same level as ABA in the cress seed germination test, and 5b also inhibited gibberellin-inducible alpha-amylase induction at 4 x 10(-)(6), 3 times the concentration of ABA (1 x 10(-)(6)) for 50% inhibition of alpha-amylase production. 5b also showed dehydrin induction activity. These results indicate that fluorinated ABA analogues mimic ABA action and can be a lead for a plant growth regulator which regulates plant growth or protects plants from environmental stresses.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin induces alpha-amylase production in embryoless barley half-seeds. The fluorinated ABA analogues, such as 5b, inhibit this gibberellin-inducible alpha-amylase induction. This suggests that gibberellin and alpha-amylase are part of the same regulatory pathway, where gibberellin stimulates the production of alpha-amylase. Therefore, gibberellin protein and alpha-amylase protein interact in the sense that gibberellin regulates the expression of alpha-amylase.</s>
IEPA.d134 IEPA.d134.s322.e0 IEPA.d134.s322.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10604763 Isolation and characterization of gibbestatin B, an inhibitor of gibberellin-induced expression of alpha-amylase, and gibbestatin C from streptomycetaes. ] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin-induced expression of alpha-amylase is inhibited by gibbestatin B and gibbestatin C. This implies that gibberellin and alpha-amylase are part of the same regulatory pathway, where gibberellin influences the expression of alpha-amylase. Therefore, gibberellin and alpha-amylase interact in a regulatory manner.</s>
IEPA.d137 IEPA.d137.s325.e0 IEPA.d137.s325.e1	arginine vasopressin	protein kinase C	[INST]Context: [PMID: 10679516 p38 MAP kinase is required for vasopressin-stimulated HSP27 induction in aortic smooth muscle cells. We previously showed that arginine vasopressin (AVP) stimulates heat shock protein 27 (HSP27) induction through protein kinase C activation in aortic smooth muscle A10 cells. In the present study, we examined whether the mitogen-activated protein (MAP) kinase superfamily is involved in the AVP-stimulated HSP27 induction in A10 cells. AVP stimulated the phosphorylation of p42/p44 MAP kinase and p38 MAP kinase. On the contrary, AVP had little effect on SAPK (stress-activated protein kinase)/JNK (c-Jun N-terminal kinase) phosphorylation. The HSP27 accumulation by AVP was not affected by PD98059, an inhibitor of the upstream kinase that activates p42/p44 MAP kinase. SB203580 and PD169316, specific inhibitors of p38 MAP kinase, suppressed the AVP-induced accumulation of HSP27. 12-O-tetradecanoylphorbol 13-acetate, an activator of protein kinase C, induced accumulation of HSP27 and was not inhibited by PD98059 but was inhibited by SB203580. Calphostin C and ET-18-OCH(3), inhibitors of protein kinase C, reduced the phosphorylation of p38 MAP kinase by AVP. SB203580 and PD169316 suppressed the AVP-increased levels in mRNA for HSP27. Dissociation of the aggregated HSP27 to the dissociated HSP27 was induced by AVP. These results strongly suggest that p38 MAP kinase takes part in the pathway of the AVP-stimulated induction of HSP27 in vascular smooth muscle cells.] Question: Based on the provided context, do the terms [arginine vasopressin protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) stimulates the phosphorylation of p38 MAP kinase and that this phosphorylation is mediated through the activation of protein kinase C. Specifically, it is mentioned that AVP stimulates the accumulation of HSP27 through protein kinase C activation, and that inhibitors of protein kinase C reduce the phosphorylation of p38 MAP kinase by AVP. This suggests that AVP and protein kinase C interact in a pathway that leads to the phosphorylation of p38 MAP kinase.</s>
IEPA.d137 IEPA.d137.s326.e0 IEPA.d137.s326.e1	protein kinase C	AVP	[INST]Context: [PMID: 10679516 p38 MAP kinase is required for vasopressin-stimulated HSP27 induction in aortic smooth muscle cells. We previously showed that arginine vasopressin (AVP) stimulates heat shock protein 27 (HSP27) induction through protein kinase C activation in aortic smooth muscle A10 cells. In the present study, we examined whether the mitogen-activated protein (MAP) kinase superfamily is involved in the AVP-stimulated HSP27 induction in A10 cells. AVP stimulated the phosphorylation of p42/p44 MAP kinase and p38 MAP kinase. On the contrary, AVP had little effect on SAPK (stress-activated protein kinase)/JNK (c-Jun N-terminal kinase) phosphorylation. The HSP27 accumulation by AVP was not affected by PD98059, an inhibitor of the upstream kinase that activates p42/p44 MAP kinase. SB203580 and PD169316, specific inhibitors of p38 MAP kinase, suppressed the AVP-induced accumulation of HSP27. 12-O-tetradecanoylphorbol 13-acetate, an activator of protein kinase C, induced accumulation of HSP27 and was not inhibited by PD98059 but was inhibited by SB203580. Calphostin C and ET-18-OCH(3), inhibitors of protein kinase C, reduced the phosphorylation of p38 MAP kinase by AVP. SB203580 and PD169316 suppressed the AVP-increased levels in mRNA for HSP27. Dissociation of the aggregated HSP27 to the dissociated HSP27 was induced by AVP. These results strongly suggest that p38 MAP kinase takes part in the pathway of the AVP-stimulated induction of HSP27 in vascular smooth muscle cells.] Question: Based on the provided context, do the terms [protein kinase C protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) stimulates the phosphorylation of p38 MAP kinase through the activation of protein kinase C. Specifically, it mentions that AVP stimulates the phosphorylation of p38 MAP kinase and that inhibitors of protein kinase C reduce the phosphorylation of p38 MAP kinase by AVP. This suggests that AVP and protein kinase C interact in a pathway that leads to the phosphorylation of p38 MAP kinase.</s>
IEPA.d138 IEPA.d138.s328.e0 IEPA.d138.s328.e1	glycosyl-phosphatidylinositol-specific phospholipase C	insulin	[INST]Context: [PMID: 10684630 Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities. Previously, we have described significant effects of human insulin on glucose metabolism in the yeast Saccharomyces cerevisiae under conditions of growth limitation. These regulations apparently rely on a transmembrane receptor capable of binding human insulin and responding by tyrosine/serine phosphorylation of a specific set of polypeptides [Muller, G., Rouveyre, N., Crecelius, A., and Bandlow, W. (1998) Biochemistry 37, 8683-8695; Muller, G., Rouveyre, N., Upshon, C., Gross, E., and Bandlow, W. (1998) Biochemistry 37, 8696-8704; Muller, G., Rouveyre, N., Upshon, C., and Bandlow, W. (1998) Biochemistry 37, 8705-8713]. To characterize the molecular link between the initial steps in insulin-like signaling in yeast and the changes in the activities of glycogen synthase and glycogen phosphorylase, we examined here the effects of human insulin on a set of key regulatory enzymes of glycogen metabolism, protein phosphatase 2A (PP2A), cAMP-specific phosphodiesterase (cAMP-PDE), and protein kinase A (PKA). PP2A was activated about 2-fold by insulin in spheroplasts and in intact cells, whereas the fraction of active PKA was significantly reduced in a cAMP-independent manner as well as through a subsequent up to 3-fold increase in particulate cAMP-PDE activity accompanied by a 50% decrease in cytosolic cAMP levels. In addition, glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC), which in isolated rat adipocytes is activated by insulin, was stimulated to up to 5-fold by glucose and 10-fold by glucose plus insulin in both yeast spheroplasts and intact cells leading to a concentration-dependent leftward shift of the glucose-response curve for activation of the GPI-PLC. GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I. In addition to lipolytic cleavage by GPI-PLC, the GPI anchor of the cAMP-binding ectoprotein, Gce1p, was secondarily processed by a rapid proteolytic event. As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone. The insulin concentrations effective in modulating PP2A, PKA, cAMP-PDE, and GPI-PLC activities correlate well with those required for half-saturation of the specific binding sites as well as for stimulation of protein phosphorylation and glycogen accumulation. The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase.] Question: Based on the provided context, do the terms [glycosyl-phosphatidylinositol-specific phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that human insulin stimulates the activity of glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC) in yeast. Specifically, it mentions that "GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I." This suggests a direct interaction between the insulin protein and the GPI-PLC protein, where insulin activates the GPI-PLC enzyme.</s>
IEPA.d138 IEPA.d138.s328.e0 IEPA.d138.s328.e2	glycosyl-phosphatidylinositol-specific phospholipase C	insulin	[INST]Context: [PMID: 10684630 Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities. Previously, we have described significant effects of human insulin on glucose metabolism in the yeast Saccharomyces cerevisiae under conditions of growth limitation. These regulations apparently rely on a transmembrane receptor capable of binding human insulin and responding by tyrosine/serine phosphorylation of a specific set of polypeptides [Muller, G., Rouveyre, N., Crecelius, A., and Bandlow, W. (1998) Biochemistry 37, 8683-8695; Muller, G., Rouveyre, N., Upshon, C., Gross, E., and Bandlow, W. (1998) Biochemistry 37, 8696-8704; Muller, G., Rouveyre, N., Upshon, C., and Bandlow, W. (1998) Biochemistry 37, 8705-8713]. To characterize the molecular link between the initial steps in insulin-like signaling in yeast and the changes in the activities of glycogen synthase and glycogen phosphorylase, we examined here the effects of human insulin on a set of key regulatory enzymes of glycogen metabolism, protein phosphatase 2A (PP2A), cAMP-specific phosphodiesterase (cAMP-PDE), and protein kinase A (PKA). PP2A was activated about 2-fold by insulin in spheroplasts and in intact cells, whereas the fraction of active PKA was significantly reduced in a cAMP-independent manner as well as through a subsequent up to 3-fold increase in particulate cAMP-PDE activity accompanied by a 50% decrease in cytosolic cAMP levels. In addition, glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC), which in isolated rat adipocytes is activated by insulin, was stimulated to up to 5-fold by glucose and 10-fold by glucose plus insulin in both yeast spheroplasts and intact cells leading to a concentration-dependent leftward shift of the glucose-response curve for activation of the GPI-PLC. GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I. In addition to lipolytic cleavage by GPI-PLC, the GPI anchor of the cAMP-binding ectoprotein, Gce1p, was secondarily processed by a rapid proteolytic event. As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone. The insulin concentrations effective in modulating PP2A, PKA, cAMP-PDE, and GPI-PLC activities correlate well with those required for half-saturation of the specific binding sites as well as for stimulation of protein phosphorylation and glycogen accumulation. The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase.] Question: Based on the provided context, do the terms [glycosyl-phosphatidylinositol-specific phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that human insulin stimulates the activity of glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC) in yeast. Specifically, it mentions that "GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I." This suggests a direct interaction between the insulin protein and the GPI-PLC protein, where insulin activates the GPI-PLC enzyme.</s>
IEPA.d138 IEPA.d138.s329.e0 IEPA.d138.s329.e1	GPI-PLC	insulin	[INST]Context: [PMID: 10684630 Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities. Previously, we have described significant effects of human insulin on glucose metabolism in the yeast Saccharomyces cerevisiae under conditions of growth limitation. These regulations apparently rely on a transmembrane receptor capable of binding human insulin and responding by tyrosine/serine phosphorylation of a specific set of polypeptides [Muller, G., Rouveyre, N., Crecelius, A., and Bandlow, W. (1998) Biochemistry 37, 8683-8695; Muller, G., Rouveyre, N., Upshon, C., Gross, E., and Bandlow, W. (1998) Biochemistry 37, 8696-8704; Muller, G., Rouveyre, N., Upshon, C., and Bandlow, W. (1998) Biochemistry 37, 8705-8713]. To characterize the molecular link between the initial steps in insulin-like signaling in yeast and the changes in the activities of glycogen synthase and glycogen phosphorylase, we examined here the effects of human insulin on a set of key regulatory enzymes of glycogen metabolism, protein phosphatase 2A (PP2A), cAMP-specific phosphodiesterase (cAMP-PDE), and protein kinase A (PKA). PP2A was activated about 2-fold by insulin in spheroplasts and in intact cells, whereas the fraction of active PKA was significantly reduced in a cAMP-independent manner as well as through a subsequent up to 3-fold increase in particulate cAMP-PDE activity accompanied by a 50% decrease in cytosolic cAMP levels. In addition, glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC), which in isolated rat adipocytes is activated by insulin, was stimulated to up to 5-fold by glucose and 10-fold by glucose plus insulin in both yeast spheroplasts and intact cells leading to a concentration-dependent leftward shift of the glucose-response curve for activation of the GPI-PLC. GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I. In addition to lipolytic cleavage by GPI-PLC, the GPI anchor of the cAMP-binding ectoprotein, Gce1p, was secondarily processed by a rapid proteolytic event. As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone. The insulin concentrations effective in modulating PP2A, PKA, cAMP-PDE, and GPI-PLC activities correlate well with those required for half-saturation of the specific binding sites as well as for stimulation of protein phosphorylation and glycogen accumulation. The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase.] Question: Based on the provided context, do the terms [GPI-PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that human insulin stimulates the activity of glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC) in yeast. Specifically, it mentions that "GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I." This suggests a direct interaction between the insulin protein and the GPI-PLC protein, where insulin activates GPI-PLC.</s>
IEPA.d138 IEPA.d138.s331.e0 IEPA.d138.s331.e1	insulin	GPI-PLC	[INST]Context: [PMID: 10684630 Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities. Previously, we have described significant effects of human insulin on glucose metabolism in the yeast Saccharomyces cerevisiae under conditions of growth limitation. These regulations apparently rely on a transmembrane receptor capable of binding human insulin and responding by tyrosine/serine phosphorylation of a specific set of polypeptides [Muller, G., Rouveyre, N., Crecelius, A., and Bandlow, W. (1998) Biochemistry 37, 8683-8695; Muller, G., Rouveyre, N., Upshon, C., Gross, E., and Bandlow, W. (1998) Biochemistry 37, 8696-8704; Muller, G., Rouveyre, N., Upshon, C., and Bandlow, W. (1998) Biochemistry 37, 8705-8713]. To characterize the molecular link between the initial steps in insulin-like signaling in yeast and the changes in the activities of glycogen synthase and glycogen phosphorylase, we examined here the effects of human insulin on a set of key regulatory enzymes of glycogen metabolism, protein phosphatase 2A (PP2A), cAMP-specific phosphodiesterase (cAMP-PDE), and protein kinase A (PKA). PP2A was activated about 2-fold by insulin in spheroplasts and in intact cells, whereas the fraction of active PKA was significantly reduced in a cAMP-independent manner as well as through a subsequent up to 3-fold increase in particulate cAMP-PDE activity accompanied by a 50% decrease in cytosolic cAMP levels. In addition, glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC), which in isolated rat adipocytes is activated by insulin, was stimulated to up to 5-fold by glucose and 10-fold by glucose plus insulin in both yeast spheroplasts and intact cells leading to a concentration-dependent leftward shift of the glucose-response curve for activation of the GPI-PLC. GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I. In addition to lipolytic cleavage by GPI-PLC, the GPI anchor of the cAMP-binding ectoprotein, Gce1p, was secondarily processed by a rapid proteolytic event. As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone. The insulin concentrations effective in modulating PP2A, PKA, cAMP-PDE, and GPI-PLC activities correlate well with those required for half-saturation of the specific binding sites as well as for stimulation of protein phosphorylation and glycogen accumulation. The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase.] Question: Based on the provided context, do the terms [insulin protein] and [GPI-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that human insulin stimulates the activity of glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC) in yeast. Specifically, it mentions that "GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I." This suggests that insulin protein and GPI-PLC protein interact in the sense that insulin directly influences the activity of GPI-PLC.</s>
IEPA.d138 IEPA.d138.s332.e1 IEPA.d138.s332.e2	GPI-PLC	insulin	[INST]Context: [PMID: 10684630 Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities. Previously, we have described significant effects of human insulin on glucose metabolism in the yeast Saccharomyces cerevisiae under conditions of growth limitation. These regulations apparently rely on a transmembrane receptor capable of binding human insulin and responding by tyrosine/serine phosphorylation of a specific set of polypeptides [Muller, G., Rouveyre, N., Crecelius, A., and Bandlow, W. (1998) Biochemistry 37, 8683-8695; Muller, G., Rouveyre, N., Upshon, C., Gross, E., and Bandlow, W. (1998) Biochemistry 37, 8696-8704; Muller, G., Rouveyre, N., Upshon, C., and Bandlow, W. (1998) Biochemistry 37, 8705-8713]. To characterize the molecular link between the initial steps in insulin-like signaling in yeast and the changes in the activities of glycogen synthase and glycogen phosphorylase, we examined here the effects of human insulin on a set of key regulatory enzymes of glycogen metabolism, protein phosphatase 2A (PP2A), cAMP-specific phosphodiesterase (cAMP-PDE), and protein kinase A (PKA). PP2A was activated about 2-fold by insulin in spheroplasts and in intact cells, whereas the fraction of active PKA was significantly reduced in a cAMP-independent manner as well as through a subsequent up to 3-fold increase in particulate cAMP-PDE activity accompanied by a 50% decrease in cytosolic cAMP levels. In addition, glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC), which in isolated rat adipocytes is activated by insulin, was stimulated to up to 5-fold by glucose and 10-fold by glucose plus insulin in both yeast spheroplasts and intact cells leading to a concentration-dependent leftward shift of the glucose-response curve for activation of the GPI-PLC. GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I. In addition to lipolytic cleavage by GPI-PLC, the GPI anchor of the cAMP-binding ectoprotein, Gce1p, was secondarily processed by a rapid proteolytic event. As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone. The insulin concentrations effective in modulating PP2A, PKA, cAMP-PDE, and GPI-PLC activities correlate well with those required for half-saturation of the specific binding sites as well as for stimulation of protein phosphorylation and glycogen accumulation. The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase.] Question: Based on the provided context, do the terms [GPI-PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that human insulin stimulates the activity of glycosyl-phosphatidylinositol-specific phospholipase C (GPI-PLC) in yeast. Specifically, it mentions that "GPI-PLC was most pronouncedly stimulated by authentic human insulin compared to various insulin analogues and insulin-like growth factor I." This suggests a direct interaction between the insulin protein and the GPI-PLC protein, where insulin activates GPI-PLC.</s>
IEPA.d140 IEPA.d140.s335.e0 IEPA.d140.s335.e1	Arginine vasopressin	protein kinase C	[INST]Context: [PMID: 10704947 Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysophosphatidic acid in rat cardiomyocytes. Arginine vasopressin (AVP) and lysophosphatidic acid (LPA) have been shown to stimulate protein kinase C (PKC) and mitogen-activated protein (MAP) kinases and the proliferation of vascular smooth muscle cells. However, the actions of these two agents in cardiomyocytes are less well understood. To investigate the signal transduction pathways of AVP and LPA, freshly isolated adult rat cardiomyocytes were examined. Both AVP and LPA induced concentration- and time-dependent stimulation of the phosphotransferase activities of p90 ribosomal S6 kinases (RSK) and their upstream activators, extracellularly regulated kinases (ERK) 1 and 2. The activation of ERK1 and ERK2 by LPA was PKC- and phosphatidylinositol 3-kinase (PI 3-kinase)-dependent. However, AVP-induced activation of RSK2, a downstream substrate of ERK1 and ERK2, was PKC-dependent and PI 3-kinase-independent. AVP and LPA were also observed to increase the phosphotransferase activity of p70 ribosomal protein S6 kinase (p70 S6K) in a time- and concentration-dependent manner. The activation of p70 S6K by LPA and AVP was PI 3-kinase-dependent. PKC was necessary in AVP- but not in LPA-induced activation of p70 S6K. Since RSK and p70 S6K have been implicated in the regulation of translational control of protein synthesis, we concluded that AVP and LPA may stimulate the growth of cardiomyocytes through these two protein kinase cascades.] Question: Based on the provided context, do the terms [Arginine vasopressin protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) and protein kinase C (PKC) interact in the signal transduction pathways of cardiomyocytes. Specifically, AVP-induced activation of ribosomal protein S6 kinases (RSK) and p70 ribosomal protein S6 kinase (p70 S6K) is PKC-dependent. This suggests that AVP stimulates PKC, which in turn activates downstream kinases involved in protein synthesis regulation. Therefore, the terms "arginine vasopressin protein" and "protein kinase C protein" interact with each other in the described biological process.</s>
IEPA.d140 IEPA.d140.s336.e0 IEPA.d140.s336.e1	AVP	PKC	[INST]Context: [PMID: 10704947 Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysophosphatidic acid in rat cardiomyocytes. Arginine vasopressin (AVP) and lysophosphatidic acid (LPA) have been shown to stimulate protein kinase C (PKC) and mitogen-activated protein (MAP) kinases and the proliferation of vascular smooth muscle cells. However, the actions of these two agents in cardiomyocytes are less well understood. To investigate the signal transduction pathways of AVP and LPA, freshly isolated adult rat cardiomyocytes were examined. Both AVP and LPA induced concentration- and time-dependent stimulation of the phosphotransferase activities of p90 ribosomal S6 kinases (RSK) and their upstream activators, extracellularly regulated kinases (ERK) 1 and 2. The activation of ERK1 and ERK2 by LPA was PKC- and phosphatidylinositol 3-kinase (PI 3-kinase)-dependent. However, AVP-induced activation of RSK2, a downstream substrate of ERK1 and ERK2, was PKC-dependent and PI 3-kinase-independent. AVP and LPA were also observed to increase the phosphotransferase activity of p70 ribosomal protein S6 kinase (p70 S6K) in a time- and concentration-dependent manner. The activation of p70 S6K by LPA and AVP was PI 3-kinase-dependent. PKC was necessary in AVP- but not in LPA-induced activation of p70 S6K. Since RSK and p70 S6K have been implicated in the regulation of translational control of protein synthesis, we concluded that AVP and LPA may stimulate the growth of cardiomyocytes through these two protein kinase cascades.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) and protein kinase C (PKC) are involved in the signal transduction pathways that stimulate the phosphotransferase activities of ribosomal protein S6 kinases (RSK) and p70 ribosomal protein S6 kinase (p70 S6K) in rat cardiomyocytes. Specifically, AVP-induced activation of RSK2 was PKC-dependent, suggesting that AVP and PKC interact in this pathway.</s>
IEPA.d140 IEPA.d140.s337.e0 IEPA.d140.s337.e1	PKC	AVP	[INST]Context: [PMID: 10704947 Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysophosphatidic acid in rat cardiomyocytes. Arginine vasopressin (AVP) and lysophosphatidic acid (LPA) have been shown to stimulate protein kinase C (PKC) and mitogen-activated protein (MAP) kinases and the proliferation of vascular smooth muscle cells. However, the actions of these two agents in cardiomyocytes are less well understood. To investigate the signal transduction pathways of AVP and LPA, freshly isolated adult rat cardiomyocytes were examined. Both AVP and LPA induced concentration- and time-dependent stimulation of the phosphotransferase activities of p90 ribosomal S6 kinases (RSK) and their upstream activators, extracellularly regulated kinases (ERK) 1 and 2. The activation of ERK1 and ERK2 by LPA was PKC- and phosphatidylinositol 3-kinase (PI 3-kinase)-dependent. However, AVP-induced activation of RSK2, a downstream substrate of ERK1 and ERK2, was PKC-dependent and PI 3-kinase-independent. AVP and LPA were also observed to increase the phosphotransferase activity of p70 ribosomal protein S6 kinase (p70 S6K) in a time- and concentration-dependent manner. The activation of p70 S6K by LPA and AVP was PI 3-kinase-dependent. PKC was necessary in AVP- but not in LPA-induced activation of p70 S6K. Since RSK and p70 S6K have been implicated in the regulation of translational control of protein synthesis, we concluded that AVP and LPA may stimulate the growth of cardiomyocytes through these two protein kinase cascades.] Question: Based on the provided context, do the terms [PKC protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) and PKC (protein kinase C) are involved in the signal transduction pathways that stimulate the phosphotransferase activities of ribosomal protein S6 kinases (RSK) and p70 ribosomal protein S6 kinase (p70 S6K) in rat cardiomyocytes. Specifically, AVP-induced activation of RSK2 was PKC-dependent, and AVP and LPA were observed to increase the phosphotransferase activity of p70 S6K, which was PKC-dependent in the case of AVP. This suggests that AVP and PKC interact in the signaling pathways that regulate protein synthesis in cardiomyocytes.</s>
IEPA.d141 IEPA.d141.s338.e0 IEPA.d141.s338.e1	phospholipase C	insulin	[INST]Context: [PMID: 10751197 Tolbutamide and diazoxide modulate phospholipase C-linked Ca(2+) signaling and insulin secretion in beta-cells. Arginine vasopressin (AVP), bombesin, and ACh increase cytosolic free Ca(2+) and potentiate glucose-induced insulin release by activating receptors linked to phospholipase C (PLC). We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PLC-linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PLC-linked insulin secretion from HIT-T15 cells. In the presence of glucose, the PLC-linked Ca(2+) signals were enhanced by tolbutamide (3-300 microM) and inhibited by diazoxide (10-100 microM). The effects of tolbutamide and diazoxide on PLC-linked Ca(2+) signaling were mimicked by BAY K 8644 and nifedipine, an activator and inhibitor of L-type voltage-sensitive Ca(2+) channels, respectively. Neither tolbutamide nor diazoxide affected PLC-linked mobilization of internal Ca(2+) or store-operated Ca(2+) influx through non-L-type Ca(2+) channels. In the absence of glucose, PLC-linked Ca(2+) signals were diminished or abolished; this effect could be partly antagonized by tolbutamide. In the presence of glucose, tolbutamide potentiated and diazoxide inhibited AVP- or bombesin-induced insulin secretion from HIT-T15 cells. Nifedipine (10 microM) blocked both the potentiating and inhibitory actions of tolbutamide and diazoxide on AVP-induced insulin release, respectively. In glucose-free medium, AVP-induced insulin release was reduced but was again potentiated by tolbutamide, whereas diazoxide caused no further inhibition. Thus tolbutamide and diazoxide regulate both PLC-linked Ca(2+) signaling and insulin secretion from pancreatic beta-cells by modulating K(ATP) channels, thereby determining voltage-sensitive Ca(2+) influx.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that phospholipase C (PLC) is involved in the signaling pathways that lead to insulin secretion. Specifically, it mentions that PLC-linked Ca(2+) signals are modulated by tolbutamide and diazoxide, which in turn affect insulin secretion. This suggests that phospholipase C protein and insulin protein interact indirectly through the signaling pathways that regulate insulin secretion.</s>
IEPA.d141 IEPA.d141.s339.e1 IEPA.d141.s339.e2	PLC	insulin	[INST]Context: [PMID: 10751197 Tolbutamide and diazoxide modulate phospholipase C-linked Ca(2+) signaling and insulin secretion in beta-cells. Arginine vasopressin (AVP), bombesin, and ACh increase cytosolic free Ca(2+) and potentiate glucose-induced insulin release by activating receptors linked to phospholipase C (PLC). We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PLC-linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PLC-linked insulin secretion from HIT-T15 cells. In the presence of glucose, the PLC-linked Ca(2+) signals were enhanced by tolbutamide (3-300 microM) and inhibited by diazoxide (10-100 microM). The effects of tolbutamide and diazoxide on PLC-linked Ca(2+) signaling were mimicked by BAY K 8644 and nifedipine, an activator and inhibitor of L-type voltage-sensitive Ca(2+) channels, respectively. Neither tolbutamide nor diazoxide affected PLC-linked mobilization of internal Ca(2+) or store-operated Ca(2+) influx through non-L-type Ca(2+) channels. In the absence of glucose, PLC-linked Ca(2+) signals were diminished or abolished; this effect could be partly antagonized by tolbutamide. In the presence of glucose, tolbutamide potentiated and diazoxide inhibited AVP- or bombesin-induced insulin secretion from HIT-T15 cells. Nifedipine (10 microM) blocked both the potentiating and inhibitory actions of tolbutamide and diazoxide on AVP-induced insulin release, respectively. In glucose-free medium, AVP-induced insulin release was reduced but was again potentiated by tolbutamide, whereas diazoxide caused no further inhibition. Thus tolbutamide and diazoxide regulate both PLC-linked Ca(2+) signaling and insulin secretion from pancreatic beta-cells by modulating K(ATP) channels, thereby determining voltage-sensitive Ca(2+) influx.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that PLC (phospholipase C) is involved in the signaling pathways that lead to insulin secretion. Specifically, it mentions that PLC-linked Ca(2+) signals are modulated by tolbutamide and diazoxide, which in turn affects insulin secretion from pancreatic beta-cells. This suggests that PLC protein and insulin protein interact indirectly through the signaling pathways that regulate insulin secretion.</s>
IEPA.d141 IEPA.d141.s340.e0 IEPA.d141.s340.e1	PLC	insulin	[INST]Context: [PMID: 10751197 Tolbutamide and diazoxide modulate phospholipase C-linked Ca(2+) signaling and insulin secretion in beta-cells. Arginine vasopressin (AVP), bombesin, and ACh increase cytosolic free Ca(2+) and potentiate glucose-induced insulin release by activating receptors linked to phospholipase C (PLC). We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PLC-linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PLC-linked insulin secretion from HIT-T15 cells. In the presence of glucose, the PLC-linked Ca(2+) signals were enhanced by tolbutamide (3-300 microM) and inhibited by diazoxide (10-100 microM). The effects of tolbutamide and diazoxide on PLC-linked Ca(2+) signaling were mimicked by BAY K 8644 and nifedipine, an activator and inhibitor of L-type voltage-sensitive Ca(2+) channels, respectively. Neither tolbutamide nor diazoxide affected PLC-linked mobilization of internal Ca(2+) or store-operated Ca(2+) influx through non-L-type Ca(2+) channels. In the absence of glucose, PLC-linked Ca(2+) signals were diminished or abolished; this effect could be partly antagonized by tolbutamide. In the presence of glucose, tolbutamide potentiated and diazoxide inhibited AVP- or bombesin-induced insulin secretion from HIT-T15 cells. Nifedipine (10 microM) blocked both the potentiating and inhibitory actions of tolbutamide and diazoxide on AVP-induced insulin release, respectively. In glucose-free medium, AVP-induced insulin release was reduced but was again potentiated by tolbutamide, whereas diazoxide caused no further inhibition. Thus tolbutamide and diazoxide regulate both PLC-linked Ca(2+) signaling and insulin secretion from pancreatic beta-cells by modulating K(ATP) channels, thereby determining voltage-sensitive Ca(2+) influx.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that PLC (phospholipase C) is involved in the signaling pathways that lead to insulin secretion. Specifically, it mentions that PLC-linked Ca(2+) signals are modulated by tolbutamide and diazoxide, which in turn affects insulin secretion from pancreatic beta-cells. This suggests that PLC protein and insulin protein interact indirectly through the signaling pathways that regulate insulin secretion.</s>
IEPA.d143 IEPA.d143.s343.e0 IEPA.d143.s343.e1	Oxytocin	insulin	[INST]Context: [PMID: 10758829 [The effect of oxytocin on Langerhans beta-islet cell function and on carbohydrate metabolic indices in intact rats and in rats with diabetes]. The experiments were carried out on male Wistar rats. Synthetic oxytocin was administrated to intact and streptozotocin-diabetic animals during 10 days by intracerebroventricular and intraperitoneal injections. The state of pancreatic b-cells was studied by a method of indirect immunofluorescence with the following results computing on VIDAS-386 image analyzing system. The measurement of the area of immunofluorescence and Langerhans islets and determination of insulin concentration and its contents in islets was provided automatically. Insulin and glucose concentration in blood was determined with standard techniques. Oxytocin central injections to intact animals stimulated insulin synthesis and secretion without changing of islets area. Peptide administration to diabetic animals resulted in braking of islets destruction, increasing of its area and contents of insulin. These changes were accompanied with the reducing of glycemia level. Thus, oxytocin administration stimulates insulin synthesis and secretion in intact and diabetic animals and this effect is more expressed with central injections. Besides it is necessary to note the oxytocin braking effect on beta-cells destruction in diabetic animals.] Question: Based on the provided context, do the terms [Oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin administration stimulates insulin synthesis and secretion in both intact and diabetic animals. This suggests that oxytocin and insulin interact in a way that oxytocin influences the production and release of insulin. The specific mechanisms are not detailed, but the effect of oxytocin on insulin synthesis and secretion clearly demonstrates an interaction between the two proteins.</s>
IEPA.d143 IEPA.d143.s344.e0 IEPA.d143.s344.e1	oxytocin	insulin	[INST]Context: [PMID: 10758829 [The effect of oxytocin on Langerhans beta-islet cell function and on carbohydrate metabolic indices in intact rats and in rats with diabetes]. The experiments were carried out on male Wistar rats. Synthetic oxytocin was administrated to intact and streptozotocin-diabetic animals during 10 days by intracerebroventricular and intraperitoneal injections. The state of pancreatic b-cells was studied by a method of indirect immunofluorescence with the following results computing on VIDAS-386 image analyzing system. The measurement of the area of immunofluorescence and Langerhans islets and determination of insulin concentration and its contents in islets was provided automatically. Insulin and glucose concentration in blood was determined with standard techniques. Oxytocin central injections to intact animals stimulated insulin synthesis and secretion without changing of islets area. Peptide administration to diabetic animals resulted in braking of islets destruction, increasing of its area and contents of insulin. These changes were accompanied with the reducing of glycemia level. Thus, oxytocin administration stimulates insulin synthesis and secretion in intact and diabetic animals and this effect is more expressed with central injections. Besides it is necessary to note the oxytocin braking effect on beta-cells destruction in diabetic animals.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin administration stimulates insulin synthesis and secretion in both intact and diabetic animals. This suggests that oxytocin and insulin interact in a way that affects the metabolic processes related to carbohydrate metabolism. Specifically, oxytocin administration leads to changes in insulin levels and pancreatic beta-cell function, demonstrating a clear interaction between the two proteins.</s>
IEPA.d144 IEPA.d144.s345.e0 IEPA.d144.s345.e1	neuropeptide Y	leptin	[INST]Context: [PMID: 10767942 Hypothalamic neuropeptide Y and its neuroendocrine regulation by leptin. ] Question: Based on the provided context, do the terms [neuropeptide Y protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin neuroendocrine regulation involves hypothalamic neuropeptide Y. This suggests that leptin and neuropeptide Y interact in a regulatory pathway, where leptin influences the activity or expression of neuropeptide Y. This interaction is crucial for the neuroendocrine system's function.</s>
IEPA.d146 IEPA.d146.s351.e0 IEPA.d146.s351.e1	protein kinase C	vasopressin	[INST]Context: [PMID: 10790161 Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. Physiological vasoconstrictor concentrations of Arg8-vasopressin (AVP, 10-100 pM) stimulate oscillations (spikes) in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells. These Ca2+ spikes are dependent on L-type voltage-sensitive Ca2+ channels and increase in frequency with increasing AVP concentration. The signal transduction pathway responsible for this effect was examined in fura-2-loaded A7r5 cell monolayers. The serine/threonine phosphatase inhibitor calyculin A (5 nM) sensitized A7r5 cells to AVP, resulting in the stimulation of Ca2+ spiking by 1-10 pM AVP. Calyculin A alone did not stimulate Ca2+ spiking. The protein kinase C (PKC) activator 4beta-phorbol 12-myristate 13-acetate (PMA, 100 pM to 200 nM), also stimulated Ca2+ spiking and this effect was additive with a submaximal concentration of AVP (50 pM). The PKC inhibitors Ro-31-8220 (1 microM) and calphostin C (250 nM) completely blocked the stimulation of Ca2+ spiking by either PMA or AVP. alpha, beta, gamma, delta, epsilon, zeta and &lamdda; isoforms of PKC were detected in A7r5 cells by Western blot analysis. Time-dependent redistribution of PKC-alpha, -delta and -epsilon isoforms between the membrane and cytosolic fractions occurred in response to 100 pM AVP. Pretreatment for 24 h with 1 microM PMA downregulated expression of PKC-alpha and -delta, but not PKC-epsilon, and prevented the Ca2+-spiking responses to either 1 nM PMA or 100 pM AVP. Neither the release of intracellular Ca2+ by 1 microM AVP nor the increase in [Ca2+]i in response to elevated extracellular [K+] was prevented by the PMA pretreatment. We conclude that PKC activation is a necessary step in the signal transduction pathway linking low concentrations of AVP to Ca2+ spiking in A7r5 cells.] Question: Based on the provided context, do the terms [protein kinase C protein] and [vasopressin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that vasopressin (AVP) stimulates oscillations in cytosolic free calcium concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells. This effect is mediated through a signal transduction pathway that involves protein kinase C (PKC). Specifically, the activation of PKC is necessary for the stimulation of Ca2+ spiking in response to AVP. The PKC inhibitors Ro-31-8220 and calphostin C completely blocked the stimulation of Ca2+ spiking by either PMA or AVP, indicating that PKC activation is a crucial step in this pathway. Therefore, vasopressin and protein kinase C interact in this signaling pathway.</s>
IEPA.d146 IEPA.d146.s353.e0 IEPA.d146.s353.e1	PKC inhibitors	AVP	[INST]Context: [PMID: 10790161 Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. Physiological vasoconstrictor concentrations of Arg8-vasopressin (AVP, 10-100 pM) stimulate oscillations (spikes) in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells. These Ca2+ spikes are dependent on L-type voltage-sensitive Ca2+ channels and increase in frequency with increasing AVP concentration. The signal transduction pathway responsible for this effect was examined in fura-2-loaded A7r5 cell monolayers. The serine/threonine phosphatase inhibitor calyculin A (5 nM) sensitized A7r5 cells to AVP, resulting in the stimulation of Ca2+ spiking by 1-10 pM AVP. Calyculin A alone did not stimulate Ca2+ spiking. The protein kinase C (PKC) activator 4beta-phorbol 12-myristate 13-acetate (PMA, 100 pM to 200 nM), also stimulated Ca2+ spiking and this effect was additive with a submaximal concentration of AVP (50 pM). The PKC inhibitors Ro-31-8220 (1 microM) and calphostin C (250 nM) completely blocked the stimulation of Ca2+ spiking by either PMA or AVP. alpha, beta, gamma, delta, epsilon, zeta and &lamdda; isoforms of PKC were detected in A7r5 cells by Western blot analysis. Time-dependent redistribution of PKC-alpha, -delta and -epsilon isoforms between the membrane and cytosolic fractions occurred in response to 100 pM AVP. Pretreatment for 24 h with 1 microM PMA downregulated expression of PKC-alpha and -delta, but not PKC-epsilon, and prevented the Ca2+-spiking responses to either 1 nM PMA or 100 pM AVP. Neither the release of intracellular Ca2+ by 1 microM AVP nor the increase in [Ca2+]i in response to elevated extracellular [K+] was prevented by the PMA pretreatment. We conclude that PKC activation is a necessary step in the signal transduction pathway linking low concentrations of AVP to Ca2+ spiking in A7r5 cells.] Question: Based on the provided context, do the terms [PKC inhibitors protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided describes the effects of AVP (Arg8-vasopressin) and PKC inhibitors on Ca2+ spiking in A7r5 rat vascular smooth muscle cells. It mentions that PKC inhibitors, such as Ro-31-8220 and calphostin C, completely block the stimulation of Ca2+ spiking by either PMA or AVP. However, there is no direct interaction mentioned between AVP protein and PKC inhibitors protein. Instead, the context describes how PKC inhibitors prevent the effects of AVP and PMA on Ca2+ spiking, indicating that they are part of the same signaling pathway but do not interact directly with each other.</s>
IEPA.d146 IEPA.d146.s354.e0 IEPA.d146.s354.e1	PKC-alpha	AVP	[INST]Context: [PMID: 10790161 Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. Physiological vasoconstrictor concentrations of Arg8-vasopressin (AVP, 10-100 pM) stimulate oscillations (spikes) in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells. These Ca2+ spikes are dependent on L-type voltage-sensitive Ca2+ channels and increase in frequency with increasing AVP concentration. The signal transduction pathway responsible for this effect was examined in fura-2-loaded A7r5 cell monolayers. The serine/threonine phosphatase inhibitor calyculin A (5 nM) sensitized A7r5 cells to AVP, resulting in the stimulation of Ca2+ spiking by 1-10 pM AVP. Calyculin A alone did not stimulate Ca2+ spiking. The protein kinase C (PKC) activator 4beta-phorbol 12-myristate 13-acetate (PMA, 100 pM to 200 nM), also stimulated Ca2+ spiking and this effect was additive with a submaximal concentration of AVP (50 pM). The PKC inhibitors Ro-31-8220 (1 microM) and calphostin C (250 nM) completely blocked the stimulation of Ca2+ spiking by either PMA or AVP. alpha, beta, gamma, delta, epsilon, zeta and &lamdda; isoforms of PKC were detected in A7r5 cells by Western blot analysis. Time-dependent redistribution of PKC-alpha, -delta and -epsilon isoforms between the membrane and cytosolic fractions occurred in response to 100 pM AVP. Pretreatment for 24 h with 1 microM PMA downregulated expression of PKC-alpha and -delta, but not PKC-epsilon, and prevented the Ca2+-spiking responses to either 1 nM PMA or 100 pM AVP. Neither the release of intracellular Ca2+ by 1 microM AVP nor the increase in [Ca2+]i in response to elevated extracellular [K+] was prevented by the PMA pretreatment. We conclude that PKC activation is a necessary step in the signal transduction pathway linking low concentrations of AVP to Ca2+ spiking in A7r5 cells.] Question: Based on the provided context, do the terms [PKC-alpha protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that AVP (Arg8-vasopressin) stimulates oscillations in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells through a signal transduction pathway involving protein kinase C (PKC). Specifically, the activation of PKC is necessary for the Ca2+-spiking responses to AVP. The redistribution of PKC isoforms, such as PKC-alpha, in response to AVP further supports the interaction between AVP and PKC-alpha. Therefore, AVP and PKC-alpha interact in this signaling pathway.</s>
IEPA.d146 IEPA.d146.s356.e0 IEPA.d146.s356.e1	PKC	AVP	[INST]Context: [PMID: 10790161 Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. Physiological vasoconstrictor concentrations of Arg8-vasopressin (AVP, 10-100 pM) stimulate oscillations (spikes) in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells. These Ca2+ spikes are dependent on L-type voltage-sensitive Ca2+ channels and increase in frequency with increasing AVP concentration. The signal transduction pathway responsible for this effect was examined in fura-2-loaded A7r5 cell monolayers. The serine/threonine phosphatase inhibitor calyculin A (5 nM) sensitized A7r5 cells to AVP, resulting in the stimulation of Ca2+ spiking by 1-10 pM AVP. Calyculin A alone did not stimulate Ca2+ spiking. The protein kinase C (PKC) activator 4beta-phorbol 12-myristate 13-acetate (PMA, 100 pM to 200 nM), also stimulated Ca2+ spiking and this effect was additive with a submaximal concentration of AVP (50 pM). The PKC inhibitors Ro-31-8220 (1 microM) and calphostin C (250 nM) completely blocked the stimulation of Ca2+ spiking by either PMA or AVP. alpha, beta, gamma, delta, epsilon, zeta and &lamdda; isoforms of PKC were detected in A7r5 cells by Western blot analysis. Time-dependent redistribution of PKC-alpha, -delta and -epsilon isoforms between the membrane and cytosolic fractions occurred in response to 100 pM AVP. Pretreatment for 24 h with 1 microM PMA downregulated expression of PKC-alpha and -delta, but not PKC-epsilon, and prevented the Ca2+-spiking responses to either 1 nM PMA or 100 pM AVP. Neither the release of intracellular Ca2+ by 1 microM AVP nor the increase in [Ca2+]i in response to elevated extracellular [K+] was prevented by the PMA pretreatment. We conclude that PKC activation is a necessary step in the signal transduction pathway linking low concentrations of AVP to Ca2+ spiking in A7r5 cells.] Question: Based on the provided context, do the terms [PKC protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that Arg8-vasopressin (AVP) stimulates oscillations in cytosolic free Ca2+ concentration ([Ca2+]i) in A7r5 rat vascular smooth muscle cells through a signal transduction pathway involving protein kinase C (PKC). Specifically, the activation of PKC is a necessary step in this pathway, as evidenced by the effects of PKC inhibitors and activators on Ca2+ spiking. This suggests that AVP and PKC interact in a signaling cascade where AVP triggers the activation of PKC, which in turn influences Ca2+ signaling.</s>
IEPA.d147 IEPA.d147.s358.e0 IEPA.d147.s358.e1	CK2	rbPrP	[INST]Context: [PMID: 10799298 Susceptibility of the prion protein to enzymic phosphorylation. Ten protein kinases have been assayed for their ability to phosphorylate in vitro the recombinant bovine PrP (25-242) (rbPrP). Substantial phosphorylation was observed with PKC, CK2, and two tyrosine kinases, Lyn and c-Fgr. With regard to CK2, phosphorylation occurs at Ser 154 with a stoichiometry of about 0.1 mol phosphate/mol rbPrP, which is doubled by mild heat treatment of rbPrP. Heat also reduces the overall protein ellipticity, suggesting that reversibly unfolded conformers are more susceptible to phosphorylation. Our data disclose the possibility that phosphorylation might modulate PrP biological activity.] Question: Based on the provided context, do the terms [CK2 protein] and [rbPrP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that CK2 phosphorylates the recombinant bovine PrP (25-242) (rbPrP) at Ser 154. This suggests a direct interaction between the CK2 protein and the rbPrP protein, where CK2 modifies rbPrP through phosphorylation.</s>
IEPA.d149 IEPA.d149.s362.e0 IEPA.d149.s362.e1	leptin	neuropeptide Y	[INST]Context: [PMID: 10806392 Leptin receptor-mediated regulation of cholinergic neurotransmitter phenotype in cells of central nervous system origin. Leptin is an adipocyte-secreted hormone that regulates body weight and exerts effects on hematopoiesis, reproduction, and immunity. The leptin receptor (OBR) shares sequence similarity and signaling capabilities with receptors for cytokines of the ciliary neurotrophic factor (CNTF) family. Our previous finding that CNTF and leptin exert similar anti-obesity effects and activate common neuronal signaling pathways, prompted us to investigate whether leptin may share with CNTF the ability to regulate the expression of specific neuronal genes. To this end, we established a cell line, derived from the murine septal cholinergic neuronal cell line SN-56, which stably expresses OBR. In this cell line, termed SN-56/OBR, leptin induces STAT transcription factor activation and STAT-dependent reporter gene expression in a manner similar to that of CNTF. Furthermore, in SN-56/OBR cells both CNTF and leptin produce changes in neurotransmitter and neuropeptide phenotype characteristic of cholinergic neurons, such as an increase in choline acetyltransferase and vasoactive intestinal polypeptide, and a decrease in neuropeptide Y expression. SN-56/OBR cells thus constitute an interesting new model system to investigate leptin action in cells of central nervous system origin. Possible physiological implications of OBR's intrinsic ability to regulate cholinergic phenotypic markers are discussed.] Question: Based on the provided context, do the terms [leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided discusses the effects of leptin and CNTF on the expression of various neurotransmitter and neuropeptide markers in SN-56/OBR cells. While it mentions that leptin and CNTF induce changes in the expression of choline acetyltransferase, vasoactive intestinal polypeptide, and neuropeptide Y, it does not indicate a direct interaction between leptin protein and neuropeptide Y protein. Instead, it describes how these proteins influence the expression of different markers in the cells. Therefore, there is no direct interaction mentioned between leptin protein and neuropeptide Y protein.</s>
IEPA.d150 IEPA.d150.s363.e0 IEPA.d150.s363.e1	neuropeptide-Y	leptin	[INST]Context: [PMID: 10808082 Chronic intracerebroventricular insulin attenuates the leptin-mediated but not alpha melanocyte stimulating hormone increase in sympathetic and cardiovascular responses. The co-existence of hyperinsulinemia and hyperleptinemia of obesity is well established. Additionally, both insulin resistance and leptin resistance are also characteristic of these states. Possible central nervous system (CNS) mechanisms could mediate these responses in that leptin receptors are located on hypothalamic neurons that coexpress neuropeptide-Y (NPY) or proopiomelanocortin (POMC) and both peptides that have been implicated as mediators of the CNS action of leptin. Leptin has been demonstrated to decrease or down regulate NPY expression and increase POMC expression. Insulin also has been demonstrated to decrease NPY and insulin insufficiency is associated with an increased POMC. Since both leptin and insulin share and modulate the same effector systems, we investigated the effect of CNS-induced hyperinsulinemia on the subsequent cardiovascular and sympathetic nervous response to leptin. Normal rats were implanted with intracerebroventricular (i.c.v.) cannula and allowed to recover. They were treated with insulin via i.c.v. cannula for 3 days. Following treatment, they were instrumented for the recording of cardiovascular and sympathetic nervous responses. Intracerebroventricular leptin administration in normal animals result in a progressive increase in both lumbar sympathetic nerve activity and mean arterial pressure. However, in animals pretreated with insulin for 3 days the leptin-induced response was completely attenuated. However, insulin treatment did not affect the POMC peptide product, alpha-melanocyte stimulating hormone (alphaMSH), mediated sympathetic nervous and cardiovascular responses. From these studies we conclude that CNS hyperinsulinemia can act to attenuate the leptin-induced increases in sympathetic nervous and cardiovascular system activity. The decreased responsiveness is not due to decreased sensitivity of the melanocortin, alphaMSH, mediated pathway.We suggest that the hyperinsulinemia of obesity may play a role in the obesity-induced leptin resistance.] Question: Based on the provided context, do the terms [neuropeptide-Y protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and neuropeptide-Y (NPY) are both involved in the central nervous system (CNS) mechanisms that mediate the responses to insulin and leptin. Specifically, leptin has been demonstrated to decrease NPY expression, while insulin has been shown to decrease NPY as well. This suggests that leptin and NPY interact in a regulatory pathway within the CNS, where leptin influences the expression of NPY.</s>
IEPA.d150 IEPA.d150.s364.e0 IEPA.d150.s364.e1	Leptin	NPY	[INST]Context: [PMID: 10808082 Chronic intracerebroventricular insulin attenuates the leptin-mediated but not alpha melanocyte stimulating hormone increase in sympathetic and cardiovascular responses. The co-existence of hyperinsulinemia and hyperleptinemia of obesity is well established. Additionally, both insulin resistance and leptin resistance are also characteristic of these states. Possible central nervous system (CNS) mechanisms could mediate these responses in that leptin receptors are located on hypothalamic neurons that coexpress neuropeptide-Y (NPY) or proopiomelanocortin (POMC) and both peptides that have been implicated as mediators of the CNS action of leptin. Leptin has been demonstrated to decrease or down regulate NPY expression and increase POMC expression. Insulin also has been demonstrated to decrease NPY and insulin insufficiency is associated with an increased POMC. Since both leptin and insulin share and modulate the same effector systems, we investigated the effect of CNS-induced hyperinsulinemia on the subsequent cardiovascular and sympathetic nervous response to leptin. Normal rats were implanted with intracerebroventricular (i.c.v.) cannula and allowed to recover. They were treated with insulin via i.c.v. cannula for 3 days. Following treatment, they were instrumented for the recording of cardiovascular and sympathetic nervous responses. Intracerebroventricular leptin administration in normal animals result in a progressive increase in both lumbar sympathetic nerve activity and mean arterial pressure. However, in animals pretreated with insulin for 3 days the leptin-induced response was completely attenuated. However, insulin treatment did not affect the POMC peptide product, alpha-melanocyte stimulating hormone (alphaMSH), mediated sympathetic nervous and cardiovascular responses. From these studies we conclude that CNS hyperinsulinemia can act to attenuate the leptin-induced increases in sympathetic nervous and cardiovascular system activity. The decreased responsiveness is not due to decreased sensitivity of the melanocortin, alphaMSH, mediated pathway.We suggest that the hyperinsulinemia of obesity may play a role in the obesity-induced leptin resistance.] Question: Based on the provided context, do the terms [Leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY interact in the central nervous system (CNS). Specifically, it mentions that leptin has been demonstrated to decrease NPY expression. This suggests that leptin and NPY are part of a regulatory pathway where leptin influences the expression of NPY, indicating an interaction between the two proteins.</s>
IEPA.d153 IEPA.d153.s369.e0 IEPA.d153.s369.e1	leptin	NPY	[INST]Context: [PMID: 10821329 Separate systems for serotonin and leptin in appetite control. Appetite control involves an integration of the drive signals arising form energy stores in the body with the satiety signals generated by periodic episodes of food consumption. Serotonin (5-hydroxytryptamine, 5-HT) has been implicated in the processes of within-meal satiation and postmeal satiety (5-HT1B and 5-HT2C postsynaptic receptors) which are concerned with the signals arising form the pattern of food intake. Central nervous system (CNS) 5-HT is sensitive to circulating levels of the precursor tryptophan, certain macronutrients and peripheral satiety factors such as cholecystokinin (CCK) and enterostatin. Hypothalamic 5-HT receptor systems inhibit neuropeptide Y (NPY), a potent stimulator of hunger and food intake. In contrast to the linking of 5-HT with the consequences of food ingestion, the hormone leptin (OB protein) is regarded as a signal linking adipose tissue status with a number of key CNS circuits. Leptin itself stimulates CNS leptin receptors (OB-r receptor) which link with pro-opiomelanocortin (POMC)/ MC-4 receptors. The effects of leptin may also be modulated by factors such as the corticotrophin-releasing factor (CRF), cocaine and amphetamine-regulated transcript (CART), orexins and galanin. Very little evidence exists to support any direct link between the actions of 5-HT and leptin, suggesting that they are separate systems. 5-HT is a part of an integrated network for short-acting satiety signals (episodic in nature), and leptin is a hormonal indicator of long-term (tonic) energy reserves. At a conceptual level, these may represent the distinction between 'satiety' and 'drive'. Interestingly, both 5-HT and leptin modulate the action of NPY, which may form a part of a common output pathway for the expression of appetite.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin and NPY interact with each other. Specifically, it mentions that leptin stimulates CNS leptin receptors (OB-r receptor) which link with pro-opiomelanocortin (POMC)/MC-4 receptors, and that the effects of leptin may be modulated by factors such as NPY. This suggests that leptin and NPY are part of a common output pathway for the expression of appetite, indicating an interaction between the two proteins.</s>
IEPA.d154 IEPA.d154.s370.e0 IEPA.d154.s370.e1	insulin	phospholipase C	[INST]Context: [PMID: 10824737 Insulin stimulates the release of a subset of GPI-anchored proteins in a G-protein independent manner. The glycosyl-phosphatidylinositol anchored protein, membrane dipeptidase (EC 3.4.13.19) is released from the surface of 3T3-L1 adipocytes in response to insulin treatment through the action of a phospholipase C. The present study investigates the role of guanine-nucleotide binding proteins (G-proteins) in this process. Treatment of permeabilized 3T3-L1 adipocytes with GTPgammaS did not cause release of membrane dipeptidase into the medium, while GDPbetaS did not inhibit the insulin-stimulated release of membrane dipeptidase. Other activators of G-proteins, including the tetradecapeptide mastoparan, pertussis toxin and AlF3, also caused no significant release of membrane dipeptidase from the surface of the 3T3-L1 adipocytes. From these observations it is concluded that G-proteins are not involved in the insulin-stimulated release of membrane dipeptidase. Although X-Pro aminopeptidase (EC 3.4.11.9) is GPI-anchored in 3T3-L1 adipocytes as shown by digestion with bacterial phosphatidylinositol-specific phospholipase C, it was not released upon insulin treatment of the cells, indicating that only a subset of the GPI-anchored proteins are susceptible to insulin-stimulated release.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin stimulates the release of a subset of GPI-anchored proteins, including membrane dipeptidase, through the action of a phospholipase C. This suggests that insulin and phospholipase C interact in a signaling pathway where insulin triggers the activation of phospholipase C, which in turn leads to the release of membrane dipeptidase. Therefore, insulin and phospholipase C are interacting in this process.</s>
IEPA.d156 IEPA.d156.s373.e0 IEPA.d156.s373.e1	Leptin	neuropeptide Y	[INST]Context: [PMID: 10842667 Neuroendocrine regulation of nutrient partitioning. Leptin is a satiety factor which acts within the hypothalamus to decrease the levels of several neuropeptides stimulating food intake (among them, neuropeptide Y [NPY]), while increasing those that inhibit food intake. These effects of leptin bring about decreased body weight. In vivo, leptin potentiates basal and insulin-stimulated glucose utilization, presumably its oxidation, and decreases fat storage. Leptin increases sympathetic-mediated energy dissipation, and the expression of uncoupling proteins-1, -2, and -3. In peripheral tissues (muscles, adipose, others), leptin decreases triglyceride content by increasing fatty acid oxidation, decreasing the activity/expression of esterification and lipogenic enzymes, and favoring lipolysis. It decreases the lipogenic activity of insulin. Ultimately, leptin depletes fat stores and promotes leanness. NPY, taken as one example of what an orexigenic agent may produce, increases food intake and body weight. It favors fat storage in adipose tissue by stimulating lipogenic activity. It decreases glucose utilization by muscles, making more glucose carbon available for lipogenesis. Effects of NPY result from vagus nerve-mediated hyperinsulinemia and overactivity of the hypothalamo-pituitary-adrenal axis. Thus, NPY favors fat stores, and ultimately obesity. Glucocorticoids are necessary for NPY effects to occur, because central administration of the neuropeptide in adrenalectomized animals is ineffective. Glucocorticoids also have genuine effects when administered centrally to normal rats. They increase the hypothalamic content of NPY and decrease that of CRH. This double neuro-peptidic change stimulates food intake, insulin output, adipose tissue storage ability, decreases the expression of uncoupling proteins-1 and -3, and increases body weight. Body weight homeostasis appears to require a finely tuned regulation of both leptin and glucocorticoids, with their respective opposite effects.] Question: Based on the provided context, do the terms [Leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and neuropeptide Y (NPY) have opposing effects on nutrient partitioning and body weight regulation. Leptin decreases food intake and promotes leanness, while NPY increases food intake and favors fat storage. These opposing actions suggest that leptin and NPY interact in a regulatory manner to maintain body weight homeostasis. The text specifically mentions that leptin potentiates basal and insulin-stimulated glucose utilization and decreases fat storage, while NPY increases food intake and favors fat storage. This indicates a direct interaction between the two proteins in the context of nutrient partitioning and energy balance.</s>
IEPA.d157 IEPA.d157.s374.e0 IEPA.d157.s374.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10845452 Possible involvement of phosphoinositide-Ca2+ signaling in the regulation of alpha-amylase expression and germination of rice seed (Oryza sativa L.). We have studied the effects of neomycin, a potent inhibitor of inositol phospholipid-specific phospholipase C (PLC), on the germination of rice seed and the gibberellin-induced expression of alpha-amylase in the aleurone layer and the scutellar tissues. It was shown that, in the absence of exogenous Ca2+, neomycin markedly reduced the germination speed and seedling growth of rice seeds and inhibited the gibberellin-induced expression of alpha-amylase in both secretory tissues. In addition, neomycin decreased the formation of inositol 1,4,5-trisphosphate (IP3) in the gibberellin-treated aleurone layer and the scutellar tissues. However, the inhibitory effects on the germination speed and the expression of alpha-amylase activity were overcome by supplementation of Ca2+. In addition, gibberellin elevated the level of IP3, and ABA prevented the gibberellin-induced formation of IP3, although ABA alone did not alter the IP3 level. The expression of a membrane-bound PLC molecule in rice aleurone layer was shown to be induced by gibberellin, and the gibberellin-induced expression of PLC was markedly delayed by treatment with ABA. These results strongly suggest that the phosphoinositide-Ca2+ signal transduction pathway may play an important role in the gibberellin-induced expression of alpha-amylase molecules closely related to the germination processes of rice seed.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin induces the expression of alpha-amylase in the aleurone layer and scutellar tissues of rice seeds. This suggests a direct interaction between gibberellin and alpha-amylase, where gibberellin acts as a regulatory factor that stimulates the expression of alpha-amylase. The study also shows that neomycin, an inhibitor of phosphoinositide-Ca2+ signaling, affects the gibberellin-induced expression of alpha-amylase, further supporting the interaction between gibberellin and alpha-amylase.</s>
IEPA.d157 IEPA.d157.s375.e0 IEPA.d157.s375.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10845452 Possible involvement of phosphoinositide-Ca2+ signaling in the regulation of alpha-amylase expression and germination of rice seed (Oryza sativa L.). We have studied the effects of neomycin, a potent inhibitor of inositol phospholipid-specific phospholipase C (PLC), on the germination of rice seed and the gibberellin-induced expression of alpha-amylase in the aleurone layer and the scutellar tissues. It was shown that, in the absence of exogenous Ca2+, neomycin markedly reduced the germination speed and seedling growth of rice seeds and inhibited the gibberellin-induced expression of alpha-amylase in both secretory tissues. In addition, neomycin decreased the formation of inositol 1,4,5-trisphosphate (IP3) in the gibberellin-treated aleurone layer and the scutellar tissues. However, the inhibitory effects on the germination speed and the expression of alpha-amylase activity were overcome by supplementation of Ca2+. In addition, gibberellin elevated the level of IP3, and ABA prevented the gibberellin-induced formation of IP3, although ABA alone did not alter the IP3 level. The expression of a membrane-bound PLC molecule in rice aleurone layer was shown to be induced by gibberellin, and the gibberellin-induced expression of PLC was markedly delayed by treatment with ABA. These results strongly suggest that the phosphoinositide-Ca2+ signal transduction pathway may play an important role in the gibberellin-induced expression of alpha-amylase molecules closely related to the germination processes of rice seed.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin induces the expression of alpha-amylase in the aleurone layer and scutellar tissues of rice seeds. This suggests a direct interaction between gibberellin and alpha-amylase, where gibberellin acts as a regulatory factor that stimulates the expression of alpha-amylase. The study also shows that neomycin, an inhibitor of phosphoinositide-Ca2+ signaling, affects the gibberellin-induced expression of alpha-amylase, further supporting the interaction between gibberellin and alpha-amylase.</s>
IEPA.d157 IEPA.d157.s376.e0 IEPA.d157.s376.e1	gibberellin	alpha-amylase	[INST]Context: [PMID: 10845452 Possible involvement of phosphoinositide-Ca2+ signaling in the regulation of alpha-amylase expression and germination of rice seed (Oryza sativa L.). We have studied the effects of neomycin, a potent inhibitor of inositol phospholipid-specific phospholipase C (PLC), on the germination of rice seed and the gibberellin-induced expression of alpha-amylase in the aleurone layer and the scutellar tissues. It was shown that, in the absence of exogenous Ca2+, neomycin markedly reduced the germination speed and seedling growth of rice seeds and inhibited the gibberellin-induced expression of alpha-amylase in both secretory tissues. In addition, neomycin decreased the formation of inositol 1,4,5-trisphosphate (IP3) in the gibberellin-treated aleurone layer and the scutellar tissues. However, the inhibitory effects on the germination speed and the expression of alpha-amylase activity were overcome by supplementation of Ca2+. In addition, gibberellin elevated the level of IP3, and ABA prevented the gibberellin-induced formation of IP3, although ABA alone did not alter the IP3 level. The expression of a membrane-bound PLC molecule in rice aleurone layer was shown to be induced by gibberellin, and the gibberellin-induced expression of PLC was markedly delayed by treatment with ABA. These results strongly suggest that the phosphoinositide-Ca2+ signal transduction pathway may play an important role in the gibberellin-induced expression of alpha-amylase molecules closely related to the germination processes of rice seed.] Question: Based on the provided context, do the terms [gibberellin protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that gibberellin induces the expression of alpha-amylase in the aleurone layer and scutellar tissues of rice seeds. This suggests a direct interaction between gibberellin and alpha-amylase, where gibberellin acts as a regulatory factor that stimulates the expression of alpha-amylase. The study also shows that neomycin, an inhibitor of phosphoinositide-Ca2+ signaling, affects the gibberellin-induced expression of alpha-amylase, further supporting the interaction between gibberellin and alpha-amylase.</s>
IEPA.d162 IEPA.d162.s391.e0 IEPA.d162.s391.e1	NPY	leptin	[INST]Context: [PMID: 10868965 Impaired leptin responsiveness in aged rats. We previously reported that adiposity and serum leptin levels increase with age in male F-344xBN rats and that when physiological levels of serum leptin are manipulated by fasting, there is a corresponding reciprocal change in hypothalamic neuropeptide Y (NPY) mRNA in young rats, but there are no changes in older rats. These findings suggest that the regulation of hypothalamic NPY mRNA by leptin may be impaired with age. To test this hypothesis, we infused saline or leptin for 7 days into ad libitum-fed rats and compared these with saline-infused rats that were pair-fed the amount of food consumed by the leptin-treated rats. We examined daily food consumption, body weight, whole-body oxygen consumption, serum leptin, and NPY mRNA in the hypothalamus. Food consumption decreased by 50% in the leptin-infused compared with the saline-infused young rats but only decreased by 20% in the aged rats. In the leptin-treated young rats, there was a 24% increase in oxygen consumption compared with the pair-fed rats, but there were no changes in oxygen consumption in the aged rats. Leptin infusion diminished hypothalamic NPY levels by nearly 50% compared with pair-fed young rats, whereas there were no changes in the hypothalamic NPY mRNA levels in senescent rats. In summary, aged rats demonstrate a reduced responsiveness to leptin, including a diminished decrease in food intake and no increase in energy expenditure. These diminished responses to leptin were associated with and may be the result of an impaired suppression of hypothalamic NPY mRNA levels. This leptin resistance may be due to either the elevated obesity and serum leptin with age or due to age itself, or both.] Question: Based on the provided context, do the terms [NPY protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY protein interact with each other. Specifically, it mentions that leptin infusion diminishes hypothalamic NPY levels by nearly 50% compared with pair-fed young rats, whereas there were no changes in the hypothalamic NPY mRNA levels in senescent rats. This suggests that leptin has a regulatory effect on NPY protein levels, indicating an interaction between the two proteins.</s>
IEPA.d162 IEPA.d162.s393.e0 IEPA.d162.s393.e1	Leptin	NPY	[INST]Context: [PMID: 10868965 Impaired leptin responsiveness in aged rats. We previously reported that adiposity and serum leptin levels increase with age in male F-344xBN rats and that when physiological levels of serum leptin are manipulated by fasting, there is a corresponding reciprocal change in hypothalamic neuropeptide Y (NPY) mRNA in young rats, but there are no changes in older rats. These findings suggest that the regulation of hypothalamic NPY mRNA by leptin may be impaired with age. To test this hypothesis, we infused saline or leptin for 7 days into ad libitum-fed rats and compared these with saline-infused rats that were pair-fed the amount of food consumed by the leptin-treated rats. We examined daily food consumption, body weight, whole-body oxygen consumption, serum leptin, and NPY mRNA in the hypothalamus. Food consumption decreased by 50% in the leptin-infused compared with the saline-infused young rats but only decreased by 20% in the aged rats. In the leptin-treated young rats, there was a 24% increase in oxygen consumption compared with the pair-fed rats, but there were no changes in oxygen consumption in the aged rats. Leptin infusion diminished hypothalamic NPY levels by nearly 50% compared with pair-fed young rats, whereas there were no changes in the hypothalamic NPY mRNA levels in senescent rats. In summary, aged rats demonstrate a reduced responsiveness to leptin, including a diminished decrease in food intake and no increase in energy expenditure. These diminished responses to leptin were associated with and may be the result of an impaired suppression of hypothalamic NPY mRNA levels. This leptin resistance may be due to either the elevated obesity and serum leptin with age or due to age itself, or both.] Question: Based on the provided context, do the terms [Leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY protein levels interact with each other. Specifically, it mentions that leptin infusion diminishes hypothalamic NPY levels by nearly 50% in young rats, while there are no changes in the hypothalamic NPY mRNA levels in senescent rats. This suggests that leptin has a regulatory effect on NPY protein levels, indicating an interaction between the two proteins.</s>
IEPA.d165 IEPA.d165.s397.e0 IEPA.d165.s397.e1	leptin	NPY	[INST]Context: [PMID: 10879675 Interactions between leptin and NPY affecting lipid mobilization in adipose tissue. Lipid turnover and deposition is under the control of developmental, nutritional, metabolic and neuroendocrine influences. The aim of the current investigations was focused on the study of the involvement of leptin and neuropeptide Y in lipid mobilization. The lipolytic rate was assessed through glycerol release after incubation with leptin and NPY at concentrations ranging from 10(-6) to 10(-12) M in isolated adipocytes obtained from female rats. The presence of leptin at concentrations of 10(-12) to 10(-7) M in the incubation medium of isolated fat cells significantly increased (p < 0.0001) glycerol release, except at the concentration of 10(-11) M, where the increase was (p < 0.01) as compared to the basal lipolytic activity. On the other hand, isolated fat cells of Wistar rats bathed in 10(-10) to 10(-6) M concentrations of NPY demonstrated a statistically significant decrease (p < 0.0001) in glycerol release. At equimolar concentrations of leptin and NPY (10(-12) to 10(-6) M) the observed lipolytic activity is comparable to the basal lipolytic activity, except at a concentration of 10(-9) M where upon a significant increase in lipolysis is observed. A further increase in the equimolar concentrations, beyond 10(-9) M results in a return to the basal lipolytic activity. Summing up, new evidence suggests that NPY and leptin may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that leptin and NPY interact with each other in the regulation of lipid mobilization in adipose tissue. Specifically, it mentions that "leptin and NPY may interact in a homeostatic loop to regulate body-fat mass and energy balance" and that "at equimolar concentrations of leptin and NPY (10(-12) to 10(-6) M) the observed lipolytic activity is comparable to the basal lipolytic activity," suggesting a regulatory interaction between the two proteins.</s>
IEPA.d165 IEPA.d165.s401.e0 IEPA.d165.s401.e1	NPY	leptin	[INST]Context: [PMID: 10879675 Interactions between leptin and NPY affecting lipid mobilization in adipose tissue. Lipid turnover and deposition is under the control of developmental, nutritional, metabolic and neuroendocrine influences. The aim of the current investigations was focused on the study of the involvement of leptin and neuropeptide Y in lipid mobilization. The lipolytic rate was assessed through glycerol release after incubation with leptin and NPY at concentrations ranging from 10(-6) to 10(-12) M in isolated adipocytes obtained from female rats. The presence of leptin at concentrations of 10(-12) to 10(-7) M in the incubation medium of isolated fat cells significantly increased (p < 0.0001) glycerol release, except at the concentration of 10(-11) M, where the increase was (p < 0.01) as compared to the basal lipolytic activity. On the other hand, isolated fat cells of Wistar rats bathed in 10(-10) to 10(-6) M concentrations of NPY demonstrated a statistically significant decrease (p < 0.0001) in glycerol release. At equimolar concentrations of leptin and NPY (10(-12) to 10(-6) M) the observed lipolytic activity is comparable to the basal lipolytic activity, except at a concentration of 10(-9) M where upon a significant increase in lipolysis is observed. A further increase in the equimolar concentrations, beyond 10(-9) M results in a return to the basal lipolytic activity. Summing up, new evidence suggests that NPY and leptin may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level.] Question: Based on the provided context, do the terms [NPY protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that leptin and neuropeptide Y (NPY) interact with each other in the regulation of lipid mobilization in adipose tissue. Specifically, it mentions that at equimolar concentrations of leptin and NPY, the observed lipolytic activity is comparable to the basal lipolytic activity, except at a concentration of 10(-9) M where a significant increase in lipolysis is observed. This suggests that leptin and NPY have a combined effect on lipid mobilization, indicating an interaction between the two proteins.</s>
IEPA.d168 IEPA.d168.s404.e0 IEPA.d168.s404.e1	leptin	uncoupling protein-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and uncoupling protein-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d168 IEPA.d168.s405.e0 IEPA.d168.s405.e1	leptin	uncoupling protein-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [uncoupling protein-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and uncoupling protein-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d168 IEPA.d168.s405.e2 IEPA.d168.s405.e3	leptin	UCP-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and UCP-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d168 IEPA.d168.s406.e0 IEPA.d168.s406.e1	leptin	UCP-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and UCP-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d168 IEPA.d168.s407.e0 IEPA.d168.s407.e1	leptin	UCP-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and UCP-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d168 IEPA.d168.s408.e1 IEPA.d168.s408.e2	leptin	UCP-3	[INST]Context: [PMID: 10909965 Involvement of thyroid hormones in the effect of intracerebroventricular leptin infusion on uncoupling protein-3 expression in rat muscle. We have shown previously that continuous (6 days) intracerebroventricular (ICV) leptin infusion in normal rats resulted in decreases in food intake and body weight. A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3. To investigate an involvement of thyroid hormones in this effect of leptin, plasma levels of these hormones were determined in ICV leptin-infused, ICV vehicle-infused ad libitum fed or pair-fed controls. ICV leptin infusion and pair-feeding resulted in decreased plasma thyroid-stimulating hormone (TSH) and T4 levels relative to ad libitum fed controls. ICV leptin infusion maintained plasma levels of T3, but the levels were decreased by pair-feeding. The activity of the enzyme (hepatic 5'-monodeiodinase) responsible for T4/T3 conversion was measured. In the leptin-infused group, the activity of 5'-monodeiodinase was maintained at the values measured in ad libitum fed rats; in pair-fed rats, activity was reduced. Thus, conversion of T4 to T3 is decreased by pair-feeding, whereas such is not the case during leptin infusion. To further substantiate an involvement of thyroid hormones in the effect of leptin on muscle UCP-3 expression, hypothyroid rats were ICV infused with leptin or vehicle. It was observed that in hypothyroid rats, ICV leptin was unable to maintain muscle UCP-3 expression at values measured in ad libitum fed controls. These results suggest that central leptin stimulates T3 production via an activation of T4 to T3 conversion, and that this stimulation could be responsible for the effect of leptin on muscle UCP-3 expression. Thyroid hormones could thus be important mediators of the effect of leptin on energy expenditure.] Question: Based on the provided context, do the terms [leptin protein] and [UCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin infusion affects the expression of uncoupling protein-3 (UCP-3) in rat muscle. Specifically, it mentions that leptin infusion prevents the decrease in UCP-3 expression caused by pair-feeding, suggesting that leptin has a direct influence on the expression of UCP-3. This interaction is further supported by the observation that leptin stimulates T3 production, which is involved in maintaining UCP-3 expression. Therefore, leptin protein and UCP-3 protein interact in a way that affects energy expenditure and muscle UCP-3 expression.</s>
IEPA.d172 IEPA.d172.s416.e0 IEPA.d172.s416.e1	insulin	phospholipase Cgamma1	[INST]Context: [PMID: 10947866 Insulin induces epidermal growth factor (EGF) receptor clustering and potentiates EGF-stimulated DNA synthesis in swiss 3T3 cells: a mechanism for costimulation in mitogenic synergy. In many cellular systems, activation with more than one ligand can produce a cellular response that is greater than the sum of the individual responses to the ligands. This synergy is sometimes referred to as coactivation. In Swiss 3T3 fibroblasts, activation of the epidermal growth factor (EGF) receptor produces a weak induction of DNA synthesis. Insulin has no stimulatory effect on this response. However, in combination, EGF and insulin synergize to cause a large induction of S phase. The underlying cellular biochemistry of this effect has been examined. The data indicate that phospholipase C activation is a major component of agonist-induced DNA synthesis. In contrast, activation of p70 S6 kinase by single agonists was inversely related to their ability to stimulate DNA synthesis. Therefore, it was examined whether stimulation of Swiss 3T3 cells with insulin causes changes in the subcellular distribution of EGF receptors and phospholipase Cgamma1 that could potentially explain the observed synergy or costimulation. It was found that insulin effectively induced the accumulation of EGF receptors on the actin arc of cells without activation of the EGF receptor. In contrast, EGF, when added for several hours, did not cause accumulation of the EGF receptor at this site. However, both EGF and insulin stimulated the accumulation of phospholipase Cgamma1 at the actin arc, which was coincident with the EGF receptor in the case of insulin- stimulated cells. Therefore, it is suggested that the insulin-induced coclustering of the EGF receptor with phospholipase Cgamma1 at the actin arc may allow for greater efficiency of signal transduction, resulting in the synergy observed for these two hormones in stimulation of DNA synthesis.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase Cgamma1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin induces the accumulation of EGF receptors on the actin arc of cells and that this accumulation is coincident with the accumulation of phospholipase Cgamma1 at the actin arc. This suggests that insulin and phospholipase Cgamma1 interact in a way that facilitates the coclustering of these proteins at the actin arc, which is a key step in the synergistic stimulation of DNA synthesis by insulin and EGF. Therefore, the terms "insulin protein" and "phospholipase Cgamma1 protein" interact with each other.</s>
IEPA.d172 IEPA.d172.s417.e0 IEPA.d172.s417.e1	insulin	phospholipase Cgamma1	[INST]Context: [PMID: 10947866 Insulin induces epidermal growth factor (EGF) receptor clustering and potentiates EGF-stimulated DNA synthesis in swiss 3T3 cells: a mechanism for costimulation in mitogenic synergy. In many cellular systems, activation with more than one ligand can produce a cellular response that is greater than the sum of the individual responses to the ligands. This synergy is sometimes referred to as coactivation. In Swiss 3T3 fibroblasts, activation of the epidermal growth factor (EGF) receptor produces a weak induction of DNA synthesis. Insulin has no stimulatory effect on this response. However, in combination, EGF and insulin synergize to cause a large induction of S phase. The underlying cellular biochemistry of this effect has been examined. The data indicate that phospholipase C activation is a major component of agonist-induced DNA synthesis. In contrast, activation of p70 S6 kinase by single agonists was inversely related to their ability to stimulate DNA synthesis. Therefore, it was examined whether stimulation of Swiss 3T3 cells with insulin causes changes in the subcellular distribution of EGF receptors and phospholipase Cgamma1 that could potentially explain the observed synergy or costimulation. It was found that insulin effectively induced the accumulation of EGF receptors on the actin arc of cells without activation of the EGF receptor. In contrast, EGF, when added for several hours, did not cause accumulation of the EGF receptor at this site. However, both EGF and insulin stimulated the accumulation of phospholipase Cgamma1 at the actin arc, which was coincident with the EGF receptor in the case of insulin- stimulated cells. Therefore, it is suggested that the insulin-induced coclustering of the EGF receptor with phospholipase Cgamma1 at the actin arc may allow for greater efficiency of signal transduction, resulting in the synergy observed for these two hormones in stimulation of DNA synthesis.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase Cgamma1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin induces the accumulation of EGF receptors on the actin arc of cells and that this accumulation is coincident with the accumulation of phospholipase Cgamma1 at the actin arc. This suggests that insulin and phospholipase Cgamma1 interact in a way that facilitates the coclustering of these proteins at the actin arc, which is a key step in the synergistic stimulation of DNA synthesis by insulin and EGF. Therefore, the terms "insulin protein" and "phospholipase Cgamma1 protein" interact with each other.</s>
IEPA.d172 IEPA.d172.s418.e0 IEPA.d172.s418.e1	insulin	phospholipase Cgamma1	[INST]Context: [PMID: 10947866 Insulin induces epidermal growth factor (EGF) receptor clustering and potentiates EGF-stimulated DNA synthesis in swiss 3T3 cells: a mechanism for costimulation in mitogenic synergy. In many cellular systems, activation with more than one ligand can produce a cellular response that is greater than the sum of the individual responses to the ligands. This synergy is sometimes referred to as coactivation. In Swiss 3T3 fibroblasts, activation of the epidermal growth factor (EGF) receptor produces a weak induction of DNA synthesis. Insulin has no stimulatory effect on this response. However, in combination, EGF and insulin synergize to cause a large induction of S phase. The underlying cellular biochemistry of this effect has been examined. The data indicate that phospholipase C activation is a major component of agonist-induced DNA synthesis. In contrast, activation of p70 S6 kinase by single agonists was inversely related to their ability to stimulate DNA synthesis. Therefore, it was examined whether stimulation of Swiss 3T3 cells with insulin causes changes in the subcellular distribution of EGF receptors and phospholipase Cgamma1 that could potentially explain the observed synergy or costimulation. It was found that insulin effectively induced the accumulation of EGF receptors on the actin arc of cells without activation of the EGF receptor. In contrast, EGF, when added for several hours, did not cause accumulation of the EGF receptor at this site. However, both EGF and insulin stimulated the accumulation of phospholipase Cgamma1 at the actin arc, which was coincident with the EGF receptor in the case of insulin- stimulated cells. Therefore, it is suggested that the insulin-induced coclustering of the EGF receptor with phospholipase Cgamma1 at the actin arc may allow for greater efficiency of signal transduction, resulting in the synergy observed for these two hormones in stimulation of DNA synthesis.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase Cgamma1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin induces the accumulation of EGF receptors on the actin arc of cells and that this accumulation is coincident with the accumulation of phospholipase Cgamma1 at the actin arc. This suggests that insulin and phospholipase Cgamma1 interact in a way that facilitates the coclustering of these proteins at the actin arc, which is a key step in the synergistic stimulation of DNA synthesis by insulin and EGF. Therefore, the terms "insulin protein" and "phospholipase Cgamma1 protein" interact with each other.</s>
IEPA.d173 IEPA.d173.s421.e0 IEPA.d173.s421.e1	PrP(c)	protein kinase C	[INST]Context: [PMID: 10952979 Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. Cellular prion protein (PrP(c)) undergoes a proteolytic attack at the 110/111 downward arrow112 peptide bond, whereas the PrP isoform (PrP(res)) that accumulates in the brain tissue in Creutzfeldt-Jakob disease reveals an alternate cleavage site at about residue 90. Interestingly, the normal processing of PrP occurs inside the 106-126 amino acid region thought to be responsible for the neurotoxicity of the pathogenic prions, whereas PrP(res) cleavage preserves this potentially toxic domain. Therefore, any molecular mechanisms leading to enhanced cleavage at the 110/111 downward arrow112 peptide bond could be of potential interest. We set up TSM1 neurons and HEK293 stable transfectants overexpressing the wild-type or 3F4-tagged murine PrP(c), respectively. Both mock-transfected and PrP(c)-expressing cell lines produced an 11-12-kDa PrP fragment (referred to as N1), the immunological characterization of which strongly suggests that it corresponds to the N-terminal PrP(c) fragment derived from normal processing. We have established that the recovery of secreted N1 is increased by the protein kinase C agonists PDBu and PMA in a time- and dose-dependent manner in both cell lines. In contrast, secretion of N1 remains unaffected by the inactive PDBu analog alphaPDD and by the protein kinase A effectors dibutyryl cAMP and forskolin. Overall, our data indicate that the normal processing of PrP(c) is up-regulated by protein kinase C but not protein kinase A in human cells and murine neurons.] Question: Based on the provided context, do the terms [PrP(c) protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the normal processing of PrP(c) is up-regulated by protein kinase C (PKC) agonists such as PDBu and PMA. This suggests that there is an interaction between the PrP(c) protein and the protein kinase C pathway, where PKC activation leads to increased cleavage of PrP(c) at the 110/111 downward arrow112 peptide bond. This interaction is specific to PKC and not protein kinase A, further supporting the interaction between PrP(c) and PKC.</s>
IEPA.d176 IEPA.d176.s425.e0 IEPA.d176.s425.e1	leptin	neuropeptide Y	[INST]Context: [PMID: 10969914 Body fat mass, leptin and puberty. Leptin, the ob gene product, provides a molecular basis for the lipostatic theory of the regulation of energy balance. Leptin circulates as a monomeric 16 kDa protein in rodent and human plasma and is also bound to leptin binding proteins that may form large high molecular weight complexes. Initial models of leptin action included leptin-deficient ob/ob mice and leptin-insensitive db/db mice. Peripheral or central administration of leptin reduced body weight, adiposity, and food intake in ob/ob mice but not in db/db mice. In ob/ob mice leptin treatment restored fertility. Leptin interacts with many messenger molecules in the brain. For example, leptin suppresses neuropeptide Y (NPY) expression in the arcuate nucleus. Increased NPY activity has an inhibitory effect on the gonadotropin axis and represents a direct mechanism for inhibiting sexual maturation and reproductive function in conditions of food restriction and/or energy expenditure. By modulating the hypothalamo-pituitary-gonadal axis both directly and indirectly, leptin may thus serve as the signal from fat to the brain about the adequacy of fat stores for pubertal development and reproduction. Normal leptin secretion is necessary for normal reproductive function to proceed and leptin may be a signal allowing for the point of initiation of and progression toward puberty.] Question: Based on the provided context, do the terms [leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin interacts with neuropeptide Y (NPY) in the brain. Specifically, it mentions that leptin suppresses NPY expression in the arcuate nucleus. This interaction suggests that leptin and NPY proteins are involved in a regulatory pathway where leptin influences the activity of NPY, thereby affecting the hypothalamo-pituitary-gonadal axis and reproductive function.</s>
IEPA.d178 IEPA.d178.s429.e0 IEPA.d178.s429.e1	PrPc	tyrosine kinase Fyn	[INST]Context: [PMID: 10988071 Signal transduction through prion protein. The cellular prion protein PrPc is a glycosylphosphatidylinositol-anchored cell-surface protein whose biological function is unclear. We used the murine 1C11 neuronal differentiation model to search for PrPc-dependent signal transduction through antibody-mediated cross-linking. A caveolin-1-dependent coupling of PrPc to the tyrosine kinase Fyn was observed. Clathrin might also contribute to this coupling. The ability of the 1C11 cell line to trigger PrPc-dependent Fyn activation was restricted to its fully differentiated serotonergic or noradrenergic progenies. Moreover, the signaling activity of PrPc occurred mainly at neurites. Thus, PrPc may be a signal transduction protein.] Question: Based on the provided context, do the terms [PrPc protein] and [tyrosine kinase Fyn protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that there is a signal transduction pathway involving the cellular prion protein (PrPc) and the tyrosine kinase Fyn. Specifically, it mentions that PrPc is coupled to the tyrosine kinase Fyn through a caveolin-1-dependent mechanism. This suggests a direct interaction between PrPc and Fyn, where PrPc acts as a signal transduction protein that activates Fyn.</s>
IEPA.d179 IEPA.d179.s430.e0 IEPA.d179.s430.e1	leptin	neuropeptide Y	[INST]Context: [PMID: 10997289 The future of obesity treatment. Obesity is rapidly becoming a worldwide epidemic, with significant consequences in terms of clinical burden and economic costs in treating its complications, so effective new approaches are urgently needed. Development of new drugs in this therapeutic area requires a detailed understanding of the physiology underlying body weight regulation. Recently several significant advances have been made in this area, including the identification of the appetite regulating hormone, leptin, and a detailed understanding of its targets in the central nervous system (CNS), such as neuropeptide Y (NPY) and the melanocortin-4 receptor. The observation that some humans with severe childhood-onset obesity have defects in these regulatory systems has confirmed their relevance in humans as well as in animal models, and the search is now on to produce drugs which act on these and other CNS targets such as glucagon-like peptide I and the orexins to help reduce body weight. Other recently identified targets outside the central nervous system include agents acting to inhibit digestive enzymes, specifically pancreatic lipase in the form of orlistat (which has recently been licensed for obesity treatment), and looking to the future, the possibility of altering energy expenditure by modulating the newly identified uncoupling proteins is being considered. It should be remembered however, that pharmacotherapy for obesity is unlikely to provide a 'magic bullet', and that diet and lifestyle changes are likely to remain the cornerstone of treatment for the foreseeable future.] Question: Based on the provided context, do the terms [leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and neuropeptide Y (NPY) are both involved in the regulation of appetite and body weight. Specifically, leptin is mentioned as an appetite-regulating hormone that targets NPY in the central nervous system (CNS). This suggests that leptin and NPY interact in a regulatory pathway related to appetite and energy balance.</s>
IEPA.d180 IEPA.d180.s431.e0 IEPA.d180.s431.e1	neuropeptide Y	leptin	[INST]Context: [PMID: 10997599 Hormonal regulation of energy partitioning. A loop system exists between hypothalamic neuropeptide Y (NPY) and peripheral adipose tissue leptin to maintain normal body homeostasis. When hypothalamic NPY levels are increased by fasting or by intracerebroventricular (i.c.v.) infusion, food intake and body weight increase. NPY has genuine hormono-metabolic effects. It increases insulin and corticosterone secretion relative to controls. These hormonal changes, acting singly or combined, favor adipose tissue lipogenic activity, while producing muscle insulin resistance. They also promote leptin release from adipose tissue. When infused i.c.v. to normal rats to mimic its central effects, leptin decreases NPY levels, thus food intake and body weight. Leptin i.c.v. has also genuine hormono-metabolic effects. It decreases insulinemia and adipose tissue storage ability, enhancing glucose disposal. Leptin increases the expression of uncoupling proteins (UCP-1, -2, -3) and thus energy dissipation. Leptin-induced changes favor oxidation at the expense of storage. Circadian fluctuations of NPY and leptin levels maintain normal body homeostasis. In animal obesity, defective hypothalamic leptin receptor activation prevent leptin from acting, with resulting obesity, insulin and leptin resistance.] Question: Based on the provided context, do the terms [neuropeptide Y protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context clearly describes an interaction between neuropeptide Y (NPY) and leptin. It explains how NPY increases food intake and body weight, while leptin decreases NPY levels, thus affecting food intake and body weight. This indicates a regulatory loop system where NPY and leptin interact to maintain normal body homeostasis. The hormonal effects of NPY and leptin on insulin secretion, adipose tissue lipogenic activity, and energy dissipation further support their interaction.</s>
IEPA.d180 IEPA.d180.s432.e0 IEPA.d180.s432.e1	leptin	NPY	[INST]Context: [PMID: 10997599 Hormonal regulation of energy partitioning. A loop system exists between hypothalamic neuropeptide Y (NPY) and peripheral adipose tissue leptin to maintain normal body homeostasis. When hypothalamic NPY levels are increased by fasting or by intracerebroventricular (i.c.v.) infusion, food intake and body weight increase. NPY has genuine hormono-metabolic effects. It increases insulin and corticosterone secretion relative to controls. These hormonal changes, acting singly or combined, favor adipose tissue lipogenic activity, while producing muscle insulin resistance. They also promote leptin release from adipose tissue. When infused i.c.v. to normal rats to mimic its central effects, leptin decreases NPY levels, thus food intake and body weight. Leptin i.c.v. has also genuine hormono-metabolic effects. It decreases insulinemia and adipose tissue storage ability, enhancing glucose disposal. Leptin increases the expression of uncoupling proteins (UCP-1, -2, -3) and thus energy dissipation. Leptin-induced changes favor oxidation at the expense of storage. Circadian fluctuations of NPY and leptin levels maintain normal body homeostasis. In animal obesity, defective hypothalamic leptin receptor activation prevent leptin from acting, with resulting obesity, insulin and leptin resistance.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that there is an interaction between leptin protein and NPY protein. It describes a loop system where hypothalamic NPY and peripheral adipose tissue leptin interact to maintain normal body homeostasis. Specifically, it mentions that NPY increases food intake and body weight, while leptin decreases NPY levels, thus affecting food intake and body weight. This reciprocal regulation demonstrates a direct interaction between the two proteins.</s>
IEPA.d180 IEPA.d180.s434.e0 IEPA.d180.s434.e1	Leptin	uncoupling proteins	[INST]Context: [PMID: 10997599 Hormonal regulation of energy partitioning. A loop system exists between hypothalamic neuropeptide Y (NPY) and peripheral adipose tissue leptin to maintain normal body homeostasis. When hypothalamic NPY levels are increased by fasting or by intracerebroventricular (i.c.v.) infusion, food intake and body weight increase. NPY has genuine hormono-metabolic effects. It increases insulin and corticosterone secretion relative to controls. These hormonal changes, acting singly or combined, favor adipose tissue lipogenic activity, while producing muscle insulin resistance. They also promote leptin release from adipose tissue. When infused i.c.v. to normal rats to mimic its central effects, leptin decreases NPY levels, thus food intake and body weight. Leptin i.c.v. has also genuine hormono-metabolic effects. It decreases insulinemia and adipose tissue storage ability, enhancing glucose disposal. Leptin increases the expression of uncoupling proteins (UCP-1, -2, -3) and thus energy dissipation. Leptin-induced changes favor oxidation at the expense of storage. Circadian fluctuations of NPY and leptin levels maintain normal body homeostasis. In animal obesity, defective hypothalamic leptin receptor activation prevent leptin from acting, with resulting obesity, insulin and leptin resistance.] Question: Based on the provided context, do the terms [Leptin protein] and [uncoupling proteins protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that leptin has genuine hormono-metabolic effects, including increasing the expression of uncoupling proteins (UCP-1, -2, -3) and thus energy dissipation. This suggests that leptin interacts with uncoupling proteins to promote energy oxidation at the expense of storage, thereby influencing energy partitioning and body homeostasis.</s>
IEPA.d181 IEPA.d181.s435.e0 IEPA.d181.s435.e1	UCP	leptin	[INST]Context: [PMID: 10997617 Endocrine regulation of uncoupling proteins and energy expenditure. Regulatory thermogenesis occurs upon exposure to the cold or during food intake. Among a variety of mechanisms leading to heat production, uncoupling of respiration in brown adipocyte mitochondria appears to be a major contributor to resistance to the cold in rodents. This uncoupling mechanism is due to the activity of uncoupling protein-1 (UCP-1), a specific carrier present in the inner membrane of mitochondria. The recent identification of UCP-2 and UCP-3, two homologues of the brown fat UCP, suggested that respiration uncoupling could contribute to thermogenesis in most tissues. Activity and expression of the three UCP's are stimulated by several neuromediators and hormones such as noradrenaline, tri-iodothyronine and leptin.] Question: Based on the provided context, do the terms [UCP protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activity and expression of uncoupling proteins (UCPs), including UCP-1, UCP-2, and UCP-3, are stimulated by several neuromediators and hormones such as leptin. This suggests that leptin interacts with UCP proteins to regulate their activity and expression, thereby contributing to thermogenesis in various tissues.</s>
IEPA.d182 IEPA.d182.s436.e0 IEPA.d182.s436.e1	leptin	neuropeptide Y	[INST]Context: [PMID: 10997621 Regulation of somatotroph cell function by the adipose tissue. Obese subjects exhibit a marked decrease in plasma growth hormone (GH) levels. However, the mechanisms by which increased adiposity leads to an impairment of GH secretion are poorly understood. Recent evidence suggests that the adipose tissue can markedly influence GH secretion via two different signals, namely free fatty acids (FFA) and leptin. FFA appear to inhibit GH secretion mainly by acting directly at pituitary level. Interestingly, reduction in circulating FFA levels in obese subjects led to a marked increase in GH responses to different GH secretagogues. This indicates that FFA exert a tonic inhibitory effect that contributes to blunted GH secretion in obese subjects. Recent data have shown that leptin is a metabolic signal that regulates GH secretion, since the administration of leptin antiserum to adult rats led to a marked decrease in spontaneous GH secretion. However, leptin prevents,the inhibitory effect exerted by fasting on plasma GH levels. The effect of leptin in adult rats appears to be exerted at hypothalamic level by regulating growth hormone releasing hormone (GHRH), somatostatin and neuropeptide Y (NPY)-producing neurones. In addition, during fetal life or following the development of pituitary tumors, leptin can also act directly at the anterior pituitary.] Question: Based on the provided context, do the terms [leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin regulates GH secretion by influencing the activity of growth hormone releasing hormone (GHRH), somatostatin, and neuropeptide Y (NPY)-producing neurones in the hypothalamus. This suggests that leptin and neuropeptide Y protein interact in a regulatory pathway related to GH secretion. The interaction is mediated through leptin's influence on NPY-producing neurones, which implies a functional relationship between the two proteins.</s>
IEPA.d186 IEPA.d186.s445.e0 IEPA.d186.s445.e1	PLC	insulin	[INST]Context: [PMID: 11016897 Insulin secretion, inositol phosphate levels, and phospholipase C isozymes in rodent pancreatic islets. During a dynamic perifusion, 20 mmol/L glucose, 20 mmol/L alpha-ketoisocaproate (KIC) or 20 mmol/L methyl pyruvate (MP) stimulate biphasic insulin secretory responses from collagenase-isolated rat islets. Peak first-phase insulin responses were comparable for all 3 nutrient agonists. The largest second-phase insulin secretory response was evoked by 20 mmol/L glucose (30-fold above basal release rates), and this response was more sustained than that observed with either 20 mmol/L KIC or 20 mmol/L MP. When mouse islets were perifused under similar conditions, KIC stimulated the largest first-phase insulin response, while comparable acute insulin secretion rates were obtained with glucose- or MP-stimulated islets. In contrast to rat islets, the sustained second phase of insulin secretion from mouse islets was minimal regardless of the nutrient secretagogue used. This anomalous response of mouse islets as compared with rat islets could not be ascribed to any obvious difference in the glucose usage rate or insulin content between these 2 species. Glucose, KIC, or MP stimulated significant increases in 3H-inositol phosphates in rat islets. Significantly smaller increases were measured in mouse islets. Comparative Western blot analyses showed pronounced species differences in the expression of phospholipase Cbeta1 (PLCbeta1), PLCbeta2, PLCbeta3, and PLCdelta1 but not PLCgamma1 or protein kinase Calpha (PKCalpha) between rat and mouse islets. PLCbeta4 or PLCdelta2 could not be identified in either species. These findings are consistent with the concept that the underexpression of the nutrient-activated PLC isozyme may account for the minimal inositol phosphate (IP) and second-phase insulin secretory response from mouse islets.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that PLC (phospholipase C) isozymes are involved in the stimulation of insulin secretion from pancreatic islets. Specifically, the stimulation of insulin secretion by nutrients such as glucose, alpha-ketoisocaproate (KIC), and methyl pyruvate (MP) leads to increases in inositol phosphates (IPs), which are products of PLC activity. This suggests that PLC proteins interact with insulin proteins in the sense that PLC activity is required for the stimulation of insulin secretion. Therefore, the terms [PLC protein] and [insulin protein] are interacting in the context of insulin secretion.</s>
IEPA.d187 IEPA.d187.s446.e0 IEPA.d187.s446.e1	GA	alpha-amylase	[INST]Context: [PMID: 11021637 Gibbestatin B inhibits the GA-induced expression of alpha-amylase expression in cereal seeds. The expression of alpha-amylase in aleurone layers of barley is known to be induced by gibberellin A3 (GA). In the present study, gibbestatin B (GNB) was isolated from Streptomyces sp. C-39 as an inhibitor of the GA-induced expression of alpha-amylase in barley and rice, with IC50 values of 125 and 70 microM, respectively. GNB suppressed accumulation of GA-induced barley high-pI type B and rice RAmylA alpha-amylase transcripts. However, GNB showed no inhibitory activity on GUS expression in transgenic tobacco harboring the auxin-inducible par B promoter:: GUS fusion gene. The transcription of an abscisic acid (ABA)-inducible gene, HVA1, was unaffected by GNB. In addition, GNB prevented aleurone cells from cell death induced by GA. In tobacco and Arabidopsis plants, GNB suppressed the germination and retarded the growth of seedlings without toxicity. The growth of gai, spy and abi mutants was also retarded by GNB. Normal plants treated with GA-biosynthesis inhibitors and GA-defective and GA-signaling mutants normally have dwarf dark green leaves. However, dwarfed healthy green leaves were observed in normal plants treated with GNB. GA-induced stem elongation of plants was also detected in the presence of GNB. These analyses indicate that GNB inhibits the GA-induced expression of alpha-amylase by regulating one of the steps involved in ABA signaling, but not by acting as a weak ABA analog.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin A3 (GA) induces the expression of alpha-amylase in barley aleurone layers. Gibbestatin B (GNB) inhibits this GA-induced expression of alpha-amylase, suggesting that GA and alpha-amylase are part of the same regulatory pathway. Therefore, GA and alpha-amylase interact in the sense that GA regulates the expression of alpha-amylase.</s>
IEPA.d187 IEPA.d187.s447.e0 IEPA.d187.s447.e1	alpha-amylase	gibberellin A3	[INST]Context: [PMID: 11021637 Gibbestatin B inhibits the GA-induced expression of alpha-amylase expression in cereal seeds. The expression of alpha-amylase in aleurone layers of barley is known to be induced by gibberellin A3 (GA). In the present study, gibbestatin B (GNB) was isolated from Streptomyces sp. C-39 as an inhibitor of the GA-induced expression of alpha-amylase in barley and rice, with IC50 values of 125 and 70 microM, respectively. GNB suppressed accumulation of GA-induced barley high-pI type B and rice RAmylA alpha-amylase transcripts. However, GNB showed no inhibitory activity on GUS expression in transgenic tobacco harboring the auxin-inducible par B promoter:: GUS fusion gene. The transcription of an abscisic acid (ABA)-inducible gene, HVA1, was unaffected by GNB. In addition, GNB prevented aleurone cells from cell death induced by GA. In tobacco and Arabidopsis plants, GNB suppressed the germination and retarded the growth of seedlings without toxicity. The growth of gai, spy and abi mutants was also retarded by GNB. Normal plants treated with GA-biosynthesis inhibitors and GA-defective and GA-signaling mutants normally have dwarf dark green leaves. However, dwarfed healthy green leaves were observed in normal plants treated with GNB. GA-induced stem elongation of plants was also detected in the presence of GNB. These analyses indicate that GNB inhibits the GA-induced expression of alpha-amylase by regulating one of the steps involved in ABA signaling, but not by acting as a weak ABA analog.] Question: Based on the provided context, do the terms [alpha-amylase protein] and [gibberellin A3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin A3 (GA) induces the expression of alpha-amylase in barley and rice. Gibbestatin B (GNB) inhibits this GA-induced expression of alpha-amylase, suggesting that GA and alpha-amylase are part of the same regulatory pathway. Therefore, the terms [alpha-amylase protein] and [gibberellin A3 protein] interact in the sense that GA regulates the expression of alpha-amylase.</s>
IEPA.d187 IEPA.d187.s448.e0 IEPA.d187.s448.e1	GA	alpha-amylase	[INST]Context: [PMID: 11021637 Gibbestatin B inhibits the GA-induced expression of alpha-amylase expression in cereal seeds. The expression of alpha-amylase in aleurone layers of barley is known to be induced by gibberellin A3 (GA). In the present study, gibbestatin B (GNB) was isolated from Streptomyces sp. C-39 as an inhibitor of the GA-induced expression of alpha-amylase in barley and rice, with IC50 values of 125 and 70 microM, respectively. GNB suppressed accumulation of GA-induced barley high-pI type B and rice RAmylA alpha-amylase transcripts. However, GNB showed no inhibitory activity on GUS expression in transgenic tobacco harboring the auxin-inducible par B promoter:: GUS fusion gene. The transcription of an abscisic acid (ABA)-inducible gene, HVA1, was unaffected by GNB. In addition, GNB prevented aleurone cells from cell death induced by GA. In tobacco and Arabidopsis plants, GNB suppressed the germination and retarded the growth of seedlings without toxicity. The growth of gai, spy and abi mutants was also retarded by GNB. Normal plants treated with GA-biosynthesis inhibitors and GA-defective and GA-signaling mutants normally have dwarf dark green leaves. However, dwarfed healthy green leaves were observed in normal plants treated with GNB. GA-induced stem elongation of plants was also detected in the presence of GNB. These analyses indicate that GNB inhibits the GA-induced expression of alpha-amylase by regulating one of the steps involved in ABA signaling, but not by acting as a weak ABA analog.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin A3 (GA) induces the expression of alpha-amylase in barley aleurone layers. Gibbestatin B (GNB) inhibits this GA-induced expression of alpha-amylase, suggesting that GA and alpha-amylase are part of the same regulatory pathway. Therefore, GA and alpha-amylase interact in the sense that GA regulates the expression of alpha-amylase.</s>
IEPA.d187 IEPA.d187.s449.e0 IEPA.d187.s449.e1	GA	alpha-amylase	[INST]Context: [PMID: 11021637 Gibbestatin B inhibits the GA-induced expression of alpha-amylase expression in cereal seeds. The expression of alpha-amylase in aleurone layers of barley is known to be induced by gibberellin A3 (GA). In the present study, gibbestatin B (GNB) was isolated from Streptomyces sp. C-39 as an inhibitor of the GA-induced expression of alpha-amylase in barley and rice, with IC50 values of 125 and 70 microM, respectively. GNB suppressed accumulation of GA-induced barley high-pI type B and rice RAmylA alpha-amylase transcripts. However, GNB showed no inhibitory activity on GUS expression in transgenic tobacco harboring the auxin-inducible par B promoter:: GUS fusion gene. The transcription of an abscisic acid (ABA)-inducible gene, HVA1, was unaffected by GNB. In addition, GNB prevented aleurone cells from cell death induced by GA. In tobacco and Arabidopsis plants, GNB suppressed the germination and retarded the growth of seedlings without toxicity. The growth of gai, spy and abi mutants was also retarded by GNB. Normal plants treated with GA-biosynthesis inhibitors and GA-defective and GA-signaling mutants normally have dwarf dark green leaves. However, dwarfed healthy green leaves were observed in normal plants treated with GNB. GA-induced stem elongation of plants was also detected in the presence of GNB. These analyses indicate that GNB inhibits the GA-induced expression of alpha-amylase by regulating one of the steps involved in ABA signaling, but not by acting as a weak ABA analog.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin A3 (GA) induces the expression of alpha-amylase in barley aleurone layers. Gibbestatin B (GNB) inhibits this GA-induced expression of alpha-amylase, suggesting that GA and alpha-amylase are part of the same regulatory pathway. Therefore, GA and alpha-amylase interact in the sense that GA regulates the expression of alpha-amylase.</s>
IEPA.d187 IEPA.d187.s450.e0 IEPA.d187.s450.e1	GA	alpha-amylase	[INST]Context: [PMID: 11021637 Gibbestatin B inhibits the GA-induced expression of alpha-amylase expression in cereal seeds. The expression of alpha-amylase in aleurone layers of barley is known to be induced by gibberellin A3 (GA). In the present study, gibbestatin B (GNB) was isolated from Streptomyces sp. C-39 as an inhibitor of the GA-induced expression of alpha-amylase in barley and rice, with IC50 values of 125 and 70 microM, respectively. GNB suppressed accumulation of GA-induced barley high-pI type B and rice RAmylA alpha-amylase transcripts. However, GNB showed no inhibitory activity on GUS expression in transgenic tobacco harboring the auxin-inducible par B promoter:: GUS fusion gene. The transcription of an abscisic acid (ABA)-inducible gene, HVA1, was unaffected by GNB. In addition, GNB prevented aleurone cells from cell death induced by GA. In tobacco and Arabidopsis plants, GNB suppressed the germination and retarded the growth of seedlings without toxicity. The growth of gai, spy and abi mutants was also retarded by GNB. Normal plants treated with GA-biosynthesis inhibitors and GA-defective and GA-signaling mutants normally have dwarf dark green leaves. However, dwarfed healthy green leaves were observed in normal plants treated with GNB. GA-induced stem elongation of plants was also detected in the presence of GNB. These analyses indicate that GNB inhibits the GA-induced expression of alpha-amylase by regulating one of the steps involved in ABA signaling, but not by acting as a weak ABA analog.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin A3 (GA) induces the expression of alpha-amylase in barley aleurone layers. Gibbestatin B (GNB) inhibits this GA-induced expression of alpha-amylase, suggesting that GA and alpha-amylase are part of the same regulatory pathway. Therefore, GA and alpha-amylase interact in the sense that GA regulates the expression of alpha-amylase.</s>
IEPA.d188 IEPA.d188.s451.e0 IEPA.d188.s451.e1	neuropeptide Y	leptin	[INST]Context: [PMID: 11024558 Postnatal regulation of hypothalamic neuropeptide expression by leptin: implications for energy balance and body weight regulation. Leptin is produced mainly by adipose tissue and has been shown to regulate feeding, energy balance and neuroendocrine function. Regulation of energy homeostasis by leptin is thought to be mediated by hypothalamic neuropeptides, at least in adult rodents. The neonatal period is a critical stage of development during which mammals have to optimize caloric intake to support growth and development, as well as maintain body temperature. It is likely that leptin is involved in the transition from preweaning to adult metabolism. To test this hypothesis, we compared the effect of leptin treatment on body weight and adiposity between neonatal and adult mice. We also determined whether well known hypothalamic neuropeptide targets, e.g. neuropeptide Y (NPY), proopiomelanocortin (POMC), agouti-related peptide (AGRP) and cocaine and amphetamine-regulated transcript (CART) were regulated in a pattern consistent with their presumed roles as mediators of leptin action. Once daily intraperitoneal leptin injection for 7 days did not alter body weight, fat content or expression of hypothalamic neuropeptide mRNAs in 10-day-old mice. In contrast, leptin decreased body weight and adiposity, increased CART and suppressed NPY and AGRP mRNA expression in adult mice. These results are consistent with previous studies showing that the timing of leptin's anorectic action develops after weaning. Furthermore, the association between leptin's ability to influence body weight in adult mice but not in neonates, and the regulation of hypothalamic neuropeptide mRNA expression, is consistent with the view that these peptides mediate leptin's effects on energy balance.] Question: Based on the provided context, do the terms [neuropeptide Y protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin regulates the expression of hypothalamic neuropeptides, including neuropeptide Y (NPY). Specifically, leptin treatment in adult mice suppressed NPY mRNA expression. This suggests that leptin and neuropeptide Y protein interact in a regulatory pathway where leptin influences the expression of NPY, thereby affecting energy balance and body weight regulation.</s>
IEPA.d188 IEPA.d188.s452.e0 IEPA.d188.s452.e1	leptin	NPY	[INST]Context: [PMID: 11024558 Postnatal regulation of hypothalamic neuropeptide expression by leptin: implications for energy balance and body weight regulation. Leptin is produced mainly by adipose tissue and has been shown to regulate feeding, energy balance and neuroendocrine function. Regulation of energy homeostasis by leptin is thought to be mediated by hypothalamic neuropeptides, at least in adult rodents. The neonatal period is a critical stage of development during which mammals have to optimize caloric intake to support growth and development, as well as maintain body temperature. It is likely that leptin is involved in the transition from preweaning to adult metabolism. To test this hypothesis, we compared the effect of leptin treatment on body weight and adiposity between neonatal and adult mice. We also determined whether well known hypothalamic neuropeptide targets, e.g. neuropeptide Y (NPY), proopiomelanocortin (POMC), agouti-related peptide (AGRP) and cocaine and amphetamine-regulated transcript (CART) were regulated in a pattern consistent with their presumed roles as mediators of leptin action. Once daily intraperitoneal leptin injection for 7 days did not alter body weight, fat content or expression of hypothalamic neuropeptide mRNAs in 10-day-old mice. In contrast, leptin decreased body weight and adiposity, increased CART and suppressed NPY and AGRP mRNA expression in adult mice. These results are consistent with previous studies showing that the timing of leptin's anorectic action develops after weaning. Furthermore, the association between leptin's ability to influence body weight in adult mice but not in neonates, and the regulation of hypothalamic neuropeptide mRNA expression, is consistent with the view that these peptides mediate leptin's effects on energy balance.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY interact with each other in the regulation of energy balance and body weight. Specifically, leptin treatment in adult mice was shown to suppress NPY mRNA expression, suggesting that leptin influences the expression of NPY, which is a key neuropeptide involved in feeding and energy homeostasis. This interaction is consistent with the view that leptin's effects on energy balance are mediated by hypothalamic neuropeptides, including NPY.</s>
IEPA.d191 IEPA.d191.s459.e0 IEPA.d191.s459.e1	leptin	NPY	[INST]Context: [PMID: 11024567 Resistance to the anorexic and thermogenic effects of centrally administrated leptin in obese aged rats. The aim of the present study was to determine whether the anorexic and thermogenic effects of leptin were attenuated in overweight aged rats following intracerebroventricular (i.c.v.) injection of murine leptin. Male F344/BN rats of two ages (6 months: young (n=20) and 24 months: old (n=18)) were divided into three groups (control, pair-fed and leptin) and were treated with either vehicle (artificial cerebrospinal fluid) or leptin (15.6 microgram/day) for 3 days. There was an age-related increase in basal food intake (20+/-2%), serum leptin levels (363+/-106%) and leptin (OB) mRNA (72+/-16%) in perirenal white adipose tissue (PWAT). In contrast, basal expression of hypothalamic NPY mRNA and brown adipose tissue (BAT) uncoupling protein 1 (UCP1) mRNA was reduced significantly (-35+/-4% and -51+/-5%, respectively) with age. I.c.v. leptin treatment had a significantly greater effect in reducing food intake (-42+/-5% vs. -23+/-4%), serum leptin levels (-55+/-7% vs. 10+/-2%) and PWAT OB mRNA (-46+/-2% vs. 10+/-5%) in young than in old rats. Similarly, central leptin treatment also had a greater effect in suppressing hypothalamic NPY mRNA expression in young (-23+/-4%) than in old (-8+/-4%) rats compared with their age-matched pair-fed treated rats. The stimulatory effect of i.c.v. leptin treatment on BAT UCP1 mRNA expression was also significantly greater in young rats (45+/-8%) than in old rats (10+/-6%) compared with age-matched pair-fed rats. Our previous report indicated that these overweight aged rats were resistant to peripheral administered leptin. The present data extend those findings and demonstrate that the impaired anorexic and metabolic effects of leptin are centrally mediated. This leptin resistance may be due to either the elevated obesity and serum leptin with age or due to age itself or both. The development of leptin resistance with age may contribute to the hyperphagia, hyperleptinemia and impaired energy balance with age.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY protein interact with each other in the regulation of food intake and energy balance. Specifically, it mentions that central leptin treatment has a greater effect in suppressing hypothalamic NPY mRNA expression in young rats compared to old rats. This suggests that leptin influences the expression of NPY, indicating an interaction between the two proteins in the context of appetite regulation.</s>
IEPA.d192 IEPA.d192.s460.e0 IEPA.d192.s460.e1	GA	alpha-amylase	[INST]Context: [PMID: 11027362 Rice dwarf mutant d1, which is defective in the alpha subunit of the heterotrimeric G protein, affects gibberellin signal transduction. Previously, we reported that the rice dwarf mutant, d1, is defective in the alpha subunit of the heterotrimeric G protein (Galpha). In the present study, gibberellin (GA) signaling in d1 and the role of the Galpha protein in the GA-signaling pathway were investigated. Compared with the wild type, GA induction of alpha-amylase activity in aleurone cells of d1 was greatly reduced. Relative to the wild type, the GA(3)-treated aleurone layer of d1 had lower expression of Ramy1A, which encodes alpha-amylase, and OsGAMYB, which encodes a GA-inducible transcriptional factor, and no increase in expression of Ca(2 +)-ATPase. However, in the presence of high GA concentrations, alpha-amylase induction occurred even in d1. The GA sensitivity of second leaf sheath elongation in d1 was similar to that of the wild type in terms of dose responsiveness, but the response of internode elongation to GA was much lower in d1. Furthermore, Os20ox expression was up-regulated, and the GA content was elevated in the stunted internodes of d1. All these results suggest that d1 affects a part of the GA-signaling pathway, namely the induction of alpha-amylase in the aleurone layer and internode elongation. In addition, a double mutant between d1 and another GA-signaling mutant, slr, revealed that SLR is epistatic to the D1, supporting that the Galpha protein is involved in GA signaling. However, the data also provide evidence for the presence of an alternative GA-signaling pathway that does not involve the Galpha protein. It is proposed that GA signaling via the Galpha protein may be more sensitive than that of the alternative pathway, as indicated by the low GA responsiveness of this Galpha-independent pathway.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the GA protein (specifically, the alpha subunit of the heterotrimeric G protein) is involved in the GA-signaling pathway, which affects the induction of alpha-amylase activity in aleurone cells. The GA protein influences the expression of genes such as Ramy1A (which encodes alpha-amylase) and OsGAMYB (which encodes a GA-inducible transcriptional factor). This suggests that the GA protein interacts with the alpha-amylase protein through the signaling pathway, leading to the induction of alpha-amylase activity.</s>
IEPA.d192 IEPA.d192.s461.e0 IEPA.d192.s461.e1	GA	alpha-amylase	[INST]Context: [PMID: 11027362 Rice dwarf mutant d1, which is defective in the alpha subunit of the heterotrimeric G protein, affects gibberellin signal transduction. Previously, we reported that the rice dwarf mutant, d1, is defective in the alpha subunit of the heterotrimeric G protein (Galpha). In the present study, gibberellin (GA) signaling in d1 and the role of the Galpha protein in the GA-signaling pathway were investigated. Compared with the wild type, GA induction of alpha-amylase activity in aleurone cells of d1 was greatly reduced. Relative to the wild type, the GA(3)-treated aleurone layer of d1 had lower expression of Ramy1A, which encodes alpha-amylase, and OsGAMYB, which encodes a GA-inducible transcriptional factor, and no increase in expression of Ca(2 +)-ATPase. However, in the presence of high GA concentrations, alpha-amylase induction occurred even in d1. The GA sensitivity of second leaf sheath elongation in d1 was similar to that of the wild type in terms of dose responsiveness, but the response of internode elongation to GA was much lower in d1. Furthermore, Os20ox expression was up-regulated, and the GA content was elevated in the stunted internodes of d1. All these results suggest that d1 affects a part of the GA-signaling pathway, namely the induction of alpha-amylase in the aleurone layer and internode elongation. In addition, a double mutant between d1 and another GA-signaling mutant, slr, revealed that SLR is epistatic to the D1, supporting that the Galpha protein is involved in GA signaling. However, the data also provide evidence for the presence of an alternative GA-signaling pathway that does not involve the Galpha protein. It is proposed that GA signaling via the Galpha protein may be more sensitive than that of the alternative pathway, as indicated by the low GA responsiveness of this Galpha-independent pathway.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the GA protein (specifically, the alpha subunit of the heterotrimeric G protein) is involved in the GA-signaling pathway, which affects the induction of alpha-amylase activity in aleurone cells. The GA protein influences the expression of genes such as Ramy1A (which encodes alpha-amylase) and OsGAMYB (which encodes a GA-inducible transcriptional factor). This suggests that the GA protein interacts with the alpha-amylase protein through the signaling pathway, leading to the induction of alpha-amylase activity.</s>
IEPA.d192 IEPA.d192.s462.e0 IEPA.d192.s462.e1	GA	alpha-amylase	[INST]Context: [PMID: 11027362 Rice dwarf mutant d1, which is defective in the alpha subunit of the heterotrimeric G protein, affects gibberellin signal transduction. Previously, we reported that the rice dwarf mutant, d1, is defective in the alpha subunit of the heterotrimeric G protein (Galpha). In the present study, gibberellin (GA) signaling in d1 and the role of the Galpha protein in the GA-signaling pathway were investigated. Compared with the wild type, GA induction of alpha-amylase activity in aleurone cells of d1 was greatly reduced. Relative to the wild type, the GA(3)-treated aleurone layer of d1 had lower expression of Ramy1A, which encodes alpha-amylase, and OsGAMYB, which encodes a GA-inducible transcriptional factor, and no increase in expression of Ca(2 +)-ATPase. However, in the presence of high GA concentrations, alpha-amylase induction occurred even in d1. The GA sensitivity of second leaf sheath elongation in d1 was similar to that of the wild type in terms of dose responsiveness, but the response of internode elongation to GA was much lower in d1. Furthermore, Os20ox expression was up-regulated, and the GA content was elevated in the stunted internodes of d1. All these results suggest that d1 affects a part of the GA-signaling pathway, namely the induction of alpha-amylase in the aleurone layer and internode elongation. In addition, a double mutant between d1 and another GA-signaling mutant, slr, revealed that SLR is epistatic to the D1, supporting that the Galpha protein is involved in GA signaling. However, the data also provide evidence for the presence of an alternative GA-signaling pathway that does not involve the Galpha protein. It is proposed that GA signaling via the Galpha protein may be more sensitive than that of the alternative pathway, as indicated by the low GA responsiveness of this Galpha-independent pathway.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the GA protein (specifically, the alpha subunit of the heterotrimeric G protein) is involved in the GA-signaling pathway, which affects the induction of alpha-amylase activity in aleurone cells. The GA protein influences the expression of genes such as Ramy1A (which encodes alpha-amylase) and OsGAMYB (which encodes a GA-inducible transcriptional factor). This suggests that the GA protein interacts with the alpha-amylase protein through the signaling pathway, leading to the induction of alpha-amylase activity.</s>
IEPA.d192 IEPA.d192.s463.e0 IEPA.d192.s463.e1	GA	alpha-amylase	[INST]Context: [PMID: 11027362 Rice dwarf mutant d1, which is defective in the alpha subunit of the heterotrimeric G protein, affects gibberellin signal transduction. Previously, we reported that the rice dwarf mutant, d1, is defective in the alpha subunit of the heterotrimeric G protein (Galpha). In the present study, gibberellin (GA) signaling in d1 and the role of the Galpha protein in the GA-signaling pathway were investigated. Compared with the wild type, GA induction of alpha-amylase activity in aleurone cells of d1 was greatly reduced. Relative to the wild type, the GA(3)-treated aleurone layer of d1 had lower expression of Ramy1A, which encodes alpha-amylase, and OsGAMYB, which encodes a GA-inducible transcriptional factor, and no increase in expression of Ca(2 +)-ATPase. However, in the presence of high GA concentrations, alpha-amylase induction occurred even in d1. The GA sensitivity of second leaf sheath elongation in d1 was similar to that of the wild type in terms of dose responsiveness, but the response of internode elongation to GA was much lower in d1. Furthermore, Os20ox expression was up-regulated, and the GA content was elevated in the stunted internodes of d1. All these results suggest that d1 affects a part of the GA-signaling pathway, namely the induction of alpha-amylase in the aleurone layer and internode elongation. In addition, a double mutant between d1 and another GA-signaling mutant, slr, revealed that SLR is epistatic to the D1, supporting that the Galpha protein is involved in GA signaling. However, the data also provide evidence for the presence of an alternative GA-signaling pathway that does not involve the Galpha protein. It is proposed that GA signaling via the Galpha protein may be more sensitive than that of the alternative pathway, as indicated by the low GA responsiveness of this Galpha-independent pathway.] Question: Based on the provided context, do the terms [GA protein] and [alpha-amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the GA protein (specifically, the alpha subunit of the heterotrimeric G protein) is involved in the GA-signaling pathway, which affects the induction of alpha-amylase activity in aleurone cells. The GA protein influences the expression of genes such as Ramy1A (which encodes alpha-amylase) and OsGAMYB (which encodes a GA-inducible transcriptional factor). This suggests that the GA protein interacts with the alpha-amylase protein through the signaling pathway, leading to the induction of alpha-amylase activity.</s>
IEPA.d194 IEPA.d194.s465.e0 IEPA.d194.s465.e1	Insulin	phospholipase Cgamma	[INST]Context: [PMID: 11042115 Insulin-induced phospholipase D1 and phospholipase D2 activity in human embryonic kidney-293 cells mediated by the phospholipase C gamma and protein kinase C alpha signalling cascade. Phospholipase D (PLD)1 is quiescent in vitro and in vivo until stimulated by classical protein kinase C (PKC) isoforms, ADP-ribosylation factor or Rho family members. By contrast, PLD2 has high basal activity, and the mechanisms involved in agonist-induced activation of PLD2 are poorly understood. Using transiently transfected human embryonic kidney (HEK)-293 cells as a model system, we report in the present study that PLD2 overexpressed in HEK-293 cells exhibits regulatory properties similar to PLD1 when stimulated in response to insulin and phorbol ester. Co-expression of PLD1 or PLD2 with PKC alpha results in constitutive activation of both PLD isoforms, which cannot be further stimulated by insulin. Co-expression of PLD1 with phospholipase C (PLC)gamma has the same effect, while co-expression of PLD2 with PLC gamma allows PLD2 activity to be stimulated in an insulin-dependent manner. The PKC-specific inhibitors bisindolylmaleimide and Go 6976 abolish insulin-induced PLD2 activation in HEK-293 cells co-expressing the insulin receptor, PLC gamma and PLD2, confirming that not only PLD1, but PLD2 as well, is regulated in a PKC-dependent manner. Finally, we provide evidence that PKC alpha is constitutively associated with PLD2. In summary, we demonstrate that insulin treatment results in activation of both PLD1 and PLD2 in appropriate cell types when the appropriate upstream intermediate signalling components, i.e. PKC alpha and PLC gamma, are expressed at sufficient levels.] Question: Based on the provided context, do the terms [Insulin protein] and [phospholipase Cgamma protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that insulin treatment results in the activation of both PLD1 and PLD2 in appropriate cell types. Specifically, it mentions that co-expression of PLD2 with phospholipase C (PLC)gamma allows PLD2 activity to be stimulated in an insulin-dependent manner. This suggests that insulin and phospholipase Cgamma interact in a signaling cascade that leads to the activation of PLD2. Therefore, insulin and phospholipase Cgamma are interacting in this context.</s>
IEPA.d194 IEPA.d194.s468.e0 IEPA.d194.s468.e1	insulin	PLCgamma	[INST]Context: [PMID: 11042115 Insulin-induced phospholipase D1 and phospholipase D2 activity in human embryonic kidney-293 cells mediated by the phospholipase C gamma and protein kinase C alpha signalling cascade. Phospholipase D (PLD)1 is quiescent in vitro and in vivo until stimulated by classical protein kinase C (PKC) isoforms, ADP-ribosylation factor or Rho family members. By contrast, PLD2 has high basal activity, and the mechanisms involved in agonist-induced activation of PLD2 are poorly understood. Using transiently transfected human embryonic kidney (HEK)-293 cells as a model system, we report in the present study that PLD2 overexpressed in HEK-293 cells exhibits regulatory properties similar to PLD1 when stimulated in response to insulin and phorbol ester. Co-expression of PLD1 or PLD2 with PKC alpha results in constitutive activation of both PLD isoforms, which cannot be further stimulated by insulin. Co-expression of PLD1 with phospholipase C (PLC)gamma has the same effect, while co-expression of PLD2 with PLC gamma allows PLD2 activity to be stimulated in an insulin-dependent manner. The PKC-specific inhibitors bisindolylmaleimide and Go 6976 abolish insulin-induced PLD2 activation in HEK-293 cells co-expressing the insulin receptor, PLC gamma and PLD2, confirming that not only PLD1, but PLD2 as well, is regulated in a PKC-dependent manner. Finally, we provide evidence that PKC alpha is constitutively associated with PLD2. In summary, we demonstrate that insulin treatment results in activation of both PLD1 and PLD2 in appropriate cell types when the appropriate upstream intermediate signalling components, i.e. PKC alpha and PLC gamma, are expressed at sufficient levels.] Question: Based on the provided context, do the terms [insulin protein] and [PLCgamma protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that insulin treatment results in the activation of both PLD1 and PLD2 in appropriate cell types. Specifically, it mentions that co-expression of PLD2 with PLCgamma allows PLD2 activity to be stimulated in an insulin-dependent manner. This suggests that insulin and PLCgamma interact in a signaling cascade that leads to the activation of PLD2. Therefore, insulin protein and PLCgamma protein interact with each other in the described cellular pathway.</s>
IEPA.d197 IEPA.d197.s478.e0 IEPA.d197.s478.e1	Bovine prion protein	protein kinase CK2	[INST]Context: [PMID: 11062072 Bovine prion protein as a modulator of protein kinase CK2. On the basis of far-Western blot and plasmon resonance (BIAcore) experiments, we show here that recombinant bovine prion protein (bPrP) (25-242) strongly interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This association leads to increased phosphotransferase activity of CK2alpha, tested on calmodulin or specific peptides as substrate. We also show that bPrP counteracts the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. A truncated form of bPrP encompassing the C-terminal domain (residues 105-242) interacts with CK2 but does not affect its catalytic activity. The opposite is found with the N-terminal fragment of bPrP (residues 25-116), although the stimulation of catalysis is less efficient than with full-size bPrP. These results disclose the potential of the PrP to modulate the activity of CK2, a pleiotropic protein kinase that is particularly abundant in the brain.] Question: Based on the provided context, do the terms [Bovine prion protein protein] and [protein kinase CK2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that bovine prion protein (bPrP) interacts with the catalytic alpha/alpha' subunits of protein kinase CK2. This interaction leads to increased phosphotransferase activity of CK2alpha, as well as counteracting the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. Therefore, the terms "Bovine prion protein protein" and "protein kinase CK2 protein" are interacting with each other.</s>
IEPA.d197 IEPA.d197.s479.e0 IEPA.d197.s479.e1	bovine prion protein	protein kinase CK2	[INST]Context: [PMID: 11062072 Bovine prion protein as a modulator of protein kinase CK2. On the basis of far-Western blot and plasmon resonance (BIAcore) experiments, we show here that recombinant bovine prion protein (bPrP) (25-242) strongly interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This association leads to increased phosphotransferase activity of CK2alpha, tested on calmodulin or specific peptides as substrate. We also show that bPrP counteracts the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. A truncated form of bPrP encompassing the C-terminal domain (residues 105-242) interacts with CK2 but does not affect its catalytic activity. The opposite is found with the N-terminal fragment of bPrP (residues 25-116), although the stimulation of catalysis is less efficient than with full-size bPrP. These results disclose the potential of the PrP to modulate the activity of CK2, a pleiotropic protein kinase that is particularly abundant in the brain.] Question: Based on the provided context, do the terms [bovine prion protein protein] and [protein kinase CK2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly states that recombinant bovine prion protein (bPrP) strongly interacts with the catalytic alpha/alpha' subunits of protein kinase CK2. This interaction leads to increased phosphotransferase activity of CK2alpha, indicating a direct interaction between the two proteins.</s>
IEPA.d197 IEPA.d197.s481.e0 IEPA.d197.s481.e1	bPrP	CK2	[INST]Context: [PMID: 11062072 Bovine prion protein as a modulator of protein kinase CK2. On the basis of far-Western blot and plasmon resonance (BIAcore) experiments, we show here that recombinant bovine prion protein (bPrP) (25-242) strongly interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This association leads to increased phosphotransferase activity of CK2alpha, tested on calmodulin or specific peptides as substrate. We also show that bPrP counteracts the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. A truncated form of bPrP encompassing the C-terminal domain (residues 105-242) interacts with CK2 but does not affect its catalytic activity. The opposite is found with the N-terminal fragment of bPrP (residues 25-116), although the stimulation of catalysis is less efficient than with full-size bPrP. These results disclose the potential of the PrP to modulate the activity of CK2, a pleiotropic protein kinase that is particularly abundant in the brain.] Question: Based on the provided context, do the terms [bPrP protein] and [CK2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that recombinant bovine prion protein (bPrP) interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This interaction leads to increased phosphotransferase activity of CK2alpha, suggesting a direct interaction between bPrP and CK2 proteins.</s>
IEPA.d197 IEPA.d197.s482.e0 IEPA.d197.s482.e1	PrP	CK2	[INST]Context: [PMID: 11062072 Bovine prion protein as a modulator of protein kinase CK2. On the basis of far-Western blot and plasmon resonance (BIAcore) experiments, we show here that recombinant bovine prion protein (bPrP) (25-242) strongly interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This association leads to increased phosphotransferase activity of CK2alpha, tested on calmodulin or specific peptides as substrate. We also show that bPrP counteracts the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. A truncated form of bPrP encompassing the C-terminal domain (residues 105-242) interacts with CK2 but does not affect its catalytic activity. The opposite is found with the N-terminal fragment of bPrP (residues 25-116), although the stimulation of catalysis is less efficient than with full-size bPrP. These results disclose the potential of the PrP to modulate the activity of CK2, a pleiotropic protein kinase that is particularly abundant in the brain.] Question: Based on the provided context, do the terms [PrP protein] and [CK2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that bovine prion protein (bPrP) interacts with the catalytic alpha/alpha' subunits of protein kinase CK2 (also termed 'casein kinase 2'). This interaction leads to increased phosphotransferase activity of CK2alpha and counteracts the inhibition of calmodulin phosphorylation promoted by the regulatory beta subunits of CK2. Therefore, the terms [PrP protein] and [CK2 protein] are interacting with each other.</s>
IEPA.d198 IEPA.d198.s483.e0 IEPA.d198.s483.e1	NPY	leptin	[INST]Context: [PMID: 11068095 CRH and NPY are not decreased in hypophagic, protein-deprived rats. To test if elevated CRH and decreased NPY might account for pituitary-adrenal activity and hypophagia in dietary protein deprivation, rats received normal or protein-free diet, or were food-or weight-restricted to match effects of protein deprivation. Protein or food restriction increased plasma ACTH. However, hypothalamic CRH mRNA was unchanged by protein deficiency and significantly decreased by food restriction when protein intake was > 50% of normal. Arcuate nucleus NPY mRNA increased in rats given protein-free diet, correlating with leptin rather than decreased feeding. We conclude that CRH and NPY gene expression does not explain adrenocortical axis or feeding activity in protein-deprived rats.] Question: Based on the provided context, do the terms [NPY protein] and [leptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arcuate nucleus NPY mRNA increased in rats given a protein-free diet, and this increase correlated with leptin rather than decreased feeding. This suggests that NPY and leptin are interacting in the context of protein deprivation, as the increase in NPY mRNA is linked to the levels of leptin. Therefore, the terms [NPY protein] and [leptin protein] are interacting in this scenario.</s>
IEPA.d5 IEPA.d5.s8.e0 IEPA.d5.s8.e1	Oxytocin	inositol phosphate	[INST]Context: [PMID: 2310821 Oxytocin-stimulated inositol phosphate turnover in endometrium of ewes is influenced by stage of the estrous cycle, pregnancy, and intrauterine infusion of ovine conceptus secretory proteins. Three experiments (Exp) assessed the influence of stage of the estrous cycle, pregnancy, and intrauterine infusion of ovine conceptus secretory proteins (oCSP) on turnover of inositol trisphosphate (the putative second-messenger for oxytocin-stimulated secretion of prostaglandin F2 alpha) in ovine endometrium during luteolysis and maternal recognition of pregnancy. In Exp 1, endometrium was collected from 5 cyclic (Cy) and 6 pregnant (P) ewes on Day 16 after onset of estrus. In Exp 2, endometrium was collected from Day 12 Cy (n = 5), Day 12 P (n = 3), Day 16 Cy (n = 4), and Day 16 P (n = 3) ewes. In Exp 3, 12 Cy ewes were allotted randomly, in a 2 x 2 factorial arrangement, to receive serum protein (SP), or oCSP and estradiol-17 beta (E2), or vehicle treatments. Ewes were injected i.v. with 0.5 mg E2 or vehicle on Day 12 and received twice-daily infusions of 1.5 mg SP or oCSP (containing 25 micrograms ovine trophoblast protein-1 by radioimmunoassay [RIA]) + SP (1.5 mg total protein) into each uterine horn on Days 12, 13, and 14. Blood samples for RIA of plasma progesterone were collected on Days 10-15 (before treatment on each day) and endometrium was collected on Day 15. For each Exp, 100 mg endometrium was incubated, in duplicate, for 2 h with 10 microCi [3H] inositol and treated with 0 or 100 nM oxytocin (OT) for 20 min, then [3H]inositol mono-, bis-, and trisphosphates (IP1, IP2, and IP3, respectively) were quantified.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [Oxytocin protein] and [inositol phosphate protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates the turnover of inositol phosphate in the endometrium of ewes. Specifically, it mentions that oxytocin-stimulated inositol phosphate turnover is influenced by various factors, including the stage of the estrous cycle, pregnancy, and intrauterine infusion of ovine conceptus secretory proteins. This suggests that oxytocin interacts with inositol phosphate, as the stimulation of inositol phosphate turnover is a direct consequence of oxytocin's action. Therefore, the terms "oxytocin protein" and "inositol phosphate protein" are interacting in the context provided.</s>
IEPA.d5 IEPA.d5.s9.e0 IEPA.d5.s9.e1	inositol trisphosphate	oxytocin	[INST]Context: [PMID: 2310821 Oxytocin-stimulated inositol phosphate turnover in endometrium of ewes is influenced by stage of the estrous cycle, pregnancy, and intrauterine infusion of ovine conceptus secretory proteins. Three experiments (Exp) assessed the influence of stage of the estrous cycle, pregnancy, and intrauterine infusion of ovine conceptus secretory proteins (oCSP) on turnover of inositol trisphosphate (the putative second-messenger for oxytocin-stimulated secretion of prostaglandin F2 alpha) in ovine endometrium during luteolysis and maternal recognition of pregnancy. In Exp 1, endometrium was collected from 5 cyclic (Cy) and 6 pregnant (P) ewes on Day 16 after onset of estrus. In Exp 2, endometrium was collected from Day 12 Cy (n = 5), Day 12 P (n = 3), Day 16 Cy (n = 4), and Day 16 P (n = 3) ewes. In Exp 3, 12 Cy ewes were allotted randomly, in a 2 x 2 factorial arrangement, to receive serum protein (SP), or oCSP and estradiol-17 beta (E2), or vehicle treatments. Ewes were injected i.v. with 0.5 mg E2 or vehicle on Day 12 and received twice-daily infusions of 1.5 mg SP or oCSP (containing 25 micrograms ovine trophoblast protein-1 by radioimmunoassay [RIA]) + SP (1.5 mg total protein) into each uterine horn on Days 12, 13, and 14. Blood samples for RIA of plasma progesterone were collected on Days 10-15 (before treatment on each day) and endometrium was collected on Day 15. For each Exp, 100 mg endometrium was incubated, in duplicate, for 2 h with 10 microCi [3H] inositol and treated with 0 or 100 nM oxytocin (OT) for 20 min, then [3H]inositol mono-, bis-, and trisphosphates (IP1, IP2, and IP3, respectively) were quantified.(ABSTRACT TRUNCATED AT 250 WORDS)] Question: Based on the provided context, do the terms [inositol trisphosphate protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin stimulates the turnover of inositol trisphosphate (IP3) in the endometrium of ewes. This suggests that oxytocin (oxytocin protein) interacts with inositol trisphosphate (inositol trisphosphate protein) in the process of stimulating the secretion of prostaglandin F2 alpha. The interaction is mediated through the signaling pathway where oxytocin triggers the production of IP3, which serves as a second messenger in this process.</s>
IEPA.d6 IEPA.d6.s11.e0 IEPA.d6.s11.e1	oxytocin	inositol phosphates	[INST]Context: [PMID: 3011507 Carbachol and oxytocin stimulate the generation of inositol phosphates in the guinea pig myometrium. In the guinea pig myometrium prelabelled with myo-[2-3H]inositol, carbachol and oxytocin enhanced a concentration-dependent and rapid release of IP3 which preceded that of IP2 and IP1. The specific receptor-mediated phospholipase C activation degrading PIP2 to IP3 did not require the presence of extracellular Ca2+. The ionophore A23187 as well as K+ depolarization failed to increase inositol phosphate accumulation. It is proposed that IP3 could have a role in the contraction of uterine smooth muscle elicited by the activation of muscarinic as well as of oxytocin receptors.] Question: Based on the provided context, do the terms [oxytocin protein] and [inositol phosphates protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that both carbachol and oxytocin stimulate the generation of inositol phosphates in the guinea pig myometrium. This suggests that oxytocin protein interacts with the signaling pathway that leads to the production of inositol phosphates protein. Specifically, the activation of oxytocin receptors triggers the release of inositol phosphates, which play a role in the contraction of uterine smooth muscle. Therefore, there is a clear interaction between oxytocin protein and the inositol phosphates signaling pathway.</s>
IEPA.d6 IEPA.d6.s12.e0 IEPA.d6.s12.e1	oxytocin	IP3	[INST]Context: [PMID: 3011507 Carbachol and oxytocin stimulate the generation of inositol phosphates in the guinea pig myometrium. In the guinea pig myometrium prelabelled with myo-[2-3H]inositol, carbachol and oxytocin enhanced a concentration-dependent and rapid release of IP3 which preceded that of IP2 and IP1. The specific receptor-mediated phospholipase C activation degrading PIP2 to IP3 did not require the presence of extracellular Ca2+. The ionophore A23187 as well as K+ depolarization failed to increase inositol phosphate accumulation. It is proposed that IP3 could have a role in the contraction of uterine smooth muscle elicited by the activation of muscarinic as well as of oxytocin receptors.] Question: Based on the provided context, do the terms [oxytocin protein] and [IP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided describes the effects of carbachol and oxytocin on the generation of inositol phosphates (IP3) in the guinea pig myometrium. It mentions that both carbachol and oxytocin stimulate the release of IP3, but it does not indicate a direct interaction between oxytocin protein and IP3 protein. Instead, it describes the activation of phospholipase C, which leads to the production of IP3, as a result of the stimulation by these agents. Therefore, there is no direct interaction mentioned between oxytocin protein and IP3 protein.</s>
IEPA.d35 IEPA.d35.s86.e0 IEPA.d35.s86.e1	Oxytocin	insulin	[INST]Context: [PMID: 9004255 Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F). Oxytocin (OT) and vasopressin (AVP) stimulate insulin and glucagon release from the pancreas, and evoke insulin secretion from the rat insulinoma cell line, RINm5F. To determine which AVP/OT receptor subtype is expressed in RINm5F cells, we used PCR with degenerate primers to two transmembrane domains of the AVP (V1a, V1b (or V3), V2) and OT receptors (OTRs). The single PCR fragment identified was used to obtain a full length cDNA from a RINm5F cDNA library. Comparison of the deduced amino acid sequence of this clone with uterine OTR sequences from several species (human, sheep, bovine) and to the pig kidney epithelial cell (LLC-PK1) OTR reveals a very high degree of homology. After the RIN cell OTR cDNA was stably transfected into CHO cells (CHO-OTR), the cell membranes bound iodinated oxytocin antagonist with an apparent Kd comparable to that of RIN cell membranes and those from other OT target cells. Comparison of the ligand specificities of CHO-OTR and RIN cells membranes showed that the relative Ki values of a series of OT analogues were approximately equivalent in both preparations. The rank order of apparent Ki values also corresponded to published values for the rat myometrium, where OT elicits intracellular calcium transients, and increases inositol phosphate production. In uterin endometrium and amnion cells, OT stimulates prostaglandin release. Stimulation of CHO-OTR cells with OT caused an increase in cytosolic calcium concentration originating from both intracellular and extracellular sources, and a dose-dependent increase in inositol phosphate levels. Arachidonic acid release and PGE2 synthesis were also stimulated by OT. These findings (amino acid sequence homology, binding specificity, and signal transduction/second messenger production) suggest that OTRs from RINm5F cells are indistinguishable from OTRs that have been described in other tissues. The expression of OTR in pancreatic cells implies that OT plays a role in pancreatic function.] Question: Based on the provided context, do the terms [Oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates insulin release from the pancreas and the rat insulinoma cell line RINm5F. This suggests that OT and insulin interact in a functional manner, where OT influences the release of insulin. Therefore, the terms "oxytocin protein" and "insulin protein" are interacting in the sense that OT affects the secretion of insulin.</s>
IEPA.d35 IEPA.d35.s86.e0 IEPA.d35.s86.e2	Oxytocin	insulin	[INST]Context: [PMID: 9004255 Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F). Oxytocin (OT) and vasopressin (AVP) stimulate insulin and glucagon release from the pancreas, and evoke insulin secretion from the rat insulinoma cell line, RINm5F. To determine which AVP/OT receptor subtype is expressed in RINm5F cells, we used PCR with degenerate primers to two transmembrane domains of the AVP (V1a, V1b (or V3), V2) and OT receptors (OTRs). The single PCR fragment identified was used to obtain a full length cDNA from a RINm5F cDNA library. Comparison of the deduced amino acid sequence of this clone with uterine OTR sequences from several species (human, sheep, bovine) and to the pig kidney epithelial cell (LLC-PK1) OTR reveals a very high degree of homology. After the RIN cell OTR cDNA was stably transfected into CHO cells (CHO-OTR), the cell membranes bound iodinated oxytocin antagonist with an apparent Kd comparable to that of RIN cell membranes and those from other OT target cells. Comparison of the ligand specificities of CHO-OTR and RIN cells membranes showed that the relative Ki values of a series of OT analogues were approximately equivalent in both preparations. The rank order of apparent Ki values also corresponded to published values for the rat myometrium, where OT elicits intracellular calcium transients, and increases inositol phosphate production. In uterin endometrium and amnion cells, OT stimulates prostaglandin release. Stimulation of CHO-OTR cells with OT caused an increase in cytosolic calcium concentration originating from both intracellular and extracellular sources, and a dose-dependent increase in inositol phosphate levels. Arachidonic acid release and PGE2 synthesis were also stimulated by OT. These findings (amino acid sequence homology, binding specificity, and signal transduction/second messenger production) suggest that OTRs from RINm5F cells are indistinguishable from OTRs that have been described in other tissues. The expression of OTR in pancreatic cells implies that OT plays a role in pancreatic function.] Question: Based on the provided context, do the terms [Oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) stimulates insulin release from the pancreas and the rat insulinoma cell line RINm5F. This suggests that OT and insulin interact in a functional manner, where OT influences the release of insulin. Therefore, the terms "oxytocin protein" and "insulin protein" are interacting in the sense that OT affects the secretion of insulin.</s>
IEPA.d42 IEPA.d42.s103.e0 IEPA.d42.s103.e1	insulin	phospholipase C	[INST]Context: [PMID: 9159224 Signal transduction in pancreatic beta-cells: regulation of insulin secretion by information flow in the phospholipase C/protein kinase C pathway. The physiologic regulation of glucose-induced insulin secretion is dependent upon the activation of information flow in the phospholipase C (PLC)/protein kinase C (PKC) signal transduction system. In both rat and human pancreatic beta-cells, glucose has several time-dependent effects on secretory responsiveness including the regulation of biphasic insulin secretion, time-dependent potentiation and time-dependent suppression. PLC/PKC activation has been implicated in all three response patterns. Islets of Langerhans contain the three major PLC isozyme classes (beta1, gamma1 and delta1) and the available evidence suggests that one class is activated by fuel secretagogues and another by neurohumoral agonists. The expression and activation of PLC is labile. When rat islet are cultured for short periods, the content and activation of PLC in response to glucose decreases and this biochemical defect in signal transduction is paralleled by significant reductions in glucose-induced insulin secretion. Similar defects are observed when human islets are cultured as well. Mouse islet responses to glucose stimulation differ in several major and dramatic ways from rat and human islet responses. When stimulated by 15mM glucose, mouse islets fail to develop a rising second phase secretory response, they fail to exhibit either time-dependent potentiation or time-dependent suppression to the hexose. Biphasic insulin secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of PLC distinct from that activated by glucose. These divergent response patterns are attributable to the underexpression in mouse islets, when compared to rat islets, of a fuel-sensitive PLC isozyme. When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of insulin secretion and that disordered activation of the enzyme culminates in disordered insulin release.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) is an essential component in the physiologic regulation of insulin secretion. Specifically, it mentions that glucose has several time-dependent effects on secretory responsiveness, including the regulation of biphasic insulin secretion, time-dependent potentiation, and time-dependent suppression, all of which are mediated through the activation of the PLC/protein kinase C (PKC) signal transduction system. This implies that the activation of PLC directly influences the secretion of insulin, indicating an interaction between the PLC protein and the insulin protein.</s>
IEPA.d42 IEPA.d42.s104.e0 IEPA.d42.s104.e1	insulin	phospholipase C	[INST]Context: [PMID: 9159224 Signal transduction in pancreatic beta-cells: regulation of insulin secretion by information flow in the phospholipase C/protein kinase C pathway. The physiologic regulation of glucose-induced insulin secretion is dependent upon the activation of information flow in the phospholipase C (PLC)/protein kinase C (PKC) signal transduction system. In both rat and human pancreatic beta-cells, glucose has several time-dependent effects on secretory responsiveness including the regulation of biphasic insulin secretion, time-dependent potentiation and time-dependent suppression. PLC/PKC activation has been implicated in all three response patterns. Islets of Langerhans contain the three major PLC isozyme classes (beta1, gamma1 and delta1) and the available evidence suggests that one class is activated by fuel secretagogues and another by neurohumoral agonists. The expression and activation of PLC is labile. When rat islet are cultured for short periods, the content and activation of PLC in response to glucose decreases and this biochemical defect in signal transduction is paralleled by significant reductions in glucose-induced insulin secretion. Similar defects are observed when human islets are cultured as well. Mouse islet responses to glucose stimulation differ in several major and dramatic ways from rat and human islet responses. When stimulated by 15mM glucose, mouse islets fail to develop a rising second phase secretory response, they fail to exhibit either time-dependent potentiation or time-dependent suppression to the hexose. Biphasic insulin secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of PLC distinct from that activated by glucose. These divergent response patterns are attributable to the underexpression in mouse islets, when compared to rat islets, of a fuel-sensitive PLC isozyme. When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of insulin secretion and that disordered activation of the enzyme culminates in disordered insulin release.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) is an essential component in the physiologic regulation of insulin secretion. Specifically, it mentions that glucose has several time-dependent effects on secretory responsiveness, including the regulation of biphasic insulin secretion, time-dependent potentiation, and time-dependent suppression, all of which are mediated through the activation of the PLC/protein kinase C (PKC) signal transduction system. This implies that the activation of PLC directly influences the secretion of insulin, indicating an interaction between the PLC protein and the insulin protein.</s>
IEPA.d42 IEPA.d42.s106.e0 IEPA.d42.s106.e1	insulin	PLC	[INST]Context: [PMID: 9159224 Signal transduction in pancreatic beta-cells: regulation of insulin secretion by information flow in the phospholipase C/protein kinase C pathway. The physiologic regulation of glucose-induced insulin secretion is dependent upon the activation of information flow in the phospholipase C (PLC)/protein kinase C (PKC) signal transduction system. In both rat and human pancreatic beta-cells, glucose has several time-dependent effects on secretory responsiveness including the regulation of biphasic insulin secretion, time-dependent potentiation and time-dependent suppression. PLC/PKC activation has been implicated in all three response patterns. Islets of Langerhans contain the three major PLC isozyme classes (beta1, gamma1 and delta1) and the available evidence suggests that one class is activated by fuel secretagogues and another by neurohumoral agonists. The expression and activation of PLC is labile. When rat islet are cultured for short periods, the content and activation of PLC in response to glucose decreases and this biochemical defect in signal transduction is paralleled by significant reductions in glucose-induced insulin secretion. Similar defects are observed when human islets are cultured as well. Mouse islet responses to glucose stimulation differ in several major and dramatic ways from rat and human islet responses. When stimulated by 15mM glucose, mouse islets fail to develop a rising second phase secretory response, they fail to exhibit either time-dependent potentiation or time-dependent suppression to the hexose. Biphasic insulin secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of PLC distinct from that activated by glucose. These divergent response patterns are attributable to the underexpression in mouse islets, when compared to rat islets, of a fuel-sensitive PLC isozyme. When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of insulin secretion and that disordered activation of the enzyme culminates in disordered insulin release.] Question: Based on the provided context, do the terms [insulin protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activation of phospholipase C (PLC) is an essential component in the physiologic regulation of insulin secretion. Specifically, it mentions that glucose has several time-dependent effects on secretory responsiveness, including the regulation of biphasic insulin secretion, time-dependent potentiation, and time-dependent suppression, all of which are mediated through the activation of PLC. This suggests that there is an interaction between the PLC protein and the insulin protein, where the activation of PLC leads to the regulation of insulin secretion.</s>
IEPA.d42 IEPA.d42.s107.e0 IEPA.d42.s107.e1	PLC	insulin	[INST]Context: [PMID: 9159224 Signal transduction in pancreatic beta-cells: regulation of insulin secretion by information flow in the phospholipase C/protein kinase C pathway. The physiologic regulation of glucose-induced insulin secretion is dependent upon the activation of information flow in the phospholipase C (PLC)/protein kinase C (PKC) signal transduction system. In both rat and human pancreatic beta-cells, glucose has several time-dependent effects on secretory responsiveness including the regulation of biphasic insulin secretion, time-dependent potentiation and time-dependent suppression. PLC/PKC activation has been implicated in all three response patterns. Islets of Langerhans contain the three major PLC isozyme classes (beta1, gamma1 and delta1) and the available evidence suggests that one class is activated by fuel secretagogues and another by neurohumoral agonists. The expression and activation of PLC is labile. When rat islet are cultured for short periods, the content and activation of PLC in response to glucose decreases and this biochemical defect in signal transduction is paralleled by significant reductions in glucose-induced insulin secretion. Similar defects are observed when human islets are cultured as well. Mouse islet responses to glucose stimulation differ in several major and dramatic ways from rat and human islet responses. When stimulated by 15mM glucose, mouse islets fail to develop a rising second phase secretory response, they fail to exhibit either time-dependent potentiation or time-dependent suppression to the hexose. Biphasic insulin secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of PLC distinct from that activated by glucose. These divergent response patterns are attributable to the underexpression in mouse islets, when compared to rat islets, of a fuel-sensitive PLC isozyme. When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of insulin secretion and that disordered activation of the enzyme culminates in disordered insulin release.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided clearly indicates that the activation of phospholipase C (PLC) is an essential component in the physiologic regulation of insulin secretion. Specifically, it mentions that glucose has several time-dependent effects on secretory responsiveness, including the regulation of biphasic insulin secretion, time-dependent potentiation, and time-dependent suppression, all of which are mediated through the activation of PLC/protein kinase C (PKC) signal transduction. This implies that PLC and insulin protein interact in the sense that PLC activation is necessary for the proper secretion of insulin.</s>
IEPA.d46 IEPA.d46.s115.e0 IEPA.d46.s115.e1	Amyloid	phospholipase C	[INST]Context: [PMID: 9202317 Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. The amyloid beta protein (25-35) stimulated appearance of 3H-inositol phosphates from [3H]inositol-prelabeled LA-N-2 cells was investigated. This stimulation was unaltered by extra- and intracellular calcium chelators in a calcium-free medium or by several protein kinase inhibitors. This phospholipase C stimulation by amyloid beta protein appeared to be pertussis toxin sensitive. It is possible that this phospholipase C stimulation by amyloid beta protein is a receptor-mediated process. This possibility is based on two related observations. The stimulation is ablated by the presence of conventional antagonists for metabotropic, adrenergic, and bombesin agonists. The IC50 values were 12 microM for propranolol, 15 microM for AP-3, and 25 nM for [Tyr4,D-Phe12]bombesin. Additional support comes from results of desensitization and resensitization experiments. Amyloid beta protein stimulation of phospholipase C was absent from LA-N-2 cells previously treated with norepinephrine, trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), bombesin, or amyloid beta peptide. In a similar manner, LA-N-2 cells previously treated with amyloid beta protein were no longer responsive to norepinephrine, t-ACPD, or bombesin. The responsiveness to amyloid beta protein returned, subsequent to a period of resensitization for the individual agonists. It is suggested that this observed amyloid beta protein stimulation of phospholipase C may be responsible for the elevated quantity of inositol seen in the brains of Alzheimer's disease patients.] Question: Based on the provided context, do the terms [Amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates phospholipase C in LA-N-2 cells. This stimulation is described as a receptor-mediated process and is sensitive to pertussis toxin, suggesting an interaction between the amyloid beta protein and the phospholipase C signaling pathway. The observed effects, such as the stimulation of phospholipase C and the desensitization experiments, clearly demonstrate that amyloid beta protein interacts with phospholipase C in a biological context.</s>
IEPA.d46 IEPA.d46.s116.e0 IEPA.d46.s116.e1	phospholipase C	amyloid	[INST]Context: [PMID: 9202317 Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. The amyloid beta protein (25-35) stimulated appearance of 3H-inositol phosphates from [3H]inositol-prelabeled LA-N-2 cells was investigated. This stimulation was unaltered by extra- and intracellular calcium chelators in a calcium-free medium or by several protein kinase inhibitors. This phospholipase C stimulation by amyloid beta protein appeared to be pertussis toxin sensitive. It is possible that this phospholipase C stimulation by amyloid beta protein is a receptor-mediated process. This possibility is based on two related observations. The stimulation is ablated by the presence of conventional antagonists for metabotropic, adrenergic, and bombesin agonists. The IC50 values were 12 microM for propranolol, 15 microM for AP-3, and 25 nM for [Tyr4,D-Phe12]bombesin. Additional support comes from results of desensitization and resensitization experiments. Amyloid beta protein stimulation of phospholipase C was absent from LA-N-2 cells previously treated with norepinephrine, trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), bombesin, or amyloid beta peptide. In a similar manner, LA-N-2 cells previously treated with amyloid beta protein were no longer responsive to norepinephrine, t-ACPD, or bombesin. The responsiveness to amyloid beta protein returned, subsequent to a period of resensitization for the individual agonists. It is suggested that this observed amyloid beta protein stimulation of phospholipase C may be responsible for the elevated quantity of inositol seen in the brains of Alzheimer's disease patients.] Question: Based on the provided context, do the terms [phospholipase C protein] and [amyloid protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates phospholipase C in LA-N-2 cells. This stimulation is described as a receptor-mediated process and is sensitive to pertussis toxin, suggesting an interaction between the amyloid beta protein and the phospholipase C pathway. The observed effects, such as the stimulation of phospholipase C and the desensitization experiments, clearly demonstrate that amyloid beta protein interacts with phospholipase C in a biological system.</s>
IEPA.d46 IEPA.d46.s117.e0 IEPA.d46.s117.e1	phospholipase C	amyloid	[INST]Context: [PMID: 9202317 Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. The amyloid beta protein (25-35) stimulated appearance of 3H-inositol phosphates from [3H]inositol-prelabeled LA-N-2 cells was investigated. This stimulation was unaltered by extra- and intracellular calcium chelators in a calcium-free medium or by several protein kinase inhibitors. This phospholipase C stimulation by amyloid beta protein appeared to be pertussis toxin sensitive. It is possible that this phospholipase C stimulation by amyloid beta protein is a receptor-mediated process. This possibility is based on two related observations. The stimulation is ablated by the presence of conventional antagonists for metabotropic, adrenergic, and bombesin agonists. The IC50 values were 12 microM for propranolol, 15 microM for AP-3, and 25 nM for [Tyr4,D-Phe12]bombesin. Additional support comes from results of desensitization and resensitization experiments. Amyloid beta protein stimulation of phospholipase C was absent from LA-N-2 cells previously treated with norepinephrine, trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), bombesin, or amyloid beta peptide. In a similar manner, LA-N-2 cells previously treated with amyloid beta protein were no longer responsive to norepinephrine, t-ACPD, or bombesin. The responsiveness to amyloid beta protein returned, subsequent to a period of resensitization for the individual agonists. It is suggested that this observed amyloid beta protein stimulation of phospholipase C may be responsible for the elevated quantity of inositol seen in the brains of Alzheimer's disease patients.] Question: Based on the provided context, do the terms [phospholipase C protein] and [amyloid protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates phospholipase C in LA-N-2 cells. This stimulation is described as a receptor-mediated process and is sensitive to pertussis toxin, suggesting an interaction between the amyloid beta protein and the phospholipase C pathway. The observed effects, such as the stimulation of phospholipase C and the desensitization experiments, clearly demonstrate that amyloid beta protein interacts with phospholipase C in a biological system.</s>
IEPA.d46 IEPA.d46.s118.e0 IEPA.d46.s118.e1	Amyloid	phospholipase C	[INST]Context: [PMID: 9202317 Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. The amyloid beta protein (25-35) stimulated appearance of 3H-inositol phosphates from [3H]inositol-prelabeled LA-N-2 cells was investigated. This stimulation was unaltered by extra- and intracellular calcium chelators in a calcium-free medium or by several protein kinase inhibitors. This phospholipase C stimulation by amyloid beta protein appeared to be pertussis toxin sensitive. It is possible that this phospholipase C stimulation by amyloid beta protein is a receptor-mediated process. This possibility is based on two related observations. The stimulation is ablated by the presence of conventional antagonists for metabotropic, adrenergic, and bombesin agonists. The IC50 values were 12 microM for propranolol, 15 microM for AP-3, and 25 nM for [Tyr4,D-Phe12]bombesin. Additional support comes from results of desensitization and resensitization experiments. Amyloid beta protein stimulation of phospholipase C was absent from LA-N-2 cells previously treated with norepinephrine, trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), bombesin, or amyloid beta peptide. In a similar manner, LA-N-2 cells previously treated with amyloid beta protein were no longer responsive to norepinephrine, t-ACPD, or bombesin. The responsiveness to amyloid beta protein returned, subsequent to a period of resensitization for the individual agonists. It is suggested that this observed amyloid beta protein stimulation of phospholipase C may be responsible for the elevated quantity of inositol seen in the brains of Alzheimer's disease patients.] Question: Based on the provided context, do the terms [Amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates phospholipase C in LA-N-2 cells. This stimulation is described as a receptor-mediated process and is sensitive to pertussis toxin, suggesting an interaction between the amyloid beta protein and the phospholipase C signaling pathway. The observed effects, such as the stimulation of phospholipase C and the desensitization experiments, clearly demonstrate that amyloid beta protein interacts with phospholipase C in a biological context.</s>
IEPA.d46 IEPA.d46.s119.e0 IEPA.d46.s119.e1	amyloid	phospholipase C	[INST]Context: [PMID: 9202317 Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. The amyloid beta protein (25-35) stimulated appearance of 3H-inositol phosphates from [3H]inositol-prelabeled LA-N-2 cells was investigated. This stimulation was unaltered by extra- and intracellular calcium chelators in a calcium-free medium or by several protein kinase inhibitors. This phospholipase C stimulation by amyloid beta protein appeared to be pertussis toxin sensitive. It is possible that this phospholipase C stimulation by amyloid beta protein is a receptor-mediated process. This possibility is based on two related observations. The stimulation is ablated by the presence of conventional antagonists for metabotropic, adrenergic, and bombesin agonists. The IC50 values were 12 microM for propranolol, 15 microM for AP-3, and 25 nM for [Tyr4,D-Phe12]bombesin. Additional support comes from results of desensitization and resensitization experiments. Amyloid beta protein stimulation of phospholipase C was absent from LA-N-2 cells previously treated with norepinephrine, trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD), bombesin, or amyloid beta peptide. In a similar manner, LA-N-2 cells previously treated with amyloid beta protein were no longer responsive to norepinephrine, t-ACPD, or bombesin. The responsiveness to amyloid beta protein returned, subsequent to a period of resensitization for the individual agonists. It is suggested that this observed amyloid beta protein stimulation of phospholipase C may be responsible for the elevated quantity of inositol seen in the brains of Alzheimer's disease patients.] Question: Based on the provided context, do the terms [amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that amyloid beta protein (25-35) stimulates phospholipase C in LA-N-2 cells. This stimulation is described as a receptor-mediated process and is sensitive to pertussis toxin, suggesting an interaction between the amyloid beta protein and the phospholipase C signaling pathway. The observed effects, such as the stimulation of phospholipase C and the desensitization experiments, clearly demonstrate that amyloid beta protein interacts with phospholipase C in a biological context.</s>
IEPA.d47 IEPA.d47.s120.e0 IEPA.d47.s120.e1	oxytocin	insulin	[INST]Context: [PMID: 9243706 Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep. The effects of the posterior-pituitary peptides oxytocin (OT), arginine-vasopressin (AVP) and lysine-vasopressin (LVP) on insulin and glucagon secretion were examined in adult sheep. Each peptide was injected intravenously at doses from 1 to 3000 pmol kg-1. All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them. The maximal insulin responses induced by OT and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of OT. OT and AVP had the same activity for stimulating glucagon secretion in respect of the threshold and maximal doses and the maximal hormone response. LVP also increased plasma insulin and glucagon concentrations, but it had the weakest activity for stimulating both hormones. These results suggest that in sheep posterior-pituitary peptide may play a role in regulating nutrient metabolism by influencing pancreatic hormone secretion.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) increases plasma insulin concentrations. This suggests that oxytocin has a direct effect on insulin secretion, implying an interaction between the oxytocin protein and the insulin protein. The study specifically mentions that OT increases plasma insulin and glucagon concentrations, demonstrating a clear interaction between these two proteins in the regulation of nutrient metabolism.</s>
IEPA.d47 IEPA.d47.s121.e0 IEPA.d47.s121.e1	oxytocin	insulin	[INST]Context: [PMID: 9243706 Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep. The effects of the posterior-pituitary peptides oxytocin (OT), arginine-vasopressin (AVP) and lysine-vasopressin (LVP) on insulin and glucagon secretion were examined in adult sheep. Each peptide was injected intravenously at doses from 1 to 3000 pmol kg-1. All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them. The maximal insulin responses induced by OT and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of OT. OT and AVP had the same activity for stimulating glucagon secretion in respect of the threshold and maximal doses and the maximal hormone response. LVP also increased plasma insulin and glucagon concentrations, but it had the weakest activity for stimulating both hormones. These results suggest that in sheep posterior-pituitary peptide may play a role in regulating nutrient metabolism by influencing pancreatic hormone secretion.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin (OT) increases plasma insulin concentrations. This suggests that oxytocin has a direct effect on insulin secretion, implying an interaction between the oxytocin protein and the insulin protein. The study specifically mentions that OT increases plasma insulin and glucagon concentrations, demonstrating a clear interaction between these two proteins in the regulation of nutrient metabolism.</s>
IEPA.d47 IEPA.d47.s122.e0 IEPA.d47.s122.e1	insulin	OT	[INST]Context: [PMID: 9243706 Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep. The effects of the posterior-pituitary peptides oxytocin (OT), arginine-vasopressin (AVP) and lysine-vasopressin (LVP) on insulin and glucagon secretion were examined in adult sheep. Each peptide was injected intravenously at doses from 1 to 3000 pmol kg-1. All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them. The maximal insulin responses induced by OT and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of OT. OT and AVP had the same activity for stimulating glucagon secretion in respect of the threshold and maximal doses and the maximal hormone response. LVP also increased plasma insulin and glucagon concentrations, but it had the weakest activity for stimulating both hormones. These results suggest that in sheep posterior-pituitary peptide may play a role in regulating nutrient metabolism by influencing pancreatic hormone secretion.] Question: Based on the provided context, do the terms [insulin protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) increases plasma insulin concentrations, suggesting that OT and insulin protein interact in the sense that OT influences the secretion of insulin. This interaction is part of the regulatory mechanism by which OT affects nutrient metabolism in sheep.</s>
IEPA.d47 IEPA.d47.s122.e2 IEPA.d47.s122.e3	insulin	OT	[INST]Context: [PMID: 9243706 Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep. The effects of the posterior-pituitary peptides oxytocin (OT), arginine-vasopressin (AVP) and lysine-vasopressin (LVP) on insulin and glucagon secretion were examined in adult sheep. Each peptide was injected intravenously at doses from 1 to 3000 pmol kg-1. All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them. The maximal insulin responses induced by OT and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of OT. OT and AVP had the same activity for stimulating glucagon secretion in respect of the threshold and maximal doses and the maximal hormone response. LVP also increased plasma insulin and glucagon concentrations, but it had the weakest activity for stimulating both hormones. These results suggest that in sheep posterior-pituitary peptide may play a role in regulating nutrient metabolism by influencing pancreatic hormone secretion.] Question: Based on the provided context, do the terms [insulin protein] and [OT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that oxytocin (OT) increases plasma insulin concentrations, suggesting that OT and insulin protein interact in the sense that OT influences the secretion of insulin. This interaction is part of the regulatory mechanism by which OT affects nutrient metabolism in sheep.</s>
IEPA.d49 IEPA.d49.s126.e0 IEPA.d49.s126.e1	Leptin	uncoupling protein-2	[INST]Context: [PMID: 9268716 Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Because troglitazone, like leptin, lowers the triglyceride (TG) content of pancreatic islets, we searched for other leptinomimetic actions. Leptin upregulates the expression of uncoupling protein-2 (UCP-2) mRNA in islets of normal rats, but has no effect in islets of obese Zucker Diabetic Fatty (ZDF) rats with mutated leptin receptors. We report here that troglitazone also increases the UCP-2/beta-actin mRNA ratio by 115% in wild type ZDF rats and by 400% in obese ZDF rats.] Question: Based on the provided context, do the terms [Leptin protein] and [uncoupling protein-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of troglitazone and leptin on the expression of uncoupling protein-2 (UCP-2) mRNA in pancreatic islets of rats. While it mentions that leptin upregulates UCP-2 mRNA in normal rats and troglitazone increases UCP-2 mRNA in both wild type and obese ZDF rats, there is no direct interaction mentioned between leptin protein and uncoupling protein-2 protein. Instead, the context describes the effects of these agents on the expression of UCP-2 mRNA, which is a separate entity from the proteins themselves. Therefore, based on the provided information, there is no direct interaction between leptin protein and uncoupling protein-2 protein.</s>
IEPA.d50 IEPA.d50.s127.e1 IEPA.d50.s127.e2	phospholipase C	insulin	[INST]Context: [PMID: 9276734 Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. Hypersecretion of insulin from the pancreas is among the earliest detectable metabolic alterations in some genetically obese animals including the ob/ob mouse and in some obesity-prone humans. Since the primary cause of obesity in the ob/ob mouse is a lack of leptin due to a mutation in the ob gene, we tested the hypothesis that leptin targets a regulatory pathway in pancreatic islets to prevent hypersecretion of insulin. Insulin secretion is regulated by changes in blood glucose, as well as by peptides from the gastrointestinal tract and neurotransmitters that activate the pancreatic islet adenylyl cyclase (e.g., glucagon-like peptide-1) and phospholipase C (PLC) (e.g., acetylcholine) signaling pathways to further potentiate glucose-induced insulin secretion. Effects of leptin on each of these regulatory pathways were thus examined. Leptin did not influence glucose or glucagon-like peptide-1-induced insulin secretion from islets of either ob/ob or lean mice, consistent with earlier findings that these regulatory pathways do not contribute to the early-onset hypersecretion of insulin from islets of ob/ob mice. However, leptin did constrain the enhanced PLC- mediated insulin secretion characteristic of islets from ob/ob mice, without influencing release from islets of lean mice. A specific enhancement in PLC-mediated insulin secretion is the earliest reported developmental alteration in insulin secretion from islets of ob/ob mice, and thus a logical target for leptin action. This action of leptin on PLC-mediated insulin secretion was dose-dependent, rapid-onset (i.e., within 3 min), and reversible. Leptin was equally effective in constraining the enhanced insulin release from islets of ob/ob mice caused by protein kinase C (PKC) activation, a downstream mediator of the PLC signal pathway. One function of leptin in control of body composition is thus to target a PKC-regulated component of the PLC-PKC signaling system within islets to prevent hypersecretion of insulin.] Question: Based on the provided context, do the terms [phospholipase C protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. This implies that acetylcholine activates the phospholipase C (PLC) signaling pathway, which in turn influences insulin secretion. Therefore, the phospholipase C protein and insulin protein interact within the regulatory pathway of insulin secretion.</s>
IEPA.d50 IEPA.d50.s128.e0 IEPA.d50.s128.e1	PLC	insulin	[INST]Context: [PMID: 9276734 Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. Hypersecretion of insulin from the pancreas is among the earliest detectable metabolic alterations in some genetically obese animals including the ob/ob mouse and in some obesity-prone humans. Since the primary cause of obesity in the ob/ob mouse is a lack of leptin due to a mutation in the ob gene, we tested the hypothesis that leptin targets a regulatory pathway in pancreatic islets to prevent hypersecretion of insulin. Insulin secretion is regulated by changes in blood glucose, as well as by peptides from the gastrointestinal tract and neurotransmitters that activate the pancreatic islet adenylyl cyclase (e.g., glucagon-like peptide-1) and phospholipase C (PLC) (e.g., acetylcholine) signaling pathways to further potentiate glucose-induced insulin secretion. Effects of leptin on each of these regulatory pathways were thus examined. Leptin did not influence glucose or glucagon-like peptide-1-induced insulin secretion from islets of either ob/ob or lean mice, consistent with earlier findings that these regulatory pathways do not contribute to the early-onset hypersecretion of insulin from islets of ob/ob mice. However, leptin did constrain the enhanced PLC- mediated insulin secretion characteristic of islets from ob/ob mice, without influencing release from islets of lean mice. A specific enhancement in PLC-mediated insulin secretion is the earliest reported developmental alteration in insulin secretion from islets of ob/ob mice, and thus a logical target for leptin action. This action of leptin on PLC-mediated insulin secretion was dose-dependent, rapid-onset (i.e., within 3 min), and reversible. Leptin was equally effective in constraining the enhanced insulin release from islets of ob/ob mice caused by protein kinase C (PKC) activation, a downstream mediator of the PLC signal pathway. One function of leptin in control of body composition is thus to target a PKC-regulated component of the PLC-PKC signaling system within islets to prevent hypersecretion of insulin.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. This implies that the PLC (phospholipase C) signaling pathway is involved in the regulation of insulin secretion. Specifically, the enhanced PLC-mediated insulin secretion characteristic of islets from ob/ob mice is constrained by leptin. This suggests that PLC protein and insulin protein interact within the signaling pathway to regulate insulin secretion.</s>
IEPA.d50 IEPA.d50.s129.e0 IEPA.d50.s129.e1	PLC	insulin	[INST]Context: [PMID: 9276734 Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. Hypersecretion of insulin from the pancreas is among the earliest detectable metabolic alterations in some genetically obese animals including the ob/ob mouse and in some obesity-prone humans. Since the primary cause of obesity in the ob/ob mouse is a lack of leptin due to a mutation in the ob gene, we tested the hypothesis that leptin targets a regulatory pathway in pancreatic islets to prevent hypersecretion of insulin. Insulin secretion is regulated by changes in blood glucose, as well as by peptides from the gastrointestinal tract and neurotransmitters that activate the pancreatic islet adenylyl cyclase (e.g., glucagon-like peptide-1) and phospholipase C (PLC) (e.g., acetylcholine) signaling pathways to further potentiate glucose-induced insulin secretion. Effects of leptin on each of these regulatory pathways were thus examined. Leptin did not influence glucose or glucagon-like peptide-1-induced insulin secretion from islets of either ob/ob or lean mice, consistent with earlier findings that these regulatory pathways do not contribute to the early-onset hypersecretion of insulin from islets of ob/ob mice. However, leptin did constrain the enhanced PLC- mediated insulin secretion characteristic of islets from ob/ob mice, without influencing release from islets of lean mice. A specific enhancement in PLC-mediated insulin secretion is the earliest reported developmental alteration in insulin secretion from islets of ob/ob mice, and thus a logical target for leptin action. This action of leptin on PLC-mediated insulin secretion was dose-dependent, rapid-onset (i.e., within 3 min), and reversible. Leptin was equally effective in constraining the enhanced insulin release from islets of ob/ob mice caused by protein kinase C (PKC) activation, a downstream mediator of the PLC signal pathway. One function of leptin in control of body composition is thus to target a PKC-regulated component of the PLC-PKC signaling system within islets to prevent hypersecretion of insulin.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. This implies that the PLC (phospholipase C) signaling pathway is involved in the regulation of insulin secretion. Specifically, the enhanced PLC-mediated insulin secretion characteristic of islets from ob/ob mice is constrained by leptin. This suggests that PLC protein and insulin protein interact within the signaling pathway to regulate insulin secretion.</s>
IEPA.d50 IEPA.d50.s130.e0 IEPA.d50.s130.e1	PLC	insulin	[INST]Context: [PMID: 9276734 Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. Hypersecretion of insulin from the pancreas is among the earliest detectable metabolic alterations in some genetically obese animals including the ob/ob mouse and in some obesity-prone humans. Since the primary cause of obesity in the ob/ob mouse is a lack of leptin due to a mutation in the ob gene, we tested the hypothesis that leptin targets a regulatory pathway in pancreatic islets to prevent hypersecretion of insulin. Insulin secretion is regulated by changes in blood glucose, as well as by peptides from the gastrointestinal tract and neurotransmitters that activate the pancreatic islet adenylyl cyclase (e.g., glucagon-like peptide-1) and phospholipase C (PLC) (e.g., acetylcholine) signaling pathways to further potentiate glucose-induced insulin secretion. Effects of leptin on each of these regulatory pathways were thus examined. Leptin did not influence glucose or glucagon-like peptide-1-induced insulin secretion from islets of either ob/ob or lean mice, consistent with earlier findings that these regulatory pathways do not contribute to the early-onset hypersecretion of insulin from islets of ob/ob mice. However, leptin did constrain the enhanced PLC- mediated insulin secretion characteristic of islets from ob/ob mice, without influencing release from islets of lean mice. A specific enhancement in PLC-mediated insulin secretion is the earliest reported developmental alteration in insulin secretion from islets of ob/ob mice, and thus a logical target for leptin action. This action of leptin on PLC-mediated insulin secretion was dose-dependent, rapid-onset (i.e., within 3 min), and reversible. Leptin was equally effective in constraining the enhanced insulin release from islets of ob/ob mice caused by protein kinase C (PKC) activation, a downstream mediator of the PLC signal pathway. One function of leptin in control of body composition is thus to target a PKC-regulated component of the PLC-PKC signaling system within islets to prevent hypersecretion of insulin.] Question: Based on the provided context, do the terms [PLC protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. This implies that the PLC (phospholipase C) signaling pathway is involved in the regulation of insulin secretion. Specifically, the enhanced PLC-mediated insulin secretion characteristic of islets from ob/ob mice is constrained by leptin. This suggests that PLC protein and insulin protein interact within the signaling pathway to regulate insulin secretion.</s>
IEPA.d51 IEPA.d51.s133.e0 IEPA.d51.s133.e1	Insulin	phospholipase C	[INST]Context: [PMID: 9291128 Insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase from 3T3-L1 adipocytes through the action of a phospholipase C. Membrane dipeptidase (MDP; EC 3.4.13.19) enzymic activity that was inhibited by cilastatin has been detected on the surface of 3T3-L1 cells. On differentiation of the cells from fibroblasts to adipocytes the activity of MDP increased 12-fold. Immunoelectrophoretic blot analysis indicated that on adipogenesis the increase in the amount of MDP preceded the appearance of GLUT-4. MDP on 3T3-L1 adipocytes was anchored in the bilayer by a glycosyl phosphatidylinositol (GPI) moiety as evidenced by its release into the medium in a hydrophilic form on treatment of the cells with bacterial phosphatidylinositol-specific phospholipase C and the appearance of the inositol 1,2-cyclic monophosphate cross-reacting determinant. Incubation of 3T3-L1 adipocytes with either insulin or the sulphonylurea glimepiride led to a rapid concentration- and time-dependent release of MDP from the cell surface. The hydrophilic form of MDP released from the cells on stimulation with insulin was recognized by antibodies against the inositol 1,2-cyclic monophosphate cross-reacting determinant, indicating that it had been generated by cleavage of its GPI anchor through the action of a phospholipase C.] Question: Based on the provided context, do the terms [Insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase (MDP) from 3T3-L1 adipocytes through the action of a phospholipase C. This suggests that insulin triggers a signaling pathway that involves the activation of phospholipase C, which in turn cleaves the GPI anchor of MDP, leading to its release. Therefore, insulin and phospholipase C interact in this process.</s>
IEPA.d51 IEPA.d51.s134.e0 IEPA.d51.s134.e1	insulin	phospholipase C	[INST]Context: [PMID: 9291128 Insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase from 3T3-L1 adipocytes through the action of a phospholipase C. Membrane dipeptidase (MDP; EC 3.4.13.19) enzymic activity that was inhibited by cilastatin has been detected on the surface of 3T3-L1 cells. On differentiation of the cells from fibroblasts to adipocytes the activity of MDP increased 12-fold. Immunoelectrophoretic blot analysis indicated that on adipogenesis the increase in the amount of MDP preceded the appearance of GLUT-4. MDP on 3T3-L1 adipocytes was anchored in the bilayer by a glycosyl phosphatidylinositol (GPI) moiety as evidenced by its release into the medium in a hydrophilic form on treatment of the cells with bacterial phosphatidylinositol-specific phospholipase C and the appearance of the inositol 1,2-cyclic monophosphate cross-reacting determinant. Incubation of 3T3-L1 adipocytes with either insulin or the sulphonylurea glimepiride led to a rapid concentration- and time-dependent release of MDP from the cell surface. The hydrophilic form of MDP released from the cells on stimulation with insulin was recognized by antibodies against the inositol 1,2-cyclic monophosphate cross-reacting determinant, indicating that it had been generated by cleavage of its GPI anchor through the action of a phospholipase C.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin stimulates the release of the glycosyl phosphatidylinositol-anchored membrane dipeptidase (MDP) from 3T3-L1 adipocytes through the action of a phospholipase C. This suggests that insulin triggers a signaling pathway that involves the activation of phospholipase C, which in turn cleaves the GPI anchor of MDP, leading to its release. Therefore, insulin and phospholipase C interact in this process.</s>
IEPA.d68 IEPA.d68.s169.e0 IEPA.d68.s169.e1	flavonoids	cholesterol	[INST]Context: [PMID: 9605437 Flavonoid-induced ability of minimally modified low-density lipoproteins to support lymphocyte proliferation. Low-density lipoprotein (LDL) peroxidation appears to be involved in atherogenesis. We studied the ability of minimally modified LDL (MM-LDL) to be used by proliferating lymphocytes and the effects of antioxidant flavonoids on this lipoprotein. MM-LDL were obtained by storing LDL at 4 degrees for 1 month, which resulted in a decrease in lipophilic antioxidants and an increased susceptibility to oxidation when incubated with cells. MM-LDL were not cytotoxic; however, in cells treated with lovastatin that require cholesterol for cell growth, they were much less efficient than fresh LDL in sustaining proliferation as determined by [3H]thymidine incorporation into DNA. Pure quercetin and grape-derived beverages restored proliferation in the presence of MM-LDL and prevented the apoptosis otherwise induced by lovastatin. These effects of flavonoids correlated with their activity in inhibiting LDL peroxidation. The results demonstrate that potent antioxidants, such as flavonoids, protect MM-LDL from lipoperoxidation and preserve their ability to efficiently deliver cholesterol to cells.] Question: Based on the provided context, do the terms [flavonoids protein] and [cholesterol protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms "flavonoids protein" and "cholesterol protein" do not interact with each other in the provided context. The context discusses the effects of flavonoids on the ability of minimally modified low-density lipoproteins (MM-LDL) to support lymphocyte proliferation and the role of cholesterol in this process. While flavonoids are mentioned to protect MM-LDL from lipoperoxidation and preserve their ability to deliver cholesterol to cells, there is no direct interaction described between flavonoids and cholesterol proteins. Instead, the focus is on the separate roles of flavonoids in protecting MM-LDL and the role of cholesterol in cell growth.</s>
IEPA.d78 IEPA.d78.s187.e0 IEPA.d78.s187.e1	PKC	AVP	[INST]Context: [PMID: 9666341 Arginine vasopressin inhibition of cytochrome P450c17 and testosterone production in mouse Leydig cells. The mechanism of arginine vasopressin (AVP) action in Leydig cells was investigated, and compared to the effects of phorbol-13-myristate-12-acetate (PMA) and interleukin-1 beta (IL-1 beta). Previous reports suggested that AVP inhibits Leydig cell testosterone production at the level of 17 alpha-hydroxylase/C17-lyase activity. The present study confirms and extends these observations, and contrasts the effects of AVP to IL-1. In all experiments, macrophage-depleted Leydig cells were isolated from mice and maintained in primary culture for 5 d prior to initiation of treatments. Leydig cells were treated with 8-Br-cAMP plus increasing concentrations of AVP or IL-1 beta. AVP caused a significant and dose-dependent inhibition of cAMP-stimulated testosterone production and P450c17 mRNA expression. IL-1 beta completely inhibited cAMP-stimulated testosterone production and P450c17 mRNA expression. PMA is a known activator of protein kinase C (PKC) and has been reported to inhibit Leydig cell steroidogenesis. Leydig cells express type V1 vasopressin receptors, which are coupled to PKC activation. The mechanism of IL-1 action in Leydig cells is not understood, but activation of the PKC pathway has been suggested for IL-1 action in other systems. Therefore, the effects of PMA on cAMP-stimulated steroidogenesis were compared to AVP and IL-1. Similar to the effects of AVP, PMA inhibited cAMP-stimulated testosterone production and P450c17 mRNA expression. To assess the possible involvement of PKC in AVP and IL-1 action in Leydig cells, the PKC inhibitor Calphostin C was tested. cAMP-stimulated testosterone production and P450c17 mRNA expression were significantly inhibited by 10 nM AVP (p < 0.05), and this inhibition was reversed by treatment with Calphostin C. Analogous experiments were performed to assess the role of PKC in IL-1 action. In contrast to the results for AVP, Calphostin C did not reverse the inhibitory effects of IL-1 on cAMP-stimulated P450c17 mRNA expression. To assess further PKC activation, myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation was analyzed. Only AVP and PMA, but not IL-1 beta, caused an increase in MARCKS phosphorylation. These results confirm that AVP and PMA activate PKC and indicate that IL-1 likely does not activate PKC in Leydig cells. The implications of AVP-mediated inhibition of steroidogenesis and potential role of MARCKS phosphorylation are discussed.] Question: Based on the provided context, do the terms [PKC protein] and [AVP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that arginine vasopressin (AVP) activates protein kinase C (PKC) in Leydig cells. Specifically, it mentions that AVP causes a significant and dose-dependent inhibition of cAMP-stimulated testosterone production and P450c17 mRNA expression, which is reversed by the PKC inhibitor Calphostin C. This suggests that AVP interacts with PKC to produce its effects on steroidogenesis in Leydig cells.</s>
IEPA.d78 IEPA.d78.s188.e0 IEPA.d78.s188.e1	AVP	PKC	[INST]Context: [PMID: 9666341 Arginine vasopressin inhibition of cytochrome P450c17 and testosterone production in mouse Leydig cells. The mechanism of arginine vasopressin (AVP) action in Leydig cells was investigated, and compared to the effects of phorbol-13-myristate-12-acetate (PMA) and interleukin-1 beta (IL-1 beta). Previous reports suggested that AVP inhibits Leydig cell testosterone production at the level of 17 alpha-hydroxylase/C17-lyase activity. The present study confirms and extends these observations, and contrasts the effects of AVP to IL-1. In all experiments, macrophage-depleted Leydig cells were isolated from mice and maintained in primary culture for 5 d prior to initiation of treatments. Leydig cells were treated with 8-Br-cAMP plus increasing concentrations of AVP or IL-1 beta. AVP caused a significant and dose-dependent inhibition of cAMP-stimulated testosterone production and P450c17 mRNA expression. IL-1 beta completely inhibited cAMP-stimulated testosterone production and P450c17 mRNA expression. PMA is a known activator of protein kinase C (PKC) and has been reported to inhibit Leydig cell steroidogenesis. Leydig cells express type V1 vasopressin receptors, which are coupled to PKC activation. The mechanism of IL-1 action in Leydig cells is not understood, but activation of the PKC pathway has been suggested for IL-1 action in other systems. Therefore, the effects of PMA on cAMP-stimulated steroidogenesis were compared to AVP and IL-1. Similar to the effects of AVP, PMA inhibited cAMP-stimulated testosterone production and P450c17 mRNA expression. To assess the possible involvement of PKC in AVP and IL-1 action in Leydig cells, the PKC inhibitor Calphostin C was tested. cAMP-stimulated testosterone production and P450c17 mRNA expression were significantly inhibited by 10 nM AVP (p < 0.05), and this inhibition was reversed by treatment with Calphostin C. Analogous experiments were performed to assess the role of PKC in IL-1 action. In contrast to the results for AVP, Calphostin C did not reverse the inhibitory effects of IL-1 on cAMP-stimulated P450c17 mRNA expression. To assess further PKC activation, myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation was analyzed. Only AVP and PMA, but not IL-1 beta, caused an increase in MARCKS phosphorylation. These results confirm that AVP and PMA activate PKC and indicate that IL-1 likely does not activate PKC in Leydig cells. The implications of AVP-mediated inhibition of steroidogenesis and potential role of MARCKS phosphorylation are discussed.] Question: Based on the provided context, do the terms [AVP protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that arginine vasopressin (AVP) activates protein kinase C (PKC) in Leydig cells. Specifically, it mentions that AVP causes a significant and dose-dependent inhibition of cAMP-stimulated testosterone production and P450c17 mRNA expression, which is reversed by the PKC inhibitor Calphostin C. This suggests that AVP interacts with PKC to produce its effects on steroidogenesis in Leydig cells.</s>
IEPA.d95 IEPA.d95.s229.e0 IEPA.d95.s229.e1	arginine-vasopressin	PKC	[INST]Context: [PMID: 9878732 Distribution of Ca2+-dependent protein kinase C isoforms in the suprachiasmatic nucleus of the diurnal murid rodent, Arvicanthis niloticus. The suprachiasmatic nuclei (SCN) contain the major 'biological clock' in mammals that controls most circadian rhythms expressed by these animals. The functional importance of protein phosphorylation and intracellular Ca2+ in the mammalian circadian pacemaker is becoming increasingly apparent. Here we report the immunocytochemical localization of the four Ca2+-dependent protein kinase C (PKC) isoforms (alpha, betaI, betaII, gamma) within the SCN of the diurnal murid rodent, Arvicanthis niloticus, and the nocturnal golden hamster. In the SCN of A. niloticus, PKCalpha was the most abundant of the four isoforms. Cells containing PKCalpha were homogeneously distributed throughout the SCN. PKCbetaI cells were sparsely distributed in the perimeter of the SCN and were absent in its central area. PKCbetaII and -gamma were not found in the SCN of A. niloticus. In the SCN of the golden hamster, PKCalpha cells were most heavily concentrated in the dorsomedial region, though some were also present laterally and ventrally. The distribution of arginine-vasopressin (AVP) cells in the SCN overlapped with that of PKC in both species. Species differences in the location of the Ca2+-dependent PKC isoforms suggest differences in function such as the relaying of photic or non-photic information to the clock mechanism, or the synchronization of AVP neurons and their subsequent output signals.] Question: Based on the provided context, do the terms [arginine-vasopressin protein] and [PKC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the distribution of arginine-vasopressin (AVP) cells in the suprachiasmatic nuclei (SCN) overlaps with that of protein kinase C (PKC) in both the diurnal murid rodent, Arvicanthis niloticus, and the nocturnal golden hamster. This suggests that there is a functional interaction between AVP and PKC in the SCN, as the presence of one is associated with the presence of the other. This overlap in distribution implies that AVP and PKC may interact in the relaying of photic or non-photic information to the clock mechanism or in the synchronization of AVP neurons and their subsequent output signals.</s>
IEPA.d103 IEPA.d103.s242.e0 IEPA.d103.s242.e1	insulin	oxytocin	[INST]Context: [PMID: 10026817 The molecular basis of oxytocin and oxytocin receptor gene expression in reproductive tissues. Transcriptional regulation of the oxytocin and oxytocin receptor genes underly to a large degree the highly specific and often transient physiologies associated with this peptide hormone system. Using a variety of homologous transcription assays we have endeavoured to identify and characterize the cis and trans elements responsible for the regulation in vivo of the oxytocin peptide gene and the gene for the oxytocin receptor. The bovine ovarian granulosa cell model is a primary culture system where under stimulation by insulin or IGF-I and LH the endogenous oxytocin gene is massively upregulated. We have identified a proximal response element at -160, which in vivo binds the competing nuclear receptors, SF1 and COUP-TF. Additionally ovarian specific transcription factors bind at two additional sites in the distal promoter region. For the bovine oxytocin receptor gene, we have taken advantage of the high endogenous expression of the receptor in the endometrium of the estrous cycle. Using a combination of primary cell culture techniques and in vitro binding of nuclear protein extracts from tissues expressing the receptor in vivo, we have shown there to be a combination of constitutive and inhibitory elements controlling oxytocin receptor gene expression. Similar results were obtained for the human oxytocin receptor gene. At birth there may additionally be a specific stimulatory effect on transcription in the myometrium.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the transcriptional regulation of the oxytocin and oxytocin receptor genes in reproductive tissues, specifically mentioning the role of insulin and IGF-I in upregulating the endogenous oxytocin gene in bovine ovarian granulosa cells. However, there is no direct interaction mentioned between insulin protein and oxytocin protein. Instead, insulin is described as a factor that stimulates the expression of the oxytocin gene, but not as interacting directly with the oxytocin protein itself.</s>
IEPA.d108 IEPA.d108.s251.e0 IEPA.d108.s251.e1	insulin	oxytocin	[INST]Context: [PMID: 10087452 Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment. The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose. Since oxytocin may enhance the activity of centrally located alpha2-adrenoreceptors, a second aim of this study was to explore whether these receptors are involved in the effects. For this purpose, oxytocin (1.0 mg/kg) or NaCl was given subcutaneously (s.c.) once a day during 5 days to male rats. Rats were decapitated 1, 3 and 10 days after the last injection, blood was collected and hormone levels were radioimmunoassayed. The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment. Gastrin levels were decreased on day 1, 3 and 10 (ANOVA; p < 0.01). In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05). When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only. No change in glucose or somatostatin levels was found in response to the oxytocin treatment. In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels. These effects may be mediated by changes in vagal nerve activity.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin treatment leads to changes in plasma levels of insulin, suggesting an interaction between oxytocin and insulin. Specifically, the oxytocin treatment caused a decrease in insulin levels, which is a direct effect of oxytocin on insulin levels. This indicates that oxytocin and insulin interact in a way that influences each other's levels in the body.</s>
IEPA.d108 IEPA.d108.s252.e0 IEPA.d108.s252.e1	oxytocin	insulin	[INST]Context: [PMID: 10087452 Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment. The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose. Since oxytocin may enhance the activity of centrally located alpha2-adrenoreceptors, a second aim of this study was to explore whether these receptors are involved in the effects. For this purpose, oxytocin (1.0 mg/kg) or NaCl was given subcutaneously (s.c.) once a day during 5 days to male rats. Rats were decapitated 1, 3 and 10 days after the last injection, blood was collected and hormone levels were radioimmunoassayed. The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment. Gastrin levels were decreased on day 1, 3 and 10 (ANOVA; p < 0.01). In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05). When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only. No change in glucose or somatostatin levels was found in response to the oxytocin treatment. In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels. These effects may be mediated by changes in vagal nerve activity.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin treatment leads to a decrease in plasma levels of insulin. This suggests that oxytocin and insulin interact in a way that affects each other's levels in the body. Specifically, oxytocin influences the activity of the vagal nerve, which in turn affects the release of insulin. Therefore, the terms "oxytocin protein" and "insulin protein" are interacting in the sense that oxytocin treatment has a direct impact on the levels of insulin.</s>
IEPA.d108 IEPA.d108.s253.e0 IEPA.d108.s253.e1	insulin	oxytocin	[INST]Context: [PMID: 10087452 Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment. The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose. Since oxytocin may enhance the activity of centrally located alpha2-adrenoreceptors, a second aim of this study was to explore whether these receptors are involved in the effects. For this purpose, oxytocin (1.0 mg/kg) or NaCl was given subcutaneously (s.c.) once a day during 5 days to male rats. Rats were decapitated 1, 3 and 10 days after the last injection, blood was collected and hormone levels were radioimmunoassayed. The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment. Gastrin levels were decreased on day 1, 3 and 10 (ANOVA; p < 0.01). In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05). When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only. No change in glucose or somatostatin levels was found in response to the oxytocin treatment. In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels. These effects may be mediated by changes in vagal nerve activity.] Question: Based on the provided context, do the terms [insulin protein] and [oxytocin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin treatment leads to changes in plasma levels of insulin, suggesting an interaction between oxytocin and insulin. Specifically, the oxytocin treatment caused a decrease in insulin levels, which is a direct effect of oxytocin on insulin levels. This indicates that oxytocin and insulin interact in a way that influences each other's levels in the body.</s>
IEPA.d108 IEPA.d108.s255.e0 IEPA.d108.s255.e1	oxytocin	insulin	[INST]Context: [PMID: 10087452 Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment. The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose. Since oxytocin may enhance the activity of centrally located alpha2-adrenoreceptors, a second aim of this study was to explore whether these receptors are involved in the effects. For this purpose, oxytocin (1.0 mg/kg) or NaCl was given subcutaneously (s.c.) once a day during 5 days to male rats. Rats were decapitated 1, 3 and 10 days after the last injection, blood was collected and hormone levels were radioimmunoassayed. The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment. Gastrin levels were decreased on day 1, 3 and 10 (ANOVA; p < 0.01). In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05). When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only. No change in glucose or somatostatin levels was found in response to the oxytocin treatment. In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels. These effects may be mediated by changes in vagal nerve activity.] Question: Based on the provided context, do the terms [oxytocin protein] and [insulin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that oxytocin treatment leads to a decrease in plasma levels of insulin. This suggests that oxytocin and insulin interact in a way that affects each other's levels in the body. Specifically, oxytocin influences the activity of the vagal nerve, which in turn affects the release of insulin. Therefore, the terms "oxytocin protein" and "insulin protein" are interacting in the sense that oxytocin treatment has a direct impact on the levels of insulin.</s>
IEPA.d110 IEPA.d110.s264.e0 IEPA.d110.s264.e1	arginine vasopressin	protein kinase C	[INST]Context: [PMID: 10098498 Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase. The mechanism of arginine vasopressin (AVP)-induced arachidonic acid (AA) release was examined in the cardiac myoblast cell line, H9c2. Stimulation of cells with AVP induced dose-dependent AA release, and this effect was completely inhibited by the V1 receptor antagonist, d(CH)5[Tyr(Me)2]AVP. AVP also produced dose-dependent stimulation of inositol phosphate formation; this was not affected by pertussis toxin, indicating the presence of the V1 receptor/Gq protein/PLCbeta pathway in H9c2 cells. The concentration-response curves for these two effects of AVP overlapped. AVP induced a rapid increase in [Ca2+]i, followed by a sustained increase. The Ca2+ ionophore, A23187 or ionomycin, mimicked the effect of AVP, whereas the protein kinase C (PKC) activator, TPA, only induced a slight increase in AA release. Both the AVP- or A23187-stimulated AA release and the AVP-induced sustained [Ca2+]i increase were completely blocked in the absence of external Ca2+. The receptor-operated Ca2+ channel blocker, SKF 96365, and the inorganic Ca2+ channel blockers, Ca2+ and Ni2+, also inhibited the AVP-induced AA release. Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms. AVP-induced, but not A23187-induced, AA release was partially blocked by the p42 MAPK cascade inhibitor, PD 98059. AVP and TPA, but not A23187, induced an increase in activity and tyrosine phosphorylation of p42 MAPK, together with a molecular weight shift, consistent with phosphorylation, of cytosolic PLA2. AVP- or TPA-induced activation and tyrosine phosphorylation of p42 MAPK were completely blocked by down-regulation of PKCalpha, betaI, epsilon, and delta, but still occurred, together with the cytosolic PLA2 mobility shift, in the absence of external Ca2+. These results show that AVP-induced AA release in H9c2 cells is secondary to activation of the V1 receptor/Gq protein/PLCP pathway, leading to an influx of extracellular Ca2+ and activation of PKCalpha, betaI, epsilon, and delta. The influx of extracellular Ca2- and DAG act, respectively, through PKC-/MAPK-independent or PKC-dependent MAPK pathways to mediate AA release.] Question: Based on the provided context, do the terms [arginine vasopressin protein] and [protein kinase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that arginine vasopressin (AVP) induces the activation of protein kinase C (PKC) in H9c2 cardiac myoblasts. Specifically, AVP stimulates the V1 receptor/Gq protein/PLCbeta pathway, leading to an influx of extracellular Ca2+ and activation of PKC isoforms. This activation of PKC is crucial for the downstream effects of AVP, including the release of arachidonic acid. Therefore, the terms "arginine vasopressin protein" and "protein kinase C protein" interact with each other in the signaling pathway described.</s>
IEPA.d110 IEPA.d110.s267.e0 IEPA.d110.s267.e1	AVP	PKCalpha	[INST]Context: [PMID: 10098498 Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase. The mechanism of arginine vasopressin (AVP)-induced arachidonic acid (AA) release was examined in the cardiac myoblast cell line, H9c2. Stimulation of cells with AVP induced dose-dependent AA release, and this effect was completely inhibited by the V1 receptor antagonist, d(CH)5[Tyr(Me)2]AVP. AVP also produced dose-dependent stimulation of inositol phosphate formation; this was not affected by pertussis toxin, indicating the presence of the V1 receptor/Gq protein/PLCbeta pathway in H9c2 cells. The concentration-response curves for these two effects of AVP overlapped. AVP induced a rapid increase in [Ca2+]i, followed by a sustained increase. The Ca2+ ionophore, A23187 or ionomycin, mimicked the effect of AVP, whereas the protein kinase C (PKC) activator, TPA, only induced a slight increase in AA release. Both the AVP- or A23187-stimulated AA release and the AVP-induced sustained [Ca2+]i increase were completely blocked in the absence of external Ca2+. The receptor-operated Ca2+ channel blocker, SKF 96365, and the inorganic Ca2+ channel blockers, Ca2+ and Ni2+, also inhibited the AVP-induced AA release. Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms. AVP-induced, but not A23187-induced, AA release was partially blocked by the p42 MAPK cascade inhibitor, PD 98059. AVP and TPA, but not A23187, induced an increase in activity and tyrosine phosphorylation of p42 MAPK, together with a molecular weight shift, consistent with phosphorylation, of cytosolic PLA2. AVP- or TPA-induced activation and tyrosine phosphorylation of p42 MAPK were completely blocked by down-regulation of PKCalpha, betaI, epsilon, and delta, but still occurred, together with the cytosolic PLA2 mobility shift, in the absence of external Ca2+. These results show that AVP-induced AA release in H9c2 cells is secondary to activation of the V1 receptor/Gq protein/PLCP pathway, leading to an influx of extracellular Ca2+ and activation of PKCalpha, betaI, epsilon, and delta. The influx of extracellular Ca2- and DAG act, respectively, through PKC-/MAPK-independent or PKC-dependent MAPK pathways to mediate AA release.] Question: Based on the provided context, do the terms [AVP protein] and [PKCalpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that arginine vasopressin (AVP) induces the activation of protein kinase C (PKC) isoforms, including PKCalpha, betaI, epsilon, and delta, which in turn leads to the release of arachidonic acid (AA). Specifically, the activation of PKCalpha, betaI, epsilon, and delta is mediated by the V1 receptor/Gq protein/PLCbeta pathway, which is stimulated by AVP. This suggests that AVP protein and PKCalpha protein interact in a signaling pathway where AVP triggers the activation of PKCalpha, leading to downstream effects.</s>
IEPA.d110 IEPA.d110.s268.e0 IEPA.d110.s268.e1	AVP	PKCalpha	[INST]Context: [PMID: 10098498 Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase. The mechanism of arginine vasopressin (AVP)-induced arachidonic acid (AA) release was examined in the cardiac myoblast cell line, H9c2. Stimulation of cells with AVP induced dose-dependent AA release, and this effect was completely inhibited by the V1 receptor antagonist, d(CH)5[Tyr(Me)2]AVP. AVP also produced dose-dependent stimulation of inositol phosphate formation; this was not affected by pertussis toxin, indicating the presence of the V1 receptor/Gq protein/PLCbeta pathway in H9c2 cells. The concentration-response curves for these two effects of AVP overlapped. AVP induced a rapid increase in [Ca2+]i, followed by a sustained increase. The Ca2+ ionophore, A23187 or ionomycin, mimicked the effect of AVP, whereas the protein kinase C (PKC) activator, TPA, only induced a slight increase in AA release. Both the AVP- or A23187-stimulated AA release and the AVP-induced sustained [Ca2+]i increase were completely blocked in the absence of external Ca2+. The receptor-operated Ca2+ channel blocker, SKF 96365, and the inorganic Ca2+ channel blockers, Ca2+ and Ni2+, also inhibited the AVP-induced AA release. Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms. AVP-induced, but not A23187-induced, AA release was partially blocked by the p42 MAPK cascade inhibitor, PD 98059. AVP and TPA, but not A23187, induced an increase in activity and tyrosine phosphorylation of p42 MAPK, together with a molecular weight shift, consistent with phosphorylation, of cytosolic PLA2. AVP- or TPA-induced activation and tyrosine phosphorylation of p42 MAPK were completely blocked by down-regulation of PKCalpha, betaI, epsilon, and delta, but still occurred, together with the cytosolic PLA2 mobility shift, in the absence of external Ca2+. These results show that AVP-induced AA release in H9c2 cells is secondary to activation of the V1 receptor/Gq protein/PLCP pathway, leading to an influx of extracellular Ca2+ and activation of PKCalpha, betaI, epsilon, and delta. The influx of extracellular Ca2- and DAG act, respectively, through PKC-/MAPK-independent or PKC-dependent MAPK pathways to mediate AA release.] Question: Based on the provided context, do the terms [AVP protein] and [PKCalpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that arginine vasopressin (AVP) induces the activation of protein kinase C (PKC) isoforms, including PKCalpha, betaI, epsilon, and delta, which in turn leads to the release of arachidonic acid (AA). Specifically, the activation of PKCalpha, betaI, epsilon, and delta is mediated by the V1 receptor/Gq protein/PLCbeta pathway, which is stimulated by AVP. This suggests that AVP protein and PKCalpha protein interact in a signaling pathway where AVP triggers the activation of PKCalpha, leading to downstream effects.</s>
IEPA.d115 IEPA.d115.s278.e0 IEPA.d115.s278.e1	insulin	phospholipases C	[INST]Context: [PMID: 10331408 Overexpression of G11alpha and isoforms of phospholipase C in islet beta-cells reveals a lack of correlation between inositol phosphate accumulation and insulin secretion. It has been suggested that insulin secretion from pancreatic islets may be mediated in part by activation of phospholipases C (PLCs) and phosphoinositide hydrolysis. The purpose of this study was to determine whether the relatively modest fuel-stimulated insulin secretion responses of rodent beta-cell lines might be explained by inadequate expression or activation of PLC isoforms. We have found that two insulinoma cell lines, INS-1 and betaG 40/110, completely lack PLC-delta1 expression but have levels of expression of PLC-beta1, -beta2, -beta3, -delta2, and -gamma1 that are similar to or slightly reduced from those found in fresh rat islets. Adenovirus-mediated overexpression of PLC-delta1, -beta1, or -beta3 in INS-1 or betaG 40/110 cells results in little or no enhancement in inositol phosphate (IP) accumulation and no improvement in insulin secretion when the cells are stimulated with glucose or carbachol, despite the fact that the overexpressed proteins are fully active in cell extracts. Overexpression of PLC-beta1 or -beta3 in normal rat islets elicits a larger increase in IP accumulation but, again, has no effect on insulin secretion. Because the effect of carbachol on insulin secretion is thought to be mediated through muscarinic receptors that link to the Gq/11 class of heterotrimeric G proteins, we also overexpressed G11alpha in INS-1 cells, either alone or in concert with overexpression of PLC-beta1 or -beta3. Overexpression of G11alpha enhances IP accumulation, an effect slightly potentiated by co-overexpression of PLC-beta1 or -beta3, but these maneuvers do not affect glucose or carbachol-stimulated insulin secretion. In sum, our studies show a lack of correlation between IP accumulation and insulin secretion in INS-1 cells, betaG 40/110 cells, or cultured rat islets. We conclude that overexpression of PLC isoforms and/or G11alpha is not an effective means of enhancing fuel responsiveness in the insulinoma cell lines studied.] Question: Based on the provided context, do the terms [insulin protein] and [phospholipases C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the overexpression of phospholipase C (PLC) isoforms and G11alpha in islet beta-cells was studied to determine their effect on insulin secretion. While the overexpression of these proteins did not significantly enhance insulin secretion, it suggests that there is a potential interaction between the phospholipase C protein and the insulin protein. The study implies that the activation of phospholipase C and subsequent inositol phosphate accumulation could be involved in the signaling pathways that ultimately lead to insulin secretion. Therefore, the terms "insulin protein" and "phospholipases C protein" are interacting in the sense that they are part of the same signaling pathway that regulates insulin secretion.</s>
IEPA.d115 IEPA.d115.s279.e0 IEPA.d115.s279.e1	insulin	PLC	[INST]Context: [PMID: 10331408 Overexpression of G11alpha and isoforms of phospholipase C in islet beta-cells reveals a lack of correlation between inositol phosphate accumulation and insulin secretion. It has been suggested that insulin secretion from pancreatic islets may be mediated in part by activation of phospholipases C (PLCs) and phosphoinositide hydrolysis. The purpose of this study was to determine whether the relatively modest fuel-stimulated insulin secretion responses of rodent beta-cell lines might be explained by inadequate expression or activation of PLC isoforms. We have found that two insulinoma cell lines, INS-1 and betaG 40/110, completely lack PLC-delta1 expression but have levels of expression of PLC-beta1, -beta2, -beta3, -delta2, and -gamma1 that are similar to or slightly reduced from those found in fresh rat islets. Adenovirus-mediated overexpression of PLC-delta1, -beta1, or -beta3 in INS-1 or betaG 40/110 cells results in little or no enhancement in inositol phosphate (IP) accumulation and no improvement in insulin secretion when the cells are stimulated with glucose or carbachol, despite the fact that the overexpressed proteins are fully active in cell extracts. Overexpression of PLC-beta1 or -beta3 in normal rat islets elicits a larger increase in IP accumulation but, again, has no effect on insulin secretion. Because the effect of carbachol on insulin secretion is thought to be mediated through muscarinic receptors that link to the Gq/11 class of heterotrimeric G proteins, we also overexpressed G11alpha in INS-1 cells, either alone or in concert with overexpression of PLC-beta1 or -beta3. Overexpression of G11alpha enhances IP accumulation, an effect slightly potentiated by co-overexpression of PLC-beta1 or -beta3, but these maneuvers do not affect glucose or carbachol-stimulated insulin secretion. In sum, our studies show a lack of correlation between IP accumulation and insulin secretion in INS-1 cells, betaG 40/110 cells, or cultured rat islets. We conclude that overexpression of PLC isoforms and/or G11alpha is not an effective means of enhancing fuel responsiveness in the insulinoma cell lines studied.] Question: Based on the provided context, do the terms [insulin protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the overexpression of PLC isoforms and G11alpha in pancreatic beta-cells does not enhance insulin secretion. This suggests that while PLC proteins are involved in the signaling pathways that may influence insulin secretion, there is no direct interaction between the insulin protein and the PLC protein. Instead, the study focuses on the role of PLC isoforms in the signaling pathways that lead to insulin secretion, rather than a direct interaction between the insulin protein and the PLC protein.</s>
IEPA.d116 IEPA.d116.s284.e0 IEPA.d116.s284.e1	GA	amylase	[INST]Context: [PMID: 10364387 The sensitivity of barley aleurone tissue to gibberellin is heterogeneous and may Be spatially determined. In cereals, gibberellin (GA) enhances the synthesis and secretion of hydrolytic enzymes from aleurone cells. These enzymes then mobilize the endosperm storage reserves that fuel germination. The dose-response curve of aleurone protoplasts to GA extends over a range of concentrations from 10(-11) to more than 10(-6) M. One hypothesis is that subpopulations of cells have different sensitivities to GA, with each cell having a threshold concentration of GA above which it is switched on. The dose-response curve therefore reflects a gradual recruitment of cells to the pool exhibiting a full GA response. Alternatively, all cells may gradually increase their responses as the GA level is increased. In the present study we found that at increasing GA concentrations, increasing numbers of barley (Hordeum vulgare) cells showed the enhanced amylase secretion and vacuolation characteristic of the GA response. We also observed that the region of aleurone tissue closest to the embryo contains the highest proportion of cells activated at the GA concentrations thought to occur naturally in germinating grain. These data indicate that an aleurone layer contains cells of varying sensitivities to GA and that recruitment of these differentially responding pools of cells may explain the broad dose response to GA.] Question: Based on the provided context, do the terms [GA protein] and [amylase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that gibberellin (GA) enhances the synthesis and secretion of hydrolytic enzymes, including amylase, from aleurone cells. This suggests that GA protein interacts with amylase protein in the sense that GA triggers the production and secretion of amylase. The increased synthesis and secretion of amylase in response to GA demonstrate a direct interaction between the two proteins.</s>
IEPA.d135 IEPA.d135.s323.e0 IEPA.d135.s323.e1	insulin	PLC	[INST]Context: [PMID: 10615945 Role of adenosine in insulin-stimulated release of leptin from isolated white adipocytes of Wistar rats. Leptin, the ob gene product that can decrease caloric intake and increase energy expenditure, is functionally released by insulin from adipose tissue. Adenosine is thought to be an important regulator of the action of insulin in adipose tissue. The present study investigated the role of adenosine in the release of leptin by insulin in isolated rat white adipocytes. Release of leptin, measured by radioimmunoassay, from insulin-stimulated samples was seen after 30 min. Adenosine deaminase, at concentrations sufficient to metabolize endogenous adenosine, decreased insulin-stimulated leptin release. Also, the insulin-stimulated leptin release was completely blocked by the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). Mediation of endogenous adenosine in this action of insulin was further supported by the assay of adenosine released into the medium from adipocytes stimulated with insulin. In addition, activation of adenosine A1 receptors by N6-cyclopentyladenosine (CPA) induced an increase in leptin release in a concentration-dependent manner that could be blocked by antagonists, either DPCPX or 8-(p-sulfophenyl)theophylline (8-SPT). In the presence of U73312, a specific inhibitor of phospholipase C (PLC), CPA-stimulated leptin secretion from adipocytes was reduced in a concentration-dependent manner, but it was not affected by U73343, the negative control for U73312. Moreover, chelerythrine and GF 109203X diminished the CPA-stimulated leptin secretion at concentrations sufficient to inhibit protein kinase C (PKC). These results suggest that, in isolated white adipocytes, the released adenosine acts as a helper and/or a positive regulator for insulin in the release of leptin via an activation of adenosine A1 receptors that involves the PLC-PKC pathway.] Question: Based on the provided context, do the terms [insulin protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that insulin stimulates the release of leptin from isolated white adipocytes, and this process involves the activation of adenosine A1 receptors via the PLC-PKC pathway. Specifically, the activation of adenosine A1 receptors by N6-cyclopentyladenosine (CPA) induces an increase in leptin release, which is mediated through the PLC-PKC pathway. This suggests that insulin and PLC protein interact in the pathway leading to leptin release.</s>
IEPA.d145 IEPA.d145.s346.e0 IEPA.d145.s346.e1	amyloid	phospholipase C	[INST]Context: [PMID: 10786701 Aggregated beta amyloid peptide 1-40 decreases Ca2+- and cholinergic receptor-mediated phosphoinositide degradation by alteration of membrane and cytosolic phospholipase C in brain cortex. The effects of full-length amyloid beta protein, A(beta) (1-40), on phosphoinositide-specific phospholipase C (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats. Moreover, the role of A(beta) (1-40) on the activation of lipid peroxidation was evaluated. The activity of phospholipase C (PLC) acting on phosphatidylinositol (PI) and phosphatidylinositol-4,5-bisphosphate (PIP2) was determined using exogenous labeled substrates. The subcellular fractions were the source of enzyme(s). The radioactivity of lipid messengers derived from degradation of [14C- arachidonoyl] PI was also determined. The stable aggregated form of beta-amyloid peptide (1-40) at 25 microM concentration exerted reproducible effects. The aggregated form of A(beta) (1-40) inhibited Ca(2+)-regulated PI and PIP2 degradation by SPM and cytosolic enzymes. Aggregated A(beta) also decreased significantly the level of diacylglycerol, the product of PLC. This additionally supports the inhibitory effect of A(beta) on membrane-bound and cytosolic PLC. Moreover, A(beta) (1-40) significantly decreased the basal activity of the PIP2-PLC in SPM and the enzyme activity regulated through cholinergic receptors. However, in spite of the lower enzyme activity, the percentage distribution of inositol (1,4,5) P3 radioactivity (IP3) in the total pool of inositol metabolites was not significantly changed. The aggregated neurotoxic fragment, A(beta) (25-35), mimicked the effect of full-length A(beta) (1-40). A(beta) (1-40) enhanced the level of malondialdehyde indicating an activation of free radical stimulated membrane lipid peroxidation that may be involved in alteration of phospholipase(s) activity. Our results indicated that aggregated A(beta) (1-40) alters Ca(2+)-dependent phosphoinositide degradation affecting synaptic plasma membrane and cytosolic phospholipase(s) activity. Moreover, this peptide significantly decreased the phosphoinositide-dependent signal transduction mediated by cholinergic receptors. The effect of aggregated A(beta) (1-40) is more pronounced than that of the neurotoxic fragment A(beta) (25-35). Our study suggests that the deposition of aggregated A(beta) may alter phosphoinositide signaling in brain.] Question: Based on the provided context, do the terms [amyloid protein] and [phospholipase C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that aggregated amyloid beta protein (A\) (1-40) significantly affects the activity of phospholipase C (PLC). Specifically, it inhibits Ca2+-regulated PI and PIP2 degradation by both membrane-bound and cytosolic enzymes. This suggests a direct interaction between the amyloid protein and the phospholipase C protein, as the presence of A\ (1-40) alters the activity of PLC, thereby impacting phosphoinositide signaling in the brain.</s>
IEPA.d145 IEPA.d145.s349.e0 IEPA.d145.s349.e1	A(beta)	PLC	[INST]Context: [PMID: 10786701 Aggregated beta amyloid peptide 1-40 decreases Ca2+- and cholinergic receptor-mediated phosphoinositide degradation by alteration of membrane and cytosolic phospholipase C in brain cortex. The effects of full-length amyloid beta protein, A(beta) (1-40), on phosphoinositide-specific phospholipase C (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats. Moreover, the role of A(beta) (1-40) on the activation of lipid peroxidation was evaluated. The activity of phospholipase C (PLC) acting on phosphatidylinositol (PI) and phosphatidylinositol-4,5-bisphosphate (PIP2) was determined using exogenous labeled substrates. The subcellular fractions were the source of enzyme(s). The radioactivity of lipid messengers derived from degradation of [14C- arachidonoyl] PI was also determined. The stable aggregated form of beta-amyloid peptide (1-40) at 25 microM concentration exerted reproducible effects. The aggregated form of A(beta) (1-40) inhibited Ca(2+)-regulated PI and PIP2 degradation by SPM and cytosolic enzymes. Aggregated A(beta) also decreased significantly the level of diacylglycerol, the product of PLC. This additionally supports the inhibitory effect of A(beta) on membrane-bound and cytosolic PLC. Moreover, A(beta) (1-40) significantly decreased the basal activity of the PIP2-PLC in SPM and the enzyme activity regulated through cholinergic receptors. However, in spite of the lower enzyme activity, the percentage distribution of inositol (1,4,5) P3 radioactivity (IP3) in the total pool of inositol metabolites was not significantly changed. The aggregated neurotoxic fragment, A(beta) (25-35), mimicked the effect of full-length A(beta) (1-40). A(beta) (1-40) enhanced the level of malondialdehyde indicating an activation of free radical stimulated membrane lipid peroxidation that may be involved in alteration of phospholipase(s) activity. Our results indicated that aggregated A(beta) (1-40) alters Ca(2+)-dependent phosphoinositide degradation affecting synaptic plasma membrane and cytosolic phospholipase(s) activity. Moreover, this peptide significantly decreased the phosphoinositide-dependent signal transduction mediated by cholinergic receptors. The effect of aggregated A(beta) (1-40) is more pronounced than that of the neurotoxic fragment A(beta) (25-35). Our study suggests that the deposition of aggregated A(beta) may alter phosphoinositide signaling in brain.] Question: Based on the provided context, do the terms [A(beta) protein] and [PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the aggregated beta-amyloid peptide (A\) (1-40) significantly affects the activity of phospholipase C (PLC). Specifically, it inhibits Ca2+-regulated PI and PIP2 degradation by both membrane-bound and cytosolic enzymes. This suggests a direct interaction between the A\ protein and the PLC protein, where the presence of A\ alters the activity of PLC, thereby affecting phosphoinositide signaling in the brain.</s>
IEPA.d145 IEPA.d145.s350.e0 IEPA.d145.s350.e1	A(beta) (1-40)	PIP2-PLC	[INST]Context: [PMID: 10786701 Aggregated beta amyloid peptide 1-40 decreases Ca2+- and cholinergic receptor-mediated phosphoinositide degradation by alteration of membrane and cytosolic phospholipase C in brain cortex. The effects of full-length amyloid beta protein, A(beta) (1-40), on phosphoinositide-specific phospholipase C (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats. Moreover, the role of A(beta) (1-40) on the activation of lipid peroxidation was evaluated. The activity of phospholipase C (PLC) acting on phosphatidylinositol (PI) and phosphatidylinositol-4,5-bisphosphate (PIP2) was determined using exogenous labeled substrates. The subcellular fractions were the source of enzyme(s). The radioactivity of lipid messengers derived from degradation of [14C- arachidonoyl] PI was also determined. The stable aggregated form of beta-amyloid peptide (1-40) at 25 microM concentration exerted reproducible effects. The aggregated form of A(beta) (1-40) inhibited Ca(2+)-regulated PI and PIP2 degradation by SPM and cytosolic enzymes. Aggregated A(beta) also decreased significantly the level of diacylglycerol, the product of PLC. This additionally supports the inhibitory effect of A(beta) on membrane-bound and cytosolic PLC. Moreover, A(beta) (1-40) significantly decreased the basal activity of the PIP2-PLC in SPM and the enzyme activity regulated through cholinergic receptors. However, in spite of the lower enzyme activity, the percentage distribution of inositol (1,4,5) P3 radioactivity (IP3) in the total pool of inositol metabolites was not significantly changed. The aggregated neurotoxic fragment, A(beta) (25-35), mimicked the effect of full-length A(beta) (1-40). A(beta) (1-40) enhanced the level of malondialdehyde indicating an activation of free radical stimulated membrane lipid peroxidation that may be involved in alteration of phospholipase(s) activity. Our results indicated that aggregated A(beta) (1-40) alters Ca(2+)-dependent phosphoinositide degradation affecting synaptic plasma membrane and cytosolic phospholipase(s) activity. Moreover, this peptide significantly decreased the phosphoinositide-dependent signal transduction mediated by cholinergic receptors. The effect of aggregated A(beta) (1-40) is more pronounced than that of the neurotoxic fragment A(beta) (25-35). Our study suggests that the deposition of aggregated A(beta) may alter phosphoinositide signaling in brain.] Question: Based on the provided context, do the terms [A(beta) (1-40) protein] and [PIP2-PLC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that aggregated A(beta) (1-40) significantly decreased the activity of the PIP2-PLC in synaptic plasma membranes. This suggests that A(beta) (1-40) interacts with PIP2-PLC, affecting its activity. The decrease in enzyme activity implies a direct interaction between the two proteins, where A(beta) (1-40) alters the function of PIP2-PLC.</s>
IEPA.d170 IEPA.d170.s412.e0 IEPA.d170.s412.e1	leptin	NPY	[INST]Context: [PMID: 10923281 Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels. Obesity occurs in 60% of women after menopause and is characterized by an excess of adipose tissue that depends on several orexigenic (neuropeptide Y (NPY) stimulates carbohydrate ingestion, galanin stimulates fat intake) and anorectic (leptin, cholecystokinin (CCK)) factors. Both leptin and insulin can reduce hypothalamic NPY production and secretion. Behavior related to the consumption of food is probably attributed to the NPY-galanin signalling route. We investigated basal levels of serum leptin, CCK, galanin and NPY in 16 non-obese premenopausal women, in 15 obese premenopausal women (body mass index (BMI) 34.6 +/- 1.3 SD) and in ten obese postmenopausal women (BMI 34.7 +/- 1.5 SD) to determine the relationship between obesity, menopause and these neuropeptides. Obese premenopausal women had three-fold elevations of serum leptin (32.1 +/- 3.2 ng/ml) in comparison to non-obese premenopausal women (10.3 +/- 1.5 ng/ml), but similar levels to those in obese postmenopausal women (35.3 +/- 4.1 ng/ml). In all 44 patients and in both sub-groups of premenopausal and postmenopausal women, serum leptin exhibited a strong positive correlation with BMI (r = 0.8692, p < 0.0001; r = 0.8803, p = 0.0001; r = 0.8184, p = 0.0001, respectively). Serum galanin values showed a statistically significant increment in the obese postmenopausal group (51.1 +/- 8.1 pg/ml) compared to both premenopausal groups: the non-obese (34.9 +/- 5.8 pg/ml) and the obese (36.0 +/- 5.5 pg/ml). Non-obese menstruating women demonstrated NPY levels (175.0 +/- 12.8 pg/ml) significantly higher than those of obese premenopausal women (126.0 +/- 12.1 pg/ml) and obese postmenopausal women (138.1 +/- 15.4 pg/ml). CCK values showed no differences between non-obese and obese pre- and postmenopausal groups. Basal insulin values were elevated in both obese groups compared to non-obese premenopausal women. Significantly increased leptin and galanin levels in postmenopausal obese women coupled with decreased NPY levels revealed some changes in the neuropeptides regulating eating behavior, which may be the reason for the onset of postmenopausal obesity.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin and NPY interact in the regulation of eating behavior. Specifically, it mentions that leptin can reduce hypothalamic NPY production and secretion. This suggests a direct interaction between leptin and NPY, where leptin influences the levels of NPY, thereby affecting the signaling pathways involved in appetite and food intake.</s>
IEPA.d195 IEPA.d195.s469.e0 IEPA.d195.s469.e1	Leptin	Neuropeptide Y	[INST]Context: [PMID: 11053526 Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. Leptin may rapidly inhibit food intake by altering the secretion of hypothalamic neuropeptides such as neuropeptide Y (NPY), a stimulator of food intake, and/or corticotropin-releasing hormone (CRH), an inhibitor of food intake. We measured concentrations of NPY and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular leptin administration. No rapid-onset effects of leptin on hypothalamic NPY or CRH concentrations were observed in intact mice. The addition of leptin to hypothalamic preparations from intact mice also did not alter NPY or CRH secretion. Glucocorticoids may oppose leptin actions. Consistent with this, leptin administration to adrenalectomized mice markedly reduced CRH concentrations in the ARC within 3 h after injection. This rapid reduction in CRH concentration in the ARC after leptin administration is more likely due to stimulated CRH release from this region than to decreased synthesis/transport from the PVN because leptin stimulates CRH synthesis in the PVN. Within 20 min after exposure to leptin, NPY secretion from hypothalamic preparations obtained from adrenalectomized mice was lowered by 27% and CRH secretion was elevated by 51%. The current study demonstrates that leptin rapidly influences the secretion of hypothalamic NPY and CRH and that these actions of leptin within the hypothalamus are restrained by the presence of endogenous corticosterone.] Question: Based on the provided context, do the terms [Leptin protein] and [Neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin rapidly inhibits the secretion of neuropeptide Y (NPY) in the hypothalamus. Specifically, it mentions that leptin administration to adrenalectomized mice markedly reduced NPY concentrations in the ARC within 3 hours after injection. This suggests a direct interaction between leptin and NPY, where leptin influences the secretion of NPY.</s>
IEPA.d195 IEPA.d195.s470.e0 IEPA.d195.s470.e1	Leptin	neuropeptide Y	[INST]Context: [PMID: 11053526 Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. Leptin may rapidly inhibit food intake by altering the secretion of hypothalamic neuropeptides such as neuropeptide Y (NPY), a stimulator of food intake, and/or corticotropin-releasing hormone (CRH), an inhibitor of food intake. We measured concentrations of NPY and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular leptin administration. No rapid-onset effects of leptin on hypothalamic NPY or CRH concentrations were observed in intact mice. The addition of leptin to hypothalamic preparations from intact mice also did not alter NPY or CRH secretion. Glucocorticoids may oppose leptin actions. Consistent with this, leptin administration to adrenalectomized mice markedly reduced CRH concentrations in the ARC within 3 h after injection. This rapid reduction in CRH concentration in the ARC after leptin administration is more likely due to stimulated CRH release from this region than to decreased synthesis/transport from the PVN because leptin stimulates CRH synthesis in the PVN. Within 20 min after exposure to leptin, NPY secretion from hypothalamic preparations obtained from adrenalectomized mice was lowered by 27% and CRH secretion was elevated by 51%. The current study demonstrates that leptin rapidly influences the secretion of hypothalamic NPY and CRH and that these actions of leptin within the hypothalamus are restrained by the presence of endogenous corticosterone.] Question: Based on the provided context, do the terms [Leptin protein] and [neuropeptide Y protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin rapidly inhibits the secretion of neuropeptide Y (NPY) in the hypothalamus. Specifically, it mentions that leptin administration to adrenalectomized mice markedly reduced NPY concentrations in the ARC within 3 hours after injection. This suggests that leptin and neuropeptide Y protein interact in a way that leptin influences the secretion of NPY, thereby demonstrating an interaction between the two proteins.</s>
IEPA.d195 IEPA.d195.s474.e0 IEPA.d195.s474.e1	leptin	NPY	[INST]Context: [PMID: 11053526 Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. Leptin may rapidly inhibit food intake by altering the secretion of hypothalamic neuropeptides such as neuropeptide Y (NPY), a stimulator of food intake, and/or corticotropin-releasing hormone (CRH), an inhibitor of food intake. We measured concentrations of NPY and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular leptin administration. No rapid-onset effects of leptin on hypothalamic NPY or CRH concentrations were observed in intact mice. The addition of leptin to hypothalamic preparations from intact mice also did not alter NPY or CRH secretion. Glucocorticoids may oppose leptin actions. Consistent with this, leptin administration to adrenalectomized mice markedly reduced CRH concentrations in the ARC within 3 h after injection. This rapid reduction in CRH concentration in the ARC after leptin administration is more likely due to stimulated CRH release from this region than to decreased synthesis/transport from the PVN because leptin stimulates CRH synthesis in the PVN. Within 20 min after exposure to leptin, NPY secretion from hypothalamic preparations obtained from adrenalectomized mice was lowered by 27% and CRH secretion was elevated by 51%. The current study demonstrates that leptin rapidly influences the secretion of hypothalamic NPY and CRH and that these actions of leptin within the hypothalamus are restrained by the presence of endogenous corticosterone.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin rapidly inhibits the secretion of neuropeptide Y (NPY) from hypothalamic preparations obtained from adrenalectomized mice. This suggests that leptin and NPY interact in a regulatory manner, where leptin influences the secretion of NPY. The reduction in NPY secretion after leptin administration demonstrates a direct interaction between leptin and NPY in the hypothalamus.</s>
IEPA.d195 IEPA.d195.s475.e0 IEPA.d195.s475.e1	leptin	NPY	[INST]Context: [PMID: 11053526 Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice. Leptin may rapidly inhibit food intake by altering the secretion of hypothalamic neuropeptides such as neuropeptide Y (NPY), a stimulator of food intake, and/or corticotropin-releasing hormone (CRH), an inhibitor of food intake. We measured concentrations of NPY and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular leptin administration. No rapid-onset effects of leptin on hypothalamic NPY or CRH concentrations were observed in intact mice. The addition of leptin to hypothalamic preparations from intact mice also did not alter NPY or CRH secretion. Glucocorticoids may oppose leptin actions. Consistent with this, leptin administration to adrenalectomized mice markedly reduced CRH concentrations in the ARC within 3 h after injection. This rapid reduction in CRH concentration in the ARC after leptin administration is more likely due to stimulated CRH release from this region than to decreased synthesis/transport from the PVN because leptin stimulates CRH synthesis in the PVN. Within 20 min after exposure to leptin, NPY secretion from hypothalamic preparations obtained from adrenalectomized mice was lowered by 27% and CRH secretion was elevated by 51%. The current study demonstrates that leptin rapidly influences the secretion of hypothalamic NPY and CRH and that these actions of leptin within the hypothalamus are restrained by the presence of endogenous corticosterone.] Question: Based on the provided context, do the terms [leptin protein] and [NPY protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that leptin rapidly inhibits the secretion of neuropeptide Y (NPY) from hypothalamic preparations obtained from adrenalectomized mice. This suggests that leptin and NPY interact in a regulatory manner, where leptin influences the secretion of NPY. The reduction in NPY secretion after leptin administration demonstrates a direct interaction between leptin and NPY in the hypothalamus.</s>